"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,S,US D0778219 S,161-090-953-456-93X,2017-02-07,2017,US 201529545781 F,2015-11-16,US 201529545781 F,2015-11-16,Control pod,,CATERPILLAR INC,CHOI KYONG;;ANDERTON JONATHAN,CATERPILLAR INC (2015-10-05),https://lens.org/161-090-953-456-93X,Design Right,no,0,6,1,1,0,,,1216;;D12/174,0,0,,,,ACTIVE
2,US,S,US D0516794 S,086-428-442-107-188,2006-03-14,2006,US 21695204 F,2004-11-10,EM 21102404 F,2004-07-27,Shoe,,CHOO JERSEY LTD J,CHOI SANDRA;;KELSEY JONATHAN,J. CHOO (JERSEY) LIMITED (2004-11-10);;J. CHOO LIMITED (2019-05-28),https://lens.org/086-428-442-107-188,Design Right,no,0,1,6,6,0,,,0299;;D 2971,0,0,,,,EXPIRED
3,US,S,US D0414044 S,023-227-344-647-045,1999-09-21,1999,US 9340998 F,1998-09-10,US 9340998 F,1998-09-10,Garment hanger with information marker,,RANDY HANGERS,CHOI YOON HO;;WILLINGER JONATHAN,HANGERS RANDY (1998-09-01),https://lens.org/023-227-344-647-045,Design Right,yes,14,30,1,1,0,,,D 6318;;0608,0,0,,,,EXPIRED
4,US,A1,US 2002/0040686 A1,073-747-158-585-904,2002-04-11,2002,US 1751401 A,2001-12-14,US 1751401 A;;US 82926101 A;;US 21825298 A,1998-12-21,Ergonomic handle for grooming brush,"
   A brush handle is formed with a continuously arched upper surface portion and a lower surface portion separated into two arched portions by a humped semi-circular ridge. One of the lower arched portions forms a trigger grip for a single finger held in either a forehand or backhand grip. The handle is preferably covered with a high friction material in the form of a contoured rubber or elastomeric sleeve which is stretched over a complimentarily contoured molded plastic handle. 
",WILLINGER JONATHAN;;CHOI YOON HO,WILLINGER JONATHAN;;CHOI YOON HO,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03),https://lens.org/073-747-158-585-904,Patent Application,yes,0,6,5,5,0,A01K13/002;;A01K13/002;;A46B5/02;;A46B5/02;;A46B2200/1093;;A46B2200/1093,A01K13/00;;A46B5/02,119/633,0,0,,,,EXPIRED
5,US,S,US D0472127 S,164-955-518-029-326,2003-03-25,2003,US 15877302 F,2002-04-10,US 15877302 F,2002-04-10,Clipper handles,,JW PET CO INC,WILLINGER JONATHAN;;CHOI YOON HO,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03);;JW PET COMPANY INC (2002-06-26),https://lens.org/164-955-518-029-326,Design Right,no,0,11,1,1,0,,,D 8107;;D8/52,0,0,,,,EXPIRED
6,US,S,US D0423733 S,139-295-971-807-520,2000-04-25,2000,US 10689599 F,1999-06-23,US 10689599 F,1999-06-23,Pet bowl,,JW PET CO INC,CHOI YOON HO;;WILLINGER JONATHAN,JW PET COMPANY INC (1999-06-10),https://lens.org/139-295-971-807-520,Design Right,yes,5,18,1,1,0,,,D30/129;;3003,0,0,,,,EXPIRED
7,US,S,US D0408998 S,045-968-393-218-315,1999-05-04,1999,US 9335198 F,1998-09-09,US 9335198 F,1998-09-09,Pet grooming brush handle,,J W PET COMPANY,CHOI YOON HO;;WILLINGER JONATHAN,J.W. PET COMPANY (1998-08-03),https://lens.org/045-968-393-218-315,Design Right,yes,5,8,1,1,0,,,D 4138;;2802,0,0,,,,EXPIRED
8,US,S,US D0405561 S,090-107-862-689-177,1999-02-09,1999,US 8524298 F,1998-03-19,US 8524298 F,1998-03-19,Pet bowl,,JW PET CO INC,WILLINGER JONATHAN;;CHOI YOON HO,J.W. PET COMPANY INC (1998-03-16),https://lens.org/090-107-862-689-177,Design Right,yes,17,28,1,1,0,,,D30/129;;3007,0,0,,,,EXPIRED
9,US,B1,US 6213055 B1,047-785-963-988-911,2001-04-10,2001,US 21825298 A,1998-12-21,US 21825298 A,1998-12-21,Ergonomic handle for grooming brush,A brush handle is formed with a continuously arched upper surface portion and a lower surface portion separated into two arched portions by a humped semi-circular ridge. One of the lower arched portions forms a trigger grip for a single finger held in either a forehand or backhand grip. The handle is preferably covered with a high friction material in the form of a contoured rubber or elastomeric sleeve which is stretched over a complimentarily contoured molded plastic handle.,J W PET COMPANY,WILLINGER JONATHAN;;CHOI YOON HO,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03);;J.W. PET COMPANY (1998-12-18),https://lens.org/047-785-963-988-911,Granted Patent,yes,13,62,5,5,0,A01K13/002;;A01K13/002;;A46B5/02;;A46B5/02;;A46B2200/1093;;A46B2200/1093,A01K13/00;;A46B5/02,119/633;;15/143.1,0,0,,,,EXPIRED
10,US,S,US D0467434 S,100-853-699-151-945,2002-12-24,2002,US 14580601 F,2001-07-30,US 14580601 F;;US 82926101 F;;US 21825298 F,1998-12-21,Head for grooming brush,,JW PET CO INC,CHOI YOON HO;;WILLINGER JONATHAN,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03);;JW PET COMPANY INC (2001-07-21),https://lens.org/100-853-699-151-945,Design Right,no,0,0,1,1,0,,,D 4127;;D4/138,0,0,,,,EXPIRED
11,US,B2,US 6450127 B2,126-601-239-875-937,2002-09-17,2002,US 82926101 A,2001-04-09,US 82926101 A;;US 21825298 A,1998-12-21,Ergonomic handle for grooming brush,"
    A brush handle is formed with a continuously arched upper surface portion and a lower surface portion separated into two arched portions by a humped semicircular ridge. One of the lower arched portions forms a trigger grip for a single finger held in either a forehand or backhand grip. The handle is preferably covered with a high friction material in the form of a contoured rubber or elastomeric sleeve which is stretched over a complimentarily contoured molded plastic handle. 
",JW PET COMPANY,WILLINGER JONATHAN;;CHOI YOON HO,,https://lens.org/126-601-239-875-937,Granted Patent,yes,13,19,5,5,0,A01K13/002;;A01K13/002;;A46B5/02;;A46B5/02;;A46B2200/1093;;A46B2200/1093,A01K13/00;;A46B5/02,119/633,0,0,,,,EXPIRED
12,US,B2,US 6543388 B2,127-786-502-381-740,2003-04-08,2003,US 1751401 A,2001-12-14,US 1751401 A;;US 82926101 A;;US 21825298 A,1998-12-21,Ergonomic handle for grooming brush,"
    A brush handle is formed with a continuously arched upper surface portion and a lower surface portion separated into two arched portions by a humped semi-circular ridge. One of the lower arched portions forms a trigger grip for a single finger held in either a forehand or backhand grip. The handle is preferably covered with a high friction material in the form of a contoured rubber or elastomeric sleeve which is stretched over a complimentarily contoured molded plastic handle. 
",J W PET COMPANY,WILLINGER JONATHAN;;CHOI YOON HO,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03),https://lens.org/127-786-502-381-740,Granted Patent,yes,13,29,5,5,0,A01K13/002;;A01K13/002;;A46B5/02;;A46B5/02;;A46B2200/1093;;A46B2200/1093,A01K13/00;;A46B5/02,119/633;;15/143.1,0,0,,,,EXPIRED
13,US,S,US D0446362 S,002-123-612-671-298,2001-08-07,2001,US 13337400 F,2000-11-29,US 13337400 F,2000-11-29,Non skid pet bowl,,JW PET CO INC,CHOI YOON HO;;WILLINGER JONATHAN,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03);;JW PET COMPANY INC (2000-11-21),https://lens.org/002-123-612-671-298,Design Right,yes,5,14,1,1,0,A01K5/0135;;A01K5/0135,,D30/129;;3003,0,0,,,,EXPIRED
14,US,A1,US 2001/0011528 A1,089-121-796-325-134,2001-08-09,2001,US 82926101 A,2001-04-09,US 82926101 A;;US 21825298 A,1998-12-21,Ergonomic handle for grooming brush,"
   A brush handle is formed with a continuously arched upper surface portion and a lower surface portion separated into two arched portions by a humped semi-circular ridge. One of the lower arched portions forms a trigger grip for a single finger held in either a forehand or backhand grip. The handle is preferably covered with a high friction material in the form of a contoured rubber or elastomeric sleeve which is stretched over a complimentarily contoured molded plastic handle. 
",WILLINGER JONATHAN;;CHOI YOON HO,WILLINGER JONATHAN;;CHOI YOON HO,,https://lens.org/089-121-796-325-134,Patent Application,yes,0,4,5,5,0,A01K13/002;;A01K13/002;;A46B5/02;;A46B5/02;;A46B2200/1093;;A46B2200/1093,A01K13/00;;A46B5/02,119/633,0,0,,,,EXPIRED
15,US,A1,US 2016/0220708 A1,057-794-996-461-224,2016-08-04,2016,US 201615010801 A,2016-01-29,US 201615010801 A;;US 201562110916 P,2015-02-02,NANO-CONSTRUCTS FOR POLYNUCLEOTIDE DELIVERY,"The present invention provides novel nano-constructs useful for delivering polynucleotides into cells, methods of using the nano-constructs, and methods of making the nano-constructs.",UNIV HONG KONG CHINESE,BIAN LIMING;;CHOI CHUNG HANG JONATHAN;;CHOI CHUN KIT,THE CHINESE UNIVERSITY OF HONG KONG (2016-04-14),https://lens.org/057-794-996-461-224,Patent Application,yes,2,5,2,2,7,C12Q1/6841;;A61K49/0065;;B82Y5/00;;C12N15/87;;C12N15/111;;C12N2310/141;;C12N2320/10;;C12N2320/32;;A61K47/6923;;A61K47/6929;;C12Q1/6834;;C12Q1/6841;;A61K49/0065;;B82Y5/00;;C12N15/87;;C12N15/111;;C12N2310/141;;C12N2320/10;;C12N2320/32;;A61K47/6923;;A61K47/6929,A61K49/00;;C12Q1/68,,3,3,042-740-170-624-041;;034-647-918-152-907;;047-831-262-100-152,pmc3258479;;10.1016/j.addr.2011.08.006;;21925556;;24654734;;10.1021/nn500722y;;pmc4564054;;25227561;;10.1021/ac501989b,"Rana et al 2012, Advanced Drug Delivery Rev. 64:200-216.;;Lin et al 2014, ACS Nano 8:3876-3883.;;Li et al 2014, Analytical Chemistry 86:10148-10156.",ACTIVE
16,US,B2,US 10240190 B2,184-251-318-141-559,2019-03-26,2019,US 201615010801 A,2016-01-29,US 201615010801 A;;US 201562110916 P,2015-02-02,Nano-constructs for polynucleotide delivery,"The present invention provides novel nano-constructs useful for delivering polynucleotides into cells, methods of using the nano-constructs, and methods of making the nano-constructs.",UNIV HONG KONG CHINESE,BIAN LIMING;;CHOI CHUNG HANG JONATHAN;;CHOI CHUN KIT,THE CHINESE UNIVERSITY OF HONG KONG (2016-04-14),https://lens.org/184-251-318-141-559,Granted Patent,yes,2,0,2,2,7,C12Q1/6841;;A61K49/0065;;B82Y5/00;;C12N15/87;;C12N15/111;;C12N2310/141;;C12N2320/10;;C12N2320/32;;A61K47/6923;;A61K47/6929;;C12Q1/6834;;C12Q1/6841;;A61K49/0065;;B82Y5/00;;C12N15/87;;C12N15/111;;C12N2310/141;;C12N2320/10;;C12N2320/32;;A61K47/6923;;A61K47/6929,C08G73/02;;A61K47/69;;A61K49/00;;B82Y5/00;;C08F283/00;;C08K3/10;;C12N15/11;;C12N15/87;;C12Q1/6834;;C12Q1/6841,,9,9,042-740-170-624-041;;034-647-918-152-907;;047-831-262-100-152;;002-791-853-794-874;;010-996-340-268-587;;054-223-092-364-167;;074-506-625-744-441;;005-089-978-712-106;;083-080-729-257-956,pmc3258479;;10.1016/j.addr.2011.08.006;;21925556;;24654734;;10.1021/nn500722y;;pmc4564054;;25227561;;10.1021/ac501989b;;23982570;;10.1039/c3nr03707j;;11283596;;10.1038/86762;;22891865;;23326189;;pmc3544340;;pmc3530415;;10.2217/nnm.12.82;;10.2147/ijn.s37924;;17947576;;pmc2601629;;10.1126/science.1147241;;21681985;;10.1002/smll.201100761;;10.1002/smll.201001314;;21294265;;pmc3099143,"Rana et al 2012, Advanced Drug Delivery Rev. 64:200-216.;;Lin et al 2014, ACS Nano 8:3876-3883.;;Li et al 2014, Analytical Chemistry 86:10148-10156.;;Heuer-Jungemann et al 2013 Nanoscale 5:9503-9510.;;Dubertret et al., Single-mismatch detection using gold-quenched fluorescent oligonucleotides nature biotechnology 2001 pp. 365-370.;;Black et al Polydopamine-enabled surface functionalization of gold nanorods for cancer cell-targeted imaging and photothermal therapy Nanomedicine (Lond). Jan. 2013; 8(1): 17-28.;;Lee et al., Mussel-Inspired Surface Chemistry for Multifunctional Coatings 2007 Science pp. 426-430.;;Lytton-Jean et al, Five Years of si RNA Delivery: Spotlight on Gold Nanoparticles Small 2011, 7, No. 14, 1932-1937.;;Koo Lee et al., Effective Gene Silencing by Multilayered siRNA-Coated Gold Nanoparticles small 2011, 7, No. 3, 364-370.",ACTIVE
17,CA,A1,CA 2888098 A1,090-699-022-534-481,2014-04-24,2014,CA 2888098 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient- specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient- specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/090-699-022-534-481,Patent Application,no,0,1,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,0,0,,,,ACTIVE
18,DE,D1,DE 69003030 D1,164-411-179-285-767,1993-10-07,1993,DE 69003030 T,1990-01-10,US 29611289 A,1989-01-12,UMWANDLUNG VON OLEFINEN IN ETHER.,,MOBIL OIL CORP,CHILD JONATHAN;;CHOI BYUNG;;RAGONESE FRANCIS,,https://lens.org/164-411-179-285-767,Granted Patent,no,0,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,0,0,,,,EXPIRED
19,WO,A1,WO 2014/062946 A1,172-497-621-379-521,2014-04-24,2014,US 2013/0065495 W,2013-10-17,US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient- specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient- specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/172-497-621-379-521,Patent Application,yes,5,6,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,0,0,,,,PENDING
20,US,A1,US 2005/0087854 A1,097-074-584-953-754,2005-04-28,2005,US 92742404 A,2004-08-26,KR 20030059487 A,2003-08-27,Power module flip chip package,"A power module flip chip package is provided. The power module flip chip package includes a package carrier having a front surface and a back surface facing the front surface, and a power semiconductor device electrically connected to the front surface of the package carrier via conductive bumps. The conductive bumps are electrically connected to a gate terminal, a source terminal, and a drain terminal of the power semiconductor device. The power module flip chip package has reduced resistance and inductance and improved reliability.",CHOI SEUNG-YONG;;NOQUIL JONATHAN A.,CHOI SEUNG-YONG;;NOQUIL JONATHAN A,FAIRCHILD KOREA SEMICONDUCTOR LTD (2004-09-10);;SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2017-11-02),https://lens.org/097-074-584-953-754,Patent Application,yes,7,23,4,4,0,H01L23/3128;;H01L23/49816;;H01L25/072;;H01L2224/73253;;H01L2924/01079;;H01L2924/15311;;H01L2224/16225;;H01L2924/13091;;H01L2224/05573;;H01L2224/05568;;H01L2924/00014;;H01L25/04;;H01L23/49816;;H01L2224/73253;;H01L2924/01079;;H01L25/072;;H01L2924/15311;;H01L23/3128;;H01L2224/16225;;H01L2924/13091;;H01L2224/05573;;H01L2224/05568;;H01L2924/00014,H01L23/31;;H01L25/04;;H01L23/498;;H01L25/07,257/686;;257/712;;257/778,0,0,,,,ACTIVE
21,KR,A,KR 20050022881 A,049-915-709-529-352,2005-03-08,2005,KR 20030059487 A,2003-08-27,KR 20030059487 A,2003-08-27,"POWER MODULE FLIP CHIP PACKAGE HAVING REDUCED RESISTANCE, REDUCED INDUCTANCE, AND IMPROVED RELIABILITY","PURPOSE: A power module flip chip package is provided to reduce a resistance and inductance, and improve reliability by connecting a power semiconductor device to a package substrate by a flip-chip method. CONSTITUTION: A package carrier(110) includes a front side(110F) and a back side(110B) opposite to the front side. A plurality of conductive bumps(BG,BS,BD) are formed on the front side of the package carrier. A power semiconductor device(120) is electrically connected to the package carrier through the conductive bumps. The conductive bumps are electrically connected to a gate terminal, a source terminal, and a drain terminal of the power semiconductor device.",FAIRCHILD KR SEMICONDUCTOR LTD,CHOI SEUNG-YONG;;NOQUIL JONATHAN A,,https://lens.org/049-915-709-529-352,Patent Application,no,0,2,4,4,0,H01L23/3128;;H01L23/49816;;H01L25/072;;H01L2224/73253;;H01L2924/01079;;H01L2924/15311;;H01L2224/16225;;H01L2924/13091;;H01L2224/05573;;H01L2224/05568;;H01L2924/00014;;H01L25/04;;H01L23/49816;;H01L2224/73253;;H01L2924/01079;;H01L25/072;;H01L2924/15311;;H01L23/3128;;H01L2224/16225;;H01L2924/13091;;H01L2224/05573;;H01L2224/05568;;H01L2924/00014,H01L23/31;;H01L25/04;;H01L23/498;;H01L25/07,,0,0,,,,EXPIRED
22,EP,B1,EP 2908719 B1,066-753-775-738-715,2023-02-15,2023,EP 13783462 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,METHODS FOR NUMERICALLY EVALUATING VASCULATURE,,HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/066-753-775-738-715,Granted Patent,yes,0,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B8/08;;G06T7/00;;G06T17/00;;G06T19/00;;G16H50/30;;G16H50/50,,1,1,091-380-822-838-24X,19758907,"GEORGIOS SIANOS ET AL: ""The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease"", EUROINTERVENTION, 1 August 2005 (2005-08-01), pages 219 - 227, XP055392801, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Antonio_Colombo2/publication/26816591_The_SYNTAX_Score_an_angiographic_tool_grading_the_complexity_of_coronary_artery_disease/links/0f31753aaed8d6fc26000000/The-SYNTAX-Score-an-angiographic-tool-grading-the-complexity-of-coronary-artery-disease.pdf> [retrieved on 20170720]",ACTIVE
23,CN,A,CN 109420177 A,154-647-419-648-431,2019-03-05,2019,CN 201810979271 A,2018-08-27,US 201762550995 P,2017-08-28,MATERIALS AND METHODS FOR EFFECTIVE IN VIVO DELIVERY OF DNA NANOSTRUCTURES TO ATHEROSCLEROTIC PLAQUES,"Provided are DNA-coated nanoparticles (DNA-NPS), superparamagnetic nanoparticles (DNA-SPNs), and superparamagnetic iron oxide nanoparticles (DNA-SPIONs) as efficient imaging agents for targeting and imaging atherosclerotic lesions and treating atherosclerotic disease. The DNA-NS, DNA-SPNs, and DNA-SPIONs can enter macrophage cells via the Class A scavenger receptor (SR-A)-mediated pathways and canbe used to specifically target atheroscleortic plaques.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;ZHANG LEI,,https://lens.org/154-647-419-648-431,Patent Application,no,3,3,4,4,0,A61P9/10;;A61K45/00;;A61K47/26;;A61K49/126;;A61K49/1854;;A61K9/513;;A61K47/6923;;A61K9/0019;;A61P9/10;;A61K47/549;;A61K47/60;;A61K47/6935;;A61K9/0019;;A61K49/186;;A61K49/0093;;A61P9/10;;A61K47/549;;A61K47/60;;A61K49/1845;;A61K47/6923;;A61K9/513,A61K47/26;;A61K45/00;;A61K49/12;;A61K49/18;;A61P9/10,,0,0,,,,ACTIVE
24,US,A1,US 2019/0060485 A1,184-110-295-928-738,2019-02-28,2019,US 201816113454 A,2018-08-27,US 201816113454 A;;US 201762550995 P,2017-08-28,MATERIALS AND METHODS FOR EFFECTIVE IN VIVO DELIVERY OF DNA NANOSTRUCTURES TO ATHEROSCLEROTIC PLAQUES,"Provided are DNA-coated nanoparticles (DNA-NPS), superparamagnetic nanoparticles (DNA-SPNs), and superparamagnetic iron oxide nanoparticles (DNA-SPIONs) as efficient imaging agents for targeting and imaging atherosclerotic lesions and treating atherosclerotic disease. The DNA-NS, DNA-SPNs, and DNA-SPIONs can enter macrophage cells via the Class A scavenger receptor (SR-A)-mediated pathways and can be used to specifically target atheroscleortic plaques.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;ZHANG LEI,THE CHINESE UNIVERSITY OF HONG KONG (2018-08-09),https://lens.org/184-110-295-928-738,Patent Application,yes,2,2,4,4,4,A61P9/10;;A61K45/00;;A61K47/26;;A61K49/126;;A61K49/1854;;A61K9/513;;A61K47/6923;;A61K9/0019;;A61P9/10;;A61K47/549;;A61K47/60;;A61K47/6935;;A61K9/0019;;A61K49/186;;A61K49/0093;;A61P9/10;;A61K47/549;;A61K47/60;;A61K49/1845;;A61K47/6923;;A61K9/513,A61K47/69;;A61K9/00;;A61K47/54;;A61K47/60;;A61K49/00;;A61K49/18;;A61P9/10,,0,0,,,,ACTIVE
25,DE,T2,DE 69003030 T2,032-817-748-685-634,1993-12-16,1993,DE 69003030 T,1990-01-10,US 29611289 A,1989-01-12,UMWANDLUNG VON OLEFINEN IN ETHER.,,MOBIL OIL CORP,CHILD JONATHAN;;CHOI BYUNG;;RAGONESE FRANCIS,,https://lens.org/032-817-748-685-634,Granted Patent,no,0,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,0,0,,,,EXPIRED
26,AU,A1,AU 2013/331213 A1,196-720-136-275-059,2015-05-07,2015,AU 2013/331213 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient- specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient- specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/196-720-136-275-059,Patent Application,no,0,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,0,0,,,,ACTIVE
27,AU,B2,AU 2016/213696 B2,044-328-650-438-529,2017-12-07,2017,AU 2016/213696 A,2016-08-08,AU 2016/213696 A;;AU 2013/331213 A;;US 201213656183 A;;US 2013/0065495 W,2012-10-19,Systems and methods for numerically evaluating vasculature,"A method for automatically generating a cardiovascular score for a patient, the method comprising: receiving, using at least one computer system, non-invasively obtained patient-specific image data regarding a geometry of one or more coronary arteries of the patient; creating, using the at least one computer system, a three-dimensional model representing a plurality of portions of the one or more coronary arteries of the patient using the patient-specific image data; automatically determining, using the at least one computer system, a value of a blood flow property for each of the plurality of portions of the one or more coronary arteries using the three-dimensional model; automatically determining, using the at least one computer system, a subset of the portions of the one or more coronary arteries having values of the blood flow property meeting a predetermined threshold of functional significance; automatically evaluating, using the at least one computer system, multiple characteristics of the subset of the portions of the one or more coronary arteries, wherein at least one of the multiple characteristics is selected from the group of left/right dominance, a total occlusion, a presence of an ostial disease, a tortuosity value, a length of a diseased vessel segment, one or more dimensions of calcified plaque, a thrombus, and a presence of a diffuse disease, and wherein automatically evaluating the multiple characteristics comprises automatically generating a numerical measurement of at least part of each characteristic; H:\mka\Interwoven\NRPortbl\DCC\MKA\10646154 1.docx - 8/8/16 - 2 automatically assigning, using the at least one computer system, a point value to each of the multiple characteristics based on the evaluation and generated numerical measurement of each characteristic; and for the subset of the portions of the one or more coronary arteries meeting the predetermined threshold of functional significance, automatically executing an algorithm using the assigned point values to generate a cardiovascular score. H:\mka\Interwoven\NRPortbl\DCC\MKA\10646154 1.docx - 8/8/16 U) 0 0 ca =1~ U) m (n U) -t 4- cU _0 cn 0 0 .0 U) 4. E a)) a) 0 c 0 0 U)U 0 E )~ Cu U)1j 0 f 0 > -- U)0 4- 4- 4- 4-Ua) 4- 4-a 24 0 00 0 0 ~ 0 0 o0 0 cou L- V c C C C Cud- r- Cu * 0 0,.-' 0 o U) o o o C 0 o a 0)~"" LO .0 .40 0 a0 C:~U) c: -' a) a) a) Cu 4- a 0 ) 0 -F ) a -0 Co n a) I-I 0~ Mu)u cv-c 0 L0 ). a2 0 >U M U) a)C cc 0 0)u 4---Q )U >0 c) -00 ) o0 U uV a)a) "" ) U U a)U; 5CU -I-, Cou*cM maaC =M- - o > > a) -a Co Co0",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/044-328-650-438-529,Granted Patent,no,2,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,0,0,,,,ACTIVE
28,CA,C,CA 2888098 C,106-126-249-072-139,2018-08-07,2018,CA 2888098 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient- specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient- specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/106-126-249-072-139,Granted Patent,no,0,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06T17/00,,0,0,,,,ACTIVE
29,JP,A,JP 2019171151 A,170-662-495-213-881,2019-10-10,2019,JP 2019124967 A,2019-07-04,US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"To provide optimal systems for providing a cardiovascular score for a patient.SOLUTION: A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least part of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.SELECTED DRAWING: Figure 3",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/170-662-495-213-881,Patent Application,no,8,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/03,,0,0,,,,ACTIVE
30,AU,B2,AU 2013/331213 B2,070-117-341-117-062,2016-05-12,2016,AU 2013/331213 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient- specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient- specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/070-117-341-117-062,Granted Patent,no,5,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,3,3,077-721-721-379-510;;086-968-191-188-063;;091-380-822-838-24X,22562911;;10.1056/nejmoa0804626;;19228612;;19758907,"Stahli, et al., ""Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,"" April 26, 2012, J Invasive Cardiol., 24(5) 196-201.;;Serruys, et al. ""Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease,"" March 5, 2009, N Engl J Med, Vol 360, No. 10, pp. 961 -972.;;Sianos et al., ""The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,"" 2005, Eurolnterv. 2005; 1 :219-227.",ACTIVE
31,AU,A1,AU 2016/213696 A1,087-423-957-442-798,2016-08-25,2016,AU 2016/213696 A,2016-08-08,AU 2016/213696 A;;AU 2013/331213 A;;US 201213656183 A;;US 2013/0065495 W,2012-10-19,Systems and methods for numerically evaluating vasculature,"A method for automatically generating a cardiovascular score for a patient, the method comprising: receiving, using at least one computer system, non-invasively obtained patient-specific image data regarding a geometry of one or more coronary arteries of the patient; creating, using the at least one computer system, a three-dimensional model representing a plurality of portions of the one or more coronary arteries of the patient using the patient-specific image data; automatically determining, using the at least one computer system, a value of a blood flow property for each of the plurality of portions of the one or more coronary arteries using the three-dimensional model; automatically determining, using the at least one computer system, a subset of the portions of the one or more coronary arteries having values of the blood flow property meeting a predetermined threshold of functional significance; automatically evaluating, using the at least one computer system, multiple characteristics of the subset of the portions of the one or more coronary arteries, wherein at least one of the multiple characteristics is selected from the group of left/right dominance, a total occlusion, a presence of an ostial disease, a tortuosity value, a length of a diseased vessel segment, one or more dimensions of calcified plaque, a thrombus, and a presence of a diffuse disease, and wherein automatically evaluating the multiple characteristics comprises automatically generating a numerical measurement of at least part of each characteristic; H:\mka\Interwoven\NRPortbl\DCC\MKA\10646154 1.docx - 8/8/16 - 2 automatically assigning, using the at least one computer system, a point value to each of the multiple characteristics based on the evaluation and generated numerical measurement of each characteristic; and for the subset of the portions of the one or more coronary arteries meeting the predetermined threshold of functional significance, automatically executing an algorithm using the assigned point values to generate a cardiovascular score. H:\mka\Interwoven\NRPortbl\DCC\MKA\10646154 1.docx - 8/8/16 U) 0 0 ca =1~ U) m (n U) -t 4- cU _0 cn 0 0 .0 U) 4. E a)) a) 0 c 0 0 U)U 0 E )~ Cu U)1j 0 f 0 > -- U)0 4- 4- 4- 4-Ua) 4- 4-a 24 0 00 0 0 ~ 0 0 o0 0 cou L- V c C C C Cud- r- Cu * 0 0,.-' 0 o U) o o o C 0 o a 0)~"" LO .0 .40 0 a0 C:~U) c: -' a) a) a) Cu 4- a 0 ) 0 -F ) a -0 Co n a) I-I 0~ Mu)u cv-c 0 L0 ). a2 0 >U M U) a)C cc 0 0)u 4---Q )U >0 c) -00 ) o0 U uV a)a) "" ) U U a)U; 5CU -I-, Cou*cM maaC =M- - o > > a) -a Co Co0",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/087-423-957-442-798,Patent Application,no,0,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,0,0,,,,ACTIVE
32,US,A1,US 2015/0162825 A1,129-420-006-075-003,2015-06-11,2015,US 201314101180 A,2013-12-09,US 201314101180 A,2013-12-09,Dynamic Load Matching Charge Pump for Reduced Current Consumption,"A charge pump is regulated based up its output level. The regulation circuitry adjusts the frequency of the pump's clock based on feedback from pump's output. The pump's clock signal is generated by an oscillator whose frequency depends on a reference voltage level. The reference voltage level is dependent upon a regulation signal. In an example, a transistor whose gate is controlled by the regulation level is part of a series of elements in voltage divider, where the reference value is taken from a node of the divider.",SANDISK TECHNOLOGIES INC,HUYNH JONATHAN;;CHOI STEVE;;PARK JONGMIN,SANDISK TECHNOLOGIES LLC (2013-12-06),https://lens.org/129-420-006-075-003,Patent Application,yes,20,3,2,2,0,H03K3/03;;H02M3/07;;H02M1/0025;;H02M3/07;;H03K3/03;;H02M1/0025,H02M3/07,,0,0,,,,ACTIVE
33,US,B2,US 7492043 B2,006-892-987-823-851,2009-02-17,2009,US 92742404 A,2004-08-26,KR 20030059487 A,2003-08-27,Power module flip chip package,"A power module flip chip package is provided. The power module flip chip package includes a package carrier having a front surface and a back surface facing the front surface, and a power semiconductor device electrically connected to the front surface of the package carrier via conductive bumps. The conductive bumps are electrically connected to a gate terminal, a source terminal, and a drain terminal of the power semiconductor device. The power module flip chip package has reduced resistance and inductance and improved reliability.",FAIRCHILD KR SEMICONDUCTOR LTD,CHOI SEUNG-YONG;;NOQUIL JONATHAN A,FAIRCHILD KOREA SEMICONDUCTOR LTD (2004-09-10);;SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2017-11-02),https://lens.org/006-892-987-823-851,Granted Patent,yes,7,24,4,4,0,H01L23/3128;;H01L23/49816;;H01L25/072;;H01L2224/73253;;H01L2924/01079;;H01L2924/15311;;H01L2224/16225;;H01L2924/13091;;H01L2224/05573;;H01L2224/05568;;H01L2924/00014;;H01L25/04;;H01L23/49816;;H01L2224/73253;;H01L2924/01079;;H01L25/072;;H01L2924/15311;;H01L23/3128;;H01L2224/16225;;H01L2924/13091;;H01L2224/05573;;H01L2224/05568;;H01L2924/00014,H01L23/34;;H01L23/31;;H01L25/04;;H01L23/48;;H01L23/498;;H01L25/07,257/724;;257/738;;X257E23026;;X257E23062,0,0,,,,ACTIVE
34,EP,A1,EP 2908719 A1,130-284-544-859-579,2015-08-26,2015,EP 13783462 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,,HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/130-284-544-859-579,Patent Application,yes,0,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T7/00;;G06T17/00,,0,0,,,,ACTIVE
35,KR,A,KR 20210094155 A,158-461-617-575-560,2021-07-28,2021,KR 20217023137 A,2013-10-17,US 201213656183 A;;KR 20167009595 A;;US 2013/0065495 W,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"환자에 대한 심혈관 스코어를 제공하는 시스템들 및 방법들이 개시된다. 방법은 적어도 하나의 컴퓨터 시스템을 사용하여, 환자의 다수의 관상 동맥들의 기하학 구조에 관한 환자 특정 데이터를 수신하는 단계; 및 적어도 하나의 컴퓨터 시스템을 사용하여, 환자 특정 데이터에 기초하여 다수의 관상 동맥들의 적어도 일부들을 나타내는 3차원 모델을 생성하는 단계를 포함한다. 방법은 또한 적어도 하나의 컴퓨터 시스템을 사용하여, 모델에 의해 표현되는 관상 동맥들의 적어도 일부의 다수의 특성들을 평가하는 단계; 및 적어도 하나의 컴퓨터 시스템을 사용하여, 다수의 특성들의 평가에 기초하여 심혈관 스코어를 생성하는 단계를 포함한다. 다른 방법은 적어도 미리 결정된 임계값의 분획 혈류 예비력 값들을 갖는 관상 동맥들의 일부들에 대한 평가된 다수의 특성들에 기초하여 심혈관 스코어를 생성하는 단계를 포함한다.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/158-461-617-575-560,Patent Application,no,6,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06T7/00;;G06T19/00;;G16H50/30;;G16H50/50,,0,0,,,,ACTIVE
36,CN,A,CN 112234046 A,030-975-291-161-101,2021-01-15,2021,CN 202010679562 A,2020-07-15,US 201962874496 P,2019-07-15,ELECTRICAL ASSEMBLIES INCLUDING COUPLERS FOR CANCELING MAGNETIC FLUX,"An electrical assembly includes (a) a first inductor including a first winding wound around a first winding axis, (b) a second inductor separated from the first inductor in a first direction, and (c)a coupler at least partially disposed between the first inductor and the second inductor in the first direction, the coupler forming at least part of an electrical circuit enabling electric current toflow through the coupler, and the coupler being asymmetric with respect to a dividing axis of the first inductor extending in a second direction that is orthogonal to the first direction.",MAXIM INTEGRATED PRODUCTS,CHOI JAEYOUNG;;HUNG JONATHAN;;HUANG TAO,,https://lens.org/030-975-291-161-101,Patent Application,no,0,0,3,3,0,H01F27/346;;H01F27/346;;H01L23/5227;;H01F27/2804;;H01F27/363;;H01F27/363;;H01F27/38,H01L23/522,,0,0,,,,PENDING
37,JP,A,JP 2017140495 A,095-649-543-856-271,2017-08-17,2017,JP 2017102448 A,2017-05-24,US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"PROBLEM TO BE SOLVED: To provide optimal systems for providing a cardiovascular score for a patient.SOLUTION: A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least part of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.SELECTED DRAWING: Figure 3",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GILWOO,,https://lens.org/095-649-543-856-271,Patent Application,no,6,0,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/12;;A61B6/03,,0,0,,,,ACTIVE
38,US,B2,US 9154027 B2,084-759-344-545-858,2015-10-06,2015,US 201314101180 A,2013-12-09,US 201314101180 A,2013-12-09,Dynamic load matching charge pump for reduced current consumption,"A charge pump is regulated based up its output level. The regulation circuitry adjusts the frequency of the pump's clock based on feedback from pump's output. The pump's clock signal is generated by an oscillator whose frequency depends on a reference voltage level. The reference voltage level is dependent upon a regulation signal. In an example, a transistor whose gate is controlled by the regulation level is part of a series of elements in voltage divider, where the reference value is taken from a node of the divider.",SANDISK TECHNOLOGIES INC,HUYNH JONATHAN;;CHOI STEVE;;PARK JONGMIN,SANDISK TECHNOLOGIES LLC (2013-12-06),https://lens.org/084-759-344-545-858,Granted Patent,yes,119,17,2,2,0,H03K3/03;;H02M3/07;;H02M1/0025;;H02M3/07;;H03K3/03;;H02M1/0025,H02M3/07,,9,1,122-601-352-218-87X,10.1109/isscc.2000.839850,"U.S. Appl. No. 12/973,641, filed Dec. 20, 2010, 26 pages.;;U.S. Appl. No. 12/973,493, filed Dec. 20, 2010, 28 pages.;;U.S. Appl. No. 13/228,605, filed Sep. 9, 2011, 21 pages.;;Louie Pylarinos et al., ""Charge Pumps: An Overview"", Department of Electrical and Computer Engineering University of Toronto, 7 pages.;;Ang et al., ""An On-Chip Voltage Regulator Using Switched Decoupling Capacitors,"" 2000 IEEE International Solid-State Circuits Conference, 2 pages.;;U.S. Appl. No. 12/506,998 entitled ""Charge Pump with Current Based Regulation"" filed Jul. 21, 2009, 21 pages.;;U.S. Appl. No. 12/634,385 entitled ""Multi-Stage Charge Pump with Variable Number of Boosting Stages"" filed Dec. 9, 2009, 33 pages.;;Notice of Allowance in U.S. Appl. No. 13/926,442, mailed May 13, 2015, 9 pages.;;First Office Action issued for Chinese Patent Application No. 2011800614031 mailed on Feb. 3, 2015, 4 pages.",ACTIVE
39,US,B2,US 10973927 B2,107-348-733-187-173,2021-04-13,2021,US 201816113454 A,2018-08-27,US 201816113454 A;;US 201762550995 P,2017-08-28,Materials and methods for effective in vivo delivery of DNA nanostructures to atherosclerotic plaques,"Provided are DNA-coated nanoparticles (DNA-NPS), superparamagnetic nanoparticles (DNA-SPNs), and superparamagnetic iron oxide nanopa rticles (DNA-SPIONs) as efficient imaging agents for targeting and imaging atherosclerotic lesions and treating atherosclerotic disease. The DNA-NS, DNA-SPNs, and DNA-SPIONs can enter macrophage cells via the Class A scavenger receptor (SR-A)-mediated pathways and can be used to specifically target atheroscleortic plaques.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;ZHANG LEI,THE CHINESE UNIVERSITY OF HONG KONG (2018-08-09),https://lens.org/107-348-733-187-173,Granted Patent,yes,40,0,4,4,4,A61P9/10;;A61K45/00;;A61K47/26;;A61K49/126;;A61K49/1854;;A61K9/513;;A61K47/6923;;A61K9/0019;;A61P9/10;;A61K47/549;;A61K47/60;;A61K47/6935;;A61K9/0019;;A61K49/186;;A61K49/0093;;A61P9/10;;A61K47/549;;A61K47/60;;A61K49/1845;;A61K47/6923;;A61K9/513,A61K47/69;;A61K9/00;;A61K9/51;;A61K47/54;;A61K47/60;;A61K49/00;;A61K49/18;;A61P9/10,,101,95,053-474-598-733-900;;060-062-119-852-21X;;066-845-201-361-611;;014-890-769-801-794;;032-373-018-822-815;;096-703-445-528-558;;006-899-835-144-755;;054-855-242-627-475;;028-186-945-894-432;;019-989-828-778-910;;023-888-372-394-725;;030-936-509-701-827;;007-399-740-677-108;;147-130-859-888-361;;152-624-960-498-019;;109-363-769-658-756;;028-841-338-124-944;;000-465-642-924-054;;022-555-097-806-497;;091-066-896-734-43X;;009-697-924-386-530;;021-442-184-012-049;;064-295-985-230-989;;016-805-724-653-955;;031-457-762-719-252;;006-360-609-612-304;;015-655-064-560-464;;071-780-508-834-889;;018-641-160-178-216;;113-175-948-008-43X;;078-785-383-302-172;;155-013-798-681-689;;048-156-270-907-749;;149-464-719-930-882;;005-132-285-516-576;;069-511-710-398-526;;020-296-639-745-902;;059-222-820-109-066;;055-230-481-446-547;;014-303-003-041-85X;;091-944-921-433-089;;090-939-222-013-373;;148-852-844-066-307;;003-588-069-803-469;;061-762-807-433-370;;057-576-330-057-094;;038-417-045-316-440;;006-915-435-714-082;;096-296-695-522-217;;048-777-649-153-613;;074-299-212-068-351;;046-205-532-504-989;;085-526-729-115-751;;109-332-799-037-406;;021-222-986-102-500;;010-621-254-843-046;;153-736-159-090-248;;036-447-419-720-443;;009-753-555-972-094;;027-374-927-547-13X;;025-813-179-941-48X;;005-734-856-647-579;;124-245-483-425-822;;090-688-421-123-918;;074-511-543-291-721;;016-561-245-840-843;;043-347-156-595-497;;004-617-674-871-124;;026-699-068-348-94X;;055-171-791-872-966;;000-023-914-169-622;;029-014-503-771-799;;062-520-276-244-910;;130-272-149-128-188;;047-515-660-746-835;;047-669-838-956-402;;089-155-940-952-999;;093-048-897-330-481;;019-428-321-426-289;;099-953-337-899-109;;039-476-832-603-402;;096-646-466-395-872;;151-524-568-255-288;;045-439-347-049-473;;092-237-305-361-249;;029-620-137-891-992;;162-694-102-592-515;;064-203-723-991-816;;174-561-177-585-172;;076-844-218-546-223;;047-281-820-773-674;;037-406-883-216-764;;080-494-510-066-443;;051-163-125-538-338;;048-236-769-458-196,10.1073/pnas.1118425109;;pmc3409786;;22773805;;10.1073/pnas.1505951112;;pmc4426446;;25902507;;pmc4387715;;10.1101/gad.257394.114;;25838542;;25775582;;pmc4386353;;10.1073/pnas.1502850112;;28373576;;pmc5402467;;10.1073/pnas.1702736114;;10.1038/srep31687;;27538453;;pmc4990839;;10.1073/pnas.1424594112;;25691739;;pmc4352838;;10.1021/acsnano.6b01114;;pmc5199136;;10.1021/acsnano.6b01114.s001;;27100066;;26308181;;pmc4581466;;10.1021/acsnano.5b02611;;10.1186/1741-7015-11-117;;pmc3658954;;23635324;;21321594;;10.1038/ni.2001;;21593864;;10.1038/nature10146;;10.1038/nmat3780;;24452356;;24352519;;10.1161/01.cir.0000441139.02102.80;;pmc5408159;;10.1080/15398285.2014.902284;;26892971;;pmc4756468;;10.1161/circresaha.115.306247;;10.1111/j.1749-6632.2001.tb03940.x;;11795266;;10.1038/nrd3578;;22015921;;pmc3623275;;pmc4918468;;26889958;;10.1021/acsnano.5b07522;;27493969;;10.1155/2016/9582430;;pmc4967433;;pmc2839076;;19883911;;10.1016/j.atherosclerosis.2009.10.009;;pmc3481783;;10.1161/atvbaha.107.145466;;17962629;;27022138;;pmc4871742;;10.1177/1535370216640940;;26877785;;10.7150/thno.13350;;pmc4729775;;10.1016/j.jcmg.2012.06.016;;pmc3653172;;23433925;;10.1016/j.nano.2014.02.002;;24566276;;pmc4077993;;21482787;;pmc3084060;;10.1073/pnas.1104540108;;19072768;;10.1002/cmmi.257;;10.1073/pnas.0606281104;;17215360;;pmc1766334;;10.1016/j.jcmg.2008.08.009;;19442953;;pmc2756539;;23324435;;pmc3562260;;10.1186/1532-429x-15-7;;10.1021/bc100354m;;20977242;;10.1016/j.biomaterials.2015.02.089;;25890732;;10.1021/acsnano.7b01385;;10.1021/acsnano.7b01385.s001;;pmc5492212;;28463501;;10.1021/acs.molpharmaceut.6b00219.s001;;27183493;;10.1021/acs.molpharmaceut.6b00219;;24972372;;10.1021/mp500188g;;pmc4144725;;20485380;;10.1038/gt.2010.69;;pmc2955163;;10.1161/circulationaha.113.002870;;24305567;;10.1155/2012/734842;;12719280;;10.1161/01.cir.0000068315.98705.cc;;15377941;;10.1097/01.rli.0000135980.08491.33;;10.1161/01.atv.19.3.461;;10073945;;10.1161/01.atv.20.2.290;;10669623;;pmc1870963;;7677178;;18680772;;10.1016/j.jconrel.2008.07.013;;23744990;;10.1161/atvbaha.112.300707;;10.1021/ja2081263;;22029389;;10.1002/adma.200401545;;21750492;;pmc3196167;;10.3791/2848;;10.1029/jb078i011p01780;;10.1021/acsnano.5b00042;;26168364;;10.1039/b902394a;;10.1021/nl072471q;;pmc8585332;;17997588;;10.1021/ac0613582;;pmc2525614;;17165821;;pmc2874426;;20307079;;10.1021/nl100477m;;25869663;;pmc4395483;;10.1083/jcb.201412052;;pmc2915475;;20543206;;10.1093/cvr/cvq146;;24250251;;10.7150/ijbs.7502;;pmc3831119;;22646927;;pmc3400701;;10.1021/nn300456z;;25424488;;pmc4253004;;10.1186/s12951-014-0045-5;;10.1038/nnano.2011.191;;22056728;;9887093;;10.1152/ajprenal.1999.276.1.f172;;6198189;;10.1016/0014-4827(84)90698-0;;24841494;;pmc4046773;;10.1021/ja503010a;;23613589;;10.1073/pnas.1305804110;;pmc3651452;;19656993;;pmc2756837;;10.1128/cvi.00194-09;;18654343;;10.1038/nnano.2007.223;;10.1124/pr.58.1.8;;16507881;;24489098;;10.4049/jimmunol.1301249;;pmc3932809;;10.1038/nrm2216;;17609668;;10.1083/jcb.141.1.101;;9531551;;pmc2132716;;10.1038/nrm2122;;17318224;;8970738;;10.1146/annurev.cellbio.12.1.575;;6309862;;10.1083/jcb.97.2.508;;pmc2112524;;pmc532021;;15456905;;10.1091/mbc.e04-08-0747;;10559966;;10.1038/14075;;10.1083/jcb.200109030;;11827983;;pmc2173336;;2584229;;10.1016/s0021-9258(19)47094-4;;19317650;;10.1146/annurev.biochem.78.081307.110540;;10.1016/j.biomaterials.2011.01.021;;21295849;;pmc3055170;;pmc5439959;;27762539;;10.1021/acs.bioconjchem.6b00483;;pmc4648695;;10.1039/c5cs00541h;;26390044;;pmc2702539;;17891134;;10.1038/nbt1340;;22315430;;pmc3286910;;10.1073/pnas.1200718109;;pmc3080986;;21464325;;10.1073/pnas.1103573108;;pmc2833353;;19276378;;10.1158/0008-5472.can-08-2495;;20131753;;pmc3004996;;10.1021/bc9003102;;14652798;;10.1002/hep.1840060505;;3758936;;8446907;;10.1055/s-2007-1007336;;18063708;;10.1152/ajpgi.00167.2007;;10.1186/1476-5926-2-s1-s22;;pmc2409441;;14960174;;10.1038/nmat4718;;27525571;;pmc5132626;;11726538;;10.1096/fj.01-0463com;;26263022;;pmc4531783;;10.1038/srep12931;;21684593;;pmc3130121;;10.1016/j.biomaterials.2011.05.024,"Zheng, D. et al., “Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation”, PNAS, Jul. 24, 2012, 109(30):11975-11980.;;Randeria, P.S. et al., “siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown”, PNAS, May 5, 2015, 112(18):5573-5578.;;Jensen, S.A. et al., “Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma”, Sci Transl Med, Oct. 30, 2013, 5(209):1-13, American Association for the Advancement of Science, Washington, DC.;;Kouri, F.M. et al., “miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma”, Genes & Development, 29:732-745, Cold Spring Harbor Laboratory Press.;;Radovic-Moreno, A.F. etal., “Immunomodulatory spherical nucleic acids”, PNAS, Mar. 31, 2015, 112(13):3892-3897.;;Sita, T.L. et al., “Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo”, PNAS, Apr. 18, 2017, 114(16):4129-4134.;;Wang, X. et al., “Spherical nucleic acid targeting microRNA-99b enhances intestinal MFG-E8 gene expression and restores enterocyte migration in lipopolysaccharide-induced septic mice”, Scientific Reports, Aug. 19, 2016, 6(31687):1-13.;;Lewis, D.R. et al., “Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo”, PNAS, Mar. 3, 2015, 112(9):2693-2698.;;Kamaly, N. etal., “Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis”, ACS Nano, Apr. 21, 2016, 10:5280-5292, American Chemical Society.;;Kheirolomoom, A. et al., “Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE-/- Mice”, ACSNANO, Aug. 26, 2015, 9(9):8885-8897, American Chemical Society.;;Mozaffarian, D. et al., “Heart disease and stroke statistics—2015 update: a report from the American Heart Association”, Dec. 17, 2014, pp. 1-4.;;Frostegård, J. “Immunity, atherosclerosis, and cardiovascular disease”, BMC Medicine, 2013, 11(117):1-13, BioMed Central.;;Hansson, G.K. et al., “The immune system in atherosclerosis”, Nature Immunology, Mar. 2011, 12(3):204-212, Nature America, Inc.;;Libby, P. et al., “Progress and challenges in translating the biology of atherosclerosis”, Nature, May 19, 2011, 473:317-325, Macmillan Publishers Limited.;;Weissleder, R. et al., “Imaging macrophages with nanoparticles”, Nature Materials, Feb. 2014, 13:125-138, Macmillan Publishers Limited.;;Go, A.S. et al., “Heart Disease and Stroke Statistics—2014 Update”, Circulation, 2013, 129:e28-e292, American Heart Association, Inc.;;Mulder, W.J.M. et al., “Imaging and Nanomedicine in Inflammatory Atherosclerosis”, Sci Transl Med, Jun. 4, 2014, 6(239):1-11, the American Association for the Advancement of Science, Washington, DC.;;Tarkin, J.M. et al., “Imaging Atherosclerosis”, Circulation Research, Feb. 19, 2016, 118:750-769, Wolters Kluwer.;;Corti, R. et al., “New Understanding of Atherosclerosis (Clinically and Experimentally) with Evolving MRI Technology in Vivo”, Annals New York Academy of Sciences, 2001, 947:181-198.;;Lobatto, M.E. et al., “Perspectives and opportunities for nanomedicine in the management of atherosclerosis”, Nat Rev Drug Discov., 2011, 10(11):835-852, Macmillan Publishers Limited.;;Kuai, R. et al., “High-Density Lipoproteins: Nature's Multifunctional Nanoparticles”, ACS Nano, 2016, 10:3015-3041, American Chemical Society.;;Bobryshev, Y.V. et al., “Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis”, BioMed Research International, 2016, 2016(9582430):13 pages, Hindawi Publishing Corporation.;;McAteer, M.A. et al., “An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide”, Atherosclerosis, 2010, 209:18-27, Elsevier Ireland Ltd.;;McAteer, M.A. et al., “Magnetic Resonance Imaging of Endothelial Adhesion Molecules in Mouse Atherosclerosis Using Dual-Targeted Microparticles of Iron Oxide”, Arterioscler Thromb Vasc Biol., Jan. 2008, 28:77-83, 2007 American Heart Association, Inc.;;Chung, E.J., “Targeting and therapeutic peptides in nanomedicine for atherosclerosis”, Experimental Biology and Medicine, 2016, 241:891-898, the Society for Experimental Biology and Medicine.;;Wang, Y. et al., “In vivo MR and Fluorescence Dual-modality Imaging of Atherosclerosis Characteristics in Mice Using Profilin-1 Targeted Magnetic Nanoparticles”, Theranostics, 2016, 6(2):272-286, Ivyspring International Publisher.;;Chen, W. et al., “Collagen-Specific Peptide Conjugated HDL Nanoparticles as MRI Contrast Agent to Evaluate Compositional Changes in Atherosclerotic Plaque Regression”, JACC: Cardiovascualr Imaging, Mar. 2013, 6(3):373-384, Elsevier Inc.;;Sinha, A. et al., “Nanoparticle targeting to diseased vasculature for imaging and therapy”, Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10:1003-1012, Elsevier Inc.;;Hamzah, J. et al., “Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice”, PNAS, Apr. 26, 2011, 108(17):7154-7159.;;Chen, W. et al., “Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis”, Contrast Media Mol. Imaging, 2008, 3:233-242, John Wiley & Sons, Ltd.;;Amirbekian, V. et al., “Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI”, PNAS, Jan. 16, 2007, 104(3):961-966.;;Lipinski, M.J. et al., “Macrophage-Specific Lipid-Based Nanoparticles Improve Cardiac Magnetic Resonance Detection and Characterization of Human Atherosclerosis”, JACC: Cardiovascular Imaging, May 2009, 2(5):637-647, Elsevier Inc.;;Dellinger, A. et al., “Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance”, Journal of Cardiovascular Magnetic Resonance, 2013, 15(7):1-12, BioMed Central.;;Kamat, M. et al., “Hyaluronic Acid Immobilized Magnetic Nanoparticles for Active Targeting and Imaging of Macrophages”, Bioconjugate Chem., 2010, 21(11):2128-2135, American Chemical Society.;;Lee, G.Y. et al., “Hyaluronic acid nanoparticles for active targeting atherosclerosis”, Biomaterials, 2015, 53:341-348, Elsevier Ltd.;;Beldman, T.J. et al., “Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis”, ACS Nano, May 2, 2017, 11:5785-5799, American Chemical Society.;;Taniguchi, R. et al., “Adequately-Sized Nanocarriers Allow Sustained Targeted Drug Delivery to Neointimal Lesions in Rat Arteries”, Mol. Pharmaceutics, May 16, 2016, 13:2108-2116, American Chemical Society.;;Petersen, L.K. et al., “Amphiphilic Nanoparticles Repress Macrophage Atherogenesis: Novel Core/Shell Designs for Scavenger Receptor Targeting and Down-Regulation”, Mol. Pharmaceutics, Jun. 27, 2014, 11:2815-2824, American Chemical Society.;;Li, J.M. et al., “Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model”, Gene Therapy, 2010, 17:1279-1287, Macmillan Publishers Limited.;;Katsuki, S. et al., “Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes”, Circulation, 2014, 129:896-906, 2013 American Heart Association, Inc.;;Boyer, C. et al., “The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications”, NPG Asia Mater., Jan. 2010, 2(1):23-30, Tokyo Institute of Technology.;;Lin, C. et al., “Positive Contrast Imaging of SPIO Nanoparticles”, Journal of Nanomaterials, 2012, 2012(734842):9 pages, Hindawi Publishing Corporation.;;Kooi, M.E. et al., “Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging”, Circulation, May 20, 2003, 107:2453-2458, American Chemical Society.;;Corot, C. et al., “Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging”, Investigative Radiology, Oct. 2004, 39(10):619-625, Lippincott Williams & Wilkins.;;Gough, P.J. et al., “Analysis of Macrophage Scavenger Receptor (SR-A) Expression in Human Aortic Atherosclerotic Lesions”, Arterioscler Thromb Vasc Biol., Mar. 1999, 19:461-471, American Heart Association, Inc.;;De Winther, M.P.J. et al., “Macrophage Scavenger Receptor Class A”, Arterioscler Thromb Vasc Biol., Feb. 2000, 20:290-297, American Heart Association, Inc.;;Rekhter, M.D. et al., “Active Proliferation of Different Cell Types, Including Lymphocytes, in Human Atherosclerotic Plaques”, American Journal of Pathology, Sep. 1995, 147(3):668-677, American Society for Investigative Pathology.;;Thapa, N. et al., “Identification of a peptide ligand recognizing dysfunctional endothelial cells for targeting atherosclerosis”, Journal of Controlled Release, 2008, 131:27-33, Elsevier B.V.;;Segers, F.M.E. et al., “Scavenger Receptor-Al-Targeted Iron Oxide Nanoparticles for In Vivo MRI Detection of Atherosclerotic Lesions”, Arterioscler Thromb Vasc Biol., Aug. 2013, 33:1812-1819, American Heart Association, Inc.;;Jia, Q. et al., “Gelification: An Effective Measure for Achieving Differently Sized Biocompatible Fe3O4 Nanocrystals through a Single Preparation Recipe”, J. Am. Chem. Soc., Oct. 27, 2011, 133:19512-19523, American Chemical Society.;;Li, Z. et al., “One-Pot Reaction to Synthesize Biocompatible Magnetite Nanoparticles”, Advanced Materials, Apr. 18, 2005, 17(8):1001-1005, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.;;Butcher, M.J. et al., “Flow Cytometry Analysis of Immune Cells Within Murine Aortas”, Journal of Visualized Experiments, 2011, pp. 1-6, Journal of Visualized Experiments.;;Dunlop, D.J., “Superparamagnetic and Single-Domain Threshold Sizes in Magnetite”, Journal of Geophysical Research, Apr. 10, 1973, 78(11):1780-1793, the American Geophysical Union.;;Kolosnjaj-Tabi, J. et al., “The One Year Fate of Iron Oxide Coated Gold Nanoparticles in Mice”, ACS NANO, Jul. 13, 2015, 9(8):7925-7939, American Chemical Society.;;Qiao, R. et al., “Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications”, Journal of Materials Chemistry, 2009, 19:6274-6293, the Royal Society of Chemistry.;;Giljohann, D.A. et al., “Oligonucleotide Loading Determines Cellular Uptake of DNA-Modified Gold Nanoparticles”, Nano Letters, 2007, 7(12):3818-3821, American Chemical Society.;;Hurst, S.J. et al., “Maximizing DNA Loading on a Range of Gold Nanoparticle Sizes”, Anal. Chem., Dec. 15, 2006, 78(24):8313-8318, American Chemical Society.;;Cutler, J.I. et al., “Polyvalent Oligonucleotide Iron Oxide Nanoparticle “Click” Conjugates”, Nano Lett., Apr. 14, 2010,10(4):1477-1480.;;Tabas, I. et al., “Recent insights into the cellular biology of atherosclerosis”, J. Cell Biol., Apr. 13, 2015, 209(1):13-22, The Rockefeller University Press.;;Tarbell, J.M., “Shear stress and the endothelial transport barrier”, Cardiovascular Research, 2010, 87:320-330, the European Society of Cardiology.;;Rajendran, P. et al., “The Vascular Endothelium and Human Diseases”, International Journal of Biological Sciences, 2013, 9(10):1057-1069, Ivyspring International Publisher.;;Gu, L. et al., “In Vivo Clearance and Toxicity of Monodisperse Iron Oxide Nanocrystals”, ACSNANO, 2012, 6(6):4947-4954, American Chemical Society.;;Bancos, S. et al., “Evaluating the effect of assay preparation on the uptake of gold nanoparticles by RAW264.7 cells”, Journal of Nanobiotechnology, 2014, 12(45):1-11, BioMed Central.;;Kim, J.A. et al., “Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population”, Nature Nanotechnology, Jan. 2012, 7:62-68, Macmillan Publishers Limited.;;Lorenz, J.N. et al., “A simple, nonradioactive method for evaluating single-nephron filtration rate using FITC-insulin”, Am. J. Physiol., 1999, 276(Renal Physiol. 15):F172-F177, the American Physiological Society.;;Geisow, M.J., “Fluorescein Conjugates as Indicators of Subcellular pH”, Experimental Cell Research, 1984, 150:29-35, Academic Press, Inc., Sweden.;;Wu, X.A. et al., “Intracellular Fate of Spherical Nucleic Acid Nanoparticle Conjugates”, Journal of the American Chemical Society, May 19, 2014, 136:7726-7733, American Chemical Society.;;Choi, C.H.J. et al., “Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates”, PNAS, May 7, 2013, 110(19):7625-7630.;;Verma, A. et al., “Analysis of the Fc Gamma Receptor-Dependent Component of Neutralization Measured by Anthrax Toxin Neutralization Assays”, Clinical and Vaccine Immunology, Oct. 2009, 16(10):1405-1412, American Society for Microbiology.;;Dobrovolskaia, M.A. et al., “Immunological properties of engineered nanomaterials”, nature nanotechnology, Aug. 2007, 2:469-478, Nature Publishing Group.;;Khalil, I.A. et al., “Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery”, Pharmacological Reviews, 2006, 58(1):32-45, The American Society for Pharmacology and Experimental Therapeutics, U.S.A.;;Luo, Y. et al., “Phagocytic efficacy of macrophage-like cells as a function of cell cycle and Fcy receptors (FcγR) and complement receptor (CR)3 expression”, Clinical and Experimental Immunology, 2006, 145:380-387, British Society for Immunology.;;Herter, S. et al., “Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity”, The Journal of Immunology, 2014, 192:2252-2260, The American Association of Immunologists, Inc., Rockville, Maryland.;;Mayor, S. et al., “Pathways of clathrin-independent endocytosis”, Nature Reviews, Aug. 2007, 8:603-612, Nature Publishing Group.;;Oh, P. et al., “Dynamin at the Neck of Caveolae Mediates Their Budding to Form Transport Vesicles by GTP-driven Fission from the Plasma Membrane of Endothelium”, The Journal of Cell Biology, Apr. 6, 1998, 141(1):101-114, The Rockefeller University Press.;;Parton, R.G. et al., “The multiple faces of caveolae”, Nature Reviews, Mar. 2007, 8:185-194, Nature Publishing Group.;;Mellman, I., “Endocytosis and Molecular Sorting”, Annu. Rev. Cell Dev. Biol., 1996, 12:575-625, Annual Reviews, Inc.;;Hopkins, C.R. et al., “Internalization and Processing of Transferrin and the Transferrin Receptor in Human Carcinoma A431 Cells”, The Journal of Cell Biology, Aug. 1983, 97:508-521, The Rockefeller University Press.;;He, K. et al., “Internalization of the TGF-β type I receptor into caveolin-1 and EEA1 double-positive early endosomes”, Cell Research, 2015, 25:738-752, IBCB, SIBS, CAS.;;Ganley, I.G. et al., “Rab9 GTPase Regulates Late Endosome Size and Requires Effector Interaction for Its Stability”, Molecular Biology of the Cell, Dec. 2004, 15:5420-5430, The American Society for Cell Biology.;;Nielsen, E. et al., “Rab5 regulates motility of early endosomes on microtubules”, Nature Cell Biology, Oct. 1999, 1:376-382.;;Barbero, P. et al., “Visualization of Rab9-mediated vesicle transport from endosomes to the trans-Golgi in living cells”, The Journal of Cell Biology, Feb. 4, 2002, 156(3):511-518, The Rockefeller University Press.;;Carlsson, S.R. et al., “Structure of Human Lysosomal Membrane Glycoprotein 1”, The Journal of Biological Chemistry, Dec. 5, 1989, 264(34):20526-20531, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A.;;Doherty, G.J. et al., “Mechanisms of Endocytosis”, Annu. Rev. Biochem., 2009, 78:857-902, Annual Reviews.;;Xiao, K. et al., “The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles”, Biomaterials, 2011, 32:3435-3446, Elsevier Ltd.;;Chinen, A.B. et al., “Relationships between Poly(ethylene glycol) Modifications on RNA-Spherical Nucleic Acid Conjugates and Cellular Uptake and Circulation Time”, Bioconjugate Chemistry, Oct. 20, 2016, 27:2715-2721, American Chemical Society.;;Arami, H. et al., “In vivo delivery, pharmacokinetics, biodistribution, and toxicity or iron oxide nanoparticles”, Chem. Soc. Rev., 2015, 44:8576-8607, The Royal Society of Chemistry.;;Choi, H.S. et al., “Renal clearance of quantum dots”, Nature Biotechnology, Oct. 2007, 25(10)1165-1170, Nature Publishing Group.;;Zuckerman, J.E. et al., “Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane”, PNAS, Feb. 21, 2012, 109(8):3137-3142.;;Choi, C.H.J. et al., “Targeting kidney mesangium by nanoparticles of defined size”, PNAS, Apr. 19, 2011, 108(16):6656-6661.;;Kimura, R.H. et al., “Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects”, Cancer Res, 2009, 69(6):2435-2442, American Association for Cancer Research.;;Kimura, R.H. et al., “A Dual-Labeled Knottin Peptide for PET and Near-Infrared Fluorescence Imaging of Integrin Expression in Living Subjects”, Bioconjugate Chem., 2010, 21:436-444, American Chemical Society.;;Knolle, P.A. et al., “Control of immune responses by scavenger liver endothelial cells”, Swiss Med Wkly, 2003, 133:501-506.;;Steffan, A. et al., “Phagocytosis, An Unrecognized Property of Murine Endothelial Liver Cells”, Hepatology, 1986, 6(5):830-836, The American Association for the Study of Liver Diseases, U.S.A.;;Shiratori, Y. et al., “Quantification of Sinusoidal Cell Function in Vivo”, Seminars in Liver Disease, 1992, 13(1):1-3, Thieme Medical Publishers, Inc. New York, NY.;;Elvevold, K. et al., “The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity”, Am J Physiol Gastroinest Liver Physiol, 2008, 294:G391-G400, the American Physiological Society.;;Smedsrød, B., “Clearance function of scavenger endothelial cells”, Comparative Hepatology, 2004, 3(Suppl I)S22:1-10, BioMed Central.;;Tsoi, K.M. et al., “Mechanism of hard-nanomaterial clearance by the liver”, Nature Materials, Nov. 2016, 15:1212-1221, Macmillan Publishers Limited.;;Moghadasian, M.H. et al., “Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans”, FASEB J., 2001, 15:2623-2630, FASEB.;;Schierwagen, R. et al., “Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis”, Scientific Reports, Aug. 11, 2015, 5(12931):1-14.;;Cole, A.J. et al., “Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles”, Biomaterials, 2011, 32:6291-6301, Elsevier Ltd.",ACTIVE
40,US,A1,US 2023/0060172 A1,060-135-722-194-930,2023-03-02,2023,US 202217811173 A,2022-07-07,US 202217811173 A;;US 202163219108 P,2021-07-07,PH-REVERSIBLE LEUCO-BODIPY PROBE FOR IN SITU VISUALIZATION OF EXTRACELLULAR VESICLES AND THEIR SECRETION FROM LIVING CELLS,"The subject invention pertains to compositions of a probe comprising two pH-reversible forms, including the boron dipyrromethene (BODIPY) fluorescent form and the non-fluorescent leuco-BODIPY form, for use in confocal imaging methods of intracellular vesicles as well as extracellular vesicles that are present in conditioned culture medium and/or secreted by living cells, without inducing severe cytotoxicity.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;LIU HANZHUANG,THE CHINESE UNIVERSITY OF HONG KONG (2023-03-25),https://lens.org/060-135-722-194-930,Patent Application,yes,0,0,1,1,0,C09K11/06;;C07F5/022;;C09B23/12;;G01N21/6486;;C07F5/022;;C09K2211/1055;;C09K11/06;;C09B57/00,G01N21/64;;C07F5/02;;C09B57/00;;C09K11/06,,0,0,,,,PENDING
41,US,B2,US 11576626 B2,072-095-229-012-891,2023-02-14,2023,US 201916573580 A,2019-09-17,US 201916573580 A;;US 201715800948 A;;US 201414254583 A;;US 201213656183 A,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/072-095-229-012-891,Granted Patent,yes,10,19,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06T19/00;;G16H50/30;;G16H50/50,,14,5,072-461-472-998-504;;000-458-203-788-147;;086-968-191-188-063;;091-380-822-838-24X;;077-721-721-379-510,17188928;;10.1016/j.ijmedinf.2006.11.006;;10.1016/s0933-3657(01)00077-x;;11470218;;10.1056/nejmoa0804626;;19228612;;19758907;;22562911,"Bellazzi, R. & Zupan, B. Predictive data mining in clinical medicine: current issues and guidelines. Int. J. Med. Inform. 77, 81-97 (2008).;;English-language translation of Notice of Final Rejection dated Jan. 6, 2016, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (2 pages).;;English-language translation of Notice of Preliminary Rejection dated Sep. 11, 2015, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (4 pages).;;English-language translation of Notice of Rejection dated May 30, 2016, in corresponding Japanese Patent Application No. 2015-537831, filed Oct. 17, 2013 (6 pages).;;Examiner's Report dated Jul. 15, 2015, in corresponding Canadian Patent Application No. 2,888,098, filed on Apr. 9, 2015 (4 pages).;;I. Kononenko, Machine learning for medical diagnosis: history, state of the art and perspective, Artif. Intell. Med. 23 (2001) 89-109.;;International Preliminary Report on Patentability dated Apr. 21, 2015, in corresponding International PCT Patent Application No. PCT/US2013/065495, filed on Oct. 17, 2013 (7 pages).;;International Search Report dated Feb. 7, 2014 in corresponding International Application No. PCT/US2013/065495.;;Patent Examination Report No. 1 dated Apr. 29, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 2 dated Jul. 31, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 3 dated Jan. 28, 2016, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Serruys et al., “Percutaneous Coronary Intervention versus Coronary-Artery Bypasss Grafting for Severe Coronary Artery Disease”, Mar. 5, 2009, pp. 961-972, vol. 360, No. 10, The New England Journal of Medicine (12 pages).;;Sianos, “The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,” 2005, EuroInterv. 2005; 1:219-227.;;Stahil, et al., “Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,” Apr. 26, 2012, J Invasive Cardiol., 24(5) 196-201.",ACTIVE
42,WO,A1,WO 2015/149074 A1,095-475-605-584-930,2015-10-01,2015,US 2015/0023391 W,2015-03-30,US 201461972137 P,2014-03-28,HYBRID FRAME SLEEVE CASE,"A sleeve case is for a portable electronic device (e.g., laptop computer or electronic tablet device) and includes neoprene panels attached to an elastic polymer frame, such as ethylene vinyl acetate (EVA). The elastic polymer frame extends around a perimeter of the sleeve to provide cushioning or padding for side edges of the sleeve. The sleeve has a magnetic opening on one side.",INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,,https://lens.org/095-475-605-584-930,Patent Application,yes,3,4,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45C11/00;;B65D85/00;;H05K5/00,,1,0,,,See also references of EP 3122203A4,PENDING
43,KR,A,KR 20150056866 A,105-936-233-823-207,2015-05-27,2015,KR 20157011241 A,2013-10-17,US 201213656183 A;;US 2013/0065495 W,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"환자에 대한 심혈관 스코어를 제공하는 시스템들 및 방법들이 개시된다. 방법은 적어도 하나의 컴퓨터 시스템을 사용하여, 환자의 다수의 관상 동맥들의 기하학 구조에 관한 환자 특정 데이터를 수신하는 단계; 및 적어도 하나의 컴퓨터 시스템을 사용하여, 환자 특정 데이터에 기초하여 다수의 관상 동맥들의 적어도 일부들을 나타내는 3차원 모델을 생성하는 단계를 포함한다. 방법은 또한 적어도 하나의 컴퓨터 시스템을 사용하여, 모델에 의해 표현되는 관상 동맥들의 적어도 일부의 다수의 특성들을 평가하는 단계; 및 적어도 하나의 컴퓨터 시스템을 사용하여, 다수의 특성들의 평가에 기초하여 심혈관 스코어를 생성하는 단계를 포함한다. 다른 방법은 적어도 미리 결정된 임계값의 분획 혈류 예비력 값들을 갖는 관상 동맥들의 일부들에 대한 평가된 다수의 특성들에 기초하여 심혈관 스코어를 생성하는 단계를 포함한다.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GIL WOO,,https://lens.org/105-936-233-823-207,Patent Application,no,9,7,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;G06F19/00;;G06T7/00;;G06T19/00,,0,0,,,,ACTIVE
44,US,A1,US 2020/0069262 A1,138-397-726-522-557,2020-03-05,2020,US 201916573580 A,2019-09-17,US 201916573580 A;;US 201715800948 A;;US 201414254583 A;;US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/138-397-726-522-557,Patent Application,yes,0,40,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/03;;A61B5/02;;A61B5/026;;A61B6/00;;G06T19/00;;G16H50/50,,0,0,,,,ACTIVE
45,CN,A,CN 106170223 A,128-133-213-260-65X,2016-11-30,2016,CN 201580016915 A,2015-03-30,US 201461972137 P;;US 2015/0023391 W,2014-03-28,Hybrid frame sleeve case,"A sleeve case is for a portable electronic device (e.g., laptop computer or electronic tablet device) and includes neoprene panels attached to an elastic polymer frame, such as ethylene vinyl acetate (EVA). The elastic polymer frame extends around a perimeter of the sleeve to provide cushioning or padding for side edges of the sleeve. The sleeve has a magnetic opening on one side.",INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,,https://lens.org/128-133-213-260-65X,Patent Application,no,5,2,8,14,0,A45C11/00;;A45C2011/003;;Y10T29/49826;;G06F2200/1633;;A45C11/00;;A45C2011/003;;Y10T29/49826;;B65D81/22;;A45C13/002;;G06F1/1656,A45C11/00;;B65D85/00;;H05K5/00,,0,0,,,,DISCONTINUED
46,US,S,US D0831658 S,158-329-148-506-598,2018-10-23,2018,US 201629578417 F,2016-09-21,US 201629578417 F;;US 201529522409 F;;US 201514673495 A,2015-03-30,Sleeve case for electronic device,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/158-329-148-506-598,Design Right,no,47,6,3,3,0,,,1402;;D14/440,0,0,,,,ACTIVE
47,US,S,US D0849751 S,157-895-980-920-56X,2019-05-28,2019,US 201829661203 F,2018-08-24,US 201829661203 F;;US 201629578406 F;;US 201529522407 F;;US 201514673495 A,2015-03-30,Electronic device sleeve,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/157-895-980-920-56X,Design Right,no,8,2,3,3,0,,,1402;;D14/440,0,0,,,,ACTIVE
48,US,B2,US 9675301 B2,047-555-752-907-954,2017-06-13,2017,US 201213656183 A,2012-10-19,US 201213656183 A,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",FONTE TIMOTHY A;;TANG JONATHAN;;CHOI GILWOO;;HEARTFLOW INC,FONTE TIMOTHY A;;TANG JONATHAN;;CHOI GILWOO,HEARTFLOW INC (2013-11-04),https://lens.org/047-555-752-907-954,Granted Patent,yes,9,30,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06F19/00;;G06T19/00,,14,5,077-721-721-379-510;;091-380-822-838-24X;;086-968-191-188-063;;072-461-472-998-504;;000-458-203-788-147,22562911;;19758907;;10.1056/nejmoa0804626;;19228612;;17188928;;10.1016/j.ijmedinf.2006.11.006;;10.1016/s0933-3657(01)00077-x;;11470218,"Stahil, et al., “Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,” Apr. 26, 2012, J Invasive Cardiol., 24(5) 196-201.;;Sianos, “The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,” 2005, EuroInterv. 2005; 1:219-227.;;Serruys, et al. “Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease,” Mar. 4, 2009, N Engl J Med, vol. 360, No. 10, pp. 961-972.;;Bellazzi, R. & Zupan, B. Predictive data mining in clinical medicine: current issues and guidelines. Int. J. Med. Inform. 77, 81-97 (2008).;;I. Kononenko, Machine learning for medical diagnosis: history, state of the art and perspective, Artif. Intell. Med. 23 (2001) 89-109.;;International Search Report issued in corresponding International Application No. PCT/US2013/065495, mailed Feb. 7, 2014.;;International Preliminary Report on Patentability mailed on Apr. 21, 2015, in corresponding International PCT Patent Application No. PCT/US2013/065495, filed on Oct. 17, 2013 (7 pages).;;Patent Examination Report No. 1 mailed on Apr. 29, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 2 mailed on Jul. 31, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 3 mailed on Jan. 28, 2016, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Examiner's Report mailed on Jul. 15, 2015, in corresponding Canadian Patent Application No. 2,888,098, filed on Apr. 9, 2015 (4 pages).;;English-language translation of Notice of Preliminary Rejection mailed on Sep. 11, 2015, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (4 pages).;;English-language translation of Notice of Final Rejection mailed on Jan. 6, 2016, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (2 pages).;;English-language translation of Notice of Rejection mailed on May 30, 2016, in corresponding Japanese Patent Application No. 2015-537831, filed Oct. 17, 2013 (6 pages).",ACTIVE
49,EP,A1,EP 3122203 A1,072-585-333-705-315,2017-02-01,2017,EP 15768376 A,2015-03-30,US 201461972137 P;;US 2015/0023391 W,2014-03-28,HYBRID FRAME SLEEVE CASE,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,,https://lens.org/072-585-333-705-315,Patent Application,yes,0,0,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45C11/00;;B65D85/00;;H05K5/00,,0,0,,,,DISCONTINUED
50,US,A1,US 2014/0114618 A1,105-728-101-523-847,2014-04-24,2014,US 201213656183 A,2012-10-19,US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",FONTE TIMOTHY A;;TANG JONATHAN;;CHOI GILWOO,FONTE TIMOTHY A;;TANG JONATHAN;;CHOI GILWOO,HEARTFLOW INC (2013-11-04),https://lens.org/105-728-101-523-847,Patent Application,yes,2,48,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,G06F19/00,703/1,5,5,077-721-721-379-510;;091-380-822-838-24X;;086-968-191-188-063;;072-461-472-998-504;;000-458-203-788-147,22562911;;19758907;;10.1056/nejmoa0804626;;19228612;;17188928;;10.1016/j.ijmedinf.2006.11.006;;10.1016/s0933-3657(01)00077-x;;11470218,"Stahil, et al., ""Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,"" April 26, 2012, J Invasive Cardiol., 24(5) 196-201.;;Sianos, ""The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,"" 2005, EuroInterv. 2005; 1:219-227.;;Serruys, et al. ""Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease,"" March 4, 2009, N Engl J Med, Vol 360, No. 10, pp. 961-972.;;Bellazzi, R. & Zupan, B. Predictive data mining in clinical medicine: current issues and guidelines. Int. J. Med. Inform. 77, 81â97 (2008).;;I. Kononenko, Machine learning for medical diagnosis: history, state of the art and perspective, Artif. Intell. Med. 23 (2001) 89â109.",ACTIVE
51,US,B2,US 9839399 B2,010-498-724-823-736,2017-12-12,2017,US 201414254583 A,2014-04-16,US 201414254583 A;;US 201213656183 A,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,,https://lens.org/010-498-724-823-736,Granted Patent,yes,9,52,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06F19/00;;G06T19/00,,12,3,077-721-721-379-510;;091-380-822-838-24X;;086-968-191-188-063,22562911;;19758907;;10.1056/nejmoa0804626;;19228612,"Stahil, et al., “Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,” Apr. 26, 2012, J Invasive Cardiol., 24(5) 196-201.;;International Search Report issued in corresponding International Application No. PCT/US2013/065495, dated Feb. 7, 2014.;;International Preliminary Report on Patentability mailed on Apr. 21, 2015, in corresponding International PCT Patent Application No. PCT/US2013/065495, filed on Oct. 17, 2013 (7 pages).;;Patent Examination Report No. 1 mailed on Apr. 29, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 2 mailed on Jul. 31, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 3 mailed on Jan. 28, 2016, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Examiner's Report mailed on Jul. 15, 2015, in corresponding Canadian Patent Application No. 2,888,098, filed on Apr. 9, 2015 (4 pages).;;English-language translation of Notice of Preliminary Rejection mailed on Sep. 11, 2015, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (4 pages).;;English-language translation of Notice of Final Rejection mailed on Jan. 6, 2016, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (2 pages).;;Sianos et al., “The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease”, 2005, pp. 219-227, vol. 1, EuroIntervention (9 pages).;;Serruys et al., “Percutaneous Coronary Intervention versus Coronary-Artery Bypasss Grafting for Severe Coronary Artery Disease”, Mar. 5, 2009, pp. 961-972, vol. 360, No. 10, The New England Journal of Medicine (12 pages).;;English-language translation of Notice of Rejection dated May 30, 2016, in corresponding Japanese Patent Application No. 2015-537831, filed Oct. 17, 2013 (6 pages).",ACTIVE
52,US,B2,US 9642428 B2,015-775-802-634-047,2017-05-09,2017,US 201514673495 A,2015-03-30,US 201514673495 A;;US 201461972137 P,2014-03-28,Hybrid frame sleeve case,"A sleeve case is for a portable electronic device (e.g., laptop computer or electronic tablet device) and includes neoprene or fabric panels attached to an elastic polymer frame, such as ethylene vinyl acetate (EVA). The elastic polymer frame extends around a perimeter of the sleeve to provide cushioning or padding for side edges of the sleeve. A magnetic or other latching mechanism is used to secure an opening on one side of the sleeve.",INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/015-775-802-634-047,Granted Patent,yes,4,5,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45C11/00,,1,0,,,"Internation Search Report and Written Opinion, PCT Application PCT/US2015/023391, Jul. 28, 2015, 10 pages.",ACTIVE
53,US,A1,US 2023/0148977 A1,170-751-494-933-363,2023-05-18,2023,US 202318150217 A,2023-01-05,US 202318150217 A;;US 201916573580 A;;US 201715800948 A;;US 201414254583 A;;US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/170-751-494-933-363,Patent Application,yes,0,7,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/03;;A61B5/02;;A61B5/026;;A61B6/00;;G06T19/00;;G16H50/50,,0,0,,,,PENDING
54,US,S,US D0848439 S,189-180-338-807-414,2019-05-14,2019,US 201829664027 F,2018-09-20,US 201829664027 F;;US 201629578417 F;;US 201529522409 F;;US 201514673495 A,2015-03-30,Electronic device sleeve,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/189-180-338-807-414,Design Right,no,8,2,3,3,0,,,1402;;D14/440,0,0,,,,ACTIVE
55,US,S,US D0775628 S,162-285-467-404-276,2017-01-03,2017,US 201529522407 F,2015-03-30,US 201529522407 F;;US 201514673495 A,2015-03-30,Sleeve case for electronic device,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/162-285-467-404-276,Design Right,no,0,13,3,3,0,,,1402;;D14/440,0,0,,,,ACTIVE
56,CN,A,CN 104736046 A,148-469-994-341-659,2015-06-24,2015,CN 201380054648 A,2013-10-17,US 2013/0065495 W;;US 201213656183 A,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GIL-WOO,,https://lens.org/148-469-994-341-659,Patent Application,no,5,12,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B6/00;;G06F19/00;;G06T19/00,,0,0,,,,ACTIVE
57,US,S,US D0776120 S,169-001-639-102-459,2017-01-10,2017,US 201529522409 F,2015-03-30,US 201529522409 F;;US 201514673495 A,2015-03-30,Sleeve case for electronic device,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-04-20),https://lens.org/169-001-639-102-459,Design Right,no,0,14,3,3,0,,,1402;;D14/440,0,0,,,,ACTIVE
58,US,S,US D0827651 S,012-726-434-068-378,2018-09-04,2018,US 201629578406 F,2016-09-21,US 201629578406 F;;US 201529522407 F;;US 201514673495 A,2015-03-30,Sleeve case for electronic device,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/012-726-434-068-378,Design Right,no,0,8,3,3,0,,,1402;;D14/440,0,0,,,,ACTIVE
59,US,A1,US 2005/0251062 A1,059-855-228-040-354,2005-11-10,2005,US 12424605 A,2005-05-06,US 12424605 A;;US 56954904 P,2004-05-10,Iterative approach for applying multiple currents to a body using voltage sources in electrical impedance tomography,Voltage sources produce desired current patterns in an ACT-type Electrical Impedance Tomography (EIT) system. An iterative adaptive algorithm generates the necessary voltage pattern that will result in the desired current pattern. The convergence of the algorithm is shown under the condition that the estimation error of the linear mapping from voltage to current is small. The simulation results are presented along with the implication of the convergence condition.,CHOI MYOUNG;;ISAACSON DAVID;;NEWELL JONATHAN C,CHOI MYOUNG;;ISAACSON DAVID;;NEWELL JONATHAN C,RENSSELAER POLYTECHNIC INSTITTUTE (2005-05-06),https://lens.org/059-855-228-040-354,Patent Application,yes,4,29,1,1,0,A61B5/0536;;A61B5/0536,A61B5/05;;A61B5/053,600/547,0,0,,,,DISCONTINUED
60,US,S,US D0507681 S,089-261-845-868-843,2005-07-19,2005,US 18550203 F,2003-06-26,US 18550203 F,2003-06-26,Handle for a double-sided grooming tool,,JW PET CO INC,CHOI YOON HO;;WOLTMANN KLAUS;;WILLINGER JONATHAN,DOSKOCIL MANUFACTURING COMPANY INC (2014-07-03);;JW PET COMPANY INC (2003-07-29),https://lens.org/089-261-845-868-843,Design Right,no,0,2,1,1,0,,,3099;;D30/158;;D4/138,0,0,,,,EXPIRED
61,EP,A4,EP 3122203 A4,099-543-480-104-186,2018-01-03,2018,EP 15768376 A,2015-03-30,US 201461972137 P;;US 2015/0023391 W,2014-03-28,HYBRID FRAME SLEEVE CASE,,INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,,https://lens.org/099-543-480-104-186,Search Report,no,5,0,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45C11/00;;B65D85/00;;H05K5/00,,1,0,,,See also references of WO 2015149074A1,DISCONTINUED
62,US,A1,US 2014/0303510 A1,083-017-752-626-543,2014-10-09,2014,US 201414254583 A,2014-04-16,US 201414254583 A;;US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,,https://lens.org/083-017-752-626-543,Patent Application,yes,1,8,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,G06F19/00;;A61B5/026,600/504;;600/481,0,0,,,,ACTIVE
63,US,S,US D0492300 S,199-287-297-215-326,2004-06-29,2004,US 19061703 F,2003-09-24,US 19061703 F,2003-09-24,Face plate for a radio telephone,,MOTOROLA INC,LEE KIO;;CHOE JONATHAN;;CHOI YOON HO,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2003-12-12),https://lens.org/199-287-297-215-326,Design Right,no,0,3,1,1,0,,,D14/248,0,0,,,,EXPIRED
64,US,B2,US 10820674 B2,143-731-599-005-099,2020-11-03,2020,US 201715497000 A,2017-04-25,US 201715497000 A;;US 201514673495 A;;US 201461972137 P,2014-03-28,Hybrid frame sleeve case,"A sleeve case is for a portable electronic device (e.g., laptop computer or electronic tablet device) and includes neoprene or fabric panels attached to an elastic polymer frame, such as ethylene vinyl acetate (EVA). The elastic polymer frame extends around a perimeter of the sleeve to provide cushioning or padding for side edges of the sleeve. A magnetic or other latching mechanism is used to secure an opening on one side of the sleeve.",INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/143-731-599-005-099,Granted Patent,yes,21,2,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45C11/00;;A45C13/00;;B65D81/22;;G06F1/16,,3,0,,,"International Search Report, PCT Application PCT/US2015/023391, dated Jul. 28, 2015.;;Written Opinion, PCT Application PCT/US2015/023391, dated Jul. 28, 2015.;;Extended European Search Report, EP15768376.4, dated Dec. 6, 2017.",ACTIVE
65,US,A1,US 2014/0303495 A1,017-081-201-132-435,2014-10-09,2014,US 201414254621 A,2014-04-16,US 201414254621 A;;US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/017-081-201-132-435,Patent Application,yes,1,30,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/03;;A61B6/00,600/425,1,1,077-721-721-379-510,22562911,"Stahil, et al., ""Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,"" April 26, 2012, J Invasive Cardiol., 24(5) 196-201.",ACTIVE
66,US,B2,US 9585623 B2,064-265-604-088-564,2017-03-07,2017,US 201414254621 A,2014-04-16,US 201414254621 A;;US 201213656183 A,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/064-265-604-088-564,Granted Patent,yes,9,22,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/02;;A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06F19/00;;G06T19/00,,12,3,077-721-721-379-510;;091-380-822-838-24X;;086-968-191-188-063,22562911;;19758907;;10.1056/nejmoa0804626;;19228612,"Stahil, et al., ""Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,"" Apr. 26, 2012, J Invasive Cardiol., 24(5) 196-201.;;International Search Report issued in corresponding International Application No. PCT/US2013/065495, mailed Feb. 7, 2014.;;International Preliminary Report on Patentability mailed on Apr. 21, 2015, in corresponding International PCT Patent Application No. PCT/US2013/065495, filed on Oct. 17, 2013 (7 pages).;;Patent Examination Report No. 1 mailed on Apr. 29, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 2 mailed on Jul. 31, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 3 mailed on Jan. 28, 2016, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Examiner's Report mailed on Jul. 15, 2015, in corresponding Canadian Patent Application No. 2,888,098, filed on Apr. 9, 2015 (4 pages).;;English-language translation of Notice of Preliminary Rejection mailed on Sep. 11, 2015, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (4 pages).;;English-language translation of Notice of Final Rejection mailed on Jan. 6, 2016, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (2 pages).;;Sianos et al., ""The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease"", 2005, pp. 219-227, vol. 1, EuroIntervention (9 pages).;;Serruys et al., ""Percutaneous Coronary Intervention versus Coronary-Artery Bypasss Grafting for Severe Coronary Artery Disease"", Mar. 5, 2009, pp. 961-972, vol. 360, No. 10, The New England Journal of Medicine (12 pages).;;English-language translation of Notice of Rejection mailed on May 30, 2016, in corresponding Japanese Patent Application No. 2015-537831, filed Oct. 17, 2013 (6 pages).",ACTIVE
67,US,A1,US 2015/0272303 A1,099-950-848-117-259,2015-10-01,2015,US 201514673495 A,2015-03-30,US 201514673495 A;;US 201461972137 P,2014-03-28,Hybrid Frame Sleeve Case,"A sleeve case is for a portable electronic device (e.g., laptop computer or electronic tablet device) and includes neoprene or fabric panels attached to an elastic polymer frame, such as ethylene vinyl acetate (EVA). The elastic polymer frame extends around a perimeter of the sleeve to provide cushioning or padding for side edges of the sleeve. A magnetic or other latching mechanism is used to secure an opening on one side of the sleeve.",INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/099-950-848-117-259,Patent Application,yes,1,13,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45F5/00;;A45C11/00,,0,0,,,,ACTIVE
68,US,A1,US 2017/0224075 A1,127-600-043-270-700,2017-08-10,2017,US 201715497000 A,2017-04-25,US 201715497000 A;;US 201514673495 A;;US 201461972137 P,2014-03-28,Hybrid Frame Sleeve Case,"A sleeve case is for a portable electronic device (e.g., laptop computer or electronic tablet device) and includes neoprene or fabric panels attached to an elastic polymer frame, such as ethylene vinyl acetate (EVA). The elastic polymer frame extends around a perimeter of the sleeve to provide cushioning or padding for side edges of the sleeve. A magnetic or other latching mechanism is used to secure an opening on one side of the sleeve.",INCASE DESIGNS CORP,BROWN JONATHAN;;HONG HYUN;;CHOI ALLEN MIN,VINCI BRANDS LLC (2021-08-06);;INCASE DESIGNS CORP (2015-08-21),https://lens.org/127-600-043-270-700,Patent Application,yes,9,2,8,14,0,A45C11/00;;A45C11/00;;A45C13/002;;A45C2011/003;;A45C2011/003;;B65D81/22;;G06F1/1656;;G06F2200/1633;;Y10T29/49826;;Y10T29/49826,A45C11/00;;G06F1/16,,0,0,,,,ACTIVE
69,US,B2,US 10456094 B2,166-841-040-869-971,2019-10-29,2019,US 201715800948 A,2017-11-01,US 201715800948 A;;US 201414254583 A;;US 201213656183 A,2012-10-19,Systems and methods for numerically evaluating vasculature,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/166-841-040-869-971,Granted Patent,yes,9,45,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/02;;A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06T19/00;;G16H50/30;;G16H50/50,,14,5,072-461-472-998-504;;000-458-203-788-147;;086-968-191-188-063;;091-380-822-838-24X;;077-721-721-379-510,17188928;;10.1016/j.ijmedinf.2006.11.006;;10.1016/s0933-3657(01)00077-x;;11470218;;10.1056/nejmoa0804626;;19228612;;19758907;;22562911,"Bellazzi, R. & Zupan, B. Predictive data mining in clinical medicine: current issues and guidelines. Int. J. Med. Inform. 77, 81-97 (2008).;;English-language translation of Notice of Final Rejection dated Jan. 6, 2016, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (2 pages).;;English-language translation of Notice of Preliminary Rejection dated Sep. 11, 2015, in corresponding Korean Patent Application No. 10-2015-7011241, filed on Apr. 29, 2015 (4 pages).;;English-language translation of Notice of Rejection dated May 30, 2016, in corresponding Japanese Patent Application No. 2015-537831, filed Oct. 17, 2013 (6 pages).;;Examiner's Report dated Jul. 15, 2015, in corresponding Canadian Patent Application No. 2,888,098, filed on Apr. 9, 2015 (4 pages).;;I. Kononenko, Machine learning for medical diagnosis: history, state of the art and perspective, Artif. Intell. Med. 23 (2001) 89-109.;;International Preliminary Report on Patentability dated Apr. 21, 2015, in corresponding International PCT Patent Application No. PCT/US2013/065495, filed on Oct. 17, 2013 (7 pages).;;International Search Report dated Feb. 7, 2014 in corresponding International Application No. PCT/US2013/065495.;;Patent Examination Report No. 1 dated Apr. 29, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 2 dated Jul. 31, 2015, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Patent Examination Report No. 3 dated Jan. 28, 2016, in corresponding Australian Patent Application No. 2013331213, filed on Apr. 17, 2015 (3 pages).;;Serruys et al., “Percutaneous Coronary Intervention versus Coronary-Artery Bypasss Grafting for Severe Coronary Artery Disease”, Mar. 5, 2009, pp. 961-972, Vol. 360, No. 10, The New England Journal of Medicine (12 pages).;;Sianos, “The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,” 2005, EuroInterv. 2005; 1:219-227.;;Stahil, et al., “Coronary Computed Tomography Angiography Indicates Complexity of Percutaneous Coronary Interventions,” Apr. 26, 2012, J Invasive Cardiol., 24(5) 196-201.",ACTIVE
70,US,A1,US 2018/0049705 A1,100-909-409-881-166,2018-02-22,2018,US 201715800948 A,2017-11-01,US 201715800948 A;;US 201414254583 A;;US 201213656183 A,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"Systems and methods are disclosed for providing a cardiovascular score for a patient. A method includes receiving, using at least one computer system, patient-specific data regarding a geometry of multiple coronary arteries of the patient; and creating, using at least one computer system, a three-dimensional model representing at least portions of the multiple coronary arteries based on the patient-specific data. The method also includes evaluating, using at least one computer system, multiple characteristics of at least some of the coronary arteries represented by the model; and generating, using at least one computer system, the cardiovascular score based on the evaluation of the multiple characteristics. Another method includes generating the cardiovascular score based on evaluated multiple characteristics for portions of the coronary arteries having fractional flow reserve values of at least a predetermined threshold value.",HEARTFLOW INC,FONTE TIMOTHY A;;CHOI GILWOO;;TANG JONATHAN,HEARTFLOW INC (2013-11-04),https://lens.org/100-909-409-881-166,Patent Application,yes,0,1,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B6/03;;A61B5/02;;A61B6/00;;G06F19/00;;G06T19/00,,0,0,,,,ACTIVE
71,KR,A,KR 20160045916 A,143-654-686-605-176,2016-04-27,2016,KR 20167009595 A,2013-10-17,US 201213656183 A;;KR 20157011241 A;;US 2013/0065495 W,2012-10-19,SYSTEMS AND METHODS FOR NUMERICALLY EVALUATING VASCULATURE,"환자에 대한 심혈관 스코어를 제공하는 시스템들 및 방법들이 개시된다. 방법은 적어도 하나의 컴퓨터 시스템을 사용하여, 환자의 다수의 관상 동맥들의 기하학 구조에 관한 환자 특정 데이터를 수신하는 단계; 및 적어도 하나의 컴퓨터 시스템을 사용하여, 환자 특정 데이터에 기초하여 다수의 관상 동맥들의 적어도 일부들을 나타내는 3차원 모델을 생성하는 단계를 포함한다. 방법은 또한 적어도 하나의 컴퓨터 시스템을 사용하여, 모델에 의해 표현되는 관상 동맥들의 적어도 일부의 다수의 특성들을 평가하는 단계; 및 적어도 하나의 컴퓨터 시스템을 사용하여, 다수의 특성들의 평가에 기초하여 심혈관 스코어를 생성하는 단계를 포함한다. 다른 방법은 적어도 미리 결정된 임계값의 분획 혈류 예비력 값들을 갖는 관상 동맥들의 일부들에 대한 평가된 다수의 특성들에 기초하여 심혈관 스코어를 생성하는 단계를 포함한다.",HEARTFLOW INC,FONTE TIMOTHY;;TANG JONATHAN;;CHOI GIL WOO,,https://lens.org/143-654-686-605-176,Patent Application,no,1,1,34,34,0,G16H50/50;;A61B5/02007;;A61B5/026;;A61B6/507;;G06T19/00;;G16H50/30;;G06T2210/41;;A61B6/504;;A61B8/0891;;A61B5/055;;A61B2576/023;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B5/02007;;A61B5/026;;A61B6/032;;A61B6/481;;A61B6/5205;;A61B2576/023;;A61B5/055;;A61B8/0891;;G16H50/50;;G06T19/00;;G06T2210/41;;A61B6/504;;A61B5/02007;;A61B5/026;;A61B2576/023;;G06T19/00;;G06T2210/41;;A61B8/0891;;A61B5/055;;A61B6/507;;G16H50/30;;G16H50/50;;Y02A90/10;;A61B6/032;;A61B6/481;;A61B6/5205,A61B5/026;;A61B5/055;;A61B6/00;;A61B6/03;;A61B8/08;;G06F19/00;;G06T19/00,,0,0,,,,ACTIVE
72,US,S,US D0519479 S,078-555-833-266-540,2006-04-25,2006,US 21829104 F,2004-11-30,US 21829104 F,2004-11-30,Radio telephone,,MOTOROLA INC,KOO JA SUNG;;CHOE JONATHAN;;CHOI YOON HO,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2004-11-26),https://lens.org/078-555-833-266-540,Design Right,no,0,6,1,1,0,,,1403;;D14/138,0,0,,,,EXPIRED
73,EP,A1,EP 3629903 A1,051-596-569-196-125,2020-04-08,2020,EP 18809757 A,2018-06-01,US 201762514468 P;;US 2018/0035691 W,2017-06-02,EPIDERMAL MICROFLUIDIC SENSOR FOR SWEAT COLLECTION AND ANALYSIS FROM AQUATIC ATHLETES,,UNIV NORTHWESTERN,ROGERS JOHN A;;CHOI JUNGIL;;REEDER JONATHAN T,,https://lens.org/051-596-569-196-125,Patent Application,yes,0,0,8,33,0,G01N33/54366;;G01N33/6881;;A61B5/6833;;A61B5/14517;;A61B2503/10;;A61B2562/164;;B01L3/502707;;B01L3/502723;;B01L2200/142;;B01L2300/0816;;B01L2300/0883;;B01L2300/123;;B01L2400/0406;;B01L2300/0654;;B01L2300/0663;;B01L2300/027;;B01L2300/022;;A61B10/0064;;A61B5/14517;;A61B5/6833;;A61B2503/10;;A61B2562/164;;C12M23/16;;G01N33/54366;;G01N33/6881;;A61B5/0002,A61B5/00;;A61B5/145;;G01N33/50,,0,0,,,,DISCONTINUED
74,US,A1,US 2023/0317287 A1,003-108-652-011-359,2023-10-05,2023,US 202318130320 A,2023-04-03,US 202318130320 A;;US 201916421368 A;;US 201862676245 P,2018-05-24,MACHINE LEARNING SYSTEM AND METHOD FOR PET HEALTH RECORDS,"A pet medical text recognizer may include one or more machine learning classifiers. The one or more machine learning classifiers may be trained using training data to associate raw text with pet clinical event codes. A performance metric may be provided, and the highest performing classifier according to the performance metric may be selected as the model for the pet medical text recognizer. The pet medical text recognizer may accept input text from a veterinary practice management system and generate a pet clinical event code for the text. A set of codes associated with a single pet may be aggregated into a pet health record.",SNOUT INC,DONG EMILY;;OZDEMIR SINAN;;CHOI ERIC;;LEVINE JONATHAN,,https://lens.org/003-108-652-011-359,Patent Application,yes,2,0,3,3,0,G16H10/60;;G16H40/20;;G06F40/284;;G06N20/20;;G06N20/10;;G06N7/01;;G06N3/044;;G16H50/20;;G06N3/08;;G06F40/284;;A61B5/7282;;G06N20/20;;G06F18/285,G16H50/20;;A61B5/00;;G06F18/20;;G06N3/08;;G06N20/20,,0,0,,,,PENDING
75,WO,A1,WO 2018/223058 A1,146-518-156-545-498,2018-12-06,2018,US 2018/0035691 W,2018-06-01,US 201762514468 P,2017-06-02,EPIDERMAL MICROFLUIDIC SENSOR FOR SWEAT COLLECTION AND ANALYSIS FROM AQUATIC ATHLETES,"Provided herein are epidermal microfluidic systems and methods that allow for the collection of biofluids in a wet or aquatic environment, for example, from the surface of the skin. The described systems allow for the efficient collection of biofluids, without loss of the biofluid to the surrounding environment or introduction of extraneous liquids from the environment. The described microfluidic systems are versatile and can provide information regarding a number of biofluid properties both electronically and colorimetrically/visually.",UNIV NORTHWESTERN,ROGERS JOHN A;;CHOI JUNGIL;;REEDER JONATHAN T,,https://lens.org/146-518-156-545-498,Patent Application,yes,5,9,8,33,0,G01N33/54366;;G01N33/6881;;A61B5/6833;;A61B5/14517;;A61B2503/10;;A61B2562/164;;B01L3/502707;;B01L3/502723;;B01L2200/142;;B01L2300/0816;;B01L2300/0883;;B01L2300/123;;B01L2400/0406;;B01L2300/0654;;B01L2300/0663;;B01L2300/027;;B01L2300/022;;A61B10/0064;;A61B5/14517;;A61B5/6833;;A61B2503/10;;A61B2562/164;;C12M23/16;;G01N33/54366;;G01N33/6881;;A61B5/0002,A61B5/00;;A61B5/145;;G01N33/50,,1,0,,,See also references of EP 3629903A4,PENDING
76,EP,A4,EP 3629903 A4,070-222-774-315-472,2021-09-01,2021,EP 18809757 A,2018-06-01,US 201762514468 P;;US 2018/0035691 W,2017-06-02,EPIDERMAL MICROFLUIDIC SENSOR FOR SWEAT COLLECTION AND ANALYSIS FROM AQUATIC ATHLETES,,UNIV NORTHWESTERN,ROGERS JOHN A;;CHOI JUNGIL;;REEDER JONATHAN T,,https://lens.org/070-222-774-315-472,Search Report,no,3,0,8,33,0,G01N33/54366;;G01N33/6881;;A61B5/6833;;A61B5/14517;;A61B2503/10;;A61B2562/164;;B01L3/502707;;B01L3/502723;;B01L2200/142;;B01L2300/0816;;B01L2300/0883;;B01L2300/123;;B01L2400/0406;;B01L2300/0654;;B01L2300/0663;;B01L2300/027;;B01L2300/022;;A61B10/0064;;A61B5/14517;;A61B5/6833;;A61B2503/10;;A61B2562/164;;C12M23/16;;G01N33/54366;;G01N33/6881;;A61B5/0002,A61B5/145;;A61B5/00;;B01L3/00;;G01N33/487;;G01N33/543,,4,3,005-500-952-231-299;;026-793-234-501-067;;026-793-234-501-067,pmc5429097;;10.1126/scitranslmed.aaf2593;;27881826;;28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355;;28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355,"AHYEON KOH ET AL: ""A soft, wearable microfluidic device for the capture, storage, and colorimetric sensing of sweat"", SCIENCE TRANSLATIONAL MEDICINE, 23 November 2016 (2016-11-23), United States, pages 366ra165 - 366ra165, XP055521314, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/8/366/366ra165> [retrieved on 20210119], DOI: 10.1126/scitranslmed.aaf2593;;JUNGIL CHOI ET AL: ""Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat"", ADVANCED HEALTHCARE MATERIALS, vol. 6, no. 5, 20 January 2017 (2017-01-20), DE, pages 1601355, XP055561869, ISSN: 2192-2640, DOI: 10.1002/adhm.201601355;;JUNGIL CHOI ET AL: ""Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat"", ADVANCED HEALTHCARE MATERIALS, vol. 6, no. 5, 20 January 2017 (2017-01-20), DE, pages 1601355, XP055766423, ISSN: 2192-2640, DOI: 10.1002/adhm.201601355;;See also references of WO 2018223058A1",DISCONTINUED
77,US,S,US D0506985 S,044-643-954-213-206,2005-07-05,2005,US 20161404 F,2004-03-18,US 20161404 F,2004-03-18,Housing for communication device or similar article,,MOTOROLA INC,KOO JA SUNG;;CHOE JONATHAN;;CHOI YOON HO,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2004-03-15),https://lens.org/044-643-954-213-206,Design Right,no,0,2,1,1,0,,,1403;;D14/138,0,0,,,,EXPIRED
78,US,A1,US 2019/0362847 A1,147-343-337-422-280,2019-11-28,2019,US 201916421368 A,2019-05-23,US 201916421368 A;;US 201862676245 P,2018-05-24,MACHINE LEARNING SYSTEM AND METHOD FOR PET HEALTH RECORDS,"A pet medical text recognizer may include one or more machine learning classifiers. The one or more machine learning classifiers may be trained using training data to associate raw text with pet clinical event codes. A performance metric may be provided, and the highest performing classifier according to the performance metric may be selected as the model for the pet medical text recognizer. The pet medical text recognizer may accept input text from a veterinary practice management system and generate a pet clinical event code for the text. A set of codes associated with a single pet may be aggregated into a pet health record.",PAWPRINT INC,DONG EMILY;;OZDEMIR SINAN;;CHOI ERIC;;LEVINE JONATHAN,SNOUT INC (2019-05-20),https://lens.org/147-343-337-422-280,Patent Application,yes,2,6,3,3,0,G16H10/60;;G16H40/20;;G06F40/284;;G06N20/20;;G06N20/10;;G06N7/01;;G06N3/044;;G16H50/20;;G06N3/08;;G06F40/284;;A61B5/7282;;G06N20/20;;G06F18/285,G16H50/20;;G06N3/08,,0,0,,,,ACTIVE
79,KR,A,KR 20210085487 A,175-483-727-239-529,2021-07-08,2021,KR 20190178558 A,2019-12-30,KR 20190178558 A,2019-12-30,Metasurface autoencoder-based communication system,"The present invention relates to a metasurface communication system using an auto-encoder, which comprises: a transmission unit receiving a comparison value between a signal transmitted from the transmission unit through a matrix of complex numbers and a channel and a signal received from a reception unit to generate a coding pattern by using an artificial neural network-based encoder; the channel consisting of a metasurface and a signal source to apply the coding pattern generated by the transmission unit and adjusting an angle between the signal source and the metasurface to accurately reflect the signal to the transmission unit; and the reception unit consisting of a plurality of receiving antennas, extracting the channel from the received signals, and transmitting the extracted channel as an input value of the transmission unit to learn a coding pattern more suitable for the current communication system. According to the present invention, an encoder adjusting a metasurface can learn from more data as communication progresses, thereby ultimately generating a coding pattern optimized for a communication environment.",RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV,CHOI KAE WON;;HARDI JONATHAN;;KIM JI SU,,https://lens.org/175-483-727-239-529,Patent Application,no,0,0,1,1,0,H04L1/0009;;H04L1/0015;;H04L1/06;;G06N3/02;;H04B7/0617,H04L1/00;;G06N3/02;;H04B7/06;;H04L1/06,,0,0,,,,PENDING
80,WO,A1,WO 2022/221454 A1,071-176-929-841-496,2022-10-20,2022,US 2022/0024689 W,2022-04-13,US 202163174402 P,2021-04-13,SYSTEMS AND METHODS FOR PROVIDING TACTILE FEEDBACK TO A USER,"A system for providing tactile feedback to a user includes a device comprising a touch surface to be touched by the user, one or more thermal elements distributed across the touch surface of the device and configured to heat the touch surface and thereby modulate the friction between the user's skin and the touch surface, and a controller connected to the one or more thermal elements and configured to control the operation of the one or more thermal elements to provide a plurality of predefined temperature distributions across the touch surface.",TEXAS A & M UNIV SYS,CHOI CHANGHYUN;;HIPWELL MARY;;MA YUAN;;FELTS JONATHAN,,https://lens.org/071-176-929-841-496,Patent Application,yes,5,0,1,1,0,G06F3/016;;G06F3/041,G06F3/01;;G06F3/041,,0,0,,,,PENDING
81,US,B2,US 11621076 B2,190-679-487-441-522,2023-04-04,2023,US 201916421368 A,2019-05-23,US 201916421368 A;;US 201862676245 P,2018-05-24,Machine learning system and method for pet health records,"A pet medical text recognizer may include one or more machine learning classifiers. The one or more machine learning classifiers may be trained using training data to associate raw text with pet clinical event codes. A performance metric may be provided, and the highest performing classifier according to the performance metric may be selected as the model for the pet medical text recognizer. The pet medical text recognizer may accept input text from a veterinary practice management system and generate a pet clinical event code for the text. A set of codes associated with a single pet may be aggregated into a pet health record.",PAWPRINT INC;;SNOUT INC,DONG EMILY;;OZDEMIR SINAN;;CHOI ERIC;;LEVINE JONATHAN,SNOUT INC (2020-07-07);;SCOUTVET INC (2019-05-20),https://lens.org/190-679-487-441-522,Granted Patent,yes,4,0,3,3,0,G16H10/60;;G16H40/20;;G06F40/284;;G06N20/20;;G06N20/10;;G06N7/01;;G06N3/044;;G16H50/20;;G06N3/08;;G06F40/284;;A61B5/7282;;G06N20/20;;G06F18/285,G06E1/00;;A61B5/00;;G06F40/284;;G06N3/08;;G06N20/20;;G16H50/20,,0,0,,,,ACTIVE
82,US,S,US D0734653 S,101-222-991-838-408,2015-07-21,2015,US 201229436820 F,2012-11-09,US 201229436820 F,2012-11-09,AC module mounting bracket,,ENPHASE ENERGY INC,MARTIN ANTHONY CHARLES;;CHOI HO GENE;;YIP JONATHAN,ENPHASE ENERGY INC (2012-11-08),https://lens.org/101-222-991-838-408,Design Right,no,0,9,1,1,0,,,0808;;D 8349,0,0,,,,ACTIVE
83,US,A1,US 2015/0214964 A1,047-117-886-780-602,2015-07-30,2015,US 201514596779 A,2015-01-14,US 201514596779 A;;US 201461932971 P,2014-01-29,Multi-Clock Generation Through Phase Locked Loop (PLL) Reference,"A circuit for providing a plurality of clock signals of differing frequencies includes: a phase locked loop section including a first voltage controller oscillator, connected to receive a reference clock value and generate therefrom a first voltage level, wherein the first voltage controller oscillator receives the first voltage level and generates therefrom a first clock signal; and one or more second voltage controller oscillators, each connected to receive the first voltage level, a corresponding trim value and a corresponding control voltage and derive therefrom a corresponding second clock signal.",SANDISK TECHNOLOGIES INC,HUYNH JONATHAN;;WANG SUNG-EN;;CHOI STEVE;;PARK JONGMIN,SANDISK TECHNOLOGIES LLC (2015-01-12),https://lens.org/047-117-886-780-602,Patent Application,yes,5,5,2,2,0,G11C16/30;;G11C16/30;;G11C5/145;;G11C5/145;;H03L7/0891;;H03L7/0891,H03L7/085;;G11C7/22;;G11C16/32,,0,0,,,,ACTIVE
84,US,S,US D0932628 S,143-167-181-664-949,2021-10-05,2021,US 201829634021 F,2018-01-17,US 201829634021 F,2018-01-17,Instrument cart,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;CHOI WONBIN,MATTER LLC (2018-05-09);;AURIS HEALTH INC (2018-05-21),https://lens.org/143-167-181-664-949,Design Right,no,167,4,4,4,0,,,2402;;D24/185,0,0,,,,ACTIVE
85,EP,B1,EP 0404931 B1,136-388-795-716-200,1993-09-01,1993,EP 90902492 A,1990-01-10,US 29611289 A,1989-01-12,CONVERSION OF OLEFINS TO ETHERS,,MOBIL OIL CORPORATION,"CHILD, JONATHAN, EDWARD;;CHOI, BYUNG, CHAN;;RAGONESE, FRANCIS, PAUL",,https://lens.org/136-388-795-716-200,Granted Patent,yes,4,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,0,0,,,,EXPIRED
86,US,A1,US 2020/0354046 A1,019-246-200-138-240,2020-11-12,2020,US 201916409605 A,2019-05-10,US 201916409605 A,2019-05-10,Differential Rotor Speed Resonance Avoidance System,"An aircraft having a differential rotor speed resonance avoidance system. The aircraft includes an airframe having structural elements subject to resonant vibration at critical frequencies. A thrust array is coupled to the airframe. The thrust array includes at least four rotor systems distributed about the airframe, each rotor system operable over a range of rotor speeds. A flight control system is operably associated with the thrust array and is configured to independently control the rotor speed of each rotor system. While preserving flight dynamics during flight operations, the flight control system selectively increases the rotor speed of some of the rotor systems by a speed delta and decreases the rotor speed of others of the rotor systems by the speed delta to avoid generating excitation frequencies by the rotor systems at the critical frequencies.",BELL TEXTRON INC,KNOLL JONATHAN A;;CHOI JOUYOUNG JASON;;PARHAM THOMAS CLEMENT,BELL TEXTRON INC (2019-07-01);;TEXTRON INNOVATIONS INC (2020-01-01),https://lens.org/019-246-200-138-240,Patent Application,yes,0,4,1,1,0,B64C27/001;;B64C27/20;;B64C27/26;;B64C27/28;;B64C29/0033;;B64C27/001;;B64C27/32;;B64C27/28;;H02P25/02;;B64C13/16,B64C27/00;;B64C13/16;;B64C27/32;;H02P25/02,,0,0,,,,DISCONTINUED
87,US,S,US D1015541 S,057-859-282-193-664,2024-02-20,2024,US 202029756561 F,2020-10-29,US 202029756561 F;;US 201829634023 F,2018-01-17,Instrument handle,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;CHOI WONBIN,,https://lens.org/057-859-282-193-664,Design Right,no,245,0,5,5,0,,,2402;;D24/185,5,0,,,"Notice of Allowance for U.S. Appl. No. 29/634,027, dated Sep. 19, 2019, 11 pages.;;Notice of Allowance for U.S. Appl. No. 29/808,573, dated Feb. 24, 2023, 7 pages.;;Notice of Allowance for U.S. Appl. No. 29/861,217 dated Jul. 17, 2023, 2 pages.;;Notice of Allowance for U.S. Appl. No. 29/861,217 dated Jun. 22, 2023, 7 pages.;;Notice of Allowance for U.S. Appl. No. 29/634,023, dated Jul. 2, 2020, 7 pages.",ACTIVE
88,US,A1,US 2015/0228351 A1,114-347-402-409-922,2015-08-13,2015,US 201414175196 A,2014-02-07,US 201414175196 A,2014-02-07,Self-Adjusting Regulation Current for Memory Array Source Line,"To maintain stability of memory array operations, a supplemental current can supply a common source line of a memory array so that the combined current from the memory array and supplemental current is at least a minimum regulation current level. When enabled for sensing operations, a driver circuit maintains the common source line's voltage level. A current subtractor circuit determines the difference between a reference current and a current proportional to the current flowing from the array, where the reference current is proportional to the minimum regulation current. The difference current is then mirrored by a self-adjusting current loop and supplied to the common source line to maintain its current level.",SANDISK TECHNOLOGIES INC,WANG SUNG-EN;;HUYNH JONATHAN;;CHOI STEVE;;PARK JONGMIN,SANDISK TECHNOLOGIES LLC (2014-02-06),https://lens.org/114-347-402-409-922,Patent Application,yes,5,12,2,2,0,G11C16/28;;G11C16/28;;G11C16/0483;;G11C16/0483;;G11C16/24;;G11C16/24;;G11C16/26,G11C16/28,,0,0,,,,ACTIVE
89,US,B2,US 9368224 B2,174-168-690-800-071,2016-06-14,2016,US 201414175196 A,2014-02-07,US 201414175196 A,2014-02-07,Self-adjusting regulation current for memory array source line,"To maintain stability of memory array operations, a supplemental current can supply a common source line of a memory array so that the combined current from the memory array and supplemental current is at least a minimum regulation current level. When enabled for sensing operations, a driver circuit maintains the common source line's voltage level. A current subtractor circuit determines the difference between a reference current and a current proportional to the current flowing from the array, where the reference current is proportional to the minimum regulation current. The difference current is then mirrored by a self-adjusting current loop and supplied to the common source line to maintain its current level.",SANDISK TECHNOLOGIES INC;;SANDISK TECHNOLOGIES INC,WANG SUNG-EN;;HUYNH JONATHAN;;CHOI STEVE;;PARK JONGMIN,SANDISK TECHNOLOGIES LLC (2014-02-06),https://lens.org/174-168-690-800-071,Granted Patent,yes,60,6,2,2,0,G11C16/28;;G11C16/28;;G11C16/0483;;G11C16/0483;;G11C16/24;;G11C16/24;;G11C16/26,G11C16/26;;G11C16/04;;G11C16/24;;G11C16/28,,2,1,118-571-555-290-872,10.1109/55.877205,"Eitan et al., ""NROM: A Novel Localized Trapping, 2-Bit Nonvolatile Memory Cell,"" IEEE Electron Device Letters, vol. 21, No. 11, Nov. 2000, pp. 543-545.;;Maeda et al., ""Multi-Stacked 1G Cell/Layer Pipe-Shaped BiCS Flash Memory,"" 2009 Symposium on VLSI Circuits, pp. 22-23.",ACTIVE
90,CA,A1,CA 2040695 A1,017-330-315-078-830,1991-10-27,1991,CA 2040695 A,1991-04-17,US 51502990 A,1990-04-26,CATALYST PRETREATMENT FOR OLEFIN HYDRATION,"F-5731 CATALYST PRETREATMENT FOR OLEFIN HYDRATION Process for production of alcohol or ether by hydration of olefinic feedstock containing at least one lower alkene by contacting the olefinic feedstock and water in a hydration zone with porous solid metal oxide acidic olefin hydration catalyst under olefins hydration conditions, characterized by pretreating porous solid catalyst, such as acid zeolite, prior to contacting with the olefinic feedstock with a wetting agent containing at least one polar aliphatic oxygenated hydrocarbon to substantially wet the solid catalyst and sorb the wetting agent into pores of the solid catalyst. After initiating hydration reaction by feeding the olefinic feedstock and water, increased catalytic activity is obtained. The process is particularly useful for making isopropanol and DIPE from propylene and water.",MOBIL OIL CORP,CHILD JONATHAN E;;CHOI BYUNG C;;RAGONESE FRANCIS P,,https://lens.org/017-330-315-078-830,Patent Application,no,0,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,D326006394   M;;26006487   S,0,0,,,,DISCONTINUED
91,US,A,US 5012014 A,029-172-504-483-16X,1991-04-30,1991,US 51502990 A,1990-04-26,US 51502990 A,1990-04-26,Catalyst pretreatment for olefin hydration,"A process for production of alcohol or ether by hydration of olefinic feedstock containing at least one lower alkene by contacting the olefinic feedstock and water in a hydration zone with porous solid metal oxide acidic olefin hydration catalyst under olefins hydration conditions. The process is characterized by the step of pretreating porous solid catalyst, such as acid zeolite, prior to contacting with the olefinic feedstock with a wetting agent containing at least one polar aliphatic oxygenated hydrocarbon to substantially wet said solid catalyst and sorb said wetting agent into pores of said solid catalyst. After initiating hydration reaction by feeding the olefinic feedstock and water, increased catalytic activity is obtained. The process is particularly useful for making isopropanol and DIPE from propene and water.",MOBIL OIL CORP,CHILD JONATHAN E;;CHOI BYUNG C;;RAGONESE FRANCIS P,MOBIL OIL CORPORATION A CORP. OF NY (1990-04-12),https://lens.org/029-172-504-483-16X,Granted Patent,yes,3,10,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,568/695;;568/897,0,0,,,,EXPIRED
92,AU,A,AU 1990/049633 A,113-402-100-163-683,1990-08-13,1990,AU 1990/049633 A,1990-01-10,US 29611289 A,1989-01-12,CONVERSION OF OLEFINS TO ETHERS,,MOBIL OIL CORP,CHILD JONATHAN EDWARD;;RAGONESE FRANCIS PAUL;;CHOI BYUNG CHAN,,https://lens.org/113-402-100-163-683,Patent Application,no,0,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,0,0,,,,EXPIRED
93,AU,B2,AU 619953 B2,140-726-052-846-964,1992-02-06,1992,AU 1990/049633 A,1990-01-10,US 29611289 A,1989-01-12,CONVERSION OF OLEFINS TO ETHERS,,MOBIL OIL CORP,CHILD JONATHAN EDWARD;;RAGONESE FRANCIS PAUL;;CHOI BYUNG CHAN,,https://lens.org/140-726-052-846-964,Granted Patent,no,2,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,0,0,,,,EXPIRED
94,AU,B2,AU 636219 B2,183-541-122-134-743,1993-04-22,1993,AU 1991/075011 A,1991-04-16,US 51502990 A,1990-04-26,CATALYST PRETREATMENT FOR OLEFIN HYDRATION,,MOBIL OIL CORPORATION,JONATHAN EDWARD CHILD;;BYUNG CHANG CHOI;;FRANCIS PAUL RAGONESE,,https://lens.org/183-541-122-134-743,Granted Patent,no,0,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,,0,0,,,,EXPIRED
95,EP,A2,EP 2648759 A2,156-724-955-735-968,2013-10-16,2013,EP 11847254 A,2011-12-09,US 42186910 P;;US 2011/0064276 W,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,,CALIFORNIA INST OF TECHN,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/156-724-955-735-968,Patent Application,yes,0,0,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/40;;A61K9/127;;A61K31/7088;;A61K31/7105;;A61K47/48;;A61K48/00;;A61P13/12,,0,0,,,,DISCONTINUED
96,EP,A2,EP 2648756 A2,052-603-627-197-695,2013-10-16,2013,EP 11846078 A,2011-12-09,US 42186910 P;;US 2011/0064272 W,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,,CALIFORNIA INST OF TECHN,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/052-603-627-197-695,Patent Application,yes,0,0,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/40;;A61K9/127;;A61K31/7088;;A61K31/7105;;A61K47/48;;A61K48/00;;A61P13/12,,0,0,,,,DISCONTINUED
97,US,B2,US 10111031 B2,142-469-746-476-855,2018-10-23,2018,US 201615003899 A,2016-01-22,US 201615003899 A,2016-01-22,Object detection and tracking system,"A system and method for automated crowd sensing object detection. The invention senses a missing object's presence in proximity which is conducted using a smartphone, with a software application running in the background that opportunistically collects and reports the data without the active involvement of the user. A small tag is attached to a tracked object or worn by a person who does not carry a smartphone (i.e., a young child), and emits a secure wireless signal periodically for geo-fencing and geo-tracking by caregivers. The information is sent to a cloud server so that the commander may be able to confirm the whereabouts of the tagged object or person in this case.",THE UNITED STATES OF AMERICA AS REPRESETNED BY THE SECRETARY OF THE AIR FORCE;;US AIR FORCE,BLOWERS MISTY;;CHOI BAEK-YOUNG;;SONG SEJUN;;WILLIAMS JONATHAN,UNITED STATES AIR FORCE (2016-01-21),https://lens.org/142-469-746-476-855,Granted Patent,yes,10,2,2,2,0,H04W4/021;;H04W8/005;;H04W4/06;;H04W84/12;;H04W4/021;;H04W8/005;;H04W4/06;;H04W84/12;;H04L67/01,H04W4/021;;H04W24/00;;H04L29/06;;H04W4/06;;H04W8/00;;H04W84/12,,0,0,,,,ACTIVE
98,US,S,US D1004782 S,008-394-340-115-281,2023-11-14,2023,US 202229861217 F,2022-11-28,US 202229861217 F;;US 202029756561 F;;US 201829634023 F,2018-01-17,Instrument handle,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;CHOI WONBIN,AURIS HEALTH INC (2018-05-01),https://lens.org/008-394-340-115-281,Design Right,no,237,0,5,5,0,,,2402;;D24/185,1,0,,,"Notice of Allowance for U.S. Appl. No. 29/634,023, dated Jul. 2, 2020, 7 pages.",ACTIVE
99,WO,A1,WO 1990/008124 A1,094-722-527-342-360,1990-07-26,1990,US 9000134 W,1990-01-10,US 29611289 A,1989-01-12,CONVERSION OF OLEFINS TO ETHERS,"Light olefins are catalytically converted to ethers, e.g., propylene is converted to diisopropyl ether, in a two stage process in which product ether is recycled to a first stage reaction zone to significantly reduce the operating temperature of the olefin hydration/etherification reactions taking place in that zone. Alcohol produced in the first stage reaction zone undergoes conversion in the second stage reaction zone, e.g., by catalytic distillation, to provide additional product ether.",MOBIL OIL CORP,CHILD JONATHAN EDWARD;;CHOI BYUNG CHAN;;RAGONESE FRANCIS PAUL,,https://lens.org/094-722-527-342-360,Patent Application,yes,4,2,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,0,0,,,,PATENTED
100,US,A1,US 2017/0215034 A1,116-967-882-161-232,2017-07-27,2017,US 201615003899 A,2016-01-22,US 201615003899 A,2016-01-22,OBJECT DETECTION AND TRACKING SYSTEM,"A system and method for automated crowd sensing object detection. The invention senses a missing object's presence in proximity which is conducted using a smartphone, with a software application running in the background that opportunistically collects and reports the data without the active involvement of the user. A small tag is attached to a tracked object or worn by a person who does not carry a smartphone (i.e., a young child), and emits a secure wireless signal periodically for geo-fencing and geo-tracking by caregivers. The information is sent to a cloud server so that the commander may be able to confirm the whereabouts of the tagged object or person in this case.",GOVERNMENT OF THE UNITED STATES AS REPRESETNED BY THE SECRETARY OF THE AIR FORCE,BLOWERS MISTY;;CHOI BAEK-YOUNG;;SONG SEJUN;;WILLIAMS JONATHAN,UNITED STATES AIR FORCE (2016-01-21),https://lens.org/116-967-882-161-232,Patent Application,yes,1,23,2,2,0,H04W4/021;;H04W8/005;;H04W4/06;;H04W84/12;;H04W4/021;;H04W8/005;;H04W4/06;;H04W84/12;;H04L67/01,H04W4/021;;H04L29/06;;H04W4/06;;H04W8/00,,0,0,,,,ACTIVE
101,US,S,US D0991459 S,015-413-362-240-221,2023-07-04,2023,US 202129808573 F,2021-09-21,US 202129808573 F;;US 201829634021 F,2018-01-17,Instrument cart element,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;CHOI WONBIN,AURIS HEALTH INC (2018-05-02),https://lens.org/015-413-362-240-221,Design Right,no,195,0,4,4,0,,,2402;;D24/185,6,0,,,"U.S. Appl. No. 29/721,949, filed Jan. 24, 2020, Frankie Vazquez.;;Notice of allowance for U.S. Appl. No. 29/634,021, dated Aug. 31, 2021, 2 pages.;;Notice of allowance for U.S. Appl. No. 29/634,021, dated Jul. 20, 2021, 4 pages.;;Notice of allowance for U.S. Appl. No. 29/634,021, dated May 26, 2021, 5 pages.;;Office action for U.S. Appl. No. 29/634,021, dated Aug. 6, 2020, 9 pages.;;Office Action for U.S. Appl. No. 29/634,021, dated Feb. 23, 2021, 8 pages.",ACTIVE
102,WO,A2,WO 2012/079043 A2,039-920-386-551-638,2012-06-14,2012,US 2011/0064272 W,2011-12-09,US 42186910 P,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,,CALIFORNIA INST OF TECHN;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/039-920-386-551-638,Patent Application,yes,0,1,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/40;;A61K9/127;;A61K31/7088;;A61K31/7105;;A61K47/48;;A61K48/00;;A61P13/12,,0,0,,,,PENDING
103,US,S,US D0901694 S,094-354-958-946-282,2020-11-10,2020,US 201829634023 F,2018-01-17,US 201829634023 F,2018-01-17,Instrument handle,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;CHOI WONBIN,MATTER LLC (2018-05-09);;AURIS HEALTH INC (2018-05-21),https://lens.org/094-354-958-946-282,Design Right,no,146,8,5,5,0,,,2402;;D24/185,0,0,,,,ACTIVE
104,EP,A4,EP 2648756 A4,191-600-067-698-710,2016-06-08,2016,EP 11846078 A,2011-12-09,US 42186910 P;;US 2011/0064272 W,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,,CALIFORNIA INST OF TECHN,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/191-600-067-698-710,Search Report,no,3,0,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/40;;A61K9/127;;A61K31/7088;;A61K31/7105;;A61K47/48;;A61K48/00;;A61P13/12,,1,1,030-497-102-085-194,10.1016/j.ijpharm.2009.04.035;;19416749,"CHANG J ET AL: ""Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 379, no. 2, 11 September 2009 (2009-09-11), pages 285 - 292, XP026519361, ISSN: 0378-5173, [retrieved on 20090503], DOI: 10.1016/J.IJPHARM.2009.04.035",DISCONTINUED
105,CA,A1,CA 2025017 A1,001-450-789-654-209,1990-07-13,1990,CA 2025017 A,1990-01-10,US 29611289 A,1989-01-12,CONVERSION OF OLEFINS TO ETHERS,"(54)Title: CONVERSION OF OLEFINS TO ETHERS (57) Light olefins are catalytically convened to ethers, e.g., propylene is converted to diisopropyl ether, in a two stage process in which product ether is recycled to a first stage reaction zone to significantly reduce the operating temperature of the olefin hydration/etherification reactions taking place in that zone. Alcohol produced in the first stage reaction zone undergoes conversion in the second stage reaction zone, e.g., by catalytic distillation, to provide additional product ether.",MOBIL OIL CORP,CHILD JONATHAN E;;CHOI BYUNG C;;RAGONESE FRANCIS P,,https://lens.org/001-450-789-654-209,Patent Application,no,0,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,D326006487   M,0,0,,,,DISCONTINUED
106,US,A1,US 2012/0148488 A1,164-732-431-714-269,2012-06-14,2012,US 201113316366 A,2011-12-09,US 201113316366 A;;US 42186910 P,2010-12-10,Targeting Kidney Mesangium With Nanoparticles of Defined Diameter,"Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject.",DAVIS MARK E;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;CALIFORNIA INST OF TECHN,DAVIS MARK E;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN,CALIFORNIA INSTITUTE OF TECHNOLOGY (2012-01-03),https://lens.org/164-732-431-714-269,Patent Application,yes,2,1,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K31/7088;;A61K9/00;;A61K38/02;;A61K51/02;;A61P13/12;;B82Y5/00;;B82Y15/00;;C12Q1/02;;G01N21/64,424/1.11;;X514 44  A;;514/1.1;;424/400;;435/29;;514/15.4;;977/773;;977/810;;977/915;;977/904,10,10,153-510-863-083-621;;108-464-752-922-430;;066-807-957-028-483;;028-467-394-897-784;;052-405-873-666-429;;151-524-568-255-288;;027-160-985-512-37X;;053-083-819-336-733;;000-360-000-122-112;;042-138-988-432-52X,18977071;;10.1016/j.canlet.2008.09.024;;10.1016/j.addr.2008.03.016;;18555555;;10.1097/01.asn.0000046961.04917.83;;12538733;;18722754;;10.1016/j.colsurfb.2008.07.004;;11514599;;10.1084/jem.194.4.417;;pmc2193503;;22315430;;pmc3286910;;10.1073/pnas.1200718109;;11553505;;10.1152/ajprenal.2001.281.4.f579;;10.1073/pnas.0707461104;;pmc1978218;;17875985;;pmc2562297;;18727041;;10.1002/mrm.21684;;16487614;;10.1016/j.jconrel.2005.12.022,"Li, J., et al., ""In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles"", 2009, Cancer Letters, pp. 319-326;;Gosh, P., et al., ""Gold nanoparticles in delivery applications"", 2008, Adv., Drug Deliv. Rev., pp. 1307-1315;;Haddad, E., et al., ""Enhanced Expression of the CD71 Mesangial IgA1 Receptor in Berger Disease and Henoch-Scho�nlein Nephritis: Association between CD71 Expression and IgA Deposits"", 2003, JASN, pp. 327-337;;Sonavane, G., et al. ""Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size"", Colloids and Surfaces B: Biointerfaces, 2008, pp. 276-280;;Moura, I. C., et al. "" Identification of the Transferrin Receptor as a Novel Immunoglobulin (Ig)A1 Receptor and Its Enhanced Expression on Mesangial Cells in IgA Nephropathy"", J. Exp. Med., 2001, pp. 417-425;;Zuckermann, J.E., et al., ""Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane"", PNSA, 2012, pp. 3137-3142;;Deen, W., M., et al., ""Structural determinants of glomerular permeability"", Am J., Physiol Renal Physiol, 2001, pp. F579-F596;;Bartlett, D.W. et al., ""Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging"", PNAS, 2007, pp. 15549-15554;;Bennett, K.M., et al., ""MRI of the Basement Membrane Using Charged Nanoparticles as Contrast Agents"" Magnetic Res. in Medicine, 2008, pp. 564-574;;Kawano, T., et al., ""Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses"", 2006, J. Controlled Release, pp. 382-389",DISCONTINUED
107,DE,T2,DE 69102198 T2,175-662-582-141-267,1994-09-08,1994,DE 69102198 T,1991-04-16,US 51502990 A,1990-04-26,Vorbehandlung eines Olefin-Hydratisierungskatalysators.,,MOBIL OIL CORP,CHILD JONATHAN EDWARD;;RAGONESE FRANCIS PAUL;;CHOI BYUNG CHANG,,https://lens.org/175-662-582-141-267,Granted Patent,no,0,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,,0,0,,,,EXPIRED
108,US,A,US 5071627 A,139-907-888-514-350,1991-12-10,1991,US 44530489 A,1989-12-04,US 44530489 A,1989-12-04,Reactor system for conducting a chemical conversion,A reactor system and process for conducting exothermic or endothermic chemical reactions achieves greater kinetic efficiency through transfer of heat between adjacent feed temperature modification and reaction zones.,MOBIL OIL CORP,CHILD JONATHAN E;;CHOI BYUNG C;;RAGONESE FRANCIS P,MOBIL OIL CORPORATION A CORP. OF NY (1989-11-20),https://lens.org/139-907-888-514-350,Granted Patent,yes,38,15,1,1,0,B01J8/0285;;B01J8/0285;;B01J2208/00123;;B01J2208/00123;;B01J2208/00176;;B01J2208/00176;;B01J2208/00283;;B01J2208/00283;;B01J2208/00309;;B01J2208/00309;;B01J2208/0053;;B01J2208/0053;;C07C29/04;;C07C29/04;;C07C41/05;;C07C41/05;;C07C41/06;;C07C41/06;;C10G35/04;;C10G35/04;;F28D7/0066;;F28D7/0066;;F28D7/0091;;F28D7/0091;;F28F1/42;;F28F1/42;;Y10S165/907;;Y10S165/907,B01J8/02;;C07C29/04;;C07C41/05;;C10G35/04;;F28D7/00;;F28F1/42,422/196;;165/154;;165/179;;165/185;;165/907;;422/188;;422/198;;422/201;;422/202;;422/203;;422/205,1,0,,,"Smith, Chemical Eng. Kinetics, 3rd Ed. , McGraw Hill Book Company p. 351, 1981.",EXPIRED
109,US,B2,US 9514831 B2,001-423-413-914-347,2016-12-06,2016,US 201514596779 A,2015-01-14,US 201514596779 A;;US 201461932971 P,2014-01-29,Multi-clock generation through phase locked loop (PLL) reference,"A circuit for providing a plurality of clock signals of differing frequencies includes: a phase locked loop section including a first voltage controller oscillator, connected to receive a reference clock value and generate therefrom a first voltage level, wherein the first voltage controller oscillator receives the first voltage level and generates therefrom a first clock signal; and one or more second voltage controller oscillators, each connected to receive the first voltage level, a corresponding trim value and a corresponding control voltage and derive therefrom a corresponding second clock signal.",SANDISK TECHNOLOGIES INC;;SANDISK TECHNOLOGIES LLC,HUYNH JONATHAN;;WANG SUNG-EN;;CHOI STEVE;;PARK JONGMIN,SANDISK TECHNOLOGIES LLC (2015-01-12),https://lens.org/001-423-413-914-347,Granted Patent,yes,27,0,2,2,0,G11C16/30;;G11C16/30;;G11C5/145;;G11C5/145;;H03L7/0891;;H03L7/0891,G11C16/04;;G11C5/14;;G11C16/30;;H03L7/089,,0,0,,,,ACTIVE
110,EP,B1,EP 0454337 B1,055-126-355-650-598,1994-06-01,1994,EP 91303340 A,1991-04-16,US 51502990 A,1990-04-26,Catalyst pretreatment for olefin hydration.,,MOBIL OIL CORP,CHILD JONATHAN EDWARD;;RAGONESE FRANCIS PAUL;;CHOI BYUNG CHANG,,https://lens.org/055-126-355-650-598,Granted Patent,yes,3,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,,0,0,,,,EXPIRED
111,EP,A1,EP 0404931 A1,141-137-007-593-890,1991-01-02,1991,EP 90902492 A,1990-01-10,US 29611289 A,1989-01-12,CONVERSION OF OLEFINS TO ETHERS.,"On procède à la conversion par voie catalytique d'oléfines légères en éthers, par exemple de propylène en éther di-isopropyle, par un procédé à deux phases, dans lequel l'éther produit est recyclé dans une zone de réaction de première phase, pour obtenir une réduction sensible de la température opérationnelle des réactions d'hydratation/éthérification des oléfines qui se produisent dans cette zone. L'alcool produit dans la zone de réaction de première phase subit une conversion dans la zone de réaction de seconde phase, par exemple par distillation catalytique, pour former un éther supplémentaire.",MOBIL OIL CORP,CHILD JONATHAN EDWARD;;CHOI BYUNG CHAN;;RAGONESE FRANCIS PAUL,,https://lens.org/141-137-007-593-890,Patent Application,yes,0,0,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,,1,0,,,See references of WO 9008124A1,EXPIRED
112,EP,A1,EP 0454337 A1,029-596-232-742-170,1991-10-30,1991,EP 91303340 A,1991-04-16,US 51502990 A,1990-04-26,Catalyst pretreatment for olefin hydration.,"Process for production of alcohol or ether by hydration of olefinic feedstock containing at least one lower alkene by contacting the olefinic feedstock and water in a hydration zone with porous solid metal oxide acidic olefin hydration catalyst under olefins hydration conditions, characterized by pretreating porous solid catalyst, such as acid zeolite, prior to contacting with the olefinic feedstock with a wetting agent containing at least one polar aliphatic oxygenated hydrocarbon to substantially wet the solid catalyst and sorb the wetting agent into pores of the solid catalyst. After initiating hydration reaction by feeding the olefinic feedstock and water, increased catalytic activity is obtained. The process is particularly useful for making isopropanol and DIPE from propylene and water.",MOBIL OIL CORP,CHILD JONATHAN EDWARD;;RAGONESE FRANCIS PAUL;;CHOI BYUNG CHANG,,https://lens.org/029-596-232-742-170,Patent Application,yes,3,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,,0,0,,,,EXPIRED
113,DE,D1,DE 69102198 D1,144-596-212-355-340,1994-07-07,1994,DE 69102198 T,1991-04-16,US 51502990 A,1990-04-26,Vorbehandlung eines Olefin-Hydratisierungskatalysators.,,MOBIL OIL CORP,CHILD JONATHAN EDWARD;;RAGONESE FRANCIS PAUL;;CHOI BYUNG CHANG,,https://lens.org/144-596-212-355-340,Granted Patent,no,0,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,,0,0,,,,EXPIRED
114,WO,A9,WO 2012/079047 A9,183-359-425-171-292,2012-11-15,2012,US 2011/0064276 W,2011-12-09,US 42186910 P,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,,CALIFORNIA INST OF TECHN;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/183-359-425-171-292,Search Report,yes,0,0,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/48;;A61K9/14;;A61K9/16;;A61K47/30;;A61P1/00;;A61P1/16,,0,0,,,,PENDING
115,US,A,US 4927977 A,015-043-327-683-523,1990-05-22,1990,US 29609389 A,1989-01-12,US 29609389 A,1989-01-12,Process and apparatus for the uniform distribution of a two-phase feed in a chemical reaction zone,"A process and apparatus are provided for the substantially uniform distribution of a two-phase feed in a chemical reaction zone. As applied, for example, to the hydration/etherification of light olefin to alcohol(s) and/or ether(s), the invention results in greater process control and in particular cases, to improved reaction product selectivities.",MOBIL OIL CORP,CHILD JONATHAN E;;CHOI BYUNG C;;RAGONESE FRANCIS P,MOBIL OIL CORPORATION A CORP. OF NY (1988-12-20),https://lens.org/015-043-327-683-523,Granted Patent,yes,25,17,1,1,0,C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06,C07C29/04;;C07C41/06,568/695;;568/694;;568/697;;568/698;;568/897,0,0,,,,EXPIRED
116,US,A1,US 2012/0148489 A1,093-712-007-759-714,2012-06-14,2012,US 201113316382 A,2011-12-09,US 201113316382 A;;US 42186910 P,2010-12-10,Targeting Kidney Mesangium With Nanoparticles of Defined Diameter,"Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject.",DAVIS MARK E;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;CALIFORNIA INST OF TECHN,DAVIS MARK E;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN,CALIFORNIA INSTITUTE OF TECHNOLOGY (2011-12-31),https://lens.org/093-712-007-759-714,Patent Application,yes,3,0,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K31/7088;;A61K9/00;;A61K38/02;;A61K51/02;;A61P9/12;;B82Y5/00;;B82Y15/00;;C12Q1/02;;G01N21/64,424/1.11;;X514 44  A;;514/1.1;;514/15.4;;424/400;;435/29;;977/773;;977/915;;977/904,10,9,076-491-895-428-135;;066-807-957-028-483;;064-401-394-137-498;;043-745-008-566-356;;151-524-568-255-288;;027-160-985-512-37X;;053-083-819-336-733;;000-360-000-122-112;;042-138-988-432-52X,15136766;;10.4161/cbt.3.7.918;;10.1097/01.asn.0000046961.04917.83;;12538733;;10.1136/jcp.36.5.539;;6302135;;pmc498283;;10.1007/bf00310191;;3631536;;22315430;;pmc3286910;;10.1073/pnas.1200718109;;11553505;;10.1152/ajprenal.2001.281.4.f579;;10.1073/pnas.0707461104;;pmc1978218;;17875985;;pmc2562297;;18727041;;10.1002/mrm.21684;;16487614;;10.1016/j.jconrel.2005.12.022,"Pun, S.H., et al., ""Targeted Delivery of RNA-Cleaving DNA Enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles"", 2004, Cancer Biology and Therapy, pp. 641-650;;Haddad, E., et al., ""Enhanced Expression of the CD71 Mesangial IgA1 Receptor in Berger Disease and Henoch-Scho�nlein Nephritis: Association between CD71 Expression and IgA Deposits"", 2003, JASN, pp. 327-337;;Gatter, K.C., et al., ""Transferrin receptors in human tissues: their distribution and possible clinical relevance"", 1983, J. Clin. Pathol., pp. 539-545;;Glomerular basement membrane, ""Glomerular Basement Membrane"" accessed on: 02/21/2016, accessed from: ""https://en.wikipedia.org/wiki/Glomerular_basement_membrane"", pp. 1-4;;Sakai, T., et al., ""The structural relationship between mesangial cells and basement membrane of the renal glomerulus."", Anat. Embryol (Berl), 1987, Abstract, pp. 1-2;;Zuckermann, J.E., et al., ""Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane"", PNSA, 2012, pp. 3137-3142;;Deen, W., M., et al., ""Structural determinants of glomerular permeability"", Am J., Physiol Renal Physiol, 2001, pp. F579-F596;;Bartlett, D.W. et al., ""Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging"", PNAS, 2007, pp. 15549-15554;;Bennett, K.M., et al., ""MRI of the Basement Membrane Using Charged Nanoparticles as Contrast Agents"" Magnetic Res. in Medicine, 2008, pp. 564-574;;Kawano, T., et al., ""Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses"", 2006, J. Controlled Release, pp. 382-389",DISCONTINUED
117,WO,A2,WO 2012/079047 A2,149-436-945-026-877,2012-06-14,2012,US 2011/0064276 W,2011-12-09,US 42186910 P,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,"Described herein are methods of treating a disorder affecting the mesangial cells in a subject by administering an engineered nanoparticle (ENP) capable of delivering a therapeutic agent to the subject. Also provided are diagnostic methods for administering to a subject an ENP, analyzing a mesangial cell of the subject and determining whether the engineered nanoparticle is present in a mesangial cell of the subject.",CALIFORNIA INST OF TECHN;;CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/149-436-945-026-877,Patent Application,yes,0,5,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/48;;A61K9/14;;A61K9/16;;A61K47/30;;A61P1/00;;A61P1/16,,0,0,,,,PENDING
118,AU,A,AU 1991/075011 A,155-457-032-251-703,1991-11-14,1991,AU 1991/075011 A,1991-04-16,US 51502990 A,1990-04-26,CATALYST PRETREATMENT FOR OLEFIN HYDRATION,,MOBIL OIL CORP,CHILD JONATHAN EDWARD;;CHOI BYUNG CHANG;;RAGONESE FRANCIS PAUL,,https://lens.org/155-457-032-251-703,Patent Application,no,0,0,9,9,0,B01J29/7007;;B01J29/7007;;C07C29/04;;C07C29/04;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09,C07B61/00;;B01J29/70;;C07C29/04;;C07C31/10;;C07C41/06;;C07C41/09;;C07C43/04,,0,0,,,,EXPIRED
119,EP,A4,EP 2648759 A4,101-654-458-997-020,2016-06-15,2016,EP 11847254 A,2011-12-09,US 42186910 P;;US 2011/0064276 W,2010-12-10,TARGETING KIDNEY MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER,,CALIFORNIA INST OF TECHN,CHOI CHUNG HANG J;;ZUCKERMAN JONATHAN;;DAVIS MARK E,,https://lens.org/101-654-458-997-020,Search Report,no,3,0,9,9,0,A61K31/7088;;A61K38/00;;B82Y5/00;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923;;A61P1/00;;A61P1/16;;A61P13/12;;A61P9/12;;B82Y5/00;;A61K38/00;;A61K31/7088;;B82Y15/00;;C12N15/111;;C12N2320/32;;A61K47/6923,A61K47/40;;A61K9/127;;A61K31/7088;;A61K31/7105;;A61K47/48;;A61K48/00;;A61P13/12,,3,3,045-439-347-049-473;;066-772-965-283-436;;030-497-102-085-194,pmc3080986;;21464325;;10.1073/pnas.1103573108;;pmc2621238;;10.1186/1743-8977-5-22;;19099552;;10.1016/j.ijpharm.2009.04.035;;19416749,"C. H. J. CHOI ET AL: ""Targeting kidney mesangium by nanoparticles of defined size"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 16, 4 April 2011 (2011-04-04), US, pages 6656 - 6661, XP055270609, ISSN: 0027-8424, DOI: 10.1073/pnas.1103573108;;L'AZOU BEATRICE ET AL: ""In vitro effects of nanoparticles on renal cells"", PARTICLE AND FIBRE TOXICOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 5, no. 1, 19 December 2008 (2008-12-19), pages 22, XP021051732, ISSN: 1743-8977, DOI: 10.1186/1743-8977-5-22;;CHANG J ET AL: ""Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 379, no. 2, 11 September 2009 (2009-09-11), pages 285 - 292, XP026519361, ISSN: 0378-5173, [retrieved on 20090503], DOI: 10.1016/J.IJPHARM.2009.04.035",DISCONTINUED
120,US,A,US 4935552 A,185-436-891-435-223,1990-06-19,1990,US 29611289 A,1989-01-12,US 29611289 A,1989-01-12,Dual stage process for the production of ethers,"Light olefins are catalytically converted to ethers, e.g., propylene is converted to diisopropyl ether, in a dual stage process in which product ether is recycled to a first stage reaction zone to significantly reduce the operating temperature of the olefin hydration/etherification reactions taking place in that zone. Alcohol produced in the first stage reaction zone undergoes conversion in the second stage reaction zone, e.g., by etherification with light olefin or by catalytic distillation, to provide additional product ether. The process contemplates the use of zeolites as olefin hydration/etherification catalysts.",MOBIL OIL CORP,CHILD JONATHAN E;;CHOI BYUNG C;;RAGONESE FRANCIS P,MOBIL OIL CORPORATION A CORP. OF NY (1988-12-20),https://lens.org/185-436-891-435-223,Granted Patent,yes,31,19,11,11,0,C07C41/42;;C07C41/42;;C07C41/06;;C07C41/06;;C07C41/09;;C07C41/09;;Y02P20/10;;Y02P20/10,B01J29/06;;C07B61/00;;C07C41/06;;C07C41/09;;C07C41/42;;C07C43/04,568/695;;568/696;;568/697;;568/698;;568/897,0,0,,,,EXPIRED
121,US,S,US D0489344 S,056-413-213-960-249,2004-05-04,2004,US 17746303 F,2003-03-10,US 17746303 F,2003-03-10,Housing for communication devices or similar articles,,MOTOROLA INC,LEE KIO;;CHOE JONATHAN;;CHOI YOON HO;;MAENG SANG KYU,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2003-04-28),https://lens.org/056-413-213-960-249,Design Right,no,0,7,1,1,0,,,D14/138,0,0,,,,EXPIRED
122,AT,T1,AT E459393 T1,113-302-577-860-904,2010-03-15,2010,AT 06773098 T,2006-06-13,US 69280905 P;;US 2006/0023068 W,2005-06-22,BEHANDLUNG DER SEXUELLEN DYSFUNKTION,,SK HOLDINGS CO LTD,CHOI YONG;;STECKLER THOMAS;;SPORN JONATHAN;;PALUMBO JOSEPH;;LEE JAMES,,https://lens.org/113-302-577-860-904,Granted Patent,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,,,0,0,,,,INACTIVE
123,EP,A1,EP 4049682 A1,116-682-486-677-844,2022-08-31,2022,EP 22158875 A,2022-02-25,US 202163153680 P,2021-02-25,A SELF-THERAPEUTIC NANOPARTICLE FOR ENHANCED TOPICAL DELIVERY TO SKIN KERATINOCYTES AND TREATING SKIN INFLAMMATION,"A composition of an anti-psoriatic drug and methods of applying the anti-psoriatic drug for transdermal delivery of nanoparticles and entry into skin cells are provided. The composition of the anti-psoriatic drug includes a core having at least one gold nanoparticle, a shell of polyethylene glycol (PEG) strands conjugated to the core, and a plurality of alkyl groups conjugated to the shell of PEG strands. Moreover, a chain length of the plurality of alkyl groups, chain loading of the plurality of alkyl groups, or a diameter of the core is configured to optimize a distribution of the composition in the skin cells. The distribution may include skin permeability or an entry into keratinocytes. Further, methods of modulating effectiveness of the anti-psoriatic drug for inhibiting development of a psoriasis phenotype or for treatment of the psoriasis phenotype are provided.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;HAN RUIFANG;;HO LOK WAI COLA,,https://lens.org/116-682-486-677-844,Patent Application,yes,1,0,3,3,12,A61K47/6935;;A61K47/60;;A61K33/242;;A61K9/0014;;A61P17/06;;A61P29/00;;B82Y5/00;;B82Y30/00;;B82Y40/00;;A61K47/60;;A61K47/6929;;A61P17/00;;A61P17/06;;A61K47/6929;;A61K47/60;;A61K9/0014,A61K47/69;;A61K47/60;;A61P17/00;;A61P17/06,,98,97,023-231-417-016-431;;075-086-487-113-905;;019-354-519-541-515;;095-891-728-033-007;;006-792-391-668-290;;031-143-969-468-495;;040-962-743-409-13X;;003-011-267-840-74X;;028-923-130-269-705;;047-867-442-848-760;;155-171-030-721-421;;007-574-750-467-337;;063-760-589-619-559;;041-716-366-374-076;;038-333-498-167-793;;000-928-197-868-717;;063-907-673-062-320;;058-170-189-269-595;;083-745-324-652-10X;;128-318-047-868-23X;;053-486-798-742-762;;015-556-665-078-901;;006-309-964-190-632;;015-281-575-159-353;;084-276-582-198-912;;109-470-299-586-682;;006-792-391-668-290;;031-143-969-468-495;;068-295-600-860-53X;;008-679-045-454-634;;053-474-598-733-900;;000-204-502-758-220;;095-891-728-033-007;;038-050-344-385-413;;026-063-289-499-051;;005-032-736-498-47X;;074-515-193-486-665;;002-704-907-918-943;;056-011-451-060-260;;010-715-422-435-883;;050-880-132-951-097;;023-231-417-016-431;;022-183-220-680-697;;049-946-056-754-959;;001-033-748-832-198;;078-568-912-560-265;;033-524-716-722-928;;062-186-917-216-688;;175-082-967-916-720;;029-129-967-591-809;;066-650-305-586-858;;013-935-785-045-415;;062-284-720-902-368;;004-661-431-603-289;;091-996-219-313-559;;011-075-438-250-860;;116-979-882-934-520;;075-504-355-613-894;;075-432-130-440-97X;;005-602-770-826-838;;099-508-450-096-185;;000-803-307-816-004;;074-016-300-449-346;;108-419-725-001-684;;018-731-221-292-813;;103-029-239-462-658;;005-523-944-780-636;;093-250-031-577-415;;030-518-130-165-976;;003-588-085-467-75X;;091-186-898-646-261;;016-594-489-540-733;;023-868-407-129-22X;;140-842-033-323-808;;059-815-450-353-638;;042-745-934-699-442;;100-728-691-708-304;;018-394-859-502-82X;;085-526-729-115-751;;094-669-431-724-719;;029-372-208-554-986;;089-106-041-261-915;;096-828-177-225-399;;168-314-977-014-348;;066-193-395-469-231;;066-205-548-187-776;;004-128-449-553-309;;018-920-769-757-826;;008-837-747-369-275;;101-333-504-462-995;;080-306-719-070-709;;066-306-024-268-80X;;031-853-269-939-125;;106-019-644-798-542;;007-977-536-712-908;;012-502-214-029-948;;019-367-723-594-828,10.1021/acsnano.7b02044;;28562003;;33586442;;10.1021/acs.nanolett.0c04932;;31725257;;10.1021/acsnano.9b06424.s001;;10.1021/acsnano.9b06424;;29074408;;10.1016/j.jconrel.2017.10.034;;10.1016/j.nano.2019.01.006;;30708054;;31678057;;10.1016/j.jid.2019.09.018;;32376432;;10.1016/j.jaad.2020.04.139;;17658397;;10.1016/s0140-6736(07)61128-3;;26025581;;10.1016/s0140-6736(14)61909-7;;10.1001/archderm.143.2.239;;17310004;;10.1038/nature05663;;17314973;;10.1016/s0190-9622(88)80237-8;;3042816;;2663325;;19932926;;10.1016/j.jaad.2009.05.017;;17980456;;10.1016/j.jaad.2007.08.030;;10.1080/14787210.2018.1544490;;30388900;;10.1111/j.1468-3083.2012.04522.x;;22512679;;32393082;;pmc7269080;;10.1080/10717544.2020.1754527;;10.1080/17425247.2017.1264386;;27882780;;26024238;;10.3109/10837450.2015.1026605;;27530292;;10.1016/j.ijpharm.2016.08.008;;28754510;;10.1016/j.ijpharm.2017.07.058;;16142971;;10.1021/la0503451;;19580617;;10.1111/j.1445-5994.2008.01716.x;;26852097;;10.1016/j.colsurfb.2016.01.021;;25445970;;10.1016/j.ijpharm.2014.10.067;;10.1016/j.nano.2019.01.006;;30708054;;31678057;;10.1016/j.jid.2019.09.018;;28779637;;10.1016/j.colsurfb.2017.07.080;;32060883;;10.1007/s13346-020-00723-6;;10.1073/pnas.1118425109;;pmc3409786;;22773805;;10.1016/j.jid.2017.04.027;;28502802;;pmc8405255;;29074408;;10.1016/j.jconrel.2017.10.034;;31421125;;pmc8375607;;10.1016/j.jid.2019.06.146;;10.1016/j.jid.2019.07.683;;31980061;;pmc8274399;;29949348;;10.1021/acsnano.8b02330;;32923608;;pmc7457336;;10.1126/sciadv.abb5274;;10.1080/10937404.2016.1168762;;27282429;;pmc3637766;;23569259;;10.1073/pnas.1214547110;;pmc6939886;;27758098;;10.1021/acsnano.6b02231;;32954051;;pmc7479257;;10.1016/j.bioactmat.2020.08.009;;10.1021/acsnano.7b02044;;28562003;;10.1021/acs.biochem.0c00631;;33169977;;10.1146/annurev-immunol-032713-120225;;pmc4229247;;24655295;;19380832;;10.4049/jimmunol.0802999;;10.1016/j.colsurfb.2008.02.013;;18499408;;29226422;;10.1111/1346-8138.14139;;10.5114/pdia.2014.40920;;10.1016/j.dsi.2012.08.004;;10.1111/bjd.15346;;28129666;;10.3390/cells8080807;;31374826;;pmc6721482;;24218583;;10.1073/pnas.1309576110;;pmc3845144;;31934626;;10.1126/sciadv.aax5849;;pmc6949033;;27180111;;10.1016/j.jid.2016.04.030;;pmc6213003;;30261611;;10.3390/ijms19102923;;24518811;;10.1016/j.gene.2014.01.068;;10.1021/cm980066h;;10.1007/bf01955405;;10.1038/physci241020a0;;10.1021/ac0702084;;17458937;;10.1002/adhm.201200084;;23184822;;10.1007/978-1-4615-7353-1_4;;pmc3930332;;20401880;;10.1002/anie.200904359;;14719978;;10.1021/cr030698+;;10.1021/ja00904a001;;10.1021/ja906506j;;20102229;;10.1021/cm980065p;;26758382;;10.1039/c5sm02787j;;17197287;;10.1016/j.proghi.2006.09.001;;10.1038/nbt.2612;;23792630;;10.1002/9781444317633.ch3;;10.1016/j.yrtph.2015.05.005;;25979643;;10.1021/acsnano.1c06081;;34379407;;10.1034/j.1600-0625.2000.009003165.x;;10839713;;10.1016/j.jconrel.2016.07.027;;27449743;;10.1111/exd.13707;;29906306;;10.1002/smll.201601483;;27442290;;10.1021/acsami.9b11391;;31303000;;10.1021/ac0613582;;pmc2525614;;17165821;;2575325;;7944617;;10.1136/ard.53.7.450;;pmc1005369;;29150843;;10.1111/bjd.16137;;16704648;;10.1111/j.1365-2133.2006.07236.x;;10.1016/b978-0-323-61211-1.00045-0;;8352950;;10.1159/000211097;;10.1007/bf03214618;;11614517;;2093439;;10.1016/s0950-3579(05)80005-6;;18523733;;10.1007/s10787-007-0021-x;;10.1158/1078-0432.ccr-04-2482;;15867256;;10.1007/bf00918675;;104927;;10.1016/0090-6980(75)90043-x;;809810;;10.1016/0006-2952(80)90216-6;;6770866;;23112137;;10.1002/smll.201201528;;29624415;;10.1165/rcmb.2017-0430tr;;pmc6096346;;18451266;;pmc2951732;;10.1126/science.1158441;;10.1242/jcs.01596;;15564373;;10.1021/acs.accounts.9b00103;;31058496,"HO LOK WAI COLA ET AL: ""Effect of Alkylation on the Cellular Uptake of Polyethylene Glycol-Coated Gold Nanoparticles"", ACS NANO, vol. 11, no. 6, 7 June 2017 (2017-06-07), US, pages 6085 - 6101, XP055940552, ISSN: 1936-0851, DOI: 10.1021/acsnano.7b02044;;YIN BOHAN ET AL: ""Sub-10 nm Substrate Roughness Promotes the Cellular Uptake of Nanoparticles by Upregulating Endocytosis-Related Genes"", NANO LETTERS, vol. 21, no. 4, 15 February 2021 (2021-02-15), US, pages 1839 - 1847, XP055940792, ISSN: 1530-6984, DOI: 10.1021/acs.nanolett.0c04932;;YIN BOHAN ET AL: ""Intrapulmonary Cellular-Level Distribution of Inhaled Nanoparticles with Defined Functional Groups and Its Correlations with Protein Corona and Inflammatory Response"", ACS NANO, vol. 13, no. 12, 14 November 2019 (2019-11-14), US, pages 14048 - 14069, XP055940797, ISSN: 1936-0851, DOI: 10.1021/acsnano.9b06424;;NEMATI HOUSHANG ET AL: ""Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 268, 23 October 2017 (2017-10-23), pages 259 - 268, XP085300192, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.10.034;;ILARIA FRATODDI ET AL: ""Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model"", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, vol. 17, 1 April 2019 (2019-04-01), AMSTERDAM, NL, pages 276 - 286, XP055674865, ISSN: 1549-9634, DOI: 10.1016/j.nano.2019.01.006;;ÖZCAN ALAZ ET AL: ""Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 140, no. 5, 1 May 2020 (2020-05-01), NL, pages 1003 - 1014.e8, XP055940863, ISSN: 0022-202X, DOI: 10.1016/j.jid.2019.09.018;;MEHRMAL, S.UPPAL, P.NEDLEY, N.GIESEY, R. L.DELOST, G. R.: ""The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017"", J. AM. ACAD. DERMATOL., vol. 84, 2021, pages 46 - 52, XP086386776, DOI: 10.1016/j.jaad.2020.04.139;;GRIFFITHS, C. E.BARKER, J. N.: ""Pathogenesis and clinical features of psoriasis"", LANCET, vol. 370, 2007, pages 263 - 271, XP022157676, DOI: 10.1016/S0140-6736(07)61128-3;;BOEHNCKE, W. H.SCHON, M. P.: ""Psoriasis"", LANCET, vol. 386, 2015, pages 983 - 994, XP055860219, DOI: https://doi.org/10.1016/S0140-6736(14)61909-7;;PARISER, D. M. ET AL.: ""National Psoriasis Foundation clinical consensus on disease severity"", ARCH. DERMATOL., vol. 143, 2007, pages 239 - 242;;LOWES, M. A.BOWCOCK, A. M.KRUEGER, J. G.: ""Pathogenesis and therapy of psoriasis"", NATURE, vol. 445, 2007, pages 866 - 873, XP055112765, DOI: 10.1038/nature05663;;AUERBACH, R.: ""Methotrexate in psoriasis: Revised guidelines"", J. AM. ACAD. DERMATOL., vol. 19, 1988, pages 145 - 156, XP023331296, DOI: 10.1016/S0190-9622(88)80237-8;;WARREN, E. W.KHANDERIA, U.: ""Use of retinoids in the treatment of psoriasis"", CLIN. PHARM., vol. 8, 1989, pages 344,351;;ROSMARIN, D. M.LEBWOHL, M.ELEWSKI, B. E.GOTTLIEB, A. B.: ""Cyclosporine and psoriasis: 2008 National Psoriasis Foundation* Consensus Conference"", J. AM. ACAD. DERMATOL., vol. 62, 2010, pages 838 - 853;;LEBWOHL, M.: ""From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologies for psoriasis "", DERMATOL, vol. 58, 2008, pages 94 - 105, XP022395587, DOI: 10.1016/j.jaad.2007.08.030;;FERNANDEZ-RUIZ, M.AGUADO, J. M.: ""Risk of infection associated with anti-TNF-a therapy"", EXPERT REV. ANTI. INFECT. THER., vol. 16, 2018, pages 939 - 956;;CASTELA, E. ET AL.: ""Topical corticosteroids in plaque psoriasis: A systematic review of efficacy and treatment modalities"", J. EUR. ACAD. DERMATOLOGY VENEREOL., vol. 26, 2012, pages 36 - 46;;FEREIG, S. A.EL-ZAAFARANY, G. M.ARAFA, M. G.ABDEL-MOTTALEB, M. M. A.: ""Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis"", DRUG DELIV., vol. 27, 2020, pages 662 - 680;;ARORA, R.KATIYAR, S. S.KUSHWAH, V.JAIN, S.: ""Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study"", EXPERT OPIN. DRUG DELIV., vol. 14, 2017, pages 165 - 177;;AVASATTHI, V. ET AL.: ""A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation"", PHARM. DEV. TECHNOL., vol. 21, 2016, pages 554 - 562;;FERREIRA, M. ET AL.: ""Methotrexate loaded lipid nanoparticles for topical management of skin-related diseases: Design, characterization and skin permeation potential"", INT. J. PHARM., vol. 512, 2016, pages 14 - 21, XP029732871, DOI: 10.1016/j.ijpharm.2016.08.008;;SAPINO, S.OLIARO-BOSSO, S.ZONARI, D.ZATTONI, A.UGAZIO, E.: ""Mesoporous silica nanoparticles as a promising skin delivery system for methotrexate"", INT. J. PHARM., vol. 530, 2017, pages 239 - 248, XP085169163, DOI: 10.1016/j.ijpharm.2017.07.058;;KOHLER, N.SUN, C.WANG, J.ZHANG, M.: ""Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells"", LANGMUIR, vol. 21, 2005, pages 8858 - 8864;;WONG, L. S.TYMMS, K. E.BUCKLEY, N. A.: ""Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant"", INTERN. MED. J., vol. 39, 2009, pages 379 - 383;;BESSAR, H. ET AL.: ""Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis"", COLLOIDS SURFACES B BIOINTERFACES, vol. 141, 2016, pages 141 - 147, XP029465891, DOI: 10.1016/j.colsurfb.2016.01.021;;PINTO, M. F. ET AL.: ""A new topical formulation for psoriasis: Development of methotrexate-loaded nanostructured lipid carriers"", INT. J. PHARM., vol. 477, 2014, pages 519 - 526;;FRATODDI, I. ET AL.: ""Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model"", NANOMEDICINE NANOTECHNOLOGY, BIOL. MED., vol. 17, 2019, pages 276 - 286, XP055674865, DOI: 10.1016/j.nano.2019.01.006;;OZCAN, A. ET AL.: ""Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis"", J. INVEST. DERMATOL., vol. 140, 2020, pages 1003 - 1014;;FERREIRA, M. ET AL.: ""Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management"", COLLOIDS SURFACES B BIOINTERFACES, vol. 159, 2017, pages 23 - 29;;VIEGAS, J. S. R. ET AL.: ""Nanostructured lipid carrier co-delivering tacrolimus and TNF-a siRNA as an innovate approach to psoriasis"", DRUG DELIV. TRANSL. RES., vol. 10, 2020, pages 646 - 660, XP037127788, DOI: 10.1007/s13346-020-00723-6;;ZHENG, D. ET AL.: ""Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation"", PROC. NATL. ACAD. SCI. U. S. A., vol. 109, 2012, pages 11975 - 11980, XP055271748, DOI: 10.1073/pnas.1118425109;;LEWANDOWSKI, K. T. ET AL.: ""Topically Delivered Tumor Necrosis Factor-a-Targeted Gene Regulation for Psoriasis"", J. INVEST. DERMATOL., vol. 137, 2017, pages 2027 - 2030;;NEMATI, H. ET AL.: ""Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis"", J. CONTROL. RELEASE, vol. 268, 2017, pages 259 - 268, XP085300192, DOI: 10.1016/j.jconrel.2017.10.034;;LIU, H. ET AL.: ""Targeting the IL-17 Receptor Using Liposomal Spherical Nucleic Acids as Topical Therapy for Psoriasis"", J. INVEST. DERMATOL., vol. 140, 2020, pages 435 - 444;;KORKMAZ, E.FALO, L. D.: ""Spherical Nucleic Acids as Emerging Topical Therapeutics: A Focus on Psoriasis"", J. INVEST. DERMATOL., vol. 140, 2020, pages 278 - 281;;KIM, J. Y. ET AL.: ""Nanoparticle-Assisted Transcutaneous Delivery of a Signal Transducer and Activator of Transcription 3-Inhibiting Peptide Ameliorates Psoriasis-like Skin Inflammation"", ACS NANO, vol. 12, 2018, pages 6904 - 6916, XP055770158, DOI: 10.1021/acsnano.8b02330;;LIANG, H. ET AL.: ""Topical nanoparticles interfering with the DNA-LL37 complex to alleviate psoriatic inflammation in mice and monkeys"", SCI. ADV., vol. 6, 2020, pages 1 - 15;;HORNOS CARNEIRO, M. F.BARBOSA, F.: ""Gold nanoparticles: A critical review of therapeutic applications and toxicological aspects"", J. TOXICOL. ENVIRON. HEAL. - PART B CRIT. REV., vol. 19, 2016, pages 129 - 148;;ARVIZO, R. R. ET AL.: ""Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle"", PROC. NATL. ACAD. SCI. U. S. A., vol. 110, 2013, pages 6700 - 6705;;SAHA, S. ET AL.: ""Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth"", ACS NANO, vol. 10, 2016, pages 10636 - 10651;;ZHANG, Y. ET AL.: ""Gold nanoparticles inhibit activation of cancer-associated fibroblasts by disrupting communication from tumor and microenvironmental cells"", BIOACT. MATER., vol. 6, 2021, pages 326 - 332;;HO, L. W. C. ET AL.: ""Effect of Alkylation on the Cellular Uptake of Polyethylene Glycol-Coated Gold Nanoparticles"", ACS NANO, vol. 11, 2017, pages 6085 - 6101;;HO, L. W. C.YIN, B.DAI, G.CHOI, C. H. J.: ""Effect of Surface Modification with Hydrocarbyl Groups on the Exocytosis of Nanoparticles"", BIOCHEMISTRY;;LOWES, M. A.SUAREZ-FARINAS, M.KRUEGER, J. G.: ""Immunology of psoriasis"", ANNU. REV. IMMUNOL., vol. 32, 2014, pages 227 - 255;;VAN DER FITS, L. ET AL.: ""Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis"", J. IMMUNOL., vol. 182, 2009, pages 5836 - 5845, XP055376245, DOI: 10.4049/jimmunol.0802999;;SONAVANE, G. ET AL.: ""In vitro permeation of gold nanoparticles through rat skin and rat intestine: Effect of particle size"", COLLOIDS SURFACES B BIOINTERFACES, vol. 65, 2008, pages 1 - 10, XP022710106, DOI: 10.1016/j.colsurfb.2008.02.013;;OGAWA, E.SATO, Y.MINAGAWA, A.OKUYAMA, R.: ""Pathogenesis of psoriasis and development of treatment"", J. DERMATOL., vol. 45, 2018, pages 264 - 272;;SOKOLOWSKA-WOJDYLO, M.NEDOSZYTKO, B.RUCKEMANN-DZIURDZINSKA, K.ROSZKIEWICZ, J.NOWICKI, R. J., CHEMOKINES AND CYTOKINES NETWORK IN THE PATHOGENESIS OF THE INFLAMMATORY SKIN DISEASES: ATOPIC DERMATITIS, PSORIASIS AND SKIN MASTOCYTOSIS, 2014;;LEE, C. H.HWANG, S. T. Y.: ""Pathophysiology of chemokines and chemokine receptors in dermatological science: A focus on psoriasis and cutaneous T-cell lymphoma"", DERMATOLOGICA SIN, vol. 30, 2012, pages 128 - 135, XP028960664, DOI: 10.1016/j.dsi.2012.08.004;;MEHUL, B. ET AL.: ""Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling"", BR. J. DERMATOL., vol. 177, 2017, pages 470 - 488, XP071119075, DOI: 10.1111/bjd.15346;;JONES, R.: ""Antimicrobial peptides in the pathogenesis of psoriasis Shin"", BONE, vol. 23, 2014, pages 1 - 7;;ZHANG, X.YIN, M.ZHANG, L. J.: ""Keratin 6, 16 and 17-Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis"", CELLS, vol. 8, 2019, pages 1 - 14, XP055815383, DOI: 10.3390/cells8080807;;LESSARD, J. C. ET AL.: ""Keratin 16 regulates innate immunity in response to epidermal barrier breach"", PROC. NATL. ACAD. SCI. U. S. A., vol. 110, 2013, pages 19537 - 19542;;BENHADOU, F. ET AL.: ""Epidermal autonomous VEGFA/Fltl/Nrpl functions mediate psoriasis-like disease"", SCI. ADV., 2020, pages 6;;RUIZ-ROMEU, E. ET AL.: ""MCPIP1 RNase Is Aberrantly Distributed in Psoriatic Epidermis and Rapidly Induced by IL-17A"", J. INVEST. DERMATOL., vol. 136, 2016, pages 1599 - 1607;;RIOUX, G. ET AL.: ""The tissue-engineered human psoriatic skin substitute: A valuable in vitro model to identify genes with altered expression in lesional psoriasis"", INT. J. MOL. SCI., vol. 19, 2018;;MEZENTSEV, A.NIKOLAEV, A.BRUSKIN, S.: ""Matrix metalloproteinases and their role in psoriasis"", GENE, vol. 540, 2014, pages 1 - 10, XP028630398, DOI: 10.1016/j.gene.2014.01.068;;R. BROWN, K.ANDREW LYON, L.P. FOX, A.D. REISS, B.J. NATAN, M.: ""Hydroxylamine Seeding of Colloidal Au Nanoparticles. 3. Controlled Formation of Conductive Au Films"", CHEM. MATER., vol. 12, 2000, pages 314 - 323, XP000927801, DOI: 10.1021/cm980066h;;MIIHLPFORDT, H.: ""The preparation of colloidal gold particles using tannic acid as an additional reducing agent"", EXPERIENTIA, vol. 38, 1982, pages 1127 - 1128;;FRENS, G.: ""Controlled nucleation for the regulation of the particle size in monodisperse gold suspension"", NATURE, vol. 241, 1973, pages 20 - 22, XP008071779;;HAISS, W.THANH, N. T. K.AVEYARD, J.FERNIG, D. G.: ""Determination of size and concentration of gold nanoparticles from UV-Vis spectra"", ANAL. CHEM., vol. 79, 2007, pages 4215 - 4221;;CHOU, L. Y. T.CHAN, W. C. W.: ""Fluorescence-Tagged Gold Nanoparticles for Rapidly Characterizing the Size-Dependent Biodistribution in Tumor Models"", ADV. HEALTHC. MATER., vol. 1, 2012, pages 714 - 721;;DUNNETT, C. W.: ""Linear Statistical Inference"", 1985, SPRINGER, article ""Multiple comparisons between several treatments and a specified treatment"", pages: 39 - 47;;GILJOHANN, D. A. ET AL.: ""Gold nanoparticles for biology and medicine"", ANGEW. CHEMIE, vol. 49, 2010, pages 3280 - 3294, XP055141717, DOI: 10.1002/anie.200904359;;DANIEL, M.-C.ASTRUC, D.: ""Gold Nanoparticles: Assembly, Supramolecular Chemistry, Quantum-Size-Related Properties, and Applications toward Biology, Catalysis, and Nanotechnology"", CHEM. REV., vol. 104, 2004, pages 293 - 346, XP001186731, DOI: 10.1021/cr030698+;;ENUSTUN, B. VTURKEVICH, J.: ""Coagulation of Colloidal Gold"", J. AM. CHEM. SOC., vol. 85, 1963, pages 3317 - 3328;;POLTE, J. ET AL.: ""Mechanism of Gold Nanoparticle Formation in the Classical Citrate Synthesis Method Derived from Coupled In Situ XANES and SAXS Evaluation"", J. AM. CHEM. SOC., vol. 132, 2010, pages 1296 - 1301;;BROWN, K. R.WALTER, D. G.NATAN, M. J.: ""Seeding of Colloidal Au Nanoparticle Solutions. 2. Improved Control of Particle Size and Shape"", CHEM. MATER., vol. 12, 2000, pages 306 - 313, XP000927800, DOI: 10.1021/cm980065p;;WORTHEN, A. J.TRAN, V.CORNELL, K. A.TRUSKETT, T. M.JOHNSTON, K. P.: ""Steric stabilization of nanoparticles with grafted low molecular weight ligands in highly concentrated brines including divalent ions"", SOFT MATTER, vol. 12, 2016, pages 2025 - 2039, XP055363498, DOI: 10.1039/C5SM02787J;;YAMASHITA, S.: ""Heat-induced antigen retrieval: Mechanisms and application to histochemistry"", PROG. HISTOCHEM. CYTOCHEM., vol. 41, 2007, pages 141 - 200, XP002482121, DOI: 10.1016/j.proghi.2006.09.001;;GILLERON, J. ET AL.: ""Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape"", NAT. BIOTECHNOL., vol. 31, 2013, pages 638 - 646, XP055450624, DOI: 10.1038/nbt.2612;;MCGRATH, J. A.UITTO, J.: ""Anatomy and organization of human skin"", ROOK'S TEXTBOOK OF DERMATOLOGY, 2010, pages 1 - 53;;LARESE FILON, F.MAURO, M.ADAMI, G.BOVENZI, M.CROSERA, M.: ""Nanoparticles skin absorption: New aspects for a safety profile evaluation"", REGUL. TOXICOL. PHARMACOL., vol. 72, 2015, pages 310 - 322;;LIU, Y. ET AL.: ""Dopamine Receptor-Mediated Binding and Cellular Uptake of Polydopamine-Coated Nanoparticles"", ACS NANO, vol. 15, 2021, pages 13871 - 13890;;BOS, J. D.MEINARDI, M. M. H. M.: ""The 500 Dalton rule for the skin penetration of chemical compounds and drugs"", EXP. DERMATOL., vol. 9, 2000, pages 165 - 169, XP055238058, DOI: 10.1034/j.1600-0625.2000.009003165.x;;VOGT, A. ET AL.: ""Nanocarriers for drug delivery into and through the skin — Do existing technologies match clinical challenges?"", J. CONTROL. RELEASE, vol. 242, 2016, pages 3 - 15, XP029809679, DOI: 10.1016/j.jconrel.2016.07.027;;CRISAN, D. ET AL.: ""Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF- B activity"", EXP. DERMATOL., vol. 27, 2016, pages 1166 - 1169;;YANG, H. ET AL.: ""Mechanism for the Cellular Uptake of Targeted Gold Nanorods of Defined Aspect Ratios"", SMALL, vol. 12, 2016, pages 5178 - 5189;;CHEN, Z. ET AL.: ""Specific Delivery of Oligonucleotides to the Cell Nucleus via Gentle Compression and Attachment of Polythymidine"", ACS APPL. MATER. INTERFACES, vol. 11, 2019, pages 27624 - 27640;;HURST, S. J.LYTTON-JEAN, A. K. R.MIRKIN, C. A.: ""Maximizing DNA loading on a range of gold nanoparticle sizes"", ANAL. CHEM., vol. 78, 2006, pages 8313 - 8318, XP002465378, DOI: 10.1021/ac0613582;;RIJZEWIJK, J. J.VAN ERP, P. E.BAUER, F. W.: ""Two binding sites for Ki67 related to quiescent and cycling cells in human epidermis"", ACTA DERM. VENEREOL., vol. 69, 1989, pages 512 - 515;;VEALE, D. J.BARNES, L.ROGERS, S.FITZGERALD, O.: ""Immunohistochemical markers for arthritis in psoriasis"", ANN. RHEUM. DIS., vol. 53, 1994, pages 450 - 454;;VASSEUR, P. ET AL.: ""Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis"", BR. J. DERMATOL., vol. 179, 2018, pages 101 - 109;;KRAGBALLE, K. ET AL.: ""A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet@/Daivobet@/Taclonex@) in the treatment of psoriasis vulgaris"", BR. J. DERMATOL., vol. 154, 2006, pages 1155 - 1160;;CAMISA, C.GAROFOLA, C.: ""Topical Corticosteroids"", 2021, ELSEVIER, pages: 511 - 527;;STENN, K. S.PAUS, R.DUTTON, T.SARBA, B.: ""Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration"", SKIN PHARMACOL. PHYSIOL., vol. 6, 1993, pages 125 - 134;;HIGBY, G. J.: ""Gold in medicine - A review of its use in the west before 1900"", GOLD BULL, vol. 15, 1982, pages 130 - 140;;CHAMPION, G. D.GRAHAM, G. G.ZIEGLER, J. B.: ""The gold complexes"", BAILLIERES. CLIN. RHEUMATOL., vol. 4, 1990, pages 491 - 534;;KEAN, W. F.KEAN, I. R. L.: ""Clinical pharmacology of gold"", INFLAMMOPHARMACOLOGY, vol. 16, 2008, pages 112 - 125;;MUKHERJEE, P. ET AL.: ""Antiangiogenic properties of gold nanoparticles"", CLIN. CANCER RES., vol. 11, 2005, pages 3530 - 3534;;DIMARTINO, M. J.WALZ, D. T.: ""Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent"", INFLAMMATION, vol. 2, 1977, pages 131 - 142;;STONE, K. J.MATHER, S. J.GIBSON, P. P.: ""Selective inhibition of prostaglandin biosynthesis by gold salts and phenylbutazone"", PROSTAGLANDINS, vol. 10, 1975, pages 241 - 251, XP023449374, DOI: 10.1016/0090-6980(75)90043-X;;GOLDBERG, R. L.PARROTT, D. P.KAPLAN, S. R.FULLER, G. C.: ""Effect of gold sodium thiomalate on proliferation of human rheumatoid synovial cells and on collagen synthesis in tissue culture"", BIOCHEM. PHARMACOL., vol. 29, 1980, pages 869 - 876, XP023871581, DOI: 10.1016/0006-2952(80)90216-6;;SUMBAYEV, V. V ET AL.: ""Gold Nanoparticles Downregulate Interleukin- I 0-Induced ProInflammatory Responses"", SMALL, vol. 9, 2013, pages 472 - 477;;KOCH, C. M. ET AL.: ""A beginner's guide to analysis of RNA sequencing data"", AM. J. RESPIR. CELLMOL. BIOL., vol. 59, 2018, pages 145 - 157;;NAGALAKSHMI, U. ET AL.: ""The Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing"", SCIENCE, vol. 320, 2008, pages 1344 - 1349;;SCHUCK, S.SIMONS, K.: ""Polarized sorting in epithelial cells: raft clustering and the biogenesis of the apical membrane"", J. CELL SCI., vol. 117, 2004, pages 5955 - 5964;;HO, L. W. C.LIU, Y.HAN, R.BAI, Q.CHOI, C. H. J.: ""Nano-Cell Interactions of Non-Cationic Bionanomaterials"", ACC. CHEM. RES., vol. 52, 2019, pages 1519 - 1530",PENDING
124,WO,A1,WO 2019/200184 A1,160-590-155-103-368,2019-10-17,2019,US 2019/0027108 W,2019-04-11,US 201862656868 P,2018-04-12,CHEMICALLY-DEFINED BACULOVIRUS EXPRESSION SYSTEM AND CELL CULTURE MEDIUM,"The present disclosure is related generally to systems and methods for high level expression of recombinant proteins from baculovirus in insect cells. In particular, the methods and systems described herein allow for high levels of baculovirus production in insect cells and/or high levels of protein production in insect cells using a chemically-defined, yeast lysate-free insect cell medium. The disclosure also relates to compositions and kits for culturing, transfecting, and/or producing recombinant protein in insect cells.",LIFE TECHNOLOGIES CORP,YOVCHEVA MAYA;;ZMUDA JONATHAN;;BARNES SARA;;CHOI CHANG;;THOMPSON KENNETH,,https://lens.org/160-590-155-103-368,Patent Application,yes,2,0,7,7,0,C12N5/0601;;C12N15/86;;C12N2710/14143;;C12N2710/14151;;C12N15/86;;C12N5/0601;;C12N2710/14143;;C12N2710/14151;;C12N2510/00;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2500/02;;C12N2500/05;;C12N2500/34;;C12N2500/38;;C12N2510/00;;C12N2710/14143;;C12N2710/14151;;C12P21/00,C12N15/86;;C12N5/00;;C12N5/07,,9,7,013-591-684-401-875;;017-616-019-160-905;;010-375-157-277-133;;081-912-196-326-926;;026-000-057-554-156;;106-796-573-456-153;;069-615-063-086-177,10.1016/j.jbiotec.2007.06.009;;17655959;;12733003;;10.1007/s00253-003-1223-9;;17278046;;10.1007/s00449-006-0099-3;;pmc3449798;;19002930;;10.1023/b:cyto.0000009816.65227.84;;10.1042/0264-6021:3420293;;10.1042/bj3420293;;10455014;;pmc1220464;;10.1007/bf02616215;;10.1007/s10616-007-9062-7;;19003015;;pmc2267510,"YOVCHEVA MAYA ET AL.: ""A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells"", 2017, XP002792438, Retrieved from the Internet <URL:https://assets.thermofisher.com/TFS-Assets/BID/posters/chemically-defined-baculovirus-expression-system-sf9-cells-poster.pdf> [retrieved on 20190625];;DATABASE WPI Week 201609, Derwent World Patents Index; AN 2016-06473H, XP002792439;;PENG ET AL: ""The histone deacetylase inhibitor sodium butyrate inhibits baculovirus-mediated transgene expression in Sf9 cells"", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 131, no. 2, 6 August 2007 (2007-08-06), pages 180 - 187, XP022184734, ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2007.06.009;;IKONOMOU L ET AL: ""Insect cell culture for industrial production of recombinant proteins"", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, DE, vol. 62, no. 1, 1 July 2003 (2003-07-01), pages 1 - 20, XP002550783, ISSN: 0175-7598, DOI: 10.1007/S00253-003-1223-9;;RONALDO ZUCATELLI MENDONÇA ET AL: ""Effect of bioactive peptides isolated from yeastolate, lactalbumin and NZCase in the insect cell growth"", BIOPROCESS AND BIOSYSTEMS ENGINEERING, SPRINGER, BERLIN, DE, vol. 30, no. 3, 4 February 2007 (2007-02-04), pages 157 - 164, XP019518081, ISSN: 1615-7605, DOI: 10.1007/S00449-006-0099-3;;DEPARIS V ET AL: ""Promoting effect of rapeseed proteins and peptides on Sf9 insect cell growth"", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 42, no. 2, 1 June 2003 (2003-06-01), pages 75 - 85, XP019236787, ISSN: 1573-0778, DOI: 10.1023/B:CYTO.0000009816.65227.84;;CORNÉ H W KLAASSEN ET AL: ""Large-scale production and purification of functional recombinant bovine rhodopsin with the use of the baculovirus expression system"", BIOCHEM. J, vol. 342, 1 January 1999 (1999-01-01), pages 293 - 300, XP055598981;;MARUNOUCHI: ""Substitution of inosine for yeastolate in the culture medium forDrosophila cells"", IN VITRO, vol. 14, no. 12, 1 January 1978 (1978-01-01), pages 1010 - 1014, XP055598926;;SHEN ET AL., CYTOTECHNOLOGY, vol. 54, no. 1, May 2007 (2007-05-01), pages 25 - 34",PENDING
125,US,B2,US 10533189 B2,017-805-272-892-774,2020-01-14,2020,US 201715708810 A,2017-09-19,US 201715708810 A;;US 201662397173 P,2016-09-20,Highly specific delivery of polynucleotides to the cell nucleus via compression,"The subject invention pertains to delivering a polynucleotide into a target cell, particularly, into the nucleus of the target cell. The method comprises the steps of contacting the polynucleotide with the cell and applying pressure on the polynucleotide and the cell in a manner that forces the polynucleotide into the cell. The pressure can be between about 0.1 Pa to about 50 Pa; whereas, the polynucleotide is contacted with the cell at a concentration of between about 0.1 μM and about 100 μM. The method can be practiced for cells in culture or cells in vivo.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;CHEN ZHONG;;ZHANG LEI;;LI HUIZE,THE CHINESE UNIVERSITY OF HONG KONG (2017-10-16),https://lens.org/017-805-272-892-774,Granted Patent,yes,2,0,2,2,8,A61K48/00;;C12N15/87;;C12N15/87;;C12N15/111;;C12N15/113;;C12N2310/11;;C12N2320/32;;C12N2320/32,C12N15/11;;A61K48/00;;C12N15/113;;C12N15/87,,31,31,033-596-578-617-152;;027-274-256-011-001;;045-791-058-371-469;;094-115-100-766-418;;063-526-246-810-428;;015-639-251-167-350;;014-430-992-456-906;;038-019-988-265-171;;026-212-052-373-801;;046-759-373-855-603;;030-600-013-462-018;;003-651-791-801-582;;038-415-332-525-473;;046-106-255-853-051;;039-405-628-963-568;;034-380-832-234-039;;111-010-848-536-851;;037-576-292-933-317;;004-035-579-568-928;;137-592-978-869-925;;093-319-495-596-801;;018-280-868-423-992;;005-447-201-545-537;;027-699-664-009-406;;073-551-480-303-464;;067-644-022-031-778;;000-362-844-900-809;;003-475-517-544-325;;014-684-224-260-150;;176-455-328-074-622;;099-803-034-744-958,10766243;;10.1038/35007077;;10.1038/nrm2184;;17519961;;10.1038/nri2690;;20098460;;10625387;;10.1038/71889;;16834560;;10.1146/annurev.bioeng.8.061505.095735;;10.1073/pnas.81.22.7161;;pmc392097;;6438633;;pmc299306;;10.1073/pnas.84.21.7413;;2823261;;10.1073/pnas.92.16.7297;;pmc41326;;7638184;;10.1073/pnas.0636277100;;12644705;;pmc153016;;10.1126/science.270.5235.404;;7569994;;8616713;;10.1038/nm0596-545;;1849273;;pmc51306;;10.1073/pnas.88.7.2702;;10.1038/nm0402-415;;11927950;;10.1038/11726;;10429244;;pmc15098;;10.1073/pnas.96.1.91;;9874777;;22424173;;10.1021/nn300296p;;pmc3337354;;17406333;;pmc2649370;;10.1038/nprot.2006.145;;10.1146/annurev.bioeng.2.1.289;;11701514;;10.1073/pnas.96.11.6411;;pmc26895;;10339601;;10.1007/s10237-016-0779-0;;26994918;;22203958;;10.1073/pnas.1118910109;;pmc3271885;;pmc307498;;8559650;;10.1093/nar/23.24.4946;;10.1093/nar/gkp1021;;10.1093/nar/gkp841;;pmc2800216;;pmc2808926;;19923233;;19854938;;10.1126/science.1125559;;16709779;;12408823;;10.1016/s1097-2765(02)00652-4;;12771196;;pmc156727;;10.1093/nar/gkg393;;10.1038/nbt1122;;16041363;;10.1038/nature03121;;15538359;;27734871;;10.1038/nature19764;;pmc4643799;;26601238;;10.1126/sciadv.1500454;;28932622;;pmc5602535;;10.1038/s41551-017-0039,"Phair, Robert D. et al., High mobility of proteins in the mammalian cell nucleus, Letters to Nature, Apr. 6, 2000, 404(6778):604-609, Macmillan Magazines Ltd.;;Boisvert, François-Michel et al., The multifunctional nucleolus, Nature Reviews Molecular Cell Biology, Jul. 2007, 8(7):574-585, Nature Publishing Group.;;Hornung, Veit et al., Intracellular DNA recognition, Nature Reviews Immunology, Feb. 2010, 10:123-130, Macmillan Publishers Limited.;;Luo, Dan et al., Synthetic DNA delivery systems, Nature Biotechnology, Jan. 2000, 18:33-37, Nature America Inc.;;Torchilin, Vladimir P., Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting, Annual Review of Biomedical Engineering, 2006, 8:343-375, Annual Reviews.;;Potter, Huntington et al., Enhancer-dependent expression of human K immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation, Proceedings of the National Academy of Sciences of the United States of America, Nov. 1984, 81(22):7161-7165.;;Felgner, Philip L. et al., Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proceedings of the National Academy of Sciences of the United States of America, Nov. 1987, 84(21):7413-7417.;;Boussif, Otmane et al., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine, Proceedings of the National Academy of Sciences of the United States of America, Aug. 1995, 92(16):7297-7301.;;Suh, Junghae et al., Efficient active transport of gene nanocarriers to the cell nucleus, Proceedings of the National Academy of Sciences of the United States of America, Apr. 1, 2003, 100(7):3878-3882.;;Crystal, Ronald G. et al., Transfer of Genes to Humans: Early Lessons and Obstacles to Success, Science, Oct. 20, 1995, 270(5235):404-410.;;Tripathy, Sandeep K. et al., Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors, Nature Medicine, May 1996, 2(5):545-550, Nature Publishing Group.;;Leonetti, Jean Paul et al., Intracellular distribution of microinjected antisense oligonucleotides, Proceedings of the National Academy of Sciences of the United States of America, Apr. 1991, 88(7):2702-2706.;;Mikszta, John A. et al., Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery, Nature Medicine, Apr. 2002, 8(4):415-419, Nature Publishing Group.;;Brandén, Lars J. et al., A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA, Nature Biotechnology, Aug. 1999, 17:784-787, Nature America Inc.;;Zanta, Maria Antonietta et al., Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus, Proceedings of the National Academy of Sciences of the United States of America, Jan. 1999, 96(1):91-96.;;Dam, Duncan Hieu M. et al., Direct Observation of Nanoparticle-Cancer Cell Nucleus Interactions, ACS Nano, 2012, 6(4):3318-3326, American Chemical Society.;;O'Brien, John A. et al., Biolistic transfection of neuronal cultures using a hand-held gene gun, Nature Protocols, 2006, 1(2):977-981, Nature Publishing Group.;;McAllister, Devin V. et al., Microfabricated Microneedles for Gene and Drug Delivery, Annual Review of Biomedical Engineering, 2000, 2:289-313, Annual Reviews.;;Mann, Michael J. et al., Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues, Proceedings of the National Academy of Sciences of the United States of America, May 1999, 96(11):6411-6416.;;Yao, Yifei et al., Effects of oxidative stress-induced changes in the actin cytoskeletal structure on myoblast damage under compressive stress: confocal-based cell-specific finite element analysis, Biomech Model Mechanobiol, 2016, 15(6):1495-1508, Springer-Verlag Berlin Heidelberg.;;Tse, Janet M. et al., Mechanical compression drives cancer cells toward invasive phenotype, Proceedings of the National Academy of Sciences of the United States of America, Jan. 17, 2012, 109(3):911-916.;;Politz, Joan C. et al., Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells, Nucleic Acids Research, 1995, 23(24):4946-4953, Oxford University Press.;;Stein, C. A. et al., Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents, Nucleic Acids Research, 2010, 38(1):e3, Oxford University Press.;;Rosi, Nathaniel L. et al., Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation, Science, May 19, 2006, 312(5776):1027-1030, American Association for the Advancement of Science.;;Chiu, Ya-Lin et al., RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA, Molecular Cell, Sep. 2002, 10(3):549-561, Cell Press.;;Czauderna, Frank et al., Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells, Nucleic Acids Research, 2003, 31(11):2705-2716, Oxford University Press.;;Morrissey, David V. et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs, Nature Biotechnology, Aug. 2005, 23(8):1002-1007, Nature Publishing Group.;;Soutschek, Jürgen et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, Nov. 11, 2004, 432(7014)1 73-178, Nature Publishing Group.;;Stewart, Martin P. et al., In vitro and ex vivo strategies for intracellular delivery, Nature, Oct. 13, 2016, 538:183-192, Macmillan Publishers Limited, part of Springer Nature.;;Han, X. et al., “CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation,” Science Advances, Aug. 14, 2015, 1(7):1-9.;;Ding, X. et al., “High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption,” Nature Biomedical Engineering, Mar. 9, 2017, 1(0039):1-7, Macmillan Publishers Limited, part of Springer Nature.",ACTIVE
126,KR,A,KR 20210003776 A,171-356-364-192-014,2021-01-12,2021,KR 20207031641 A,2019-04-11,US 201862656868 P;;US 2019/0027108 W,2018-04-12,화학적으로-정의된 바큘로바이러스 발현 시스템 및 세포 배양 배지,"본 개시내용은 일반적으로 곤충 세포에서 바큘로바이러스로부터 재조합 단백질의 고수준 발현을 위한 시스템 및 방법에 관한 것이다. 특히, 본원에서 기재된 방법 및 시스템은 화학적으로 정의된, 효모 용해물-미함유 곤충 세포 배지를 이용하여 곤충 세포에서 높은 수준의 단백질 생성 및/또는 곤충 세포에서 높은 수준의 바큘로바이러스 생성을 허용한다. 본 개시내용은 또한 재조합 단백질을 곤충 세포에서 배양, 트랜스펙션, 및/또는 생성하기 위한 조성물 및 키트에 관한 것이다.",LIFE TECHNOLOGIES CORP,YOVCHEVA MAYA;;ZMUDA JONATHAN;;BARNES SARA;;CHOI CHANG;;THOMPSON KENNETH,,https://lens.org/171-356-364-192-014,Patent Application,no,0,1,7,7,0,C12N5/0601;;C12N15/86;;C12N2710/14143;;C12N2710/14151;;C12N15/86;;C12N5/0601;;C12N2710/14143;;C12N2710/14151;;C12N2510/00;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2500/02;;C12N2500/05;;C12N2500/34;;C12N2500/38;;C12N2510/00;;C12N2710/14143;;C12N2710/14151;;C12P21/00,C12N15/86;;C12N5/07,,0,0,,,,PENDING
127,US,A1,US 2021/0020358 A1,025-561-494-448-347,2021-01-21,2021,US 202016929567 A,2020-07-15,US 202016929567 A;;US 201962874496 P,2019-07-15,ELECTRICAL ASSEMBLIES INCLUDING COUPLERS FOR CANCELING MAGNETIC FLUX,"An electrical assembly includes (a) a first inductor including a first winding wound around a first winding axis, (b) a second inductor separated from the first inductor in a first direction, and (c) a coupler at least partially disposed between the first inductor and the second inductor in the first direction, the coupler forming at least part of an electrical circuit enabling electric current to flow through the coupler, and the coupler being asymmetric with respect to a dividing axis of the first inductor extending in a second direction that is orthogonal to the first direction.",MAXIM INTEGRATED PRODUCTS,CHOI JAEYOUNG;;HUNG JONATHAN C H (CHENG-HSIEN);;HUANG TAO,,https://lens.org/025-561-494-448-347,Patent Application,yes,6,1,3,3,0,H01L23/5227;;H01F27/346;;H01F27/363;;H01F27/2804;;H01F27/346;;H01F27/363;;H01F27/38,H01F27/34;;H01F27/36;;H01F27/38,,0,0,,,,PENDING
128,US,B2,US 8999623 B2,175-458-308-761-350,2015-04-07,2015,US 201313831193 A,2013-03-14,US 201313831193 A,2013-03-14,Degradable neutral layers for block copolymer lithography applications,Polymer films comprising crosslinked random copolymers and methods for making the films are provided. Also provided are polymer films comprising random copolymers that are covalently linked to an underlying substrate. The polymer films can be incorporated into structures in which the films are employed as surface-modifying layers for domain-forming block copolymers and the structures can be used for pattern transfer applications via block copolymer lithography. The crosslinks between the random copolymer chains in the polymer films or the links between the random copolymer chains and the substrate surface are characterized in that they can be cleaved under relatively mild conditions.,WISCONSIN ALUMNI RES FOUND;;WISCOUSIN ALUMNI RES FOUNDATION,GOPALAN PADMA;;SWEAT DANIEL PATRICK;;CHOI JONATHAN WOOSUN;;KIM MYUNGWOONG,WISCONSIN ALUMNI RESEARCH FOUNDATION (2013-04-01),https://lens.org/175-458-308-761-350,Granted Patent,yes,48,1,2,2,0,B81C1/00031;;B81C1/00031;;B32B27/30;;B81C2201/0149;;B81C2201/0149;;B82Y30/00;;B82Y30/00;;C09D153/00;;C09D153/00,G03C1/00;;B32B27/30;;B82Y30/00;;C09D153/00;;G03F7/00,430/270.1;;430/285.1;;430/296,26,22,038-672-447-150-197;;066-897-874-344-618;;009-282-021-411-18X;;130-678-318-352-405;;109-752-052-733-543;;025-861-520-018-290;;015-881-354-664-793;;020-304-683-917-721;;010-029-940-880-08X;;019-004-358-143-734;;088-899-711-016-641;;036-160-663-477-176;;063-780-627-071-570;;031-256-812-065-250;;038-102-999-944-177;;064-707-032-067-56X;;155-417-576-608-006;;014-582-325-273-754;;108-589-998-598-051;;005-803-122-428-998;;068-672-412-195-529;;037-480-909-335-637,10.1002/pola.25069;;23108922;;10.1002/chem.201202685;;10.1021/ma901987q;;10.1002/macp.201200486;;10.1039/jm9920200811;;10.1021/nn101491g;;20738125;;10.1116/1.3253607;;10.1039/jm9910101045;;10.1021/ma011003e;;10.1021/nn7001079;;19206681;;10.1021/ma702291k;;10.1016/s0032-3861(99)00623-0;;10.1021/ma201924h;;23088516;;10.1021/la304141m;;10.1021/ma102856t;;10.1021/la060748g.s001;;16922574;;10.1021/la060748g;;10.1021/ma8018393;;19791776;;10.1021/la902483m;;10.1002/adma.200602708;;10.1021/ma9002903;;10.1016/s0040-4020(01)88528-8;;10.1002/macp.200300168,"Pillai et al., Synthesis of thioredoxin partial sequences on a polyethyleneglycol-grafted polystyrene support with a photolytically detachable 2-nitrobenzyl anchoring group, Indian Journal of Chemistry, vol. 30B, Feb. 1991, pp. 205-212.;;Schumers et al., Synthesis and Self-Assembly of Diblock Copolymers Bearing 2-Nitrobenzyl Photocleavable Side Groups, Journal of Polymer Science Part A: Polymer Chemistry, vol. 50, Nov. 9, 2011, pp. 599-608.;;Song et al., Functionalized Soft Nanoporous Materials through Supramolecular Assembly of End-Functionalized Polymer Blends, Chem. Eur. J., vol. 18, Oct. 25, 2012, pp. 15662-15668.;;Suh et al., Orientation of Block Copolymer Resists on Interlayer Dielectrics with Tunable Surface Energy, Macromolecules, vol. 43, Nov. 13, 2009, pp. 461-466.;;S. Thomas III, New Applications of Photolabile Nitrobenzyl Groups in Polymers, Macromol. Chem. Phys., vol. 213, Dec. 13, 2012, pp. 2443-2449.;;Yamada et al., Positive and Negative Tone Water Processable Photoresists: A Progress Report, Advances in Resist Technology and Processing XV, Santa Clara, CA, Feb. 23, 1998, pp. 245-253.;;Beecher et al., Photogeneration of Polymeric Amines: Synthesis, Photocrosslinking and Photoimaging of Copolymers containing Photoactive Carbamate Pendant Groups, J. Mater. Chem., vol. 2, 1992, pp. 811-816.;;Kim et al., Surface Energy Modification by Spin-Cast, Large-Area Graphene Film for Block Copolymer Lithography, ACS Nano, vol. 4, Aug. 25, 2010, pp. 5464-5470.;;Liu et al., Modification of a polystyrene brush layer by insertion of poly(methylmethacrylate) molecules, J. Vac. Sci. Technol. B, vol. 27, Nov. 2009, pp. 3038-3042.;;Matuszczak et al., Photogenerated Amines and their Use in the Design of a Positive-tone Resist Material based on Electrophilic Aromatic Substitution, J. Mater. Chem., vol. 1, 1991, pp. 1045-1050.;;Peters et al., Morphology of Thin Films of Diblock Copolymers on Surfaces Micropatterned with Regions of Different Interfacial Energy, Macromolecules, vol. 35, Jan. 26, 2002, pp. 1822-1834.;;Palmieri et al., Design of Reversible Cross-Linkers for Step and Flash Imprint Lithography Imprint Resists, ACS Nano, vol. 1, No. 4, Nov. 30, 2007, pp. 307-312.;;Heath et al., Degradable Cross-Linkers and Strippable Imaging Materials for Step-and-Flash Imprint Lithography, Macromolecules, vol. 41, Jan. 1, 2008, pp. 719-726.;;Moon et al., Three-component photoresists based on thermal crosslinking and acidolytic cleavage, Polymer, vol. 41, 2000, pp. 4013-4019.;;Zhao et al., o-Nitrobenzyl Alcohol Derivatives: Opportunities in Polymer and Materials Science, Macromolecules, vol. 45, Jan. 26, 2012, pp. 1723-1736.;;Somervell et al., Comparison of Directed Self-Assembly Integrations, Advances in Resist Materials and Processing Technology XXIX. Edited by Somervell, Mark H.; Wallow, Thomas I. Proceedings of the SPIE, vol. 8325, article id. 83250G, 14 pp. (2012).;;Keen et al., Control of the Orientation of Symmetric Poly(styrene)-blockpoly(D,L.lactide) Block Copolymers Using Statistical Copolymers of Dissimilar Composition, Langmuir, vol. 28, Oct. 22, 2012, pp. 15876-15888.;;Liu et al., Fabrication of Lithographically Defined Chemically Patterned Polymer Brushes and Mats, Macromolecules, vol. 44, Mar. 18, 2011, pp. 1876-1885.;;Liu et al., Integration of block copolymer directed assembly with 193 immersion lithography, J. Vac. Sci. Technol. B, vol. 28, No. 6, Nov. 30, 2010, pp. C6B30-C6B34.;;In et al., Side-Chain-Grafted Random Copolymer Brushes as Neutral Surfaces for Controlling the Orientation of Block Copolymer Microdomains in Thin Films, Langmuir, vol. 22, No. 18, Aug. 1, 2006, pp. 7855-7860.;;Han et al., Effect of Composition of Substrate-Modifying Random Copolymers on the Orientation of Symmetric and Asymmetric Diblock Copolymer Domains, Macromolecules, vol. 41, Nov. 6, 2008, pp. 9090-9097.;;Han et al., Cross-Linked Random Copolymer Mats as Ultrathin Nonpreferential Layers for Block Copolymer Self-Assembly, Langmuir, vol. 26, Sep. 30, 2009, pp. 1311-1315.;;Han et al., Photopatternable Imaging Layers for Controlling Block Copolymer Microdomain Orientation, Adv. Mat., vol. 19, 2007, pp. 4448-4452.;;Han et al., Perpendicular Orientation of Domains in Cylinder-Forming Block Copolymer Thick Films by Controlled Interfacial Interactions, Macromolecules, vol. 42, Jun. 11, 2009, pp. 4896-4901.;;M. Keegstra, Copper Catalysed Preparation of Vinyl Ethers from Unactivated Vinylic Halides, Tetrahedron, vol. 48, No. 13, 1992, pp. 2681-2690.;;Trenor et al., Photoreversible Chain Extension of Poly(ethylene glycol), Macromol. Chem. Phys., vol. 205, 2004, pp. 715-723.",ACTIVE
129,US,A1,US 2021/0310024 A1,044-310-498-760-365,2021-10-07,2021,US 201917046693 A,2019-04-11,US 201917046693 A;;US 201862656868 P;;US 2019/0027108 W,2018-04-12,CHEMICALLY-DEFINED BACULOVIRUS EXPRESSION SYSTEM,"The present disclosure is related generally to systems and methods for high level expression of recombinant proteins from baculovirus in insect cells. In particular, the methods and systems described herein allow for high levels of baculovirus production in insect cells and/or high levels of protein production in insect cells using a chemically-defined, yeast lysate-free insect cell medium. The disclosure also relates to compositions and kits for culturing, transfecting, and/or producing recombinant protein in insect cells.",LIFE TECHNOLOGIES CORP,YOVCHEVA MAYA;;ZMUDA JONATHAN;;BARNES SARA;;CHOI CHANG;;THOMPSON KENNETH,LIFE TECHNOLOGIES CORPORATION (2018-04-27),https://lens.org/044-310-498-760-365,Patent Application,yes,0,0,7,7,0,C12N5/0601;;C12N15/86;;C12N2710/14143;;C12N2710/14151;;C12N15/86;;C12N5/0601;;C12N2710/14143;;C12N2710/14151;;C12N2510/00;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2500/02;;C12N2500/05;;C12N2500/34;;C12N2500/38;;C12N2510/00;;C12N2710/14143;;C12N2710/14151;;C12P21/00,C12N15/86;;C12N5/07;;C12N7/00;;C12P21/00,,0,0,,,,PENDING
130,CN,A,CN 116635416 A,152-757-126-603-357,2023-08-22,2023,CN 202180087080 A,2021-12-21,US 202063129091 P;;IB 2021062126 W,2020-12-22,Method for reducing oxidation level of cysteine residues in secreted recombinant expressed proteins during cell culture,"The present disclosure relates to methods for reducing the oxidation level of cysteine residues in recombinant polypeptides, such as anti-IL-17 antibodies, that mammalian cells have recombinantly produced during cell culture (e.g., preparation of secukinumab antibodies). Also provided are purified formulations of recombinant polypeptides such as anti-IL-17 antibodies or antigen-binding fragments thereof, e.g., secukinumab, produced by such methods. Also provided are purified formulations of recombinant polypeptides produced by such methods, wherein the levels of active recombinant polypeptides in the formulations are high.",NOVARTIS AG,BAKALINHAS NIKOLAOS;;CHOI HYUNGRYUL;;GARCIA DEVIN;;GOEBEL MICHAEL;;SCHULTZ JONATHAN,,https://lens.org/152-757-126-603-357,Patent Application,no,0,0,8,8,0,C07K16/244;;C07K2317/14;;C07K2317/40;;C07K16/244;;C12N5/0018;;C12N2500/32;;C07K2317/14;;C07K2317/40;;C12N5/0018;;C12N2500/32;;C12P21/005,C07K16/24,,0,0,,,,PENDING
131,CN,A,CN 112041450 A,025-036-583-786-529,2020-12-04,2020,CN 201980027699 A,2019-04-11,US 201862656868 P;;US 2019/0027108 W,2018-04-12,CHEMICALLY-DEFINED BACULOVIRUS EXPRESSION SYSTEM AND CELL CULTURE MEDIUM,"The present disclosure is related generally to systems and methods for high level expression of recombinant proteins from baculovirus in insect cells. In particular, the methods and systems describedherein allow for high levels of baculovirus production in insect cells and/or high levels of protein production in insect cells using a chemically-defined, yeast lysate-free insect cell medium. The disclosure also relates to compositions and kits for culturing, transfecting, and/or producing recombinant protein in insect cells.",LIFE TECHNOLOGIES CORP,YOVCHEVA MAYA;;ZMUDA JONATHAN;;BARNES SARA;;CHOI CHANG;;THOMPSON KENNETH,,https://lens.org/025-036-583-786-529,Patent Application,no,1,0,7,7,0,C12N5/0601;;C12N15/86;;C12N2710/14143;;C12N2710/14151;;C12N15/86;;C12N5/0601;;C12N2710/14143;;C12N2710/14151;;C12N2510/00;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2500/02;;C12N2500/05;;C12N2500/34;;C12N2500/38;;C12N2510/00;;C12N2710/14143;;C12N2710/14151;;C12P21/00,C12N15/86;;C12N5/00;;C12N5/07,,3,0,,,"YOVCHEVA MAYA等: ""A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells"", 《HTTPS://ASSETS.THERMOFISHER.COM/TFS-ASSETS/BID/POSTERS/CHEMICALLY-DEFINED-BACULOVIRUS-EXPRESSION-SYSTEM-SF9-CELLS-POSTER.PDF》, pages 257 - 259;;乌海飞等: ""杆状病毒载体介导钠碘转运体基因放射治疗肝癌的实验研究"", 《上海交通大学学报(医学版)》, vol. 32, no. 5, pages 560 - 566;;宋姗姗等: ""构建具有巨细胞病毒(CMV)启动子的杆状病毒高效表达载体并利用其在鸡胚原代细胞中表达eGFP基因"", 《微生物学报》, vol. 53, no. 6, pages 586 - 595",PENDING
132,KR,B1,KR 102606513 B1,109-907-170-409-748,2023-11-29,2023,KR 20230043468 A,2023-04-03,KR 20230043468 A,2023-04-03,Apparatus and Method for Backwash Sludge Treatment of High-Rate Filtration Process Capable of Recovering Carbon Source,"고속여과장치가 포함된 오·폐수 처리장치에 대하여, 고속여과장치에서 발생한 역세슬러지로부터 탄소원을 회수하고 슬러지를 처리하기 위한 역세슬러지 처리장치를 개시한다. 본 발명의 일 측면에 의하면, 고속여과공정의 역세슬러지를 처리하기 위한 장치에 있어서, 역세슬러지로부터 침사물질 및 협잡물을 제거하기 위한 전처리 장치와 상기 전처리부를 거친 역세슬러지를 침전/농축/발효 처리하는 제1 반응조와 상기 제1 반응조에서 배출된 슬러지 및/또는 상기 전처리부를 거친 역세슬러지를 유입받아 침전시켜 침전슬러지와 상등수로 분리하는 제2 반응조 및 상기 역세슬러지 처리장치 내의 각 구성의 동작을 제어하는 제어부를 포함하는 것을 특징으로 하는 고속여과공정의 역세슬러지 처리장치를 제공한다.",BKT CO LTD,RHU DAE HWAN;;JONATHAN LIBERZON;;KATYA PRONICHENKO;;CHOI BONG CHOEL,,https://lens.org/109-907-170-409-748,Granted Patent,no,4,0,1,1,0,,C02F9/00;;C02F11/12;;C02F11/14,,0,0,,,,ACTIVE
133,US,A1,US 2014/0263164 A1,007-933-713-124-644,2014-09-18,2014,US 201313831193 A,2013-03-14,US 201313831193 A,2013-03-14,DEGRADABLE NEUTRAL LAYERS FOR BLOCK COPOLYMER LITHOGRAPHY APPLICATIONS,Polymer films comprising crosslinked random copolymers and methods for making the films are provided. Also provided are polymer films comprising random copolymers that are covalently linked to an underlying substrate. The polymer films can be incorporated into structures in which the films are employed as surface-modifying layers for domain-forming block copolymers and the structures can be used for pattern transfer applications via block copolymer lithography. The crosslinks between the random copolymer chains in the polymer films or the links between the random copolymer chains and the substrate surface are characterized in that they can be cleaved under relatively mild conditions.,WISCONSIN ALUMNI RES FOUND;;WISCONSIN ALUMNI RES FOUND,GOPALAN PADMA;;SWEAT DANIEL PATRICK;;CHOI JONATHAN WOOSUN;;KIM MYUNGWOONG,WISCONSIN ALUMNI RESEARCH FOUNDATION (2013-04-01),https://lens.org/007-933-713-124-644,Patent Application,yes,3,1,2,2,0,B81C1/00031;;B81C1/00031;;B32B27/30;;B81C2201/0149;;B81C2201/0149;;B82Y30/00;;B82Y30/00;;C09D153/00;;C09D153/00,C09D153/00,216/12;;427/265;;427/264;;427/553,0,0,,,,ACTIVE
134,DE,A1,DE 102020118743 A1,137-215-296-838-749,2021-01-21,2021,DE 102020118743 A,2020-07-15,US 201962874496 P,2019-07-15,"ELEKTRISCHE BAUGRUPPEN, DIE KOPPLER ZUM AUSLÖSCHEN EINES MAGNETISCHEN FLUSSES BEINHALTEN","Eine elektrische Baugruppe beinhaltet eine erste Spule, die eine erste um eine erste Wicklungsachse herumgewickelte Wicklung beinhaltet, eine zweite Spule, von der ersten Spule in einer ersten Richtung separiert, und einen Koppler, der zumindest teilweise zwischen der ersten Spule und der zweiten Spule in der ersten Richtung angeordnet ist, wobei der Koppler zumindest einen Teil einer elektrischen Schaltung ausbildet, die ermöglicht, dass elektrischer Strom durch den Koppler fließt.",MAXIM INTEGRATED PRODUCTS,CHOI JAEYOUNG;;HUNG JONATHAN C H (CHENG-HSIEN);;HUANG TAO,,https://lens.org/137-215-296-838-749,Patent Application,no,0,0,3,3,0,H01F27/346;;H01F27/346;;H01L23/5227;;H01F27/2804;;H01F27/363;;H01F27/363;;H01F27/38,H01F27/36;;H01F17/02;;H01F27/40;;H01L27/08,,0,0,,,,PENDING
135,EP,A1,EP 3775232 A1,002-002-650-910-13X,2021-02-17,2021,EP 19721451 A,2019-04-11,US 201862656868 P;;US 2019/0027108 W,2018-04-12,CHEMICALLY-DEFINED BACULOVIRUS EXPRESSION SYSTEM AND CELL CULTURE MEDIUM,,LIFE TECHNOLOGIES CORP,YOVCHEVA MAYA;;ZMUDA JONATHAN;;BARNES SARA;;CHOI CHANG;;THOMPSON KENNETH,,https://lens.org/002-002-650-910-13X,Patent Application,yes,0,0,7,7,0,C12N5/0601;;C12N15/86;;C12N2710/14143;;C12N2710/14151;;C12N15/86;;C12N5/0601;;C12N2710/14143;;C12N2710/14151;;C12N2510/00;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2500/02;;C12N2500/05;;C12N2500/34;;C12N2500/38;;C12N2510/00;;C12N2710/14143;;C12N2710/14151;;C12P21/00,C12N15/86;;C12N5/00;;C12N5/07,,0,0,,,,PENDING
136,US,A1,US 2018/0080050 A1,055-034-647-947-563,2018-03-22,2018,US 201715708810 A,2017-09-19,US 201715708810 A;;US 201662397173 P,2016-09-20,HIGHLY SPECIFIC DELIVERY OF POLYNUCLEOTIDES TO THE CELL NUCLEUS VIA COMPRESSION,"The subject invention pertains to delivering a polynucleotide into a target cell, particularly, into the nucleus of the target cell. The method comprises the steps of contacting the polynucleotide with the cell and applying pressure on the polynucleotide and the cell in a manner that forces the polynucleotide into the cell. The pressure can be between about 0.1 Pa to about 50 Pa; whereas, the polynucleotide is contacted with the cell at a concentration of between about 0.1 μM and about 100 μM. The method can be practiced for cells in culture or cells in vivo.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;CHEN ZHONG;;ZHANG LEI;;LI HUIZE,THE CHINESE UNIVERSITY OF HONG KONG (2017-10-16),https://lens.org/055-034-647-947-563,Patent Application,yes,1,1,2,2,8,A61K48/00;;C12N15/87;;C12N15/87;;C12N15/111;;C12N15/113;;C12N2310/11;;C12N2320/32;;C12N2320/32,C12N15/87;;C12N15/113,,0,0,,,,ACTIVE
137,US,A1,US 2023/0048258 A1,123-345-838-110-881,2023-02-16,2023,US 202217652559 A,2022-02-25,US 202217652559 A;;US 202163153680 P,2021-02-25,SELF-THERAPEUTIC NANOPARTICLE FOR ENHANCED TOPICAL DELIVERY TO SKIN KERATINOCYTES AND TREATING SKIN INFLAMMATION,"A composition of an anti-psoriatic drug and methods of applying the anti-psoriatic drug for transdermal delivery of nanoparticles and entry into skin cells are provided. The composition of the anti-psoriatic drug includes a core having at least one gold nanoparticle, a shell of polyethylene glycol (PEG) strands conjugated to the core, and a plurality of alkyl groups conjugated to the shell of PEG strands. Moreover, a chain length of the plurality of alkyl groups, chain loading of the plurality of alkyl groups, or a diameter of the core is configured to optimize a distribution of the composition in the skin cells. The distribution may include skin permeability or an entry into keratinocytes. Further, methods of modulating effectiveness of the anti-psoriatic drug for inhibiting development of a psoriasis phenotype or for treatment of the psoriasis phenotype are provided.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;HAN RUIFANG;;HO LOK WAI COLA,THE CHINESE UNIVERSITY OF HONG KONG (2022-11-02),https://lens.org/123-345-838-110-881,Patent Application,yes,1,0,3,3,12,A61K47/6935;;A61K47/60;;A61K33/242;;A61K9/0014;;A61P17/06;;A61P29/00;;B82Y5/00;;B82Y30/00;;B82Y40/00;;A61K47/60;;A61K47/6929;;A61P17/00;;A61P17/06;;A61K47/6929;;A61K47/60;;A61K9/0014,A61K47/69;;A61K9/00;;A61K47/60,,1,1,023-231-417-016-431,10.1021/acsnano.7b02044;;28562003,Ho et al. “Effect of Alkylation on the Cellular Uptake of Polyethylene Glycol-Coated Gold Nanoparticles”.,PENDING
138,US,A1,US 2017/0054800 A1,071-220-966-986-761,2017-02-23,2017,US 201514831578 A,2015-08-20,US 201514831578 A,2015-08-20,Intelligent Predictive Stream Caching,"Some embodiments provide intelligent predictive stream caching for live, linear, or video-on-demand streaming content using prefetching, segmented caching, and request clustering. Prefetching involves retrieving streaming content segments from an origin server prior to the segments being requested by users. Prefetching live or linear streaming content segments involves continually reissuing requests to the origin until the segments are obtained or a preset retry duration is completed. Prefetching is initiated in response to a first request for a segment falling within a particular interval. Request clustering commences thereafter. Subsequent requests are queued until the segments are retrieved. Segmented caching involves caching segments for one particular interval. Segments falling within a next interval are not prefetched until a first request for one such segment in the next interval is received. Cached segments from the previous interval can be replaced in cache with segments for the current interval, thereby minimizing cache footprint utilization.",VERIZON DIGITAL MEDIA SERVICES INC;;EDGECAST NETWORKS INC,DIVINCENZO JONATHAN;;CHOI SEUNGYEOB;;SATHYANARAYANA KARTHIK;;PETERS ROBERT J;;DYONIZIAK ERIC,EDGECAST INC (2021-11-01);;EDGIO INC (2022-10-21),https://lens.org/071-220-966-986-761,Patent Application,yes,10,39,4,4,0,H04L67/02;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/5681;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/02;;H04L67/5681,G11B27/10;;H04L29/08;;H04N21/2187;;H04N21/231;;H04N21/845,,0,0,,,,ACTIVE
139,WO,A1,WO 2019/173869 A1,113-778-833-962-517,2019-09-19,2019,AU 2019/050223 W,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A,2018-03-12,ORAL APPLIANCE AND VALVE ARRANGEMENT,"A breathing assistance apparatus includes an oral appliance and a valve arrangement. The oral appliance has an appliance body shaped to be at least partially positioned within the oral cavity of a user. The valve arrangement includes a valve body and a valve member. The valve body includes a valve airway in fluid communication with a user airway, and the valve member is positioned in the valve airway, movable between first and second positions at least in part as a result of airflow through the valve airway. The valve member at least partially obstructs the valve airway in the second position so that there is a differential resistance during inhalation and exhalation.",OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,,https://lens.org/113-778-833-962-517,Patent Application,yes,12,1,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/06,,1,0,,,See also references of EP 3764962A4,PENDING
140,US,A1,US 2005/0206010 A1,026-597-141-946-413,2005-09-22,2005,US 80346404 A,2004-03-18,US 80346404 A,2004-03-18,Multi-flip chip on lead frame on over molded IC package and method of assembly,"A multichip module package uses bond wire with plastic resin on one side of a lead frame to package an integrated circuit and flip chip techniques to attach one or more mosfets to the other side of the lead frame. The assembled multichip module 30 has an integrated circuit controller 14 on a central die pad. Wire bonds 16 extend from contact areas on the integrated circuit to outer leads 2.6 of the lead frame 10 . On the opposite, lower side of the central die pad, the sources and gates of the mosfets 24, 26 are bump or stud attached to the half etched regions of the lead frame. The drains 36 of the mosfets and the ball contacts 22.1 on the outer leads are soldered to a printed circuit board.",NOQUIL JONATHAN A;;CHOI SEUNG Y;;JOSHI RAJEEV;;WU CHUNG-LIN,NOQUIL JONATHAN A;;CHOI SEUNG Y;;JOSHI RAJEEV;;WU CHUNG-LIN,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2021-07-22);;FAIRCHILD SEMICONDUCTOR CORPORATION (2004-07-19),https://lens.org/026-597-141-946-413,Patent Application,yes,17,68,4,4,0,H01L23/3128;;H01L23/49575;;H01L24/97;;H01L25/16;;H01L2224/16;;H01L2224/32245;;H01L2224/48091;;H01L2224/48247;;H01L2224/48472;;H01L2224/73265;;H01L2224/92247;;H01L2224/97;;H01L2924/01013;;H01L2924/01029;;H01L2924/01046;;H01L2924/01047;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2924/13091;;H01L2924/15311;;H01L2924/1532;;H01L24/48;;H01L2924/01006;;H01L2924/01033;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14;;H01L25/16;;H01L23/3128;;H01L2224/48472;;H01L2924/01047;;H01L24/97;;H01L2224/48091;;H01L2924/01029;;H01L23/49575;;H01L2924/01078;;H01L2224/92247;;H01L2924/13091;;H01L2924/01013;;H01L2924/01046;;H01L2224/16;;H01L2224/48247;;H01L2224/97;;H01L2224/73265;;H01L2924/01079;;H01L2924/1532;;H01L2924/15311;;H01L2924/01082;;H01L2224/32245;;H01L2924/01033;;H01L2924/01006;;H01L24/48;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14,H01L21/48;;H01L23/31;;H01L23/495;;H01L23/52;;H01L25/16,257/778;;438/108;;257/685;;257/676;;438/123,0,0,,,,INACTIVE
141,CN,A,CN 111867527 A,052-649-356-107-216,2020-10-30,2020,CN 201980018923 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,ORAL APPLIANCE AND VALVE ARRANGEMENT,"A breathing assistance apparatus includes an oral appliance and a valve arrangement. The oral appliance has an appliance body shaped to be at least partially positioned within the oral cavity of a user. The valve arrangement includes a valve body and a valve member. The valve body includes a valve airway in fluid communication with a user airway, and the valve member is positioned in the valve airway, movable between first and second positions at least in part as a result of airflow through the valve airway. The valve member at least partially obstructs the valve airway in the second positionso that there is a differential resistance during inhalation and exhalation.",OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,,https://lens.org/052-649-356-107-216,Patent Application,no,7,0,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/06,,0,0,,,,PENDING
142,US,A1,US 2007/0072347 A1,120-532-420-522-47X,2007-03-29,2007,US 56093506 A,2006-11-17,US 56093506 A;;US 80346404 A,2004-03-18,METHOD OF ASSEMBLY FOR MULTI-FLIP CHIP ON LEAD FRAME ON OVERMOLDED IC PACKAGE,"A multichip module package uses bond wire with plastic resin on one side of a lead frame to package an integrated circuit and flip chip techniques to attach one or more mosfets to the other side of the lead frame. The assembled multichip module 30 has an integrated circuit controller 14 on a central die pad. Wire bonds 16 extend from contact areas on the integrated circuit to outer leads 2.6 of the lead frame 10 . On the opposite, lower side of the central die pad, the sources and gates of the mosfets 24, 26 are bump or stud attached to the half etched regions of the lead frame. The drains 36 of the mosfets and the ball contacts 22.1 on the outer leads are soldered to a printed circuit board.",NOQUIL JONATHAN A;;CHOI SEUNG Y;;JOSHI RAJEEV;;WU CHUNG-LIN,NOQUIL JONATHAN A;;CHOI SEUNG Y;;JOSHI RAJEEV;;WU CHUNG-LIN,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2021-07-22),https://lens.org/120-532-420-522-47X,Patent Application,yes,20,4,4,4,0,H01L23/3128;;H01L23/49575;;H01L24/97;;H01L25/16;;H01L2224/16;;H01L2224/32245;;H01L2224/48091;;H01L2224/48247;;H01L2224/48472;;H01L2224/73265;;H01L2224/92247;;H01L2224/97;;H01L2924/01013;;H01L2924/01029;;H01L2924/01046;;H01L2924/01047;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2924/13091;;H01L2924/15311;;H01L2924/1532;;H01L24/48;;H01L2924/01006;;H01L2924/01033;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14;;H01L25/16;;H01L23/3128;;H01L2224/48472;;H01L2924/01047;;H01L24/97;;H01L2224/48091;;H01L2924/01029;;H01L23/49575;;H01L2924/01078;;H01L2224/92247;;H01L2924/13091;;H01L2924/01013;;H01L2924/01046;;H01L2224/16;;H01L2224/48247;;H01L2224/97;;H01L2224/73265;;H01L2924/01079;;H01L2924/1532;;H01L2924/15311;;H01L2924/01082;;H01L2224/32245;;H01L2924/01033;;H01L2924/01006;;H01L24/48;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14,H01L21/00;;H01L21/48;;H01L23/31;;H01L23/495;;H01L23/52;;H01L25/16,438/124,0,0,,,,INACTIVE
143,WO,A1,WO 2021/142090 A1,136-938-269-055-127,2021-07-15,2021,US 2021/0012455 W,2021-01-07,US 202062958209 P,2020-01-07,SYSTEMS AND METHODS FOR ROBOTICALLY-ASSISTED HISTOTRIPSY TARGETING BASED ON MRI/CT SCANS TAKEN PRIOR TO TREATMENT,"Methods and devices for producing cavitation in tissue are provided. Methods and devices are also provided for surgical navigation, including defining a target treatment zone and navigating a focus of a therapy transducer to the target treatment zone. Embodiments are provided for co-registering a plurality of surgical imaging and navigation systems. Systems for performing Histotripsy therapy are also discussed.",UNIV MICHIGAN REGENTS,XU ZHEN;;PANDEY ADITA;;SUKOVICH JONATHAN;;GERHARDSON TYLER;;CHOI SANG WON,,https://lens.org/136-938-269-055-127,Patent Application,yes,6,1,7,7,0,A61B34/20;;A61B2090/363;;A61B90/361;;A61B5/055;;A61B8/485;;A61B6/032;;A61B6/037;;A61B6/5235;;A61B6/5247;;A61B6/12;;A61B8/5261;;A61B8/0841;;A61N7/00;;A61N2007/0039;;A61N2007/0043;;A61N2007/0095;;A61B34/20;;A61B2034/2051;;A61B2034/2055;;A61B2034/2063;;A61B34/30;;A61B2090/364;;A61B2090/3762;;A61B2090/3983;;A61N7/00,A61B8/08;;A61B8/00;;A61B8/13;;A61B8/14;;A61B34/20,,1,0,,,See also references of EP 4087493A4,PENDING
144,US,A1,US 2018/0336725 A1,170-120-002-784-71X,2018-11-22,2018,US 201816040381 A,2018-07-19,US 201816040381 A;;US 201514855656 A,2015-09-16,Immersive Design Management System,"An object management system, an aircraft design system, and a method for managing an object. A three-dimensional environment with a model of an object and an avatar representing a human operator from a viewpoint relative to the avatar is displayed on a display system. A motion of the human operator is detected. An interaction between the avatar and the model of the object is identified in real time using information about motions of the human operator that are detected in real time. The interaction changes a group of dimensions in the model of the object. Further, the interaction between the avatar and the model of the object in the three-dimensional environment is displayed on the display system, enabling design changes in the model of the object made by the human operator.",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2015-09-15),https://lens.org/170-120-002-784-71X,Patent Application,yes,3,0,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/00;;G06F3/01;;G06F17/50;;G06T17/00,,3,1,075-908-431-910-913,10.1016/j.compind.2005.12.005,"Jayaram, Sankar, et al. ""VADE: a virtual assembly design environment."" IEEE computer graphics and applications 19.6 (1999): 44-50. (Year: 1999);;Lee, Sangyoon, et al. ""Affective property evaluation of virtual product designs."" IEEE Virtual Reality 2004. IEEE, 2004. (Year: 2004);;Jayaram, Uma, et al. ""Introducing quantitative analysis methods into virtual environments for real-time and continuous ergonomic evaluations."" Computers in industry 57.3 (2006): 283-296. (Year: 2006)",ACTIVE
145,EP,B1,EP 1893291 B1,030-986-230-696-237,2010-03-03,2010,EP 06773098 A,2006-06-13,US 2006/0023068 W;;US 69280905 P,2005-06-22,TREATMENT OF SEXUAL DYSFUNCTION,,SK HOLDINGS CO LTD,CHOI YONG;;STECKLER THOMAS;;SPORN JONATHAN;;PALUMBO JOSEPH;;LEE JAMES S,"SK BIOPHARMACEUTICALS CO., LTD. (2012-04-09);;SK BIOPHARMACEUTICALS CO., LTD., KR (2012-01-31)",https://lens.org/030-986-230-696-237,Granted Patent,yes,3,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61P15/10;;A61K31/165;;A61K45/06,,0,0,,,,ACTIVE
146,US,B2,US 10043311 B2,115-717-779-144-09X,2018-08-07,2018,US 201514855656 A,2015-09-16,US 201514855656 A,2015-09-16,Immersive design management system,"An object management system, an aircraft design system, and a method for managing an object. A three-dimensional environment with a model of an object and an avatar representing a human operator from a viewpoint relative to the avatar is displayed on a display system. A motion of the human operator is detected. An interaction between the avatar and the model of the object is identified in real time using information about motions of the human operator that are detected in real time. The interaction changes a group of dimensions in the model of the object. Further, the interaction between the avatar and the model of the object in the three-dimensional environment is displayed on the display system, enabling design changes in the model of the object made by the human operator.",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2015-09-15),https://lens.org/115-717-779-144-09X,Granted Patent,yes,6,2,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/00;;G06F3/01;;G06F17/50;;G06T17/00,,17,5,046-999-917-133-928;;080-180-884-387-493;;028-205-116-006-785;;001-787-377-414-974;;029-182-768-404-364,10.1007/s00170-013-5207-3;;10.1145/1077534.1077550;;10.1016/j.cirp.2013.05.005;;10.1145/1281500.1281542;;10.1016/j.cad.2008.10.015,"Qiu, Shiguang, et al. “Virtual human modeling for interactive assembly and disassembly operation in virtual reality environment.” The International Journal of Advanced Manufacturing Technology 69.9-12 (2013): 2355-2372.;;Roberts, David, et al. “Supporting social human communication between distributed walk-in displays.” Proceedings of the ACM symposium on Virtual reality software and technology. ACM, 2004.;;“CAD/CAM—VROOM,” WorldViz, LLC, copyright 2002-2015, 3 pages, accessed Aug. 5, 2015. http://www.worldviz.com/industries/cad#Training_Tool.;;“Vicon Engineering,” Vicon Motion Systems Ltd., 6 pages, accessed Aug. 5, 2015. http://www.vicon.com/motion-capture/engineering.;;“Kinect Fusion,” Microsoft Corporation, copyright 2015, 5 pages, accessed Aug. 5, 2015. https://msdn.microsoft.com/en-us/enus/library/dn188670.aspx.;;Krassenstein, “New Details on VRClay, The Virtual Reality CAD Software Which Could Transform the 3D Modelling Space,” 3DPrint.com, Oct. 2014, 4 pages, accessed Aug. 28, 2015. http://3dprint.com/17752/vrclay-3d-model-oculus-rift/.;;Mings, “SolidWorks World: Post3D Brings Immersive 3D Product Design,” SolidSmack, Jan. 2011, 12 pages, accessed Aug. 5, 2015. http://www.solidsmack.com/cad-design-news/solidworks-world-post3d-brings-immersive-3d-to-product-design-sww11/.;;Gabrys et al., “Immersive Object Testing System,” U.S. Appl. No. 14/855,700, filed Sep. 16, 2015, 69 pages.;;Extended European Search Report, dated Nov. 7, 2016, regarding Application No. EP16177460.9, 13 pages.;;Leu et al., “CAD model based virtual assembly simulation, planning and training,” CIRP Annals—Manufacturing Technology, vol., 62, No. 2, Dec. 2013, pp. 799-822.;;Masry et al., “A Sketch-Based Interface for Iterative Design and Analysis of 3D Objects,” Proceedings of ACM SIGGRAPH 2007 courses, Article No. 31, Aug. 2007, 10 pages.;;Office Action, dated Jan. 26, 2017, regarding U.S. Appl. No. 14/855,700, 24 pages.;;Clothier et al., “Augmented Reality Visualization Tool for Kings Stormwater Bridge”, the Proceedings of Visualization, Imaging and Image Processing (VIIP 2004), Sep. 2004, 6 pages.;;Florentino et al., “Interactive ‘touch and see’ FEM Simulation using Augmented Reality”, International Journal of Engineering Education, Jan. 2009, 16 pages.;;Uva et al., “Distributed design review using tangible augmented technical drawings”, Computer-Aided Design, vol. 42, © 2010 pp. 364-372. www.elsevier.com/locate/cad.;;Final Office Action, dated May 31, 2017, regarding U.S. Appl. No. 14/855,700. 38 pages.;;Notice of Allowance, dated Sep. 13, 2017, regarding U.S. Appl. No. 14/855,700, 9 pages.",ACTIVE
147,CN,A,CN 106547939 A,168-799-022-719-909,2017-03-29,2017,CN 201610586927 A,2016-07-22,US 201514855656 A,2015-09-16,"Object management system, aircraft design system, and method for managing an object.","The invention discloses an object management system, an aircraft design system, and a method for managing an object. A three-dimensional environment (112) with a model (104) of an object (102) and an avatar (118) representing a human operator (111) from a viewpoint (121) relative to the avatar (118) is displayed on a display system (122). A motion of the human operator (111) is detected. An interaction between the avatar (118) and the model (104) of the object (102) is identified in real time using information (126) about motions of the human operator (111) that are detected in real time. The interaction changes a group of dimensions (132) in the model (104) of the object (102). Further, the interaction between the avatar (118) and the model (104) of the object (102) in the three-dimensional environment (112) is displayed on the display system, enabling design changes in the model (104) of the object (102) made by the human operator (111).",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,,https://lens.org/168-799-022-719-909,Patent Application,no,5,3,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06F17/50,,0,0,,,,ACTIVE
148,US,B2,US 10567493 B2,094-018-247-581-229,2020-02-18,2020,US 201815899653 A,2018-02-20,US 201815899653 A;;US 201514831578 A,2015-08-20,Intelligent predictive stream caching,"Some embodiments provide intelligent predictive stream caching for live, linear, or video-on-demand streaming content using prefetching, segmented caching, and request clustering. Prefetching involves retrieving streaming content segments from an origin server prior to the segments being requested by users. Prefetching live or linear streaming content segments involves continually reissuing requests to the origin until the segments are obtained or a preset retry duration is completed. Prefetching is initiated in response to a first request for a segment falling within a particular interval. Request clustering commences thereafter. Subsequent requests are queued until the segments are retrieved. Segmented caching involves caching segments for one particular interval. Segments falling within a next interval are not prefetched until a first request for one such segment in the next interval is received. Cached segments from the previous interval can be replaced in cache with segments for the current interval, thereby minimizing cache footprint utilization.",VERIZON DIGITAL MEDIA SERVICES INC,DIVINCENZO JONATHAN;;CHOI SEUNGYEOB;;SATHYANARAYANA KARTHIK;;PETERS ROBERT J;;DYONIZIAK ERIC,EDGECAST INC (2021-11-01);;EDGIO INC (2022-10-21),https://lens.org/094-018-247-581-229,Granted Patent,yes,60,2,4,4,0,H04L67/02;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/5681;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/02;;H04L67/5681,H04L29/08;;H04N21/2187;;H04N21/231;;H04N21/845,,0,0,,,,ACTIVE
149,EP,A1,EP 3830286 A1,095-005-876-371-279,2021-06-09,2021,EP 19749651 A,2019-07-26,US 201862711106 P;;EP 2019070217 W,2018-07-27,FORMAMIDE FREE TARGET ENRICHMENT COMPOSITIONS FOR NEXT-GENERATION SEQUENCING APPLICATIONS,,HOFFMANN LA ROCHE;;ROCHE DIAGNOSTICS GMBH,CHOI JONATHAN S;;KUSHWAHA GARIMA;;MOEHLENKAMP CYNTHIA;;NGUYEN DUYLINH;;RATERMAN DENISE,,https://lens.org/095-005-876-371-279,Patent Application,yes,0,0,6,6,0,C12Q1/6832;;C12Q1/6806;;C12Q1/6806;;C12Q1/6832,C12Q1/6806;;C12Q1/6832,,0,0,,,,PENDING
150,US,A1,US 2018/0176297 A1,135-316-165-978-426,2018-06-21,2018,US 201815899653 A,2018-02-20,US 201815899653 A;;US 201514831578 A,2015-08-20,Intelligent Predictive Stream Caching,"Some embodiments provide intelligent predictive stream caching for live, linear, or video-on-demand streaming content using prefetching, segmented caching, and request clustering. Prefetching involves retrieving streaming content segments from an origin server prior to the segments being requested by users. Prefetching live or linear streaming content segments involves continually reissuing requests to the origin until the segments are obtained or a preset retry duration is completed. Prefetching is initiated in response to a first request for a segment falling within a particular interval. Request clustering commences thereafter. Subsequent requests are queued until the segments are retrieved. Segmented caching involves caching segments for one particular interval. Segments falling within a next interval are not prefetched until a first request for one such segment in the next interval is received. Cached segments from the previous interval can be replaced in cache with segments for the current interval, thereby minimizing cache footprint utilization.",VERIZON DIGITAL MEDIA SERVICES INC,DIVINCENZO JONATHAN;;CHOI SEUNGYEOB;;SATHYANARAYANA KARTHIK;;PETERS ROBERT J;;DYONIZIAK ERIC,EDGECAST INC (2021-11-01);;EDGIO INC (2022-10-21),https://lens.org/135-316-165-978-426,Patent Application,yes,4,2,4,4,0,H04L67/02;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/5681;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/02;;H04L67/5681,H04L29/08;;H04N21/2187;;H04N21/231;;H04N21/845,,0,0,,,,ACTIVE
151,EP,A1,EP 3144901 A1,174-753-852-975-139,2017-03-22,2017,EP 16177460 A,2016-07-01,US 201514855656 A,2015-09-16,IMMERSIVE DESIGN MANAGEMENT SYSTEM,"An object management system (108), an aircraft design system, and a method for managing an object (102). A three-dimensional environment (112) with a model (104) of an object (102) and an avatar (118) representing a human operator (111) from a viewpoint (121) relative to the avatar (118) is displayed on a display system (122). A motion of the human operator (111) is detected. An interaction between the avatar (118) and the model (104) of the object (102) is identified in real time using information (126) about motions (128) of the human operator (111) that are detected in real time. The interaction changes a group of dimensions (132) in the model (104) of the object (102). Further, the interaction between the avatar (118) and the model (104) of the object (102) in the three-dimensional environment (112) is displayed on the display system (122), enabling design changes (134) in the model (104) of the object (102) made by the human operator (111).
",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,,https://lens.org/174-753-852-975-139,Patent Application,yes,1,2,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/00;;G06F3/01;;G06F17/50,,1,1,028-205-116-006-785,10.1016/j.cirp.2013.05.005,"LEU MING C ET AL: ""CAD model based virtual assembly simulation, planning and training"", CIRP ANNALS, vol. 62, no. 2, 31 December 2013 (2013-12-31), pages 799 - 822, XP028697846, ISSN: 0007-8506, DOI: 10.1016/J.CIRP.2013.05.005",ACTIVE
152,CA,A1,CA 3093591 A1,032-593-517-691-308,2019-09-19,2019,CA 3093591 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,ORAL APPLIANCE AND VALVE ARRANGEMENT,"A breathing assistance apparatus includes an oral appliance and a valve arrangement. The oral appliance has an appliance body shaped to be at least partially positioned within the oral cavity of a user. The valve arrangement includes a valve body and a valve member. The valve body includes a valve airway in fluid communication with a user airway, and the valve member is positioned in the valve airway, movable between first and second positions at least in part as a result of airflow through the valve airway. The valve member at least partially obstructs the valve airway in the second position so that there is a differential resistance during inhalation and exhalation.",OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,,https://lens.org/032-593-517-691-308,Patent Application,no,0,0,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/06,,0,0,,,,PENDING
153,CN,A,CN 112534061 A,080-692-177-679-410,2021-03-19,2021,CN 201980050220 A,2019-07-26,US 201862711106 P;;EP 2019070217 W,2018-07-27,FORMAMIDE FREE TARGET ENRICHMENT COMPOSITIONS FOR NEXT-GENERATION SEQUENCING APPLICATIONS,The invention is a novel composition of a nucleic acid hybridization solution used in a sequencing workflow.,HOFFMANN LA ROCHE,CHOI JONATHAN S;;KUSHWAHA GARIMA;;MOEHLENKAMP CYNTHIA;;D RUAN;;RATERMAN DENISE,,https://lens.org/080-692-177-679-410,Patent Application,no,9,0,6,6,0,C12Q1/6832;;C12Q1/6806;;C12Q1/6806;;C12Q1/6832,C12Q1/6806;;C12Q1/6832,,0,0,,,,PENDING
154,EP,B1,EP 3144901 B1,090-252-823-749-748,2020-10-28,2020,EP 16177460 A,2016-07-01,US 201514855656 A,2015-09-16,IMMERSIVE DESIGN MANAGEMENT SYSTEM,,BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,,https://lens.org/090-252-823-749-748,Granted Patent,yes,1,0,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/20;;G06F3/01;;G06F30/15,,1,1,039-618-390-066-590,10.1016/s0010-4485(96)00094-2,"JAYARAM S ET AL: ""Virtual assembly using virtual reality techniques"", COMPUTER AIDED DESIGN, ELSEVIER PUBLISHERS BV., BARKING, GB, vol. 29, no. 8, 1 August 1997 (1997-08-01), pages 575 - 584, XP004089543, ISSN: 0010-4485, DOI: 10.1016/S0010-4485(96)00094-2",ACTIVE
155,KR,A,KR 20210008830 A,186-326-290-100-881,2021-01-25,2021,KR 20207028700 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,구강 기구 및 밸브 배열,"호흡 보조 장치는 구강 기구 및 밸브 배열을 포함한다. 상기 구강 기구는 사용자의 구강 내에 적어도 부분적으로 위치되도록 형성된 기구 본체를 갖는다. 상기 밸브 배열은 밸브 본체 및 밸브 부재를 포함한다. 상기 밸브 본체는 사용자 기도와 유체 연통되는 밸브 기도를 포함하고, 상기 밸브 부재는 밸브 기도를 통한 공기 흐름의 결과로서 제1 위치와 제2 위치 사이에서 적어도 부분적으로 이동 가능한 밸브 기도에 위치된다. 상기 밸브 부재는 흡기 및 호기 중 차동 저항이 있도록 상기 제2 위치에서 상기 밸브 기도를 적어도 부분적으로 차단한다.",OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,,https://lens.org/186-326-290-100-881,Patent Application,no,0,0,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/00;;A61M16/04;;A61M16/06;;A61M16/20,,0,0,,,,DISCONTINUED
156,KR,A,KR 20080028445 A,197-118-059-613-871,2008-03-31,2008,KR 20087001754 A,2006-06-13,US 69280905 P;;US 2006/0023068 W,2005-06-22,TREATMENT OF SEXUAL DYSFUNCTION,"A method for treating sexual dysfunction is provided to treat male sexual dysfunction(MSD) and female sexual dysfunction(FSD) successfully by administering a specific carbamate compound alone or a combination of the compound with other drugs into a subject in need of the treatment. A method for treating sexual dysfunction comprises a step of administering a therapeutically effective amount of a compound represented by the formula(1) or a pharmaceutically acceptable salt thereof or an ester thereof into a subject in need of the treatment or administering a therapeutically effective amount of an enantiomer of the formula(1) substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the formula(1) predominates in a subject in need of the treatment, or a pharmaceutically acceptable salt thereof or an ester thereof. In the formula(1), R is H, C1-8 lower alkyl, halogen, C1-3 alkoxy, nitro, hydroxy, trifluoromethyl, and C1-3 thioalkoxy; x is an integer of 1 to 3 provided that R may be the same or different when x is 2 or 3; each R1 and R2 is independently selected from the group consisting of H, C1-8 lower alkyl, aryl, arylalkyl, C3-7 cycloalkyl; R1 and R2 may be joined to form a 5 to 7-membered heterocycle substituted by H, alkyl and aryl, wherein the cyclic compound may include 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.",SK HOLDINGS CO LTD,PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG;;LEE JAMES S,,https://lens.org/197-118-059-613-871,Patent Application,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61K31/165;;A61P15/10,,0,0,,,,ACTIVE
157,US,B2,US 9906590 B2,020-202-455-664-016,2018-02-27,2018,US 201514831578 A,2015-08-20,US 201514831578 A,2015-08-20,Intelligent predictive stream caching,"Some embodiments provide intelligent predictive stream caching for live, linear, or video-on-demand streaming content using prefetching, segmented caching, and request clustering. Prefetching involves retrieving streaming content segments from an origin server prior to the segments being requested by users. Prefetching live or linear streaming content segments involves continually reissuing requests to the origin until the segments are obtained or a preset retry duration is completed. Prefetching is initiated in response to a first request for a segment falling within a particular interval. Request clustering commences thereafter. Subsequent requests are queued until the segments are retrieved. Segmented caching involves caching segments for one particular interval. Segments falling within a next interval are not prefetched until a first request for one such segment in the next interval is received. Cached segments from the previous interval can be replaced in cache with segments for the current interval, thereby minimizing cache footprint utilization.",VERIZON DIGITAL MEDIA SERVICES INC,DIVINCENZO JONATHAN;;CHOI SEUNGYEOB;;SATHYANARAYANA KARTHIK;;PETERS ROBERT J;;DYONIZIAK ERIC,EDGECAST INC (2021-11-01);;EDGIO INC (2022-10-21),https://lens.org/020-202-455-664-016,Granted Patent,yes,10,4,4,4,0,H04L67/02;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/5681;;H04L67/1014;;H04L67/1008;;H04N21/8456;;H04N21/2187;;H04N21/23106;;H04L67/02;;H04L67/5681,G06F15/16;;H04L29/08;;H04N21/2187;;H04N21/231;;H04N21/845,,0,0,,,,ACTIVE
158,WO,A1,WO 2020/021084 A1,173-508-240-980-214,2020-01-30,2020,EP 2019070217 W,2019-07-26,US 201862711106 P,2018-07-27,FORMAMIDE FREE TARGET ENRICHMENT COMPOSITIONS FOR NEXT-GENERATION SEQUENCING APPLICATIONS,The invention is a novel composition of a nucleic acid hybridization solution used in a sequencing workflow.,HOFFMANN LA ROCHE;;ROCHE DIAGNOSTICS GMBH;;ROCHE SEQUENCING SOLUTIONS INC,CHOI JONATHAN S;;KUSHWAHA GARIMA;;MOEHLENKAMP CYNTHIA;;NGUYEN DUYLINH;;RATERMAN DENISE,,https://lens.org/173-508-240-980-214,Patent Application,yes,4,1,6,6,0,C12Q1/6832;;C12Q1/6806;;C12Q1/6806;;C12Q1/6832,C12Q1/6806;;C12Q1/6832,,9,4,158-261-806-420-924;;069-386-380-985-233;;047-014-823-614-517;;029-802-173-094-517,10.1016/s0040-4039(01)90461-7;;10.1021/ja00401a041;;22911704;;10.1371/journal.pone.0040675;;pmc3404051;;11376156;;pmc55707;;10.1093/nar/29.11.2377,"SEELA ET AL., HELV. CHIM. ACTA, vol. 82, 1999, pages 1640;;NARANG ET AL., METH. ENZYMOL., vol. 68, 1979, pages 109 - 151;;BEAUCAGE ET AL., TETRAHEDRON LETT., vol. 22, 1981, pages 1859 - 1862;;MATTEUCCI ET AL., J. AM. CHEM. SOC., vol. 103, 1981, pages 3185 - 3191;;""PCR Strategies"", 1995, ACADEMIC PRESS;;""PCR Protocols : A Guide to Methods and Applications"", 1990, ACADEMIC PRESS;;MATTHIESEN, S. ET AL.: ""Fast and Non-Toxic In Situ Hybridization without Blocking of Repetitive Sequences"", PLOS ONE, vol. 7, 2012, pages e40675, XP055193680, doi:10.1371/journal.pone.0040675;;HANSEN, CHARLES: ""Hansen Solubility Parameters: A user's handbook"", 2007, CRC PRESS;;CHAKRABARTI, R. ET AL.: ""The enhancement of PCR amplification by low molecular weight amides"", N.A.R, vol. 29, 2001, pages 2377, XP002227234, doi:10.1093/nar/29.11.2377",PENDING
159,DE,D1,DE 602006012670 D1,195-226-453-700-821,2010-04-15,2010,DE 602006012670 T,2006-06-13,US 69280905 P;;US 2006/0023068 W,2005-06-22,BEHANDLUNG DER SEXUELLEN DYSFUNKTION,,SK HOLDINGS CO LTD,CHOI YONG;;STECKLER THOMAS;;SPORN JONATHAN;;PALUMBO JOSEPH;;LEE JAMES S,,https://lens.org/195-226-453-700-821,Granted Patent,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61P15/10;;A61K31/165;;A61K45/06,,0,0,,,,ACTIVE
160,US,B2,US 7335532 B2,181-927-938-462-036,2008-02-26,2008,US 56093506 A,2006-11-17,US 56093506 A;;US 80346404 A,2004-03-18,Method of assembly for multi-flip chip on lead frame on overmolded IC package,"A multichip module package uses bond wire with plastic resin on one side of a lead frame to package an integrated circuit and flip chip techniques to attach one or more mosfets to the other side of the lead frame. The assembled multichip module 30 has an integrated circuit controller 14 on a central die pad. Wire bonds 16 extend from contact areas on the integrated circuit to outer leads 2.6 of the lead frame 10 . On the opposite, lower side of the central die pad, the sources and gates of the mosfets 24, 26 are bump or stud attached to the half etched regions of the lead frame. The drains 36 of the mosfets and the ball contacts 22.1 on the outer leads are soldered to a printed circuit board.",FAIRCHILD SEMICONDUCTOR,NOQUIL JONATHAN A;;CHOI SEUNG YONG;;JOSHI RAJEEV;;WU CHUNG-LIN,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2021-07-22),https://lens.org/181-927-938-462-036,Granted Patent,yes,20,7,4,4,0,H01L23/3128;;H01L23/49575;;H01L24/97;;H01L25/16;;H01L2224/16;;H01L2224/32245;;H01L2224/48091;;H01L2224/48247;;H01L2224/48472;;H01L2224/73265;;H01L2224/92247;;H01L2224/97;;H01L2924/01013;;H01L2924/01029;;H01L2924/01046;;H01L2924/01047;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2924/13091;;H01L2924/15311;;H01L2924/1532;;H01L24/48;;H01L2924/01006;;H01L2924/01033;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14;;H01L25/16;;H01L23/3128;;H01L2224/48472;;H01L2924/01047;;H01L24/97;;H01L2224/48091;;H01L2924/01029;;H01L23/49575;;H01L2924/01078;;H01L2224/92247;;H01L2924/13091;;H01L2924/01013;;H01L2924/01046;;H01L2224/16;;H01L2224/48247;;H01L2224/97;;H01L2224/73265;;H01L2924/01079;;H01L2924/1532;;H01L2924/15311;;H01L2924/01082;;H01L2224/32245;;H01L2924/01033;;H01L2924/01006;;H01L24/48;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14,H01L21/44;;H01L21/48;;H01L23/31;;H01L23/495;;H01L23/52;;H01L25/16,438/108;;438/124;;X257E21503,0,0,,,,INACTIVE
161,EP,A1,EP 3764962 A1,001-388-348-209-156,2021-01-20,2021,EP 19767515 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,ORAL APPLIANCE AND VALVE ARRANGEMENT,,OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,OPEN AIRWAYS DENTAL SOLUTIONS LTD. (2023-08-09),https://lens.org/001-388-348-209-156,Patent Application,yes,0,0,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/06,,0,0,,,,PENDING
162,ES,T3,ES 2344469 T3,001-011-687-828-541,2010-08-27,2010,ES 06773098 T,2006-06-13,US 69280905 P,2005-06-22,TRATAMIENTO DE DISFUNCION SEXUAL.,"Un compuesto de la Fórmula I: **(Ver fórmula)** O una sal farmacéuticamente aceptable o éster de la misma: En donde R es una miembro seleccionado del grupo que consiste de hidrógeno, alquilo inferior de 1 a 8 átomos de carbono, halógenos seleccionado de F, Cl, Br e I, alcoxi que contiene 1 a 3 átomos de carbono, nitro, hidroxi, trifluorometilo, y tioalcoxi que contiene 1 a 3 átomos de carbono; X es un entero de 1 a 3, con la condición de que R puede ser igual o diferente cuando X es 2 o 3; R1 y R2 pueden ser iguales o diferentes uno del otro y se seleccionan independientemente del grupo que consiste de hidrógeno, alquilo inferior de 1 a 8 átomos de carbono, arilo, arilalquilo, cicloalquilo que contiene de 3 a 7 átomos de carbono; R1 y R2 se pueden unir para formar un heterociclo de 5 a 7 miembros sustituido con un miembro seleccionado de grupo que consiste de hidrógeno, de grupos arilo y arilalquilo, En donde el compuesto cíclico puede comprender 1 a 2 átomos de nitrógeno y 0 a 1 átomos de oxígeno, En donde los átomos de nitrógeno no están directamente conectados el uno con el otro o con el átomo de oxígeno, para uso en un método para tratar disfunción sexual en sujeto.",SK HOLDINGS CO LTD,CHOI YONG;;STECKLER THOMAS;;SPORN JONATHAN;;PALUMBO JOSEPH;;LEE JAMES S,,https://lens.org/001-011-687-828-541,Granted Patent,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61P15/10;;A61K31/165;;A61K45/06,,0,0,,,,ACTIVE
163,US,B2,US 11367256 B2,037-783-503-490-002,2022-06-21,2022,US 201816040381 A,2018-07-19,US 201816040381 A;;US 201514855656 A,2015-09-16,Immersive design management system,"An object management system, an aircraft design system, and a method for managing an object. A three-dimensional environment with a model of an object and an avatar representing a human operator from a viewpoint relative to the avatar is displayed on a display system. A motion of the human operator is detected. An interaction between the avatar and the model of the object is identified in real time using information about motions of the human operator that are detected in real time. The interaction changes a group of dimensions in the model of the object. Further, the interaction between the avatar and the model of the object in the three-dimensional environment is displayed on the display system, enabling design changes in the model of the object made by the human operator.",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2015-09-15),https://lens.org/037-783-503-490-002,Granted Patent,yes,10,0,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/00;;G06F3/01;;G06F30/00;;G06F30/15;;G06T17/00;;G06T19/20,,32,12,003-415-926-702-326;;075-908-431-910-913;;147-071-920-429-07X;;028-205-116-006-785;;001-787-377-414-974;;046-999-917-133-928;;080-180-884-387-493;;029-182-768-404-364;;039-618-390-066-590;;154-065-376-081-366;;067-874-294-580-23X;;033-276-900-144-048,10.1109/38.799739;;10.1016/j.compind.2005.12.005;;10.1109/vr.2004.1310076;;10.1016/j.cirp.2013.05.005;;10.1145/1281500.1281542;;10.1007/s00170-013-5207-3;;10.1145/1077534.1077550;;10.1016/j.cad.2008.10.015;;10.1016/s0010-4485(96)00094-2;;10.1145/2702123.2702389;;10.1145/1450579.1450591;;pmc3192118;;22022442;;10.1371/journal.pone.0025759,"Jayaram, Sankar, et al. “VADE: a virtual assembly design environment.” IEEE computer graphics and applications 19.6 (1999): 44-50. (Year: 1999).;;Jayaram, Uma, et al. “Introducing quantitative analysis methods into virtual environments for real-time and continuous ergonomic evaluations.” Computers in industry 57.3 (2006): 283-296. (Year: 2006).;;Lee, Sangyoon, et al. “Affective property evaluation of virtual product designs.” IEEE Virtual Reality 2004. IEEE, 2004. (Year: 2004).;;Extended European Search Report, dated Nov. 7, 2016, regarding Application No. EP16177460.9, 13 pages.;;“CAD/CAM—VROOM,” WorldViz, LLC, copyright 2002-2015, 3 pages, accessed Aug. 5, 2015. http://www.worldviz.com/industries/cad#Training_Tool.;;“Vicon Engineering,” Vicon Motion Systems Ltd., 6 pages, accessed Aug. 5, 2015. http://www.vicon.com/motion-capture/engineering.;;“Kinect Fusion,” Microsoft Corporation, copyright 2015, 5 pages, accessed Aug. 5, 2015. https://msdn.microsoft.com/en-us/enus/library/dn188670.aspx.;;Clothier et al., “Augmented Reality Visulaization Tool for Kings Stormwater Bridge”, the Proceedings of Visualization, Imaaging and Image Processing (VHP 2004), Sep. 2004, 6 pages.;;Florentino et al., “Interactive ‘touch and see’ FEM Simulation using Augmented Reality”, International Journal of Engineering Education, Jan. 2009, 16 pages.;;Krassenstein, “New Details on VRClay, The Virtual Reality CAD Software Which Could Transform the 3D Modelling Space,” 3DPrint.com, Oct. 2014, 4 pages, accessed Aug. 28, 2015. http://3dprint.com/17752/vrclay-3d-model-oculus-rift/.;;Leu et al., “CAD model based virtual assembly simulation, planning and training,” CIRP Annals—Manufacturing Technology, vol. 62, No. 2, Dec. 2013, pp. 799-822.;;Masry et al., “A Sketch-Based Interface for Iterative Design and Analysis of 3D Objects,” Proceedings of AAM SIGGRAPH 2007 courses, Article No. 31, Aug. 2007, 10 pages.;;Mings, “SolidWorks World: Post3D Brings Immersive 3D Product Design,” SolidSmack, Jan. 2011, 12 pages, accessed Aug. 5, 2015. http://www.solidsmack.com/cad-design-news/solidworks-world-post3d-brings-immersive-3d-to-product-design-sww11/.;;Qiu et al.,“Virtual human modeling for interactive assembly and disassebmly operation in virtual reality environment”, International Journal of Advanced Manufactuing Technology 2013, Jan. 31, 2013, pp. 2355-2372.;;Roberts et al., “Supporting Social Human Communication between Distributed Walk-in Displays”, Proceedings of the ACM Symposium on Virtual Reality Software and Technology, Nov. 2004, pp. 81-88.;;Uva et al., “Distributed design review using tanglible augmented technical drawings”, Computer-Aided Design, vol. 42, © 2010, pp. 364-372. www.elsevier.com/locate/cad.;;Office Action, dated Mar. 3, 2017, regarding U.S. Appl. No. 14/855,656, 33 pages.;;Final Office Action, dated Jun. 21, 2017, regarding U.S. Appl. No. 14/855,656, 22 pages.;;Office Action, dated Jul. 24, 2017, regarding U.S. Appl. No. 14/855,656, 23 pages.;;Final Office Action, dated Nov. 15, 2017, regarding U.S. Appl. No. 14/855,656, 39 pages.;;Office Action, dated Jan. 26, 2017, regarding U.S. Appl. No. 14/855,700, 24 pages.;;Final Office Action, dated May 31, 2017, regarding U.S. Appl. No. 14/855,700. 38 pages.;;Notice of Allowance, dated Sep. 13, 2017, regarding U.S. Appl. No. 14/855,700, 9 pages.;;Notice of Allowance, dated Apr. 6, 2018, regarding U.S. Appl. No. 14/855,656, 7 pages.;;European Patent Office Communication Pursuant to Article 94(3), dated Sep. 3, 2019, regarding Application No. 16177460.9, 7 pages.;;Jayaram, “Virtual Assembly Using Virtual Reality Techniques,” Computer Aided Design, Elsevier Publishers BV., Barking, GB, vol. 29, No. 8, Aug. 1, 1997, pp. 575-584.;;European Patent Office Extended Search Report, dated Nov. 27, 2020, regarding Application No. 20194332.1, 11 pages.;;Fiorentino et al., “Interactive “Touch and see” FEM Simulation using Augmented Reality,” International Journal of Engineering Education, Jan. 1, 2009, 16 pages.;;Simeone et al., “Substitutional Reality: Using the Physical Environment to Design Virtual Reality Experiences,” Augmented & Virtual Reality in the Real World, CHI 2015, Apr. 18, 2015, Seoul, Korea, pp. 3307-3316.;;Kry et al., “HandNavigator: Hands-on Interaction for Desktop Virtual Reality,” Proceedings of the 2008 ACM Symposium on Virtual Reality Software and Technology, VRST ' 08, Oct. 27, 2008, New York, New York, 8 pages.;;Dodds et al., “Talk to the Virtual Hands: Self-Animated Avatars Improve Communication in Head-Mounted Display Virtual Environments,” PLOS ONE, vol. 6, Issue 10, Oct. 12, 2011, 12 pages.;;Gokhale, “Sheet Metal Forming in a Virtual Reality Environment using LS-DYNA and Neural Networks,” 4th European LS-DYNA Users Conference, Metal Forming III, Aug. 11, 2003, 14 pages.",ACTIVE
164,US,A1,US 2021/0285034 A1,151-356-787-613-962,2021-09-16,2021,US 201917263441 A,2019-07-26,US 201917263441 A;;US 201862711106 P;;EP 2019070217 W,2018-07-27,FORMAMIDE FREE TARGET ENRICHMENT COMPOSITIONS FOR NEXT-GENERATION SEQUENCING APPLICATIONS,The invention is a novel composition of a nucleic acid hybridization solution used in a sequencing workflow.,ROCHE SEQUENCING SOLUTIONS INC,CHOI JONATHAN S;;KUSHWAHA GARIMA;;MOEHLENKAMP CYNTHIA;;NGUYEN DUYLINH;;RATERMAN DENISE,ROCHE SEQUENCING SOLUTIONS INC (2021-07-12),https://lens.org/151-356-787-613-962,Patent Application,yes,0,0,6,6,0,C12Q1/6832;;C12Q1/6806;;C12Q1/6806;;C12Q1/6832,C12Q1/6832;;C12Q1/6806,,0,0,,,,PENDING
165,EP,A1,EP 3767595 A1,167-489-365-290-788,2021-01-20,2021,EP 20194332 A,2016-07-01,US 201514855656 A;;EP 16177460 A,2015-09-16,IMMERSIVE DESIGN MANAGEMENT SYSTEM,"An object management system (108), an aircraft design system, and a method for managing an object (102). A three-dimensional environment (112) with a model (104) of an object (102) and an avatar (118) representing a human operator (111) from a viewpoint (121) relative to the avatar (118) is displayed on a display system (122). A motion of the human operator (111) is detected. An interaction between the avatar (118) and the model (104) of the object (102) is identified in real time using information (126) about motions (128) of the human operator (111) that are detected in real time. The interaction changes a group of dimensions (132) in the model (104) of the object (102). Further, the interaction between the avatar (118) and the model (104) of the object (102) in the three-dimensional environment (112) is displayed on the display system (122), enabling design changes (134) in the model (104) of the object (102) made by the human operator (111).
",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2023-03-22),https://lens.org/167-489-365-290-788,Patent Application,yes,0,0,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/20;;G06F3/01;;G06F30/15,,5,2,067-874-294-580-23X;;033-276-900-144-048,10.1145/1450579.1450591;;pmc3192118;;22022442;;10.1371/journal.pone.0025759,"MICHELE FIORENTINO ET AL: ""Interactive ""touch and see"" FEM Simulation using Augmented Reality"", INTERNATIONAL JOURNAL OF ENGINEERING EDUCATION, 1 January 2009 (2009-01-01), pages 1 - 16, XP055749947, Retrieved from the Internet <URL:https://www.researchgate.net/publication/279647768_Interactive_touch_and_see_FEM_Simulation_using_Augmented_Reality/link/55e0841908ae2fac471bced9/download> [retrieved on 20201112];;ADALBERTO L SIMEONE ET AL: ""Substitutional Reality"", HUMAN FACTORS IN COMPUTING SYSTEMS, ACM, 2 PENN PLAZA, SUITE 701 NEW YORK NY 10121-0701 USA, 18 April 2015 (2015-04-18), pages 3307 - 3316, XP058068264, ISBN: 978-1-4503-3145-6, DOI: 10.1145/2702123.2702389;;PAUL G KRY ET AL: ""HandNavigator"", PROCEEDINGS OF THE 2008 ACM SYMPOSIUM ON VIRTUAL REALITY SOFTWARE AND TECHNOLOGY, VRST '08, ACM PRESS, NEW YORK, NEW YORK, USA, 27 October 2008 (2008-10-27), pages 53 - 60, XP058133317, ISBN: 978-1-59593-951-7, DOI: 10.1145/1450579.1450591;;TREVOR J. DODDS ET AL: ""Talk to the Virtual Hands: Self-Animated Avatars Improve Communication in Head-Mounted Display Virtual Environments"", PLOS ONE, vol. 6, no. 10, 12 October 2011 (2011-10-12), pages e25759, XP055751408, DOI: 10.1371/journal.pone.0025759;;ASHWINI S GOKHALE: ""Sheet Metal Forming in a Virtual Reality Environment using LS-DYNA and Neural Networks Author: th European LS-DYNA Users Conference Metal Forming III E - III -23"", FOURTH EUROPEAN LS-DYNA USERS CONFERENCE, 11 August 2003 (2003-08-11), XP055749974, Retrieved from the Internet <URL:https://www.dynalook.com/conferences/european-conf-2003/sheet-metal-forming-in-a-virtual-reality.pdf> [retrieved on 20201112]",PENDING
166,EP,A1,EP 1893291 A1,184-058-013-422-478,2008-03-05,2008,EP 06773098 A,2006-06-13,US 2006/0023068 W;;US 69280905 P,2005-06-22,TREATMENT OF SEXUAL DYSFUNCTION,,SK HOLDINGS CO LTD,CHOI YOUNG;;STECKLER THOMAS;;SPORN JONATHAN;;PALUMBO JOSEPH;;LEE JAMES S,"SK BIOPHARMACEUTICALS CO., LTD. (2012-04-09);;SK BIOPHARMACEUTICALS CO., LTD., KR (2012-01-31)",https://lens.org/184-058-013-422-478,Patent Application,yes,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61P15/10;;A61K31/165;;A61K45/06,,0,0,,,,ACTIVE
167,AU,A1,AU 2019/235611 A1,004-157-751-405-561,2020-10-15,2020,AU 2019/235611 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,Oral appliance and valve arrangement,"A breathing assistance apparatus includes an oral appliance and a valve arrangement. The oral appliance has an appliance body shaped to be at least partially positioned within the oral cavity of a user. The valve arrangement includes a valve body and a valve member. The valve body includes a valve airway in fluid communication with a user airway, and the valve member is positioned in the valve airway, movable between first and second positions at least in part as a result of airflow through the valve airway. The valve member at least partially obstructs the valve airway in the second position so that there is a differential resistance during inhalation and exhalation.",OPEN AIRWAY DENTAL SOLUTIONS LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,OPEN AIRWAY DENTAL SOLUTIONS LTD (2023-03-16),https://lens.org/004-157-751-405-561,Patent Application,no,0,0,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/06,,0,0,,,,PENDING
168,US,B2,US 7154186 B2,022-220-976-604-328,2006-12-26,2006,US 80346404 A,2004-03-18,US 80346404 A,2004-03-18,Multi-flip chip on lead frame on over molded IC package and method of assembly,"A multichip module package uses bond wire with plastic resin on one side of a lead frame to package an integrated circuit and flip chip techniques to attach one or more mosfets to the other side of the lead frame. The assembled multichip module 30 has an integrated circuit controller 14 on a central die pad. Wire bonds 16 extend from contact areas on the integrated circuit to outer leads 2.6 of the lead frame 10 . On the opposite, lower side of the central die pad, the sources and gates of the mosfets 24, 26 are bump or stud attached to the half etched regions of the lead frame. The drains 36 of the mosfets and the ball contacts 22.1 on the outer leads are soldered to a printed circuit board.",FAIRCHILD SEMICONDUCTOR,NOQUIL JONATHAN A;;CHOI SEUNG YONG;;JOSHI RAJEEV;;WU CHUNG-LIN,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2021-07-22);;FAIRCHILD SEMICONDUCTOR CORPORATION (2004-07-19),https://lens.org/022-220-976-604-328,Granted Patent,yes,17,39,4,4,0,H01L23/3128;;H01L23/49575;;H01L24/97;;H01L25/16;;H01L2224/16;;H01L2224/32245;;H01L2224/48091;;H01L2224/48247;;H01L2224/48472;;H01L2224/73265;;H01L2224/92247;;H01L2224/97;;H01L2924/01013;;H01L2924/01029;;H01L2924/01046;;H01L2924/01047;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2924/13091;;H01L2924/15311;;H01L2924/1532;;H01L24/48;;H01L2924/01006;;H01L2924/01033;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14;;H01L25/16;;H01L23/3128;;H01L2224/48472;;H01L2924/01047;;H01L24/97;;H01L2224/48091;;H01L2924/01029;;H01L23/49575;;H01L2924/01078;;H01L2224/92247;;H01L2924/13091;;H01L2924/01013;;H01L2924/01046;;H01L2224/16;;H01L2224/48247;;H01L2224/97;;H01L2224/73265;;H01L2924/01079;;H01L2924/1532;;H01L2924/15311;;H01L2924/01082;;H01L2224/32245;;H01L2924/01033;;H01L2924/01006;;H01L24/48;;H01L2224/45144;;H01L2224/45124;;H01L2924/181;;H01L2924/00014;;H01L2924/12042;;H01L24/45;;H01L24/73;;H01L2924/14,H01L23/48;;H01L21/48;;H01L23/31;;H01L23/495;;H01L23/52;;H01L25/16,257/778;;257/723;;257/676,0,0,,,,INACTIVE
169,US,B2,US 8552060 B2,094-166-075-282-963,2013-10-08,2013,US 92212806 A,2006-06-13,US 92212806 A;;US 69280905 P;;US 2006/0023068 W,2005-06-22,Methods for treatment of sexual dysfunction,"This invention is directed to a method of treating sexual dysfunction in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, CI, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R 1 and R 2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and O to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.",PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG;;LEE JAMES S;;SK BIOPHARMACEUTICALS CO LTD,PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG;;LEE JAMES S,SK CORPORATION (2006-09-25);;SK BIOPHARMACEUTICALS CO. LTD (2011-10-04),https://lens.org/094-166-075-282-963,Granted Patent,yes,8,45,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61K31/24,514/534;;514/540,2,0,,,"International Search Report and Written Opinion dated Oct. 20, 2006.;;NovaScreen: dated: Oct. 24, 1994.",ACTIVE
170,JP,A,JP 2017059213 A,116-553-978-690-972,2017-03-23,2017,JP 2016111619 A,2016-06-03,US 201514855656 A,2015-09-16,IMMERSIVE DESIGN MANAGEMENT SYSTEM,"PROBLEM TO BE SOLVED: To provide a method and an apparatus that overcome a technical problem with managing design changes in models of objects.SOLUTION: A three-dimensional environment (112) with a model (104) of an object (102) and an avatar (118) representing a human operator (111) is displayed from a viewpoint (121) of the avatar (118). Motions of the human operator (111) are reflected in the avatar (118), and a group of dimensions (132) in the model (104) of the object (102) is changed. Further, an interaction between the avatar (118) and the model (104) of the object (102) in the three-dimensional environment (112) is displayed on a display system (122), enabling design changes (134) in the model (104) of the object (102) made by the human operator (111).SELECTED DRAWING: Figure 1",BOEING CO,JONATHAN WAYNE GABRYS;;DAVID WILLIAM BOWEN;;ANTHONY MATHEW MONTALBANO;;CHOI CHONG,,https://lens.org/116-553-978-690-972,Patent Application,no,3,4,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/00;;G06F17/50,,0,0,,,,ACTIVE
171,US,A1,US 2017/0076494 A1,192-656-686-370-182,2017-03-16,2017,US 201514855656 A,2015-09-16,US 201514855656 A,2015-09-16,Immersive Design Management System,"An object management system, an aircraft design system, and a method for managing an object. A three-dimensional environment with a model of an object and an avatar representing a human operator from a viewpoint relative to the avatar is displayed on a display system. A motion of the human operator is detected. An interaction between the avatar and the model of the object is identified in real time using information about motions of the human operator that are detected in real time. The interaction changes a group of dimensions in the model of the object. Further, the interaction between the avatar and the model of the object in the three-dimensional environment is displayed on the display system, enabling design changes in the model of the object made by the human operator.",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2015-09-15),https://lens.org/192-656-686-370-182,Patent Application,yes,2,15,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06T19/00;;G06F3/01;;G06F17/50;;G06T17/00,,2,2,046-999-917-133-928;;080-180-884-387-493,10.1007/s00170-013-5207-3;;10.1145/1077534.1077550,"Qiu, Shiguang, et al. ""Virtual human modeling for interactive assembly and disassembly operation in virtual reality environment."" The International Journal of Advanced Manufacturing Technology 69.9-12 (2013): 2355-2372.;;Roberts, David, et al. ""Supporting social human communication between distributed walk-in displays."" Proceedings of the ACM symposium on Virtual reality software and technology. ACM, 2004.",ACTIVE
172,US,A1,US 2021/0077293 A1,002-822-676-280-870,2021-03-18,2021,US 201916980142 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,ORAL APPLIANCE AND VALVE ARRANGEMENT,"A breathing assistance apparatus includes an oral appliance and a valve arrangement. The oral appliance has an appliance body shaped to be at least partially positioned within the oral cavity of a user. The valve arrangement includes a valve body and a valve member. The valve body includes a valve airway in fluid communication with a user airway, and the valve member is positioned in the valve airway, movable between first and second positions at least in part as a result of airflow through the valve airway. The valve member at least partially obstructs the valve airway in the second position so that there is a differential resistance during inhalation and exhalation.",OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,OVENTUS MEDICAL LIMITED (2019-05-14);;OPEN AIRWAY DENTAL SOLUTIONS LTD (2023-01-30),https://lens.org/002-822-676-280-870,Patent Application,yes,0,2,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/04;;A61M16/06;;A61M16/08;;A61M16/20,,0,0,,,,PENDING
173,US,S,US D0448784 S,168-994-876-149-958,2001-10-02,2001,US 12944500 F,2000-09-13,US 12944500 F,2000-09-13,Electronic camera,,POLAROID CORP,PEREZ JOSE M;;GUERRA JONATHAN;;CHOI SUSAN SHUJAN;;LAITURI DAVID W,OEP IMAGINIG OPERATING CORPORATION (2002-07-31);;PLR IP HOLDINGS LLC (2009-08-19);;MITCHAM GLOBAL INVESTMENTS LTD (2010-01-21);;POLAROID CORPORATION (2002-08-01),https://lens.org/168-994-876-149-958,Design Right,yes,5,1,1,1,0,,,D16/202;;1601,0,0,,,,EXPIRED
174,EP,A4,EP 3764962 A4,006-745-377-437-689,2021-12-22,2021,EP 19767515 A,2019-03-12,AU 2018/900813 A;;AU 2018/901486 A;;AU 2018/903622 A;;AU 2019/050223 W,2018-03-12,ORAL APPLIANCE AND VALVE ARRANGEMENT,,OVENTUS MEDICAL LTD,OGLE DAVID;;HART CHRISTOPHER PATRICK;;ANDERSON NEIL;;LOW BENJAMIN;;CHOI JONATHAN,OPEN AIRWAYS DENTAL SOLUTIONS LTD. (2023-08-09),https://lens.org/006-745-377-437-689,Search Report,no,6,0,9,9,0,A61F5/566;;A61M16/0666;;A61M16/208;;A61M16/1045;;A61F5/566;;A61M16/0493;;A61M16/208;;A61M2205/42;;A61M16/0666;;A61M2205/8281;;A61M2205/0216;;A61M2205/0272;;A61M16/1045;;A61F5/566;;A61M16/208;;A61M16/0666;;A61M16/0493;;A61M16/0003;;A61M16/0066;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281;;A61M2016/0027;;A61M16/049;;A61F5/566;;A61M16/0666;;A61M16/0875;;A61M16/1045;;A61M16/208;;A61M2205/0216;;A61M2205/0272;;A61M2205/42;;A61M2205/8281,A61F5/56;;A61M16/04;;A61M16/06;;A61M16/10;;A61M16/20,,1,0,,,See also references of WO 2019173869A1,PENDING
175,CN,A,CN 113449383 A,098-403-039-028-927,2021-09-28,2021,CN 202110764210 A,2016-07-22,CN 202110764210 A;;CN 201610586927 A;;US 201514855656 A,2015-09-16,Object management system and method for managing object,"The invention discloses an object management system and a method for managing an object. The method comprises steps of displaying a model with the object and a three-dimensional environment of a virtual person from a viewpoint relative to the virtual person on a display system; using information about the motion of a human operator detected in real time from the motion capture system to identify the interaction between the virtual person and the model of the object in real time; determining whether the interaction constitutes a design change in the model of the object; and in response to determining that the interaction constitutes a design change in the model of the object, implementing the design change in the model of the object so that the human operator to use the virtual person to make design changes to the model of the object; wherein the object is an airplane, and wherein the interaction tests the usability of controls in the airplane.",BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,,https://lens.org/098-403-039-028-927,Patent Application,no,8,0,13,13,0,G06F30/15;;G06F30/23;;G06F3/011;;G06T17/00;;G06T19/003;;G06T19/006;;G06T19/20;;G06T2219/2008;;G06T2219/2016;;G06T2219/2012;;G06T2219/012;;G06T2219/2021;;G06T2215/16;;G06F2119/14;;G06F3/011;;G06F30/15;;G06T2219/2016;;G06T19/20;;G06T2215/16;;G06T19/003;;G06T17/00;;G06T19/006;;G06F3/011;;G06T2219/012;;G06T2219/2008;;G06T2219/2021;;G06T2219/2012;;G06F30/00;;G06F30/15;;G06T19/20;;G06T2215/16;;G06T2219/2016,G06F30/15;;G06F3/01;;G06F30/23;;G06F119/14;;G06T17/00;;G06T19/00;;G06T19/20,,0,0,,,,ACTIVE
176,US,A1,US 2017/0076495 A1,144-966-139-663-747,2017-03-16,2017,US 201514855700 A,2015-09-16,US 201514855700 A,2015-09-16,Immersive Object Testing System,An object testing system and method for testing an object. A three-dimensional environment is displayed with a model of an object and an avatar from a viewpoint relative to the avatar on a display system viewed by a human operator. The object is under testing in a live environment. Information about motions of the human operator that are detected is generated. Live information about the object that is under testing in the live environment is received. A change in the object from applying the live information to the model of the object is identified. The change in the model of the object is displayed on the display system as seen from the viewpoint relative to the avatar in the three-dimensional environment.,BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2015-09-15),https://lens.org/144-966-139-663-747,Patent Application,yes,0,8,2,2,0,G06F3/017;;G06T19/00;;G06F3/011;;G06F30/00;;G06F3/011;;G06T19/006;;G06T13/40;;G06F3/017;;G06T19/00;;G06F30/00;;G06Q50/04,G06T19/00;;G06F3/01;;G06F17/50;;G06T17/00,,0,0,,,,ACTIVE
177,US,B2,US 9852237 B2,195-326-018-778-788,2017-12-26,2017,US 201514855700 A,2015-09-16,US 201514855700 A,2015-09-16,Immersive object testing system,An object testing system and method for testing an object. A three-dimensional environment is displayed with a model of an object and an avatar from a viewpoint relative to the avatar on a display system viewed by a human operator. The object is under testing in a live environment. Information about motions of the human operator that are detected is generated. Live information about the object that is under testing in the live environment is received. A change in the object from applying the live information to the model of the object is identified. The change in the model of the object is displayed on the display system as seen from the viewpoint relative to the avatar in the three-dimensional environment.,BOEING CO,GABRYS JONATHAN WAYNE;;BOWEN DAVID WILLIAM;;MONTALBANO ANTHONY MATHEW;;CHOI CHONG,THE BOEING COMPANY (2015-09-15),https://lens.org/195-326-018-778-788,Granted Patent,yes,7,3,2,2,0,G06F3/017;;G06T19/00;;G06F3/011;;G06F30/00;;G06F3/011;;G06T19/006;;G06T13/40;;G06F3/017;;G06T19/00;;G06F30/00;;G06Q50/04,G06F17/50;;G06F3/01;;G06Q50/04;;G06T13/40;;G06T19/00,,17,5,001-787-377-414-974;;029-182-768-404-364;;028-205-116-006-785;;046-999-917-133-928;;080-180-884-387-493,10.1145/1281500.1281542;;10.1016/j.cad.2008.10.015;;10.1016/j.cirp.2013.05.005;;10.1007/s00170-013-5207-3;;10.1145/1077534.1077550,"Masry, Mark, and Hod Lipson. “A sketch-based interface for iterative design and analysis of 3d objects.” ACM SIGGRAPH 2007 courses. ACM, 2007.;;Fiorentino, M., G. Monno, and A. Uva. “Interactive “touch and see” FEM Simulation using Augmented Reality.” International Journal of Engineering Education 25.6 (2009).;;Uva, Antonio E., et al. “Distributed design review using tangible augmented technical drawings.” Computer-Aided Design 42.5 (2010): 364-372.;;Clothier, Matthew, and Mike Bailey. “Augmented reality visualization tool for kings stormwater bridge.” IASTED International Conference on Visualization, Imaging and Image Processing (VIIP). 2004.;;“CAD/CAM—VROOM,” WorldViz, LLC, copyright 2002-2015, 3 pages, accessed Aug. 5, 2015. http://www.worldviz.com/industries/cad#Training—Tool.;;“Vicon Engineering,” Vicon Motion Systems Ltd., 6 pages, accessed Aug. 5, 2015.;;“Kinect Fusion,” Microsoft Corporation, copyright 2015, 5 pages, accessed Aug. 5, 2015.;;Krassenstein, “New Details on VRClay, the Virtual Reality CAD Software Which Could Transform the 3D Modelling Space,” 3DPrint.com, Oct. 2014, 4 pages, accessed Aug. 28, 2015. http://3dprint.com/17752/vrclay-3d-model-oculus-rift/.;;Mings, “SolidWorks World: Post3D Brings Immersive 3D Product Design,” SolidSmack, Jan. 2011, 12 pages, accessed Aug. 5, 2015. http://www.solidsmack.com/cad-design-news/solidworks-world-post3d-brings-immersive-3d-to-product-design-sww11/.;;Gabrys et al., “Immersive Design Management System,” U.S. Appl. No. 14/855,656, filed Sep. 16, 2015, 69 pages.;;Extended European Search Report, dated Nov. 7, 2016, regarding Application No. EP16177460.9, 13 pages.;;Leu et al., “CAD model based virtual assembly simulation, planning and training,” CIRP Annals—Manufacturing Technology, vol. 62, No. 2, Dec. 2013, pp. 799-822.;;Office Action, dated Mar. 3, 2017, regarding U.S. Appl. No. 14/855,656, 33 pages.;;Qiu et al., “Virtual human modeling for interactive assembly and disassembly operation in virtual reality environment”, International Journal of Advanced Manufacturing Technology 2013, Jan. 31, 2013, pp. 2355-2372.;;Final Office Action, dated Jun. 21, 2017, regarding U.S. Appl. No. 14/855,656, 22 pages.;;Office Action, dated Jul. 24, 2017, regarding U.S. Appl. No. 14/855,656, 23 pages.;;Roberts et al., “Supporting Social Human Communication between Distributed Walk-in Displays”, Proceedings of the ACM Symposium on Virtual Reality Software and Technology, Nov. 2004, pp. 81-88.",ACTIVE
178,US,A1,US 2017/0026772 A1,015-109-701-041-475,2017-01-26,2017,US 201615216623 A,2016-07-21,US 201615216623 A;;US 201562196160 P,2015-07-23,ORIENTATION AWARE AUDIO SOUNDSTAGE MAPPING FOR A MOBILE DEVICE,"A mobile device with orientation aware audio mapping capability is disclosed. The mobile device has an aux speaker, a loud speaker, a sensor for device orientation detection, and a processor (or processors) coupled to the sensor and the speakers. Depending on the device orientation, the processor sends a mapped audio output to the speakers. The mapped audio output may be a mono audio signal or a stereo audio signal. The stereo audio output signal may be a stereo audio output signal with a balanced or biased audio power distribution between the aux speaker and the loud speaker.",MAXIM INTEGRATED PRODUCTS,DOY ANTHONY STEPHEN;;CHIEN JONATHAN;;POLLEROS ROBERT;;NIGAM VIVEK;;CHOI SANG YOUL,MAXIM INTEGRATED PRODUCTS INC (2016-07-22),https://lens.org/015-109-701-041-475,Patent Application,yes,17,4,4,4,0,H04R3/14;;H04S7/308;;H04S7/308;;H04R2430/01;;H04R2499/11;;H04R2499/11;;H04S1/007,H04S7/00;;H04S1/00,,0,0,,,,ACTIVE
179,CA,A1,CA 3164003 A1,141-266-079-043-40X,2021-07-15,2021,CA 3164003 A,2021-01-07,US 202062958209 P;;US 2021/0012455 W,2020-01-07,SYSTEMS AND METHODS FOR ROBOTICALLY-ASSISTED HISTOTRIPSY TARGETING BASED ON MRI/CT SCANS TAKEN PRIOR TO TREATMENT,"Methods and devices for producing cavitation in tissue are provided. Methods and devices are also provided for surgical navigation, including defining a target treatment zone and navigating a focus of a therapy transducer to the target treatment zone. Embodiments are provided for co-registering a plurality of surgical imaging and navigation systems. Systems for performing Histotripsy therapy are also discussed.",UNIV MICHIGAN REGENTS,XU ZHEN;;PANDEY ADITA S;;SUKOVICH JONATHAN;;GERHARDSON TYLER;;CHOI SANG WON,,https://lens.org/141-266-079-043-40X,Patent Application,no,0,0,7,7,0,A61B34/20;;A61B2090/363;;A61B90/361;;A61B5/055;;A61B8/485;;A61B6/032;;A61B6/037;;A61B6/5235;;A61B6/5247;;A61B6/12;;A61B8/5261;;A61B8/0841;;A61N7/00;;A61N2007/0039;;A61N2007/0043;;A61N2007/0095;;A61B34/20;;A61B2034/2051;;A61B2034/2055;;A61B2034/2063;;A61B34/30;;A61B2090/364;;A61B2090/3762;;A61B2090/3983;;A61N7/00,A61B8/08;;A61B8/00;;A61B8/13;;A61B8/14;;A61B34/20,,0,0,,,,PENDING
180,EP,A1,EP 4087493 A1,009-336-164-532-465,2022-11-16,2022,EP 21738971 A,2021-01-07,US 202062958209 P;;US 2021/0012455 W,2020-01-07,SYSTEMS AND METHODS FOR ROBOTICALLY-ASSISTED HISTOTRIPSY TARGETING BASED ON MRI/CT SCANS TAKEN PRIOR TO TREATMENT,,UNIV MICHIGAN REGENTS,XU ZHEN;;PANDEY ADITA S;;SUKOVICH JONATHAN;;GERHARDSON TYLER;;CHOI SANG WON,,https://lens.org/009-336-164-532-465,Patent Application,yes,0,0,7,7,0,A61B34/20;;A61B2090/363;;A61B90/361;;A61B5/055;;A61B8/485;;A61B6/032;;A61B6/037;;A61B6/5235;;A61B6/5247;;A61B6/12;;A61B8/5261;;A61B8/0841;;A61N7/00;;A61N2007/0039;;A61N2007/0043;;A61N2007/0095;;A61B34/20;;A61B2034/2051;;A61B2034/2055;;A61B2034/2063;;A61B34/30;;A61B2090/364;;A61B2090/3762;;A61B2090/3983;;A61N7/00,A61B8/08;;A61B8/00;;A61B8/13;;A61B8/14;;A61B34/20,,0,0,,,,PENDING
181,US,A1,US 2022/0152220 A1,055-403-387-420-829,2022-05-19,2022,US 202117452041 A,2021-10-22,US 202117452041 A;;US 202063104262 P,2020-10-22,DUAL TARGETING AND THERAPEUTIC NANOPARTICLE FOR TREATING RENAL FIBROSIS,"The subject invention pertains to compositions and methods for making and use of metal-based coated nanoparticles. The metal-based, PEG-coated nanoparticles of the invention comprise folic acid molecules on their surface exercise dual functionality by specifically targeting renal tubule cells and treating renal fibrosis.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;CHAN CECILIA KA WING;;LAU YUN WONG JAMES,THE CHINESE UNIVERSITY OF HONG KONG (2023-05-05),https://lens.org/055-403-387-420-829,Patent Application,yes,1,0,2,2,0,A61K33/24;;A61K33/26;;A61K33/242;;A61K33/38;;A61P13/12;;A61K33/243;;A61K47/551;;A61K47/60;;A61K47/6929;;A61K47/6923;;B82Y5/00;;A61K47/6929;;A61K33/242;;A61K33/38;;A61K33/26;;A61P13/12;;A61K33/243;;A61K47/545;;A61K9/5146;;A61K33/24,A61K47/69;;A61K9/51;;A61K33/24;;A61K33/242;;A61K33/243;;A61K33/26;;A61K33/38;;A61K47/54;;A61P13/12,,4,4,074-572-359-212-631;;074-152-620-041-127;;074-572-359-212-631;;074-152-620-041-127,31140629;;10.1002/ddr.21545;;pmc4090709;;25018664;;10.1016/j.bej.2013.09.008;;31140629;;10.1002/ddr.21545;;pmc4090709;;25018664;;10.1016/j.bej.2013.09.008,"DOI: 10.1002/ddr.21545 - Folic acid functionalized nanoparticles as pharmaceutical Asghar Narmani1 e Melina Rezvani2 Bagher Farhood3 Parvaneh Darkhor4 Javad Mohammadnejad1 Bahram Amini5 Soheila Refahi6 Nouraddin Abdi Goushbolagh7 (Year: 2019);;Biochemical Engineeringjournal 89 (2014) 33-41 Engineered drug-protein nanoparticle complexes for folate receptor targeting Dongmei Ren a, Felix Kratz b, Szu-Wen Wanga,* (Year: 2014);;Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems Asghar Narmani, Melina Rezvani Bagher Farhood Parvaneh Darkhor Javad Mohammadnejad Bahram Amini Soheila Refahi Nouraddin Abdi Goushbolagh; DOI: 10.1002/ddr.21545 (Year: 2019);;Engineered drug-protein nanoparticle complexes for folate receptor targeting CrossMark Dongmei Ren a, Felix Kratz b, Szu-Wen Wanga, Biochemical Engineeringjournal 89 (2014) 33-41 (Year: 2014)",ACTIVE
182,AU,A1,AU 2021/206666 A1,057-489-936-289-580,2022-07-21,2022,AU 2021/206666 A,2021-01-07,US 202062958209 P;;US 2021/0012455 W,2020-01-07,Systems and methods for robotically-assisted histotripsy targeting based on MRI/CT scans taken prior to treatment,"Methods and devices for producing cavitation in tissue are provided. Methods and devices are also provided for surgical navigation, including defining a target treatment zone and navigating a focus of a therapy transducer to the target treatment zone. Embodiments are provided for co-registering a plurality of surgical imaging and navigation systems. Systems for performing Histotripsy therapy are also discussed.",UNIV MICHIGAN REGENTS,XU ZHEN;;PANDEY ADITA S;;SUKOVICH JONATHAN;;GERHARDSON TYLER;;CHOI SANG WON,,https://lens.org/057-489-936-289-580,Patent Application,no,0,0,7,7,0,A61B34/20;;A61B2090/363;;A61B90/361;;A61B5/055;;A61B8/485;;A61B6/032;;A61B6/037;;A61B6/5235;;A61B6/5247;;A61B6/12;;A61B8/5261;;A61B8/0841;;A61N7/00;;A61N2007/0039;;A61N2007/0043;;A61N2007/0095;;A61B34/20;;A61B2034/2051;;A61B2034/2055;;A61B2034/2063;;A61B34/30;;A61B2090/364;;A61B2090/3762;;A61B2090/3983;;A61N7/00,A61B8/08;;A61B8/00;;A61B8/13;;A61B8/14;;A61B34/20,,0,0,,,,PENDING
183,CA,A1,CA 2982382 A1,167-469-361-654-021,2016-10-20,2016,CA 2982382 A,2016-04-15,US 201562148350 P;;CA 2016050439 W,2015-04-16,GENETICALLY ENGINEERED C1-UTILIZING MICROORGANISMS AND PROCESSES FOR THEIR PRODUCTION AND USE,"Described are genetically engineered C1 -utilizing bacteria for the preparation of dicarboxylic acids, e.g. succinic acid. For instance, the bacteria comprise a mutation in a gene encoding a tricarboxylic acid cycle (TCA) succinate dehydrogenase (Sdh), preferably a mutation which inactivates or reduces Sdh's activity. Processes for the production of the modified bacteria as well as their use in the preparation of succinic acid on a C1 -compound as carbon source are also discussed.",NAT RES COUNCIL CANADA,LAMARCHE MARTIN G;;PERREAULT JONATHAN;;MIGUEZ CARLOS;;ARBOUR MELANIE;;CHOI YOUNG JUN,,https://lens.org/167-469-361-654-021,Patent Application,no,0,0,5,5,22,C12N9/88;;C12P7/46;;C07K14/195;;C12Y402/01011;;C12N9/001;;C12Y602/01005;;C12N9/1029;;C12Y103/05001;;C12Y203/01;;C12N9/93;;C12N15/52;;C12N1/32;;C12N9/0006;;C12Y604/01001;;C12N9/88;;C07K14/195;;C12N15/52;;C12P7/46;;C12N9/93;;C12Y602/01005;;C12Y402/01011;;C12N9/1029;;C12Y203/01;;C12N9/001;;C12Y103/05001;;C12N1/205;;C12R2001/26;;C12N1/32;;C12N9/0006;;C12Y604/01001,C12N1/21;;C12N9/00;;C12N9/02;;C12N9/10;;C12N9/88;;C12N15/00;;C12N15/52;;C12N15/53;;C12N15/54;;C12N15/60;;C12N15/63;;C12P7/46,,0,0,,,,DISCONTINUED
184,US,B2,US 11904021 B2,045-236-216-883-652,2024-02-20,2024,US 202117452041 A,2021-10-22,US 202117452041 A;;US 202063104262 P,2020-10-22,Dual targeting and therapeutic nanoparticle for treating renal fibrosis,"The subject invention pertains to compositions and methods for making and use of metal-based coated nanoparticles. The metal-based, PEG-coated nanoparticles of the invention comprise folic acid molecules on their surface exercise dual functionality by specifically targeting renal tubule cells and treating renal fibrosis.",UNIV HONG KONG CHINESE,CHOI CHUNG HANG JONATHAN;;CHAN CECILIA KA WING;;LAU YUN WONG JAMES,,https://lens.org/045-236-216-883-652,Granted Patent,yes,1,0,2,2,0,A61K33/24;;A61K33/26;;A61K33/242;;A61K33/38;;A61P13/12;;A61K33/243;;A61K47/551;;A61K47/60;;A61K47/6929;;A61K47/6923;;B82Y5/00;;A61K47/6929;;A61K33/242;;A61K33/38;;A61K33/26;;A61P13/12;;A61K33/243;;A61K47/545;;A61K9/5146;;A61K33/24,A61K47/69;;A61K9/51;;A61K33/24;;A61K33/242;;A61K33/243;;A61K33/26;;A61K33/38;;A61K47/54;;A61P13/12,,58,0,,,"DOI: 10.1002/ddr.21545—Folic acid functionalized nanoparticles as pharmaceutical Asghar Narmani1 e Melina Rezvani2 Bagher Farhood3 Parvaneh Darkhor4 Javad Mohammadnejad1 Bahram Amini5 Soheila Refahi6 Nouraddin Abdi Goushbolagh7 (Year: 2019).;;Biochemical Engineeringjournal 89 (2014) 33-41 Engineered drug-protein nanoparticle complexes for folate receptor targeting Dongmei Ren a, Felix Kratz b, Szu-Wen Wanga,* (Year: 2014).;;Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems Asghar Narmani, Melina Rezvani Bagher Farhood Parvaneh Darkhor Javad Mohammadnejad Bahram Amini Soheila Refahi Nouraddin Abdi Goushbolagh; DOI: 10.1002/ddr.21545 (Year: 2019).;;Engineered drug-protein nanoparticle complexes for folate receptor targeting CrossMark Dongmei Ren a, Felix Kratz b, Szu-Wen Wanga, Biochemical Engineeringjournal 89 (2014) 33-41 (Year: 2014).;;Haidong, W., et al., “Global, regional, and national life expectancy, all-cause morality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015,” Lancet, 2016, 388: 1459-1544.;;Zeisberg, M., et al., “Mechanisms of Tubulointerstitial Fibrosis,” Journal of the American Society of Nephrology, 2010, 21:1819-1834.;;Williams, R.M., et al., “Nanomedicines for Kidney Diseases,” Kidney International Author manuscript, pp. 1-14.;;Yang, C.; Nilsson, L.; Cheema, M. U.; Wang, Y.; Frøkiær, J.; Gao, S.; Kjems, J.; Nørregaard, R. Chitosan/SiRNA Nanoparticles Targeting Cyclooxygenase Type 2 Attenuate Unilateral Ureteral Obstruction-Induced Kidney Injury in Mice. Theranostics 2015, 5, 110-123.;;Meng, X.- M., et al., “Treatment of renal fibrosis by rebalancing TGF-β/Smad signaling with the combination of asiatic acid and naringenin,” Oncotarget, 2015, 6(35):36984-36997.;;Dolman, M.E.M., et al., “Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells,” Advanced Drug Delivery Reviews, 2010, 62:1344-1357.;;Birn, H., “The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins,” Am J Physiol Renal Physiol, 2006, 291:F22-F36.;;Zhao, X., et al., “Targeted drug delivery via folate receptors,” Expert Opinion on Drug Delivery, 2008, 5(3):309-319.;;Knight, S.F., et al., “Folate Receptor-Targeted Antioxidant Therapy Ameliorates Renal Ischemia-Reperfusion Injury,” Journal of the American Society of Nephrology, 2012, 23:793-800.;;Sarin, H., “Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability,” Journal of Angiogenesis Research, 2010, 2:1-19.;;Du, B., et al., “Transport and interactions of nanoparticles in the kidneys,” Nature Reviews Materials, 2018, 3:358-374.;;Hesketh, E.E., et al., “A Murine Model of Irreversible and Reversible Unilateral Ureteric Obstruction,” Journal of Visualized Experiments, 2014, 94:1-6.;;Ho, L.W.C., et al., “Nano-Cell Interactions of Non-Cationic Bionanomaterials,” Accounts of Chemical Research, 2019, 52:1519-1530.;;Yang, H.-C., et al., “Models of chronic kidney disease,” Drug Discovery Today: Disease Models, 2010, 7(1-2):13-19.;;Liu, Y., “Renal fibrosis: New insights into the pathogenesis and therapeutics,” Kidney International, 2006, 69:213-217.;;Nogueira, A., et al., “Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies,” In Vivo, 2017, 31:1-22.;;Liu, Y., “Cellular and molecular mechanisms of renal fibrosis,” Nature Reviews Nephrology, 2011, 7:684-696.;;Chaar, M.E., et al., “Effect of combination therapy with enalapril and the TGF-β antagonist 1D11 in unilateral ureteral obstruction,” Am J Physiol Renal Physiol, 2007, 292:F1291-F1301.;;Gao, X., et al., “Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy,” Kidney International, 2002, 62:1238-1248.;;Lan, H.U., et al., “Inhibition of Renal Fibrosis by Gene Transfer of Inducible Smad7 Using Ultrasound-Microbubble System in Rat UUO Model,” Journal of the American Society of Nephrology, 2003, 14:1535-1548.;;He, W., et al., “Wnt/β-Catenin Signaling Promotes Renal Interstitial Fibrosis,” Journal of the American Society of Nephrology, 2009, 20:765-776.;;Tan, R.J., et al., “Wnt/β-catenin signaling and kidney fibrosis,” Kidney International Supplements, 2014, 4:84-90.;;Huo, S., et al., “Ultrasmall Gold Nanoparticles Behavior in Vivo Modulated by Surface Polyethylene Glycol (PEG) Grafting,” Bioconjugate Chemistry, 2017, 28:239-243.;;Piella, J., et al., “Size-Controlled Synthesis of Sub-10-nanometer Citrate-Stabilized Gold Nanoparticles and Related Optical Properties,” Chemistry of Materials, 2016, 28:1066-1075.;;Bastus, N.G., et al., “Kinetically Controlled Seeded Growth Synthesis of Citrate-Stabilized Gold Nanoparticles of up to 200 nm: Size Focusing versus Ostwald Ripening,” Langmuir, 2011, 27:11098-11105.;;Haiss, W., et al., “Determination of Size and Concentration of Gold Nanoparticles from UV-Vis Spectra,” Analytical Chemistry, 2007, 79(11):4215-4221.;;Hurst, S.J., et al., “Maximizing DNA Loading on a Range of Gold Nanoparticle Sizes,” Analytical Chemistry, 2006, 78(24):8313-8318.;;Ho, L.W.C., et al., “Effect of Alkylation on the Cellular Uptake of Polyethylene Glycol-Coated Gold Nanoparticles,” ACS Nano, 2017, 11:6085-6101.;;Chevalier, R.L., et al., “Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy,” Kidney International, 2009, 75:1145-1152.;;Takemoto, M., et al., “A New Method for Large Scale Isolation of Kidney Glomeruli from Mice,” American Journal of Pathology, 2002, 161(3):799-805.;;Kah, J.C.Y., et al., “Molecular contrast of EGFR expression using gold nanoparticles as a reflectance-based imaging probe,” Molecular and Cellular Probes, 2008, 22:14-23.;;Yamashita, S., “Heat-induced antigen retrieval: Mechanisms and application to histochemistry,” Progress in Histochemistry and Cytochemistry, 2007, 41:141-200.;;Veenstra, D.L., et al., “Incidence and Long-Term Cost of Steroid-Related Side Effects After Renal Transplantation,” American Journal of Kidney Diseases, 1999, 33(5):829-839.;;Fried, L.F., “Combined Angiotensin Inhibition for the treatment of Diabetic Nephropathy,” The New England Journal of Medicine, 2013, 369:1892-1903.;;Choi, C.H.J., et al., “Targeting kidney mesangium by nanoparticles of defined size,” PNAS, 2011, 108(16):6656-6661.;;Zuckerman, J.E., et al., “Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane,” PNAS, 2012, 109(8):3137-3142.;;Huang, Y., et al., “The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles,” Bioengineering & Translational Medicine, 2020, 5:1-11.;;Williams, R.M., et al., “Selective Nanoparticle Targeting of the Renal Tubules,” Hypertension, 2018, 71(1):1-17.;;Du, B., et al., “Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime,” Nature Nanotechnology, 2017, 12:1-9.;;Kamaly, N., et al., “Nanomedicines for renal disease: current status and future applications,” Nature Reviews Nephrology, 2016, 12:738-753.;;Wang, J., et al., “Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease,” Journal of Controlled Release, 2021, 329:1198-1209.;;Huang, C. et al., “Folate Receptor-Mediated Renal-Targeting Nanoplatform for the Specific Delivery of Triptolide to Treat Renal Ischemia/Reperfusion Injury,” ACS Biomater. Sci. Eng., 2019, 5:2877-2886.;;Zhang, Y.-N., et al., “Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination,” Journal of Controlled Release, 2016, 240:332-348.;;Choi, H.S., et al., “Renal clearance of quantum dots,” Nature Biotechnology, 2007, 25(10):1165-1170.;;Wu, Z., et al., “Solubility of Folic Acid in Water at pH Values between 0 and 7 at Temperatures (298.15, 303.15, and 313.15) K,” Journal of Chemical & Engineering Data, 2010, 55(9):3958-3961.;;Nestor, J., et al., “Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors,” Journal of Experimental Medicine, 2018, 215(10):2554-2566.;;Keppler, A., et al., “Plasma creatinine determination in mice and rats: An enzymatic method compares favorably with a high-performance liquid chromatography assay,” Kidney International, 2007, 71:74-78.;;Dunnett, C.W., “A Multiple Comparison Procedure for Comparing Several Treatments with a Control,” Journal of the American Statistical Association, 1955, 50(272):1096-1121.;;Yin, B., et al., “Intrapulmonary Cellular-Level Distribution of Inhaled Nanoparticles with Defined Functional Groups and Its Correlations with Protein Corona and Inflammatory Response,” ACS Nano, 2019, 13:14048-14069.;;Cobley, C.M., et al., “Gold nanostructures: a class of multifunctional materials for biomedical applications,” Chem. Soc. Rev., 2011, 40:44-56.;;Ucero, A.C., et al., “Unilateral ureteral obstruction: beyond obstruction,” Int Urol Nephrol, 2014, 46:765-776.;;Forbes, M.S., et al., “Fight-or-flight: murine unilateral ureteral obstruction causes extensive proximal tubular degenernation, collecting duct dilation, and minimal fibrosis,” Am J Physiol Renal Physiol, 2012, 303:F120-F129.;;Malyala, P., et al., “Endotoxin Limits in Formulations for Preclinical Research,” Journal of Pharmaceutical Sciences, 2008, 97(6): 2041-2044.;;Jiang, D., et al., “Nanomedicines for Renal Management: From Imaging to Treatment,” Accounts of Chemical Research, 2020, 53:1869-1880.",ACTIVE
185,US,S,US D0924410 S,096-890-094-866-681,2021-07-06,2021,US 201829634007 F,2018-01-17,US 201829634007 F,2018-01-17,Instrument tower,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;HUFFSTETLER QUINN SLATER;;CHOI WONBIN,MATTER LLC (2018-05-03);;AURIS HEALTH INC (2018-05-21),https://lens.org/096-890-094-866-681,Design Right,no,177,7,4,4,0,,,2402;;D24/185,0,0,,,,ACTIVE
186,EP,A1,EP 3283616 A1,096-501-883-066-597,2018-02-21,2018,EP 16779374 A,2016-04-15,US 201562148350 P;;CA 2016050439 W,2015-04-16,GENETICALLY ENGINEERED C1-UTILIZING MICROORGANISMS AND PROCESSES FOR THEIR PRODUCTION AND USE,,NAT RES COUNCIL CANADA,LAMARCHE MARTIN G;;PERREAULT JONATHAN;;MIGUEZ CARLOS;;ARBOUR MÉLANIE;;CHOI YOUNG JUN,,https://lens.org/096-501-883-066-597,Patent Application,yes,0,0,5,5,22,C12N9/88;;C12P7/46;;C07K14/195;;C12Y402/01011;;C12N9/001;;C12Y602/01005;;C12N9/1029;;C12Y103/05001;;C12Y203/01;;C12N9/93;;C12N15/52;;C12N1/32;;C12N9/0006;;C12Y604/01001;;C12N9/88;;C07K14/195;;C12N15/52;;C12P7/46;;C12N9/93;;C12Y602/01005;;C12Y402/01011;;C12N9/1029;;C12Y203/01;;C12N9/001;;C12Y103/05001;;C12N1/205;;C12R2001/26;;C12N1/32;;C12N9/0006;;C12Y604/01001,C12N1/21;;C12N9/00;;C12N9/02;;C12N9/10;;C12N9/88;;C12N15/00;;C12N15/52;;C12N15/53;;C12N15/54;;C12N15/60;;C12N15/63;;C12P7/46,,0,0,,,,DISCONTINUED
187,US,S,US D0994890 S,125-322-270-880-285,2023-08-08,2023,US 202129797871 F,2021-07-02,US 202129797871 F;;US 201829634007 F,2018-01-17,Instrument tower,,AURIS HEALTH INC,MENDOZA JONATHAN;;VAZQUEZ FRANKIE;;STOPPER TOBY A;;HUFFSTETLER QUINN SLATER;;CHOI WONBIN,AURIS HEALTH INC (2018-05-01),https://lens.org/125-322-270-880-285,Design Right,no,182,0,4,4,0,,,2402;;D24/185,2,0,,,"Non-Final Rejection for U.S. Appl. No. 29/634,007, dated Aug. 7, 2020, 9 pages.;;Notice of Allowance for U.S. Appl. No. 29/634,007, dated Mar. 2, 2021, 6 pages.",ACTIVE
188,EP,A4,EP 3283616 A4,081-904-754-676-219,2018-08-22,2018,EP 16779374 A,2016-04-15,US 201562148350 P;;CA 2016050439 W,2015-04-16,GENETICALLY ENGINEERED C1-UTILIZING MICROORGANISMS AND PROCESSES FOR THEIR PRODUCTION AND USE,,NAT RES COUNCIL CANADA,LAMARCHE MARTIN G;;PERREAULT JONATHAN;;MIGUEZ CARLOS;;ARBOUR MÉLANIE;;CHOI YOUNG JUN,,https://lens.org/081-904-754-676-219,Search Report,no,2,0,5,5,0,C12N9/88;;C12P7/46;;C07K14/195;;C12Y402/01011;;C12N9/001;;C12Y602/01005;;C12N9/1029;;C12Y103/05001;;C12Y203/01;;C12N9/93;;C12N15/52;;C12N1/32;;C12N9/0006;;C12Y604/01001;;C12N9/88;;C07K14/195;;C12N15/52;;C12P7/46;;C12N9/93;;C12Y602/01005;;C12Y402/01011;;C12N9/1029;;C12Y203/01;;C12N9/001;;C12Y103/05001;;C12N1/205;;C12R2001/26;;C12N1/32;;C12N9/0006;;C12Y604/01001,C12N1/21;;C12N9/00;;C12N9/02;;C12N9/10;;C12N9/88;;C12N15/00;;C12N15/52;;C12N15/53;;C12N15/54;;C12N15/60;;C12N15/63;;C12P7/46,,1,0,,,See also references of WO 2016165025A1,DISCONTINUED
189,TW,B,TW I387452 B,085-365-202-041-560,2013-03-01,2013,TW 95122189 A,2006-06-21,US 69280905 P,2005-06-22,Methods for treating sexual dysfunction,,SK BIOPHARMACEUTICALS CO LTD,PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG MOON;;LEE S JAMES,,https://lens.org/085-365-202-041-560,Granted Patent,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,,,0,0,,,,ACTIVE
190,US,B2,US 10805760 B2,160-743-168-478-550,2020-10-13,2020,US 201615216623 A,2016-07-21,US 201615216623 A;;US 201562196160 P,2015-07-23,Orientation aware audio soundstage mapping for a mobile device,"A mobile device with orientation aware audio mapping capability is disclosed. The mobile device has an aux speaker, a loud speaker, a sensor for device orientation detection, and a processor (or processors) coupled to the sensor and the speakers. Depending on the device orientation, the processor sends a mapped audio output to the speakers. The mapped audio output may be a mono audio signal or a stereo audio signal. The stereo audio output signal may be a stereo audio output signal with a balanced or biased audio power distribution between the aux speaker and the loud speaker.",MAXIM INTEGRATED PRODUCTS,DOY ANTHONY STEPHEN;;CHIEN JONATHAN;;POLLEROS ROBERT;;NIGAM VIVEK;;CHOI SANG YOUL,MAXIM INTEGRATED PRODUCTS INC (2016-07-22),https://lens.org/160-743-168-478-550,Granted Patent,yes,16,0,4,4,0,H04R3/14;;H04S7/308;;H04S7/308;;H04R2430/01;;H04R2499/11;;H04R2499/11;;H04S1/007,H04S7/00;;H04S1/00,,2,0,,,"Office Action for Chinese Patent Application No. 201610840076.4 dated Oct. 25, 2019, (24 pgs).;;CN Office Action No. 2 dated Aug. 4, 2020 in related Chinese Patent Application No. 201610840076.4, (23 pgs).",ACTIVE
191,CN,A,CN 106375910 A,061-299-641-315-005,2017-02-01,2017,CN 201610840076 A,2016-07-25,US 201562196160 P;;US 201615216623 A,2015-07-23,Orientation aware audio soundstage mapping for a mobile device,"A mobile device with orientation aware audio mapping capability is disclosed. The mobile device has an aux speaker, a loud speaker, a sensor for device orientation detection, and a processor (or processors) coupled to the sensor and the speakers. Depending on the device orientation, the processor sends a mapped audio output to the speakers. The mapped audio output may be a mono audio signal or a stereo audio signal. The stereo audio output signal may be a stereo audio output signal with a balanced or biased audio power distribution between the aux speaker and the loud speaker.",MAXIM INTEGRATED PRODUCTS,DOY ANTHONY STEPHEN;;CHIEN JONATHAN;;POLLEROS ROBERT;;NIGAM VIVEK;;CHOI SANG YOUL,,https://lens.org/061-299-641-315-005,Patent Application,no,8,1,4,4,0,H04R3/14;;H04S7/308;;H04S7/308;;H04R2430/01;;H04R2499/11;;H04R2499/11;;H04S1/007,H04R3/14,,0,0,,,,ACTIVE
192,EP,A4,EP 4087493 A4,110-136-238-393-379,2024-01-24,2024,EP 21738971 A,2021-01-07,US 202062958209 P;;US 2021/0012455 W,2020-01-07,SYSTEMS AND METHODS FOR ROBOTICALLY-ASSISTED HISTOTRIPSY TARGETING BASED ON MRI/CT SCANS TAKEN PRIOR TO TREATMENT,,UNIV MICHIGAN REGENTS,XU ZHEN;;PANDEY ADITA S;;SUKOVICH JONATHAN;;GERHARDSON TYLER;;CHOI SANG WON,,https://lens.org/110-136-238-393-379,Search Report,no,4,0,7,7,0,A61B34/20;;A61B2090/363;;A61B90/361;;A61B5/055;;A61B8/485;;A61B6/032;;A61B6/037;;A61B6/5235;;A61B6/5247;;A61B6/12;;A61B8/5261;;A61B8/0841;;A61N7/00;;A61N2007/0039;;A61N2007/0043;;A61N2007/0095;;A61B34/20;;A61B2034/2051;;A61B2034/2055;;A61B2034/2063;;A61B34/30;;A61B2090/364;;A61B2090/3762;;A61B2090/3983;;A61N7/00,A61B8/08;;A61B5/055;;A61B6/00;;A61B6/03;;A61B6/12;;A61B8/00;;A61B8/13;;A61B8/14;;A61B17/22;;A61B34/20;;A61B90/00;;A61N7/00,,1,0,,,See also references of WO 2021142090A1,PENDING
193,TW,A,TW 200727893 A,193-174-275-981-805,2007-08-01,2007,TW 95122189 A,2006-06-21,US 69280905 P,2005-06-22,Methods for treating sexual dysfunction,"This invention is directed to a method of treating sexual dysftinction in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; X is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same of different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.",SK CORP,PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG-MOON;;LEE S JAMES,,https://lens.org/193-174-275-981-805,Patent of Addition,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61K31/165;;A61P15/10,,0,0,,,,ACTIVE
194,MY,A,MY 145066 A,194-998-860-198-502,2011-12-15,2011,MY PI20062920 A,2006-06-20,US 69280905 P,2005-06-22,METHODS FOR TREATING SEXUAL DYSFUNCTION,"52 METHODS FOR TREATING SEXUAL DYSFUNCTION ABSTRACT OF THE INVENTION THIS INVENTION IS DIRECTED TO A METHOD OF TREATING SEXUAL DYSFUNCTION IN A 5 SUBJECT, COMPRISING THE STEP OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF FORMULA (1): 0 11 OCNRIR, NHI R OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF WHEREIN 10 RX IS A MEMBER SELECTED FROM THE GROUP CONSISTING OF HYDROGEN, LOWER ALKYL OF 1 TO 8 CARBON ATOMS, HALOGEN SELECTED FROM F, CL, BR AND 1, ALKOXY CONTAINING 1 TO 3 CARBON ATOMS, NITRO, HYDROXY, TRIFLUOROMETHYL, AND THIOALKOXY CONTAINING I TO 3 CARBON ATOMS; X IS AN INTEGER OF I TO 3, WITH THE PROVISO THAT R MAY BE THE SAME OR 15 DIFFERENT WHEN X IS 2 OR 3; R, AND R2 CAN BE THE SAME OR DIFFERENT FROM EACH OTHER AND ARE INDEPENDENTLY SELECTED FROM THE GROUP CONSISTING OF HYDROGEN, LOWER ALKYL OF 1 TO 8 CARBON ATOMS, ARYL, ARYLALKYL, CYCLOALKYL OF 3 TO 7 CARBON ATOMS; R, AND R2 CAN BE JOINED TO FORM A 5 TO 7-MEMBERED HETEROCYCLE 20 SUBSTITUTED WITH A MEMBER SELECTED FROM THE GROUP CONSISTING OF HYDROGEN, ALKYL, AND ARYL GROUPS, WHEREIN THE CYCLIC COMPOUND CAN COMPRISE 1 TO 2 NITROGEN ATOMS AND 0 TO 1 OXYGEN ATOM, WHEREIN THE NITROGEN ATOMS ARE NOT DIRECTLY CONNECTED WITH EACH OTHER OR 25 WITH THE OXYGEN ATOM.",SK HOLDINGS CO LTD,PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG MOON;;LEE JAMES S,,https://lens.org/194-998-860-198-502,Granted Patent,no,0,0,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61P15/10,,0,0,,,,ACTIVE
195,US,A1,US 2009/0221553 A1,074-166-146-914-695,2009-09-03,2009,US 92212806 A,2006-06-13,US 92212806 A;;US 69280905 P;;US 2006/0023068 W,2005-06-22,Methods for Treatment of Sexual Dysfunction,"This invention is directed to a method of treating sexual dysfunction in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, CI, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R 1 and R 2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and O to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.",PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG MOON;;LEE JAMES S,PALUMBO JOSEPH;;SPORN JONATHAN;;STECKLER THOMAS;;CHOI YONG MOON;;LEE JAMES S,SK BIOPHARMACEUTICALS CO. LTD (2011-10-04),https://lens.org/074-166-146-914-695,Patent Application,yes,4,9,18,18,0,A61K31/165;;A61P15/00;;A61P15/08;;A61P15/10;;A61K31/165;;A61K31/165,A61K31/27;;A61K31/553;;A61K31/55;;A61P15/00,514/211.13;;514/489;;514/217,0,0,,,,ACTIVE
196,US,A1,US 2023/0038498 A1,143-365-539-099-268,2023-02-09,2023,US 202117790975 A,2021-01-07,US 202117790975 A;;US 202062958209 P;;US 2021/0012455 W,2020-01-07,SYSTEMS AND METHODS FOR ROBOTICALLY-ASSISTED HISTOTRIPSY TARGETING BASED ON MRI/CT SCANS TAKEN PRIOR TO TREATMENT,"Methods and devices for producing cavitation in tissue are provided. Methods and devices are also provided for surgical navigation, including defining a target treatment zone and navigating a focus of a therapy transducer to the target treatment zone. Embodiments are provided for co-registering a plurality of surgical imaging and navigation systems. Systems for performing Histotripsy therapy are also discussed.",UNIV MICHIGAN REGENTS,XU ZHEN;;PANDEY ADITA S;;SUKOVICH JONATHAN;;GERHARDSON TYLER;;CHOI SANG WON,,https://lens.org/143-365-539-099-268,Patent Application,yes,0,3,7,7,0,A61B34/20;;A61B2090/363;;A61B90/361;;A61B5/055;;A61B8/485;;A61B6/032;;A61B6/037;;A61B6/5235;;A61B6/5247;;A61B6/12;;A61B8/5261;;A61B8/0841;;A61N7/00;;A61N2007/0039;;A61N2007/0043;;A61N2007/0095;;A61B34/20;;A61B2034/2051;;A61B2034/2055;;A61B2034/2063;;A61B34/30;;A61B2090/364;;A61B2090/3762;;A61B2090/3983;;A61N7/00,A61B34/20;;A61B34/30;;A61N7/00,,0,0,,,,PENDING
197,US,A1,US 2018/0087024 A1,193-662-018-192-488,2018-03-29,2018,US 201615566579 A,2016-04-15,US 201615566579 A;;US 201562148350 P;;CA 2016050439 W,2015-04-16,GENETICALLY ENGINEERED C1-UTILIZING MICROORGANISMS AND PROCESSES FOR THEIR PRODUCTION AND USE,"Described are genetically engineered C1-utilizing bacteria for the preparation of dicarboxylic acids, e.g. succinic acid. For instance, the bacteria comprise a mutation in a gene encoding a tricarboxylic acid cycle (TCA) succinate dehydrogenase (Sdh), preferably a mutation which inactivates or reduces Sdh's activity. Processes for the production of the modified bacteria as well as their use in the preparation of succinic acid on a C1-compound as carbon source are also discussed.",NAT RES COUNCIL CANADA,LAMARCHE MARTIN G;;PERREAULT JONATHAN;;MIGUEZ CARLOS;;ARBOUR MELANIE;;CHOI YOUNG JUN,NATIONAL RESEARCH COUNCIL OF CANADA (2016-04-15),https://lens.org/193-662-018-192-488,Patent Application,yes,3,2,5,5,22,C12N9/88;;C12P7/46;;C07K14/195;;C12Y402/01011;;C12N9/001;;C12Y602/01005;;C12N9/1029;;C12Y103/05001;;C12Y203/01;;C12N9/93;;C12N15/52;;C12N1/32;;C12N9/0006;;C12Y604/01001;;C12N9/88;;C07K14/195;;C12N15/52;;C12P7/46;;C12N9/93;;C12Y602/01005;;C12Y402/01011;;C12N9/1029;;C12Y203/01;;C12N9/001;;C12Y103/05001;;C12N1/205;;C12R2001/26;;C12N1/32;;C12N9/0006;;C12Y604/01001,C12N1/32;;C07K14/195;;C12N9/04;;C12N9/88;;C12N15/52;;C12R1/26,,0,0,,,,DISCONTINUED
198,US,A1,US 2022/0011496 A1,102-913-842-354-679,2022-01-13,2022,US 202117482149 A,2021-09-22,US 202117482149 A;;US 2021/0013504 W;;US 202062961972 P,2020-01-16,Optical Systems Having Gradient Index Optical Structures,"An electronic device may include a waveguide with an input coupler and an output coupler. The input coupler may receive the image light from imaging optics. The input coupler may be an input coupling prism and the imaging optics may include lens elements. World light may be viewable at an eye box through the output coupler. Biasing, compensation, and/or prescription lenses may overlap the output coupler. The input coupling prism, the lens elements in the imaging optics, and/or one or more of the biasing, compensation, and prescription lenses may be formed from gradient index (GRIN) material. The GRIN material may have a gradient refractive index that varies in one or more gradient directions. Use of GRIN materials may minimize the volume required to form the device without sacrificing optical performance. In addition, the GRIN materials may compensate for dispersion and aberrations in the device.",APPLE INC,BHAKTA VIKRANT;;DELAPP SCOTT M;;PFEIFFER JONATHAN B;;CHOI HYUNGRYUL;;PENG GUOLIN,,https://lens.org/102-913-842-354-679,Patent Application,yes,0,4,2,2,0,G02B6/0023;;G02B6/005;;G02B6/0036;;G02B6/34;;G02B3/0087;;G02B27/0172;;G02B2027/0174;;G02B2027/0178;;G02B27/0093;;G02B2027/014;;G02B2027/0138;;G02B3/0087;;G02B6/0023;;G02B6/34;;G02B27/0172;;G02B2027/0178,F21V8/00;;G02B3/00;;G02B6/34;;G02B27/01,,0,0,,,,PENDING
199,US,B2,US 9105480 B2,146-230-006-559-330,2015-08-11,2015,US 201313829078 A,2013-03-14,US 201313829078 A,2013-03-14,Methods for the fabrication of graphene nanoribbon arrays using block copolymer lithography,"Methods of fabricating patterned substrates, including patterned graphene substrates, using etch masks formed from self-assembled block copolymer films are provided. Some embodiments of the methods are based on block copolymer (BCP) lithography in combination with graphoepitaxy. Some embodiments of the methods are based on BCP lithography techniques that utilize hybrid organic/inorganic etch masks derived from BCP templates. Also provided are field effect transistors incorporating graphene nanoribbon arrays as the conducting channel and methods for fabricating such transistors.",WISCONSIN ALUMNI RES FOUND,ARNOLD MICHAEL S;;GOPALAN PADMA;;SAFRON NATHANIEL S;;KIM MYUNGWOONG;;CHOI JONATHAN WOOSUN,WISCONSIN ALUMNI RESEARCH FOUNDATION (2013-04-11),https://lens.org/146-230-006-559-330,Granted Patent,yes,3,1,2,2,0,H01L21/3065;;H01L21/3086;;H01L21/31058;;H01L21/31116;;H01L21/31138;;B82Y40/00;;H01L29/66015;;H01L29/66439;;H01L29/778;;H01L29/0673;;H01L29/1606;;C01B2204/065;;C01B32/194;;B82Y10/00;;H01L21/042;;B82Y10/00;;H01L21/3065;;H01L21/3086;;H01L21/31058;;H01L21/31116;;H01L21/31138;;H01L29/66015;;C01B2204/065;;H01L29/778;;H01L29/0673;;H01L29/1606;;H01L29/66439;;B82Y40/00;;C01B32/194,C01B31/04;;B82Y10/00;;H01L21/04;;H01L21/3065;;H01L21/308;;H01L21/3105;;H01L21/311,,21,18,001-085-590-538-750;;007-036-627-079-760;;050-170-865-203-946;;063-562-595-872-801;;113-726-938-008-987;;025-363-809-301-802;;063-039-554-314-153;;032-845-340-093-801;;057-025-086-281-711;;116-521-364-838-163;;046-867-122-454-096;;089-241-601-029-965;;138-967-160-624-977;;110-658-310-224-624;;013-283-662-465-064;;103-932-689-814-48X;;028-804-588-086-079;;064-707-032-067-56X,23078122;;10.1021/nn303127y;;10.1021/nn301515a;;22780305;;10.1021/nl9032318;;20192229;;20827673;;10.1002/adma.201002465;;19206575;;10.1021/nn700341s;;17570733;;10.1021/nl070924l;;20806266;;10.1002/adma.201001669;;10.1002/adma.200601421;;19507886;;10.1021/nl9004833;;10.1038/nnano.2007.227;;18654348;;10.1007/s12274-012-0209-2;;10.1021/nn2003234;;21545142;;10.1063/1.1631070;;10.1016/s0040-6090(03)00533-9;;10.1016/j.mee.2008.09.036;;10.1063/1.1388026;;10.1039/c3tc00930k;;10.1021/la060748g.s001;;16922574;;10.1021/la060748g,"Liang et al., ""Transport Characteristics of Multichannel Transistors Made from Densely Aligned Sub-10 nm Half-Pitch Graphene Nanoribbons,"" ACS Nano, vol. 6, No. 11, Oct. 13, 2012, pp. 9700-9710.;;Liu et al., ""Epitaxial Graphene Nanoribbon Array Fabrication Using BCP-Assisted Nanolithography,"" ACS Nano, vol. 6, No. 8, Jul. 10, 2012, pp. 6786-6792.;;Kim et al., ""Fabrication and Characterization of Large-Area, Semiconducting Nanoperforated Grahene Materials,"" NanoLetters, vol. 10, 2010, pp. 1125-1131.;;Peng et al., Nanoscopic Patterned Materials with Tunable Dimensions via Atomic Layer Deposition on Block Copolymers, Adv. Mater., vol. 22, Sep. 8, 2010, pp. 5129-5133.;;Chai et al., Using Cylindrical Domains of Block Copolymers To Self-Assemble and Align Metallic Nanowires, ACS Nano, vol. 2, No. 3, Feb. 5, 2008, pp. 489-501.;;Jung et al., ""Orientation-Controlled Self-Assembled Nanolithography Using a Polystyrene-Polydimethylsiloxane Block Copolymer,"" NanoLetters, vol. 7, No. 7, 2007, pp. 2046-2050.;;B. Dumé´, Graphene nanoribbon arrays break size record, Published on Aug. 31, 2012 by nanotechweb.org at http://nanotechweb.org/cws/article/tech/50666.;;Gopalan et al., Graphoepitaxial Assembly of Symmetric Block Copolymers on Weakly Preferential Substrates, Adv. Mater., vol. 22, Aug. 30, 2010, pp. 4325-4329.;;Nealey et al., Directed Assembly of Lamellae-Forming Block Copolymers by Using Chemically and Topographically Patterned Substrates, Adv. Mater., vol. 19, Jan. 26, 2007, pp. 607-611.;;Jeong et al., Soft Graphoepitaxy of Block Copolymer Assembly with Disposable Photoresist Confinement, Nano Letters, vol. 9, No. 6, May 7, 2009, pp. 2300-2305.;;Chai et al., Assembly of aligned linear metallic patterns on silicon, Nature Nanotechnology, vol. 2, Aug. 3, 2007, pp. 500-506.;;Jiao et al., Densely Aligned Graphene Nanoribbons at ~35 nm Pitch, Nano Research, vol. 5, No. 4, Apr. 2012, pp. 292-296.;;Peng et al., A Route to Nanoscopic Materials via Sequential Infiltration Synthesis on Block Copolymer Templates, ACS Nano, vol. 5, No. 6, May 5, 2011, pp. 4600-4606.;;Liang et al., Transport Characteristics of Multichannel Transistors Made from Densely Aligned Sub-10 nm Half-Pitch Graphene Nanoribbons, ACS Nano, vol. 6, No. 11, Oct. 13, 2012, pp. 9700-9710.;;Liu et al., Epitaxial Graphene Nanoribbon Array Fabrication Using BCP-Assisted Nanolithography, ACS Nano, vol. 6, No. 8, Jul. 10, 2012, pp. 6786-6792.;;Hoyas et al., Growth and characterization of atomic layer deposited WC0.7N0.3 on polymer films, Journal of Applied Physics, vol. 95, No. 1, Jan. 1, 2004, pp. 381-388.;;Elam et al., Surface chemistry and film growth during TiN atomic layer deposition using TDMAT and NH3, Thin Solid Films, vol. 436, No. 2, Jul. 31, 2003, pp. 145-156.;;Musschoot et al., Atomic layer deposition of titanium nitride from TDMAT precursor, Microelectronic Engineering, vol. 86, Oct. 2, 2008, pp. 72-77.;;Nakajima et al., Low-temperature formation of silicon nitride gate dielectrics by atomic-layer deposition, Applied Physics Letters, vol. 79, No. 5, Jul. 30, 2001, pp. 665-667.;;Ramanathan et al., Emerging trends in metal-containing block copolymers: synthesis, self-assembly, and nanomanufacturing applications, Journal of Materials Chemistry C, Jan. 21, 2013, pp. 2080-2091.;;In et al., Side-Chain-Grafted Random Copolymer Brushes as Neutral Surfaces for Controlling the Orientation of Block Copolymer Microdomains in Thin Films, Langmuir, vol. 22, Aug. 1, 2006, pp. 7855-7860.",ACTIVE
200,WO,A1,WO 2020/060976 A1,029-745-325-126-699,2020-03-26,2020,US 2019/0051413 W,2019-09-17,US 201862732605 P,2018-09-18,HIGH POWER SURFACE MOUNT FILTER,"A filter assembly is disclosed that includes a monolithic filter having a surface and a heat sink coupled to the surface of the monolithic filter. The heat sink includes a layer of thermally conductive material that can have a thickness greater than about 0.02 mm. The heat sink may provide electrical shielding for the monolithic filter. In some embodiments, the filter assembly may include an organic dielectric material, such as liquid crystalline polymer or polyphenyl ether. In some embodiments, the filter assembly may include an additional monolithic filter.",AVX CORP,CHOI KWANG;;BEROLINI MARIANNE;;KIRK MICHAEL W;;FUENTES HECTOR;;HERR JONATHAN;;SEITHER BRYAN,,https://lens.org/029-745-325-126-699,Patent Application,yes,5,0,9,9,0,H03H2001/0078;;H03H2001/0085;;H03H7/0115;;H03H7/175;;H03H7/1775;;H03H7/54;;H05K7/20918;;H05K9/0071;;H03H7/0161,H01P11/00;;H01P1/203;;H01P1/30,,0,0,,,,PENDING
201,US,A1,US 2014/0273361 A1,193-154-448-537-174,2014-09-18,2014,US 201313829078 A,2013-03-14,US 201313829078 A,2013-03-14,METHODS FOR THE FABRICATION OF GRAPHENE NANORIBBON ARRAYS USING BLOCK COPOLYMER LITHOGRAPHY,"Methods of fabricating patterned substrates, including patterned graphene substrates, using etch masks formed from self-assembled block copolymer films are provided. Some embodiments of the methods are based on block copolymer (BCP) lithography in combination with graphoepitaxy. Some embodiments of the methods are based on BCP lithography techniques that utilize hybrid organic/inorganic etch masks derived from BCP templates. Also provided are field effect transistors incorporating graphene nanoribbon arrays as the conducting channel and methods for fabricating such transistors.",WISCONSIN ALUMNI RES FOUND,ARNOLD MICHAEL S;;GOPALAN PADMA;;SAFRON NATHANIEL S;;KIM MYUNGWOONG;;CHOI JONATHAN WOOSUN,WISCONSIN ALUMNI RESEARCH FOUNDATION (2013-04-11),https://lens.org/193-154-448-537-174,Patent Application,yes,3,15,2,2,0,H01L21/3065;;H01L21/3086;;H01L21/31058;;H01L21/31116;;H01L21/31138;;B82Y40/00;;H01L29/66015;;H01L29/66439;;H01L29/778;;H01L29/0673;;H01L29/1606;;C01B2204/065;;C01B32/194;;B82Y10/00;;H01L21/042;;B82Y10/00;;H01L21/3065;;H01L21/3086;;H01L21/31058;;H01L21/31116;;H01L21/31138;;H01L29/66015;;C01B2204/065;;H01L29/778;;H01L29/0673;;H01L29/1606;;H01L29/66439;;B82Y40/00;;C01B32/194,H01L21/04;;C01B31/04;;H01L21/02;;H01L21/027,438/158;;216/49;;977/938;;977/734;;977/888,6,6,001-085-590-538-750;;007-036-627-079-760;;050-170-865-203-946;;063-562-595-872-801;;113-726-938-008-987;;025-363-809-301-802,23078122;;10.1021/nn303127y;;10.1021/nn301515a;;22780305;;10.1021/nl9032318;;20192229;;20827673;;10.1002/adma.201002465;;19206575;;10.1021/nn700341s;;17570733;;10.1021/nl070924l,"Liang et al., ""Transport Characteristics of Multichannel Transistors Made from Densely Aligned Sub-10 nm Half-Pitch Graphene Nanoribbons,"" ACS Nano, vol. 6, no. 11, October 13, 2012, pp. 9700-9710.;;Liu et al., ""Epitaxial Graphene Nanoribbon Array Fabrication Using BCP-Assisted Nanolithography,"" ACS Nano, vol. 6, no. 8, July 10, 2012, pp. 6786-6792.;;Kim et al., ""Fabrication and Characterization of Large-Area, Semiconducting Nanoperforated Grahene Materials,"" NanoLetters, vol. 10, 2010, pp. 1125-1131.;;Peng et al., Nanoscopic Patterned Materials with Tunable Dimensions via Atomic Layer Deposition on Block Copolymers, Adv. Mater., vol. 22, September 8, 2010, pp. 5129-5133.;;Chai et al., Using Cylindrical Domains of Block Copolymers To Self-Assemble and Align Metallic Nanowires, ACS Nano, vol. 2, no. 3, February 5, 2008, pp. 489-501.;;Jung et al., ""Orientation-Controlled Self-Assembled Nanolithography Using a Polystyrene-Polydimethylsiloxane Block Copolymer,"" NanoLetters, vol. 7, no. 7, 2007, pp. 2046-2050.",ACTIVE
202,US,A1,US 2013/0105328 A1,005-907-674-904-397,2013-05-02,2013,US 201213620554 A,2012-09-14,US 201213620554 A;;US 201161534658 P,2011-09-14,MICROBIOSENSORS BASED ON DNA MODIFIED SINGLE-WALLED CARBON NANOTUBE AND PT BLACK NANOCOMPOSITES,"Glucose and ATP biosensors have important applications in diagnostics and research. Combining single-walled carbon nanotubes (SWCNTs) with Pt nanoparticles can significantly enhance the performance of electrochemical biosensors. This disclosure illustrates the use of single-stranded DNA (ssDNA) to modify SWCNTs to increase SWCNT solubility in water. Multiple embodiments with this configuration allows for exploration of new schemes of combining ssDNASWCNT and Pt black in aqueous media systems. These embodiments resulted in a nanocomposite with enhanced biosensor performance. The ssDNA-SWCNT/Pt black nanocomposite constructed by a layered scheme proved most effective in terms of biosensor activity. The key feature of this structure and method of use is the exploitation of ssDNASWCNTs as molecular templates for Pt black electrodeposition. Glucose and ATP microbiosensors fabricated utilizing this structure and method of use exhibited high sensitivity, wide linear range and low limit of detection.",CHA TAE-GON;;CHOI JONG HYUN;;CLAUSSEN JONATHAN C;;DIGGS ALFRED R;;SHI JIN;;PURDUE RESEARCH FOUNDATION,CHA TAE-GON;;CHOI JONG HYUN;;CLAUSSEN JONATHAN C;;DIGGS ALFRED R;;SHI JIN,PURDUE RESEARCH FOUNDATION (2012-09-24),https://lens.org/005-907-674-904-397,Patent Application,yes,6,5,2,2,0,B82Y5/00;;B82Y5/00;;B82Y15/00;;B82Y15/00;;C12Q1/001;;C12Q1/001;;C12Q1/006;;C12Q1/006;;C12Q1/68;;G01N27/327;;G01N27/3278;;G01N27/3278;;Y10S977/75;;Y10S977/75;;Y10S977/892;;Y10S977/892;;Y10S977/904;;Y10S977/904,C12Q1/00;;C12Q1/68,205/109;;204/403.01;;204/403.14;;205/777.5;;977/750;;977/892;;977/904,0,0,,,,ACTIVE
203,US,A1,US 2012/0307035 A1,128-431-734-614-789,2012-12-06,2012,US 201213358254 A,2012-01-25,US 201213358254 A;;US 201161436026 P,2011-01-25,SINGLE-SHOT FULL-FIELD REFLECTION PHASE MICROSCOPY,"The present invention relates to a full-field reflection phase microscope. In a preferred embodiment, the invention can combine low-coherence interferometry and off-axis digital holographic microscopy (DHM). The reflection-based DHM provides highly sensitive and a single-shot imaging of cellular dynamics while the use of low coherence source provides a depth-selective measurement. A preferred embodiment of the system uses a diffraction grating in the reference arm to generate an interference image of uniform contrast over the entire field-of-view albeit low-coherence light source. With improved path-length sensitivity, the present invention is suitable for full-field measurement of membrane dynamics in live cells with sub-nanometer-scale sensitivity.",YAQOOB ZAHID;;CHOI WONSHIK;;YAMAUCHI TOYOHIKO;;FELD MICHAEL;;FELD DAVID;;HEARN ALISON;;FELD JONATHAN,YAQOOB ZAHID;;CHOI WONSHIK;;YAMAUCHI TOYOHIKO;;FELD MICHAEL;;FELD DAVID;;HEARN ALISON;;FELD JONATHAN,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2012-07-02);;HAMAMATSU PHOTONICS K.K (2012-09-14),https://lens.org/128-431-734-614-789,Patent Application,yes,10,35,9,9,0,G01B9/04;;G01B9/02032;;G01B9/02047;;G01B9/02064;;G01B9/0207;;G01B9/02084;;G01B9/02091;;G01N21/45;;G02B27/1086;;G02B27/50;;G03H1/0443;;G03H2001/005;;G03H2001/0456;;G03H2001/0467;;G03H2222/24,H04N7/18,348/79;;X348E07085,1,1,038-262-343-742-460,10.1364/ao.44.001806;;15813516,"Massatsch et al., ""Time-domain optical coherence tomography with digital holography microscopy"", Optical Society of America, 2005.",ACTIVE
204,DE,T5,DE 112019004661 T5,156-823-702-508-154,2021-08-26,2021,DE 112019004661 T,2019-09-17,US 201862732605 P;;US 2019/0051413 W,2018-09-18,Oberflächenmontierter Hochleistungsfilter,"Eine Filterbaugruppe wird offenbart, die einen monolithischen Filter mit einer Oberfläche und einer an die Oberfläche des monolithischen Filters gekoppelten Wärmesenke umfasst. Die Wärmesenke umfasst eine Schicht aus wärmeleitendem Material, die eine Dicke von mehr als etwa 0,02 mm aufweist. Die Wärmesenke kann für eine elektrische Abschirmung des monolithischen Filters sorgen. In einigen Ausführungsformen kann die Filterbaugruppe ein organisches dielektrisches Material umfassen, wie ein flüssigkristallines Polymer oder Polyphenylether. In einigen Ausführungsformen kann die Filterbaugruppe einen zusätzlichen monolithischen Filter umfassen.",AVX CORP,CHOI KWANG;;BEROLINI MARIANNE;;KIRK MICHAEL W;;FUENTES HECTOR;;HERR JONATHAN C;;SEITHER BRYAN R,"KYOCERA AVX COMPONENTS CORPORATION (N. D. GES., US (2022-04-25)",https://lens.org/156-823-702-508-154,Patent Application,no,1,0,9,9,0,H03H2001/0078;;H03H2001/0085;;H03H7/0115;;H03H7/175;;H03H7/1775;;H03H7/54;;H05K7/20918;;H05K9/0071;;H03H7/0161,H01P11/00,,0,0,,,,PENDING
205,US,A1,US 2016/0272623 A1,061-136-547-197-499,2016-09-22,2016,US 201615074779 A,2016-03-18,US 201615074779 A;;US 201562136425 P,2015-03-20,FORMATION OF MACROMOLECULES USING ITERATIVE GROWTH AND RELATED COMPOUNDS,"In some embodiments, macromolecules and related methods are provided. In some embodiments, an iterative growth process may be used to form a macromolecule comprising one or more repeat units comprising a functionalizable pendant group, with precise control over mass, length, backbone sequence, pendant group sequence, and/or stereochemistry, amongst other features. Macromolecules (e.g., non-natural macromolecules) form from the iterative growth process, described herein, may be used for a wide variety of applications, including the delivery of active agents.",MASSACHUSETTS INST TECHNOLOGY,JOHNSON JEREMIAH A;;BARNES JONATHAN CHRISTOPHER;;EHRLICH DEBORAH JUNE CHOI;;JIANG YIVAN;;GAO ANGELA XIAODI,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2016-04-27),https://lens.org/061-136-547-197-499,Patent Application,yes,0,4,3,3,0,C07D405/12;;C07D405/12;;C07D303/22;;C07D303/22;;C07D405/14;;C07D405/14;;C08G65/02,C07D405/12;;C07D303/22;;C07D405/14,,3,2,043-889-801-872-132;;032-229-270-213-660,10.1039/c5ob00250h;;25739445;;23353733;;10.1016/j.ejmech.2012.12.005,"Althuon et al, Org. Biomol. Chem., 2015, 13, 4226.;;Furlani et al, Eur. J. Med. Chem., 62, (2013), 59-70.;;STN Registry database entry for CAS RN 171494-22-7 (Entered STN database 19 December 1995), Accessed 30 August 2017..",ACTIVE
206,US,A1,US 2022/0174848 A1,192-610-677-544-212,2022-06-02,2022,US 202117344059 A,2021-06-10,US 202117344059 A;;US 201916572740 A;;US 201862732605 P,2018-09-18,High Power Surface Mount Filter,"A filter assembly is disclosed that includes a monolithic filter having a surface and a heat sink coupled to the surface of the monolithic filter. The heat sink includes a layer of thermally conductive material that can have a thickness greater than about 0.02 mm. The heat sink may provide electrical shielding for the monolithic filter. In some embodiments, the filter assembly may include an organic dielectric material, such as liquid crystalline polymer or polyphenyl ether. In some embodiments, the filter assembly may include an additional monolithic filter.",AVX CORP,CHOI KWANG;;BEROLINI MARIANNE;;KIRK MICHAEL W;;FUENTES HECTOR;;HERR JONATHAN C;;SEITHER BRYAN R,KYOCERA AVX COMPONENTS CORPORATION (2021-09-13),https://lens.org/192-610-677-544-212,Patent Application,yes,10,0,9,9,0,H03H2001/0078;;H03H2001/0085;;H03H7/0115;;H03H7/175;;H03H7/1775;;H03H7/54;;H05K7/20918;;H05K9/0071;;H03H7/0161,H05K7/20;;H03H7/01;;H05K9/00,,0,0,,,,PENDING
207,CN,A,CN 112689927 A,104-400-940-045-836,2021-04-20,2021,CN 201980059616 A,2019-09-17,US 201862732605 P;;US 2019/0051413 W,2018-09-18,HIGH POWER SURFACE MOUNT FILTER,"A filter assembly is disclosed that includes a monolithic filter having a surface and a heat sink coupled to the surface of the monolithic filter. The heat sink includes a layer of thermally conductive material that can have a thickness greater than about 0.02 mm. The heat sink may provide electrical shielding for the monolithic filter. In some embodiments, the filter assembly may include an organic dielectric material, such as liquid crystalline polymer or polyphenyl ether. In some embodiments, the filter assembly may include an additional monolithic filter.",AVX CORP,CHOI KWANG;;BEROLINI MARIANNE;;KIRK MICHAEL W;;FUENTES HECTOR;;HERR JONATHAN C;;SEITHER BRYAN R,,https://lens.org/104-400-940-045-836,Patent Application,no,11,0,9,9,0,H03H2001/0078;;H03H2001/0085;;H03H7/0115;;H03H7/175;;H03H7/1775;;H03H7/54;;H05K7/20918;;H05K9/0071;;H03H7/0161,H01P11/00;;H01P1/203;;H01P1/30,,1,0,,,"赵军: ""高功率模块式有源电力滤波器结构和散热系统设计"", 《电气时代》",ACTIVE
208,US,B2,US 10125124 B2,171-677-375-441-116,2018-11-13,2018,US 201615074779 A,2016-03-18,US 201615074779 A;;US 201562136425 P,2015-03-20,Formation of macromolecules using iterative growth and related compounds,"In some embodiments, macromolecules and related methods are provided. In some embodiments, an iterative growth process may be used to form a macromolecule comprising one or more repeat units comprising a functionalizable pendant group, with precise control over mass, length, backbone sequence, pendant group sequence, and/or stereochemistry, amongst other features. Macromolecules (e.g., non-natural macromolecules) form from the iterative growth process, described herein, may be used for a wide variety of applications, including the delivery of active agents.",MASSACHUSETTS INST TECHNOLOGY,JOHNSON JEREMIAH A;;BARNES JONATHAN CHRISTOPHER;;EHRLICH DEBORAH JUNE CHOI;;JIANG YIVAN;;GAO ANGELA XIAODI,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2016-04-27),https://lens.org/171-677-375-441-116,Granted Patent,yes,12,0,3,3,0,C07D405/12;;C07D405/12;;C07D303/22;;C07D303/22;;C07D405/14;;C07D405/14;;C08G65/02,C07D303/22;;C07D405/12;;C07D405/14,,26,18,043-889-801-872-132;;032-229-270-213-660;;087-446-726-501-481;;000-482-654-084-43X;;010-308-558-905-17X;;028-200-279-550-694;;123-223-393-071-799;;115-400-399-881-455;;133-142-542-704-181;;151-281-954-599-683;;007-966-561-855-560;;029-409-842-344-528;;015-490-538-083-872;;054-335-439-515-611;;015-778-387-330-030;;053-570-403-835-094;;094-791-135-404-955;;083-934-735-952-679,10.1039/c5ob00250h;;25739445;;23353733;;10.1016/j.ejmech.2012.12.005;;26391080;;10.1038/nchem.2346;;19655362;;10.1002/anie.200903156;;10.1002/marc.201000548;;21433136;;10.1055/s-2006-944221;;10.1021/ja972027x;;10.1002/hlca.19960790311;;10.1016/j.tetlet.2005.10.113;;10.1021/ma981073u;;10.1126/science.1238149;;23929982;;10.1039/b9py00329k;;10.1002/anie.199209221;;10.1039/c39820001165;;10.1021/ja980052c;;10.1021/ma00086a062;;12240211;;10.1039/b105185g;;10.1002/anie.199400821,"Althuon et al, Org. Biomol. Chem., 2015, 13, 4226.;;Furlani et al, Eur. J. Med. Chem., 62, (2013), 59-70.;;STN Registry database entry for CAS RN 171494-22-7 (Entered STN database Dec. 19, 1995), Accessed Aug. 30, 2017.;;International Search Report and Written Opinion for Application No. PCT/US16/23201 dated Jun. 10, 2016.;;Barnes et al., Iterative exponential growth of stereo- and sequence-controlled polymers. Nature Chemistry. Sep. 2015;7:810-5. Supplementary Information Included.;;Barnes, Functional Macromolecular Platforms for Sequence-Defined Polymers and Multidrug-Loaded Nanoparticle Chemotherapeutics. 251st ACS National Meeting. San Diego, CA. Mar. 14, 2016. Presentation. 11 pages.;;Binauld et al., A modular approach to functionalized and expanded crown ether based macrocycles using click chemistry. Angew Chem Int Ed Engl. 2009;48(36):6654-8. doi: 10.1002/anie.200903156.;;Binauld et al., Precise synthesis of molecularly defined oligomers and polymers by orthogonal iterative divergent/convergent approaches. Macromol Rapid Commun. Jan. 17, 2011;32(2):147-68. doi: 10.1002/marc.201000548. Epub Dec. 3, 2010.;;Franz et al., A Post-Modification Strategy for the Synthesis of Uniform, Hydrophilic/Hydrophobic Patterned α-Hydroxy Acid Oligomers. Eur. J. Org. Chem. Nov. 2009;31:5390-405.;;Franz et al., Synthesis of uniform, non-natural oligomers. Synlett. 2006;12:1793-815.;;Hawker et al., Exact Linear Analogs of Dendritic Polyether Macromolecules: Design, Synthesis, and Unique Properties. J. Am. Chem. Soc. 1997;119(41):9903-4.;;Johnson, Progress towards the efficient synthesis of polymers with precisely defined mass, sequence and stereochemistry. 249th ACS National Meeting. Denver, CO. Mar. 22, 2015. Presentation. 16 pages.;;Johnson, Progress towards the efficient synthesis of polymers with precisely defined mass, sequence and stereochemistry. 249th ACS National Meeting. Denver, CO. Mar. 22, 2015. Abstract. 2 pages.;;Lengweiler et al., Synthese monodisperser linearer and cyclischer Oligomere der (R)-3-Hydroxybuttersäure mit bis zu 128 Einheiten. Helv. Chim. Acta. May 1996;79(3):670-701.;;Li et al., A novel in situ deprotection/coupling and iterative divergent/convergent strategy for the synthesis of oligo(1,4-phenyleneethynylene)s. Tetrahedron Letters. Dec. 2005;46(52):8971-3.;;Louie et al., The Largest Discrete Oligo(m-aniline). An Exponential Growth Strategy Using Palladium-Catalyzed Amination of Aryl Sulfonates. Macromolecules. 1998;31(19):6737-9.;;Lutz et al., Sequence-controlled polymers. Science. Aug. 9, 2013;341(6146):1238149. doi: 10.1126/science.1238149-1-1238149-8.;;Lutz, Sequence-controlled polymerizations: the next Holy Grail in polymer science? Polymer Chemistry. 2010;1:55-62.;;Moore et al., Efficient Synthesis of Nanoscale Macrocyclic Hydrocarbons. Angew. Chem. Int. Ed. Jul. 1992;31(7):922-4.;;Paynter et al., The synthesis of long-chain unbranched aliphatic compounds by molecular doubling. Journal of the Chemical Society, Chemical Communications. 1982;20:1165-6.;;Sadighi et al., Palladium-Catalyzed Synthesis of Monodisperse, Controlled-Length, and Functionalized Oligoanilines. J. Am. Chem. Soc. 1998;120(20):4960-76.;;Tour, Iterative Divergent/Convergent Approach to Conjugated Oligomers by a Doubling of Molecular Length at Each Iteration. A Rapid Route to Potential Molecular Wires. Macromolecules. 1994;27(8):2348-50.;;Van Hest et at., Protein-based materials, toward a new level of structural control. Chemical Communications. 2001;19:1897-904.;;Wooley et al., A “Branched-Monomer Approach” for the Rapid Synthesis of Dendimers. Angew. Chem. Int. Ed. Jan. 1994;33(1):82-5.;;Gao, Development of Novel Polymeric Architectures for Applications in Drug Delivery and Studies Towards the Synthesis of Perfect Polymers by Iterative Exponential Growth “Plus” (IEG+). Master's Thesis. Massachusetts Institute of Technology. Jun. 2014. 88 pages. Available online as of Oct. 21, 2014 at <http://hdl.handle.net/1721.1/91119>.;;International Preliminary Report on Patentability dated Oct. 5, 2017 for PCT/US2016/023201.",ACTIVE
209,WO,A1,WO 2016/154029 A1,028-195-825-075-074,2016-09-29,2016,US 2016/0023201 W,2016-03-18,US 201562136425 P,2015-03-20,FORMATION OF MACROMOLECULES USING ITERATIVE GROWTH AND RELATED COMPOUNDS,"In some embodiments, macromolecules and related methods are provided. In some embodiments, an iterative growth process may be used to form a macromolecule comprising one or more repeat units comprising a functionalizable pendant group, with precise control over mass, length, backbone sequence, pendant group sequence, and/or stereochemistry, amongst other features. Macromolecules (e.g., non-natural macromolecules) form from the iterative growth process, described herein, may be used for a wide variety of applications, including the delivery of active agents.",MASSACHUSETTS INST TECHNOLOGY,JOHNSON JEREMIAH A;;BARNES JONATHAN CHRISTOPHER;;EHRLICH DEBORAH JUNE CHOI;;JIANG YIVAN;;GAO ANGELA XIAODI,,https://lens.org/028-195-825-075-074,Patent Application,yes,8,0,3,3,0,C07D405/12;;C07D405/12;;C07D303/22;;C07D303/22;;C07D405/14;;C07D405/14;;C08G65/02,B01J39/26;;B01D15/36;;B01J41/04,,0,0,,,,PENDING
210,AT,T1,AT E520655 T1,046-123-528-459-645,2011-09-15,2011,AT 96919298 T,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"SUBSTITUIERTE ((SULFINSÄURE, SULFONSÄURE, SULFONYLAMINO ODER SULFINYLAMINO)N- (AMINOIMONOMETHYL)PHENYLALKYL)- AZAHETEROCYCLYLAMID-DERIVATE",,AVENTIS PHARMA INC,EWING WILLIAM;;BECKER MICHAEL;;PAULS HENRY;;CHENEY DANIEL;;MASON JONATHAN;;SPADA ALFRED;;CHOI-SLEDESKI YONG,,https://lens.org/046-123-528-459-645,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
211,US,B2,US 11071239 B2,146-283-058-511-397,2021-07-20,2021,US 201916572740 A,2019-09-17,US 201916572740 A;;US 201862732605 P,2018-09-18,High power surface mount filter,"A filter assembly is disclosed that includes a monolithic filter having a surface and a heat sink coupled to the surface of the monolithic filter. The heat sink includes a layer of thermally conductive material that can have a thickness greater than about 0.02 mm. The heat sink may provide electrical shielding for the monolithic filter. In some embodiments, the filter assembly may include an organic dielectric material, such as liquid crystalline polymer or polyphenyl ether. In some embodiments, the filter assembly may include an additional monolithic filter.",AVX CORP,CHOI KWANG;;BEROLINI MARIANNE;;KIRK MICHAEL W;;FUENTES HECTOR;;HERR JONATHAN C;;SEITHER BRYAN R,KYOCERA AVX COMPONENTS CORPORATION (2019-09-27),https://lens.org/146-283-058-511-397,Granted Patent,yes,42,0,9,9,0,H03H2001/0078;;H03H2001/0085;;H03H7/0115;;H03H7/175;;H03H7/1775;;H03H7/54;;H05K7/20918;;H05K9/0071;;H03H7/0161,H05K7/20;;H03H7/01;;H05K9/00,,2,0,,,"International Search Report and Written Opinion for PCT/US2019/051413 dated Jan. 3, 2020, 14 pages.;;Dissertation of Seunghyun Eddy Hwang to Georgia Institute of Technology entitled “Characterization and Design of Embedded Passive Circuits for Applications Up to Millimeter-Wave Frequency,” dated Aug. 2011, 196 pages.",ACTIVE
212,US,A1,US 2020/0120836 A1,071-857-895-886-314,2020-04-16,2020,US 201916572740 A,2019-09-17,US 201916572740 A;;US 201862732605 P,2018-09-18,High Power Surface Mount Filter,"A filter assembly is disclosed that includes a monolithic filter having a surface and a heat sink coupled to the surface of the monolithic filter. The heat sink includes a layer of thermally conductive material that can have a thickness greater than about 0.02 mm. The heat sink may provide electrical shielding for the monolithic filter. In some embodiments, the filter assembly may include an organic dielectric material, such as liquid crystalline polymer or polyphenyl ether. In some embodiments, the filter assembly may include an additional monolithic filter.",AVX CORP,CHOI KWANG;;BEROLINI MARIANNE;;KIRK MICHAEL W;;FUENTES HECTOR;;HERR JONATHAN C;;SEITHER BRYAN R,KYOCERA AVX COMPONENTS CORPORATION (2019-09-27),https://lens.org/071-857-895-886-314,Patent Application,yes,0,1,9,9,0,H03H2001/0078;;H03H2001/0085;;H03H7/0115;;H03H7/175;;H03H7/1775;;H03H7/54;;H05K7/20918;;H05K9/0071;;H03H7/0161,H05K7/20;;H03H7/01;;H05K9/00,,0,0,,,,ACTIVE
213,US,S,US D0749672 S,007-251-593-273-881,2016-02-16,2016,US 201429481992 F,2014-02-12,US 201429481992 F,2014-02-12,Multifunction printer,,SAMSUNG ELECTRONICS CO LTD,CHUNG WON-SUK;;GROSSMAN JONATHAN;;BRAUER KRISTIAAN A;;GROTE MARK J;;HOWES PATRICIA;;CHOI SOO-SHIN,HP PRINTING KOREA CO. LTD (2016-11-30);;SAMSUNG ELECTRONICS CO. LTD (2014-03-05),https://lens.org/007-251-593-273-881,Design Right,no,0,2,1,1,0,,,1802;;D18/53,0,0,,,,ACTIVE
214,WO,A1,WO 2018/098445 A1,144-466-351-787-068,2018-05-31,2018,US 2017/0063314 W,2017-11-27,US 201615362757 A;;US 201615362765 A;;US 201615362751 A,2016-11-28,MANAGING MESSAGING PROTOCOL COMMUNICATIONS,Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages and process the message to determine how the communication message will be routed or otherwise processed according to business rules or logic.,AMAZON TECH INC,KUO CALVIN;;BROOKER MARC;;SORENSON JAMES;;RAFN MARK;;TANDON AMBUJ;;TUROW JONATHAN;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI,,https://lens.org/144-466-351-787-068,Patent Application,yes,5,38,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L29/06;;H04L12/58;;H04L12/66;;H04L29/08;;H04W4/00,,1,0,,,See also references of EP 3545662A4,PENDING
215,US,A1,US 2022/0355720 A1,095-393-721-282-906,2022-11-10,2022,US 202217705486 A,2022-03-28,US 202217705486 A;;US 202163184762 P;;US 202163218823 P,2021-05-05,CONNECTED MODULAR CAMPER TRAILER SYSTEMS AND METHODS,"A portable dwelling system includes a rigid dwelling, an external frame, and a plurality of modular amenity units. The rigid dwelling is capable of being removably mountable to a trailer. The external frame is coupled to an exterior of the rigid dwelling and includes an integrated powered rail electrically connected to a power source. The external frame defines receiving areas having a standard size on the exterior of the rigid dwelling. The plurality of modular amenity units each removably interchangeable at any one of the receiving areas via a connector configuration. The connector configuration electrically couples the powered rail to each of the plurality of modular amenity units.",HONDA MOTOR CO LTD,KANE DILLON;;MOSS JONATHAN;;CHOI SHINNGARAM;;HARP KYLE;;STAAL MATTHEW;;BALDWIN SCOTT;;MELIKIAN LILI;;ACUNA VICTOR,HONDA MOTOR CO. LTD (2022-03-07),https://lens.org/095-393-721-282-906,Patent Application,yes,0,0,1,1,0,B60P3/36;;B60P3/36;;B60P3/34,B60P3/34;;B60P3/36,,0,0,,,,PENDING
216,US,B2,US 9835570 B2,016-424-722-170-424,2017-12-05,2017,US 201414484517 A,2014-09-12,US 201414484517 A;;US 201361877416 P,2013-09-13,X-ray diffraction (XRD) characterization methods for sigma=3 twin defects in cubic semiconductor (100) wafers,"An X-ray defraction (XRD) characterization method for sigma=3 twin defects in cubic semiconductor (100) wafers includes a concentration measurement method and a wafer mapping method for any cubic tetrahedral semiconductor wafers including GaAs (100) wafers and Si (100) wafers. The methods use the cubic semiconductor's (004) pole figure in order to detect sigma=3/{111} twin defects. The XRD methods are applicable to any (100) wafers of tetrahedral cubic semiconductors in the diamond structure (Si, Ge, C) and cubic zinc-blend structure (InP, InGaAs, CdTe, ZnSe, and so on) with various growth methods such as Liquid Encapsulated Czochralski (LEC) growth, Molecular Beam Epitaxy (MBE), Organometallic Vapor Phase Epitaxy (OMVPE), Czochralski growth and Metal Organic Chemical Vapor Deposition (MOCVD) growth.",NASA;;NASA,PARK YEONJOON;;KIM HYUN JUNG;;SKUZA JONATHAN R;;LEE KUNIK;;KING GLEN C;;CHOI SANG HYOUK,UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (2014-09-11);;UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NASA (2014-10-14),https://lens.org/016-424-722-170-424,Granted Patent,yes,24,4,2,2,0,G01N23/207;;G01N23/207;;G01N23/20;;G01N2223/0566;;G01N2223/0566;;G01N2223/6116;;G01N2223/6116;;G01N2223/646;;G01N2223/6462;;G01N2223/6462,G01N23/207;;G01N23/20,,28,25,013-183-054-226-563;;091-232-000-540-108;;104-777-935-800-526;;029-987-072-533-473;;021-579-476-343-381;;158-833-869-407-437;;143-092-297-796-974;;016-725-956-270-830;;110-869-457-970-576;;038-371-848-891-667;;024-186-751-466-047;;133-746-423-095-798;;066-598-062-003-48X;;059-846-593-609-41X;;069-164-337-838-752;;128-482-105-689-315;;095-290-252-835-237;;005-927-531-949-975;;145-956-317-200-452;;134-421-603-280-027;;082-758-262-026-256;;138-495-837-921-891;;158-948-332-919-643;;153-089-327-473-523;;056-041-264-238-024,10383990;;10.1017/s1431927699000124;;10.1016/j.jcrysgro.2008.02.010;;10.1023/a:1026187726360;;10.1002/pssa.2211360104;;10.1002/pssa.2210450125;;10.1103/physrevb.56.3564;;10.1143/jjap.31.2061;;10.1021/cg060420l;;10.1016/s0022-0248(96)00663-x;;10.1016/j.jcrysgro.2009.10.006;;10.1021/cg800270q;;10.1016/j.jcrysgro.2008.11.067;;10.1109/tadvp.2002.805315;;10.1109/lmwc.2003.811059;;10.1002/mop.23651;;10.1143/jjap.45.3423;;10.1063/1.347421;;10.1002/crat.2170320811;;10.1016/0169-4332(92)90417-v;;10.1143/jjap.31.l853;;10.1016/0022-0248(93)90239-s;;10.1016/s0925-8388(03)00595-4;;10.1016/s0022-0248(98)00712-x;;10.1016/j.jcrysgro.2007.11.146;;10.1002/pssa.2211220113,"B. D. Cullity and S. R. Stock. Elements of X-Ray Diffraction, Third Edition (Upper Saddle River, New Jersey: Prentice Hall, 2001), pp. 66-88.;;Park, Y.; “Analysis of twin defects in GaAs(111)B molecular beam epitaxy growth,” Journal of Vacuum Science and Technology B, 2000, 18(3), 1566-1571.;;Cohen, D.; McKernan, S.; Carter, C.B., “Characterization of the Absolute Crystal Polarity across Twin Boundaries in Gallium Phosphide Using Convergent-Beam Electron Diffraction,” Microscopy and Microanalysis, vol. 5, p. 173-186, 1999.;;Park, Y.; King, G.; Choi, S. H., “Rhombohedral epitaxy of cubic SiGe on trigonal c-plane sapphire,” Journal of Crystal Growth 2008, 310 (11), 2724-2731.;;Cohen, D.; Carter, C.B., “Sigma=, {11(2)over-bar} lateral twin boundaries in GaP,” Interface Science 2003, 11.(4), 391-401.;;Gerthsen, D; Carter, C.B., “Stacking-Fault Energies of Gaas,” Phys Status Solidi A, Applied research, vol. 136, (1), pp. 29-43, 1993.;;Gottschalk, H.; Patzer, G.; Alexander, H., “Stacking-fault Energy and Ionicity of Cubic-III-V compounds,” Physcia status solidi. a-Applied research, 1978, 45 (1), pp. 207-217.;;Bandic, Z.Z., McGill, T.C.; Ikonic, Z., “Electronic Structure of GaN Stacking Faults,” Physical Review B, vol. 56, (7), pp. 3564-3566, 1997.;;Koguchi, M.; Kakibayashi, H.; Yazawa, M.; Hiruma, K.; Katsuyama, T., “Crystal-Structure Change of GaAs and InAs Whiskers from Zinc-Blende to Wurtzite Type,” Jpn. J. Appl. Phys. vol. 31 (1992) pp. 2061-2055, Part 1, No. 7, Jul. 1992.;;Latu-Romain, L.; Chaussende, D.; Pons, M., “High-Temperature Nucleation of Cubic Silicon Carbide on (0001) Hexagonal-SiC Nominal Surfaces,” Crystal Growth and Design 2006, vol. 6. No. 12, pp. 2788-2794.;;Xin, Y.; Brown, P.D.; Duninborkowski, Humphreys, C.J.; Cheng, T.S.; Foxon, C.T., “Microstructural characterisation of GaN(As) films grown on (001) GaP by molecular beam epitaxy,” Journal of Crystal Growth, 1997, 171 (3-4), pp. 321-332.;;Yoshida, H.; Ikejiri, K.; Sato, T.; Hara, S., Hiruma, K.; Motohisa, J.; Fukui, T , “Analysis of twin defectsin GaAs nanowires and tetrahedra and their correlation of GaAs(111)B surface reconstructions in selective-area metal organic vapour-phase epitaxy,” Journal of Crysat Growth 2009, 312 (1), 52-57.;;Johansson, J.; Karlsson, L.S.; Dick, K.A.; Bolinsson, J.; Wacaser, B.A.; Deppert, K.; Samuelson, L.,“Effects of Supersatuation on the Crystal Structure of Gold Seeded III-V nanowires,” Crystal Growth and Design, 2009, vol. 9, No. 2 , pp. 766-773.;;Nishinaga, J.; Takada, T.; Hayashi, T.; Horikoshi, Y., “Crystalline and electrical characteristics of C60-doped GaAs films,” Journal of Crystal Growth, 2009, 311 (7), 2232-2235.;;Lee, C.H.; Sutono, A.; Han, S.; Lim. K., Pinel, S.; Tentzeris, E.M.; Laskar, J., “A Compact LTCC-Based Ku-Band Transmitter Module,” IEEE Transactions on Advanced Packing, vol. 25, No. 3, pp. 374-384. Aug. 2002.;;Chang H.Y.; Wang, H.; Yu, M., Shu. Y.H., “A 77-GHz MMIC Power Amplifier for Automotive Radar Applications,” IEEE Microwave and Wireless Components Letters, vol. 13, No. 4, pp. 143-145, Apr. 2003.;;Kang, D.M., Hong, J.Y., Yoon, H.S.; Lee, K.H.; Choi, I.G., “A Transceiver Module for Automotive Radar Sensors Using W-Band Monolithic Microwave-Integrated Circuit One-Chip Set,” Microwave and Optical Technology Letters. vol. 50, No. 9, pp. 2371-2376, Sep. 2008.;;Yamamoto, N., Akahane, K., Gozu, S., Ueta, A., and Ohtani, N , “1.55-mu M-Waveband Emissions from Sb-Based Quantum-Dot Vertical-Cavity,” Japanese Journal of Applied Physics, vol. 45, No. 4B, 2006, pp. 3423-3426.;;Fang, Z-Q, and Look, D.C., “Comparison of deep centers in semi-insulating liquid-encapsulated Czochralski and vertical-gradient freeze GaAs,” Journal of Applied Physics, 69 (12), Jun. 15, 1991, pp. 8177-8182.;;Fornari, R. Giliolo, E., Mignoni, G., and Masi, M., “A Study of Convection, Striations and Interface Shape in InP Crystals Grown by the Double-Crucible LEC Technique,” Cryst. Res. Technol, 32, 1997, 8, pp. 1085-1093.;;Joyce, B.A., Shitara, T., Yoshinaga, A., Vvedensky, D. D., et. al., “Elementary processes in the MBE growth of GaAs,” Applied Surface Science, 1992, 60-1, pp. 200-209.;;Breiland, W. G., Coltrin, M. E., Creighton, J.R., et. al., “Organometallic vapor phase epitaxy (OMVPE),” Materials Science and Engineering, R24 (6) (1999), 241-274.;;Weyers, M. Sato, M., and Ando, H., “Red Shift of Photoluminescence and Absorption in Dilute GaAsN Alloy Layers,” Japanese Journal of Applied Physics Part 2, No. 7A, Jul. 1, 1992.;;Bak-Misiuk, J., Paszkowica, W., Domagala, J., et. al., “Determination of Ga1—xAl xAs epitaxial layer compostion by X-ray intensity measurements of quasi-forbidden reflections,” Journal of Crystal Growth 126 (1993), pp. 168-173.;;Frymarck, I., Kowalski, G., Kaminska, M., and Krotkus, A., “Structure of GaAs: Be crystals studied by X-ray quasi-forbidden reflections,” Journal of Alloys and Compunds 362 (2004), pp. 261-264.;;Velling, P., Janssen, G., Agethen, M., Prost, W., and Tegude, F. J., “InGaP/GaAs hole barrier asymmetry determined by (002) X-ray reflections and p-type DB-RTD hole transport,” Journal of Crystal Growth 195 (1998), pp. 117-123.;;Marchenko, M.P., Liu, W.G., Badawi, M.H., and Yin, P., “The influence of the scatter of heat flux at the m/c interface on the frequency of appearance of poly body and twin defects during 6″ semi-insulating GaAs crystal growth by the VGF method,” Journal of Crystal Growth 310 (2008) 2134-2140.;;Sajovec, F.; Wolf, R.; Fattah, A.; Bickmann, K.; Wenzl, H.; Nagel, G.; Rufer, H.; Tomzig, E.; Debievre, P., Defect Analysis on Gaas Crystals by Precision-Measurements of Density and Lattice-Parameter. Phys Status Solidi A 1990. 122 (1), pp. 139-152.",ACTIVE
217,US,S,US D0735267 S,082-553-076-909-232,2015-07-28,2015,US 201429481985 F,2014-02-12,US 201429481985 F,2014-02-12,Multifunction printer,,SAMSUNG ELECTRONICS CO LTD,CHUNG WON-SUK;;GROSSMAN JONATHAN;;BRAUER KRISTIAAN A;;GROTE MARK J;;HOWES PATRICIA;;CHOI SOO-SHIN,HP PRINTING KOREA CO. LTD (2016-11-30);;SAMSUNG ELECTRONICS CO. LTD (2014-03-05),https://lens.org/082-553-076-909-232,Design Right,no,0,9,1,1,0,,,1402;;D18/50,0,0,,,,ACTIVE
218,US,B2,US 11597889 B2,012-719-106-717-652,2023-03-07,2023,US 202017119096 A,2020-12-11,US 202017119096 A;;US 201962952612 P,2019-12-23,Production of high-value fuel mixtures from synthetic and biologically derived hydrocarbon molecules,"A process for converting light paraffins and/or light hydrocarbons to a high octane gasoline composition is disclosed. The process involves: (1) oxidation of iso-paraffins to alkyl hydroperoxides and alcohol; (2) conversion of the alkyl hydroperoxides and alcohol to dialkyl peroxides; and (3) radical coupling of one or more iso-paraffins and/or iso-hydrocarbons using the dialkyl peroxides as radical initiators, thereby forming a gasoline composition comprising gasoline-range molecules including a C7 enriched gasoline composition having a road octane number (RON) greater than 100.",EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY,ABUSALIM DEYAA I;;CHOI EUGINE;;WANG KUN;;GUPTA HIMANSHU;;KANG DONGIL;;PARK JUNG;;MITCHELL JONATHAN E,,https://lens.org/012-719-106-717-652,Granted Patent,yes,17,0,2,2,0,C10L2200/0423;;C10L2270/023;;C10G2300/305;;C10G2400/02;;C10G29/205;;C10G50/00;;C10L10/10;;C07C407/00;;C10L1/04;;C10L2200/0453;;C07C2/862;;C10L2200/0423;;C07C29/48;;C10G29/205;;C10G50/00;;C10G2300/305;;C10G2400/02,C10L10/10;;C07C2/86;;C07C29/48;;C07C407/00;;C10G29/20;;C10G50/00;;C10L1/04,,0,0,,,,ACTIVE
219,US,A1,US 2021/0189276 A1,197-250-914-685-170,2021-06-24,2021,US 202017119096 A,2020-12-11,US 202017119096 A;;US 201962952612 P,2019-12-23,PRODUCTION OF HIGH-VALUE FUEL MIXTURES FROM SYNTHETIC AND BIOLOGICALLY DERIVED HYDROCARBON MOLECULES,"A process for converting light paraffins and/or light hydrocarbons to a high octane gasoline composition is disclosed. The process involves: (1) oxidation of iso-paraffins to alkyl hydroperoxides and alcohol; (2) conversion of the alkyl hydroperoxides and alcohol to dialkyl peroxides; and (3) radical coupling of one or more iso-paraffins and/or iso-hydrocarbons using the dialkyl peroxides as radical initiators, thereby forming a gasoline composition comprising gasoline-range molecules including a C7 enriched gasoline composition having a road octane number (RON) greater than 100.",EXXONMOBIL RES & ENG CO,ABUSALIM DEYAA I;;CHOI EUGINE;;WANG KUN;;GUPTA HIMANSHU;;KANG DONGIL;;PARK JUNG;;MITCHELL JONATHAN E,,https://lens.org/197-250-914-685-170,Patent Application,yes,0,0,2,2,0,C10L2200/0423;;C10L2270/023;;C10G2300/305;;C10G2400/02;;C10G29/205;;C10G50/00;;C10L10/10;;C07C407/00;;C10L1/04;;C10L2200/0453;;C07C2/862;;C10L2200/0423;;C07C29/48;;C10G29/205;;C10G50/00;;C10G2300/305;;C10G2400/02,C10L10/10;;C07C2/86;;C07C29/48;;C07C407/00;;C10L1/04,,0,0,,,,ACTIVE
220,US,A1,US 2015/0078526 A1,006-219-610-829-41X,2015-03-19,2015,US 201414484517 A,2014-09-12,US 201414484517 A;;US 201361877416 P,2013-09-13,X-ray Diffraction (XRD) Characterization Methods for Sigma=3 Twin Defects in Cubic Semiconductor (100) Wafers,"An X-ray defraction (XRD) characterization method for sigma=3 twin defects in cubic semiconductor (100) wafers includes a concentration measurement method and a wafer mapping method for any cubic tetrahedral semiconductor wafers including GaAs (100) wafers and Si (100) wafers. The methods use the cubic semiconductor's (004) pole figure in order to detect sigma=3/{111} twin defects. The XRD methods are applicable to any (100) wafers of tetrahedral cubic semiconductors in the diamond structure (Si, Ge, C) and cubic zinc-blende structure (InP, InGaAs, CdTe, ZnSe, and so on) with various growth methods such as Liquid Encapsulated Czochralski (LEC) growth, Molecular Beam Epitaxy (MBE), Organometallic Vapor Phase Epitaxy (OMVPE), Czochralski growth and Metal Organic Chemical Vapor Deposition (MOCVD) growth.",U S A REPRESENTED BY THE ADMINISTRATOR OF THE NAT AERONAUTICS AND SPACE ADMINISTRATION,PARK YEONJOON;;KIM HYUN JUNG;;SKUZA JONATHAN R;;LEE KUNIK;;KING GLEN C;;CHOI SANG HYOUK,UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (2014-09-11);;UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NASA (2014-10-14),https://lens.org/006-219-610-829-41X,Patent Application,yes,24,7,2,2,0,G01N23/207;;G01N23/207;;G01N23/20;;G01N2223/0566;;G01N2223/0566;;G01N2223/6116;;G01N2223/6116;;G01N2223/646;;G01N2223/6462;;G01N2223/6462,G01N23/207,378/71,1,0,,,"B. D. Cullity and S. R. Stock. Elements of X-Ray Diffraction, Third Edition (Upper Saddle River, New Jersey: Prentice Hall, 2001), pp. 66-88.",ACTIVE
221,US,A1,US 2014/0146947 A1,022-352-450-274-170,2014-05-29,2014,US 201314091542 A,2013-11-27,US 201314091542 A;;US 201261730670 P,2012-11-28,CHANNELING X-RAYS,"Various examples are provided for channeling X-rays. In one example, among others, a system includes an electron gun including afield-emitting cathode capable of producing an electron beam with exquisitely small emittance, an accelerator capable of accelerating the emitted electrons to relativistic energies, and a focusing assembly capable of focusing the accelerated electrons into a focal spot on a diamond crystal to produce hard X-rays. In another example, a method includes producing an exquisitely small emittance of electrons from a field-emitting cathode, accelerating the emitted electrons to relativistic energies, focusing the accelerated electrons into a focal spot on a diamond crystal, and emitting hard X-rays from the diamond crystal.",UNIV VANDERBILT,BRAU CHARLES A;;CHOI BO KYOUNG;;PIOT PHILIPPE;;JARVIS JONATHAN D;;MENDENHALL MARCUS H;;GABELLA WILLIAM E,NORTHERN ILLINOIS UNIVERSITY (2014-08-14);;VANDERBILT UNIVERSITY (2013-12-17),https://lens.org/022-352-450-274-170,Patent Application,yes,15,3,1,1,0,H01J3/022;;H01J3/022;;H05G2/00;;H05G2/00,H01J35/06,378/122,4,0,,,"Emittance Diagnostics CAS Beam diagnostic Dourdan, 2.6.2008Hans Braun / CERN;;Design and Modeling of Field-Emitter Arrays for a High Brilliance Electron Source M. Dehler∗ Paul Scherrer Institut, Villigen PSI, Switzerland TUPPP10 Proceedings of ICAP 2006, Chamonix, France;;Full scale simulation of a field-emitter arrays based electron source for free-electron lasers M. Dehler, A. Candel, and E. Gjonaj Citation: Journal of Vacuum Science & Technology B 24, 892 (2006); doi: 10.1116/1.2181988;;Emittance of a field emission electron source K. L. Jensen, P. G. O’Shea, D. W. Feldman, and J. L. Shaw Citation: Journal of Applied Physics 107, 014903 (2010); doi: 10.1063/1.3267288",DISCONTINUED
222,EP,A4,EP 2069542 A4,137-983-590-417-672,2012-02-29,2012,EP 07872591 A,2007-07-27,US 2007/0017000 W;;US 83373806 P,2006-07-27,"METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES",,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,,https://lens.org/137-983-590-417-672,Search Report,no,3,0,6,6,0,C12Q1/04;;C12Q1/045;;C12Q1/04;;C12Q1/045,G01N33/569;;C12Q1/04,,2,2,112-919-252-720-35X;;044-087-114-386-054,10.1016/j.mimet.2005.08.008;;16182396;;2482843;;10.1016/0166-0934(89)90114-6,"MCLAUGHLIN M R ET AL: ""Enhanced contrast of bacteriophage plaques in Salmonella with ferric ammonium citrate and sodium thiosulfate (FACST) and tetrazolium red (TZR)"", JOURNAL OF MICROBIOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 65, no. 2, 1 May 2006 (2006-05-01), pages 318 - 323, XP025073033, ISSN: 0167-7012, [retrieved on 20060501], DOI: 10.1016/J.MIMET.2005.08.008;;NAKASHIMA H ET AL: ""Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds"", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 26, no. 3, 1 December 1989 (1989-12-01), pages 319 - 329, XP023794796, ISSN: 0166-0934, [retrieved on 19891201], DOI: 10.1016/0166-0934(89)90114-6",DISCONTINUED
223,US,B2,US 11687538 B2,177-521-257-848-182,2023-06-27,2023,US 202117195592 A,2021-03-08,US 202117195592 A,2021-03-08,Multi-data store content identification and display interface,"Systems and methods directed to grouping and displaying query results from multiple data stores are described. More specifically, a plurality of data stores to search utilizing a received keyword may be determined, where each data store includes a different search index. A data store specific query for each data store is generated such that results from each data store are received based on the respective data store specific query, where results from each data store include a plurality of file identifiers identifying files located at the respective data store that are relevant to the keyword. In addition results from each data store are grouped into a plurality of groups based on metadata associated with each file identifier of the plurality of file identifiers. The plurality of groups are ranked based on a relevancy associated with each group and information associated with a ranked group is displayed at a user interface.",MICROSOFT TECHNOLOGY LICENSING LLC,LAL ANKUR;;CURLETT KYLE PATRICK;;CHOI DANIEL SUNGJE;;GASAWAY FIONA LIEURANCE;;SILVER CARA LEGGETT;;HOLLANDER JONATHAN ARI,MICROSOFT TECHNOLOGY LICENSING LLC (2021-03-08),https://lens.org/177-521-257-848-182,Granted Patent,yes,2,0,2,2,0,G06F16/14;;G06F16/24578;;G06F2203/04803;;G06F3/04817,G06F16/2457;;G06F3/04817,,0,0,,,,ACTIVE
224,US,B2,US 8882977 B2,148-471-779-784-759,2014-11-11,2014,US 201213620554 A,2012-09-14,US 201213620554 A;;US 201161534658 P,2011-09-14,Microbiosensors based on DNA modified single-walled carbon nanotube and PT black nanocomposites,"Glucose and ATP biosensors have important applications in diagnostics and research. Combining single-walled carbon nanotubes (SWCNTs) with Pt nanoparticles can significantly enhance the performance of electrochemical biosensors. This disclosure illustrates the use of single-stranded DNA (ssDNA) to modify SWCNTs to increase SWCNT solubility in water. Multiple embodiments with this configuration allows for exploration of new schemes of combining ssDNASWCNT and Pt black in aqueous media systems. These embodiments resulted in a nanocomposite with enhanced biosensor performance. The ssDNA-SWCNT/Pt black nanocomposite constructed by a layered scheme proved most effective in terms of biosensor activity. The key feature of this structure and method of use is the exploitation of ssDNASWCNTs as molecular templates for Pt black electrodeposition. Glucose and ATP microbiosensors fabricated utilizing this structure and method of use exhibited high sensitivity, wide linear range and low limit of detection.",PORTERFIELD D MARSHALL;;CHA TAE-GON;;CHOI JONG HYUN;;CLAUSSEN JONATHAN C;;DIGGS ALFRED R;;SHI JIN;;PURDUE RESEARCH FOUNDATION,PORTERFIELD D MARSHALL;;CHA TAE-GON;;CHOI JONG HYUN;;CLAUSSEN JONATHAN C;;DIGGS ALFRED R;;SHI JIN,PURDUE RESEARCH FOUNDATION (2012-09-24),https://lens.org/148-471-779-784-759,Granted Patent,yes,6,0,2,2,0,B82Y5/00;;B82Y5/00;;B82Y15/00;;B82Y15/00;;C12Q1/001;;C12Q1/001;;C12Q1/006;;C12Q1/006;;C12Q1/68;;G01N27/327;;G01N27/3278;;G01N27/3278;;Y10S977/75;;Y10S977/75;;Y10S977/892;;Y10S977/892;;Y10S977/904;;Y10S977/904,G01N27/327;;B82Y5/00;;B82Y15/00;;C12Q1/00;;C12Q1/68,204/403.01;;205/109;;205/777.5;;435/287.1;;422/68.1;;422/82.01;;977/892;;977/904;;977/750;;156/242,1,1,036-580-279-933-879,21828892;;10.1088/0957-4484/22/35/355502,"Shi et al., ""A comparative study of enzyme immobilization strategies for multi-walled carbon nanotube glucose biosensors,"" Nanotechnology 22 (2011), 10 pp.",ACTIVE
225,US,B2,US 8377678 B2,183-545-241-436-179,2013-02-19,2013,US 30967007 A,2007-07-27,US 30967007 A;;US 83373806 P;;US 2007/0017000 W,2006-07-27,"Methodology for detection, enumeration, propagation and manipulation of bacteriophages","A method to propagate, enumerate and quantify bacteriophage(s) in a water sample or other aqueous sample was designed which contains ingredients to stimulate the growth of select bacterial species which are susceptible to infection by specific bacteriophage(s), in which interfering background organisms are either inhibited or inconsequential. Important features of the medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, and temperature-independent gelling agent(s). A preferred combination is the growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-B-D-galactoside, and appropriate gelling agents, which (when properly used) produces a dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, all discernible to the eye in visible light. The procedure can also be readily applied towards automatic counting systems under artificial illumination. The procedure can be employed with water samples and with elution buffers that can retain bacteriophages in suspension following contact by the buffer with foods, soils, hard surfaces and other solids that may be contaminated by bacteriophages.",MICROLOGY METHODS LLC;;ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-IOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-IOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,MICROLOGY METHODS LLC (2013-01-08);;INSTITUTE FOR ENVIRONMENTAL HEALTH INC (2021-06-24),https://lens.org/183-545-241-436-179,Granted Patent,yes,1,0,6,6,0,C12Q1/04;;C12Q1/045;;C12Q1/04;;C12Q1/045,C12N1/20;;C12N1/00;;C12N7/00,435/243;;435/5;;435/235.1,2,2,013-019-743-456-220;;075-304-716-502-414,pmc186965;;10.1128/am.29.2.305-306.1975;;1115502;;pmc167496;;10.1128/aem.61.6.2252-2256.1995;;7793945,"Fraser et al., Applied Microbiology, Feb. 1975, 29(2):305-306.;;Huang, et al. Nonuniform Spatial Patterns . . . ; Applied and Environmental Microbiology, Jun. 1995, p. 2252-2256.",INACTIVE
226,EP,A2,EP 2069542 A2,196-091-681-125-137,2009-06-17,2009,EP 07872591 A,2007-07-27,US 2007/0017000 W;;US 83373806 P,2006-07-27,"METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES",,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,,https://lens.org/196-091-681-125-137,Patent Application,yes,0,0,6,6,0,C12Q1/04;;C12Q1/045;;C12Q1/04;;C12Q1/045,G01N33/569;;C12Q1/04,,0,0,,,,DISCONTINUED
227,US,A1,US 2023/0008809 A1,083-793-152-533-791,2023-01-12,2023,US 202217859647 A,2022-07-07,US 202217859647 A;;US 202163219139 P,2021-07-07,SYSTEMS AND METHODS FOR ENHANCING INFECTION DETECTION AND MONITORING THROUGH DECOMPOSED PHYSIOLOGICAL DATA,"Systems and methods for enhancing infection detection and monitoring through decomposed physiological data are disclosed. An example method includes receiving, from a wearable device of a user, physiological data of the user and decomposing the physiological data, by applying a heart rate algorithm, to generate one or more physiological parameters. The example method further includes analyzing, by applying the heart rate algorithm, the one or more physiological parameters to output a period classification, and determining whether or not the period classification is indicative of an infection. The example method further includes, responsive to determining that the period classification is indicative of the infection, displaying, in a user interface, a warning to the user that indicates the infection, and receiving, from the wearable device of the user, additional physiological data of the user to monitor the infection.",UNIV MICHIGAN REGENTS,FORGER DANIEL;;TYLER JONATHAN;;MAYER CALEB;;SEN SRIJAN;;FANG YU;;FLORA CHRISTOPHER;;CHOI SUNG WON;;TEWARI MUNEESH,THE REGENTS OF THE UNIVERSITY OF MICHIGAN (2021-06-11),https://lens.org/083-793-152-533-791,Patent Application,yes,0,0,1,1,0,A61B5/412;;A61B5/02055;;A61B5/02438;;A61B5/01;;A61B5/1118;;A61B5/0531;;A61B2560/0242;;A61B5/7264;;A61B5/7275;;A61B5/0004;;G16H50/20;;A63B2230/06;;A61B5/222,A61B5/22,,0,0,,,,PENDING
228,WO,A2,WO 2008/094202 A2,126-438-430-331-789,2008-08-07,2008,US 2007/0017000 W,2007-07-27,US 83373806 P,2006-07-27,"METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES","A method to propagate, enumerate and quantify bacteriophage(s) in a water sample or other aqueous sample was designed which contains ingredients to stimulate the growth of select bacterial species which are susceptible to infection by specific bacteriophage(s), in which interfering background organisms are either inhibited or inconsequential. Important features of the medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, and temperature- independent gelling agent(s). A preferred combination is the growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-B-D-galactoside, and appropriate gelling agents, which (when properly used) produces a dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, all discernible to the eye in visible light. The procedure can also be readily applied towards automatic counting systems under artificial illumination. The procedure can be employed with water samples and with elution buffers that can retain bacteriophages in suspension following contact by the buffer with foods, soils, hard surfaces and other solids that may be contaminated by bacteriophages.",ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,,https://lens.org/126-438-430-331-789,Patent Application,yes,0,4,6,6,0,C12Q1/04;;C12Q1/045;;C12Q1/04;;C12Q1/045,,,0,0,,,,PENDING
229,WO,A3,WO 2008/094202 A3,052-399-764-469-460,2008-10-09,2008,US 2007/0017000 W,2007-07-27,US 83373806 P,2006-07-27,"METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES","A method to propagate, enumerate and quantify bacteriophage(s) in a water sample or other aqueous sample was designed which contains ingredients to stimulate the growth of select bacterial species which are susceptible to infection by specific bacteriophage(s), in which interfering background organisms are either inhibited or inconsequential. Important features of the medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, and temperature- independent gelling agent(s). A preferred combination is the growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-B-D-galactoside, and appropriate gelling agents, which (when properly used) produces a dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, all discernible to the eye in visible light. The procedure can also be readily applied towards automatic counting systems under artificial illumination. The procedure can be employed with water samples and with elution buffers that can retain bacteriophages in suspension following contact by the buffer with foods, soils, hard surfaces and other solids that may be contaminated by bacteriophages.",ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,ROTH JONATHAN;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-LOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,,https://lens.org/052-399-764-469-460,Search Report,yes,2,0,6,6,0,C12Q1/04;;C12Q1/045;;C12Q1/04;;C12Q1/045,G01N33/569;;C12Q1/70,,0,0,,,,PENDING
230,US,A1,US 2022/0284029 A1,021-636-084-296-211,2022-09-08,2022,US 202117195592 A,2021-03-08,US 202117195592 A,2021-03-08,MULTI-DATA STORE CONTENT IDENTIFICATION AND DISPLAY INTERFACE,"Systems and methods directed to grouping and displaying query results from multiple data stores are described. More specifically, a plurality of data stores to search utilizing a received keyword may be determined, where each data store includes a different search index. A data store specific query for each data store is generated such that results from each data store are received based on the respective data store specific query, where results from each data store include a plurality of file identifiers identifying files located at the respective data store that are relevant to the keyword. In addition results from each data store are grouped into a plurality of groups based on metadata associated with each file identifier of the plurality of file identifiers. The plurality of groups are ranked based on a relevancy associated with each group and information associated with a ranked group is displayed at a user interface.",MICROSOFT TECHNOLOGY LICENSING LLC,LAL ANKUR;;CURLETT KYLE PATRICK;;CHOI DANIEL SUNGJE;;GASAWAY FIONA LIEURANCE;;SILVER CARA LEGGETT;;HOLLANDER JONATHAN ARI,MICROSOFT TECHNOLOGY LICENSING LLC (2021-03-08),https://lens.org/021-636-084-296-211,Patent Application,yes,2,1,2,2,0,G06F16/14;;G06F16/24578;;G06F2203/04803;;G06F3/04817,G06F16/2457;;G06F3/0481,,0,0,,,,ACTIVE
231,US,A1,US 2010/0291539 A1,027-356-416-442-943,2010-11-18,2010,US 30967007 A,2007-07-27,US 30967007 A;;US 83373806 P;;US 2007/0017000 W,2006-07-27,"METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES","A method to propagate, enumerate and quantify bacteriophage(s) in a water sample or other aqueous sample was designed which contains ingredients to stimulate the growth of select bacterial species which are susceptible to infection by specific bacteriophage(s), in which interfering background organisms are either inhibited or inconsequential. Important features of the medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, and temperature-independent gelling agent(s). A preferred combination is the growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-B-D-galactoside, and appropriate gelling agents, which (when properly used) produces a dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, all discernible to the eye in visible light. The procedure can also be readily applied towards automatic counting systems under artificial illumination. The procedure can be employed with water samples and with elution buffers that can retain bacteriophages in suspension following contact by the buffer with foods, soils, hard surfaces and other solids that may be contaminated by bacteriophages.",ROTH JONATHAN N;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-IOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,ROTH JONATHAN N;;LARKIN JAMES;;HSU FU-CHIH;;WONG CHOI-IOK REBECCA;;BATTIGELLI DAVID A;;ROTH GEOFFREY N,MICROLOGY METHODS LLC (2013-01-08);;INSTITUTE FOR ENVIRONMENTAL HEALTH INC (2021-06-24),https://lens.org/027-356-416-442-943,Patent Application,yes,1,1,6,6,0,C12Q1/04;;C12Q1/045;;C12Q1/04;;C12Q1/045,C12Q1/70,435/5,1,1,013-019-743-456-220,pmc186965;;10.1128/am.29.2.305-306.1975;;1115502,"Fraser et al., Applied Microbiology, February 1975, 29(2):305-306.",INACTIVE
232,US,S,US D0794656 S,027-885-700-663-202,2017-08-15,2017,US 201529550228 F,2015-12-31,US 201529550228 F,2015-12-31,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/027-885-700-663-202,Design Right,no,0,23,2,2,0,,,1404;;D14/485,0,0,,,,ACTIVE
233,US,S,US D0794655 S,112-663-244-029-845,2017-08-15,2017,US 201529550223 F,2015-12-31,US 201529550223 F,2015-12-31,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/112-663-244-029-845,Design Right,no,0,16,2,2,0,,,1404;;D14/485,0,0,,,,ACTIVE
234,US,S,US D0794654 S,134-874-792-223-006,2017-08-15,2017,US 201529550218 F,2015-12-31,US 201529550218 F,2015-12-31,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/134-874-792-223-006,Design Right,no,0,16,2,2,0,,,1404;;D14/485,0,0,,,,ACTIVE
235,US,S,US D0794042 S,135-309-589-664-185,2017-08-08,2017,US 201529550210 F,2015-12-31,US 201529550210 F,2015-12-31,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/135-309-589-664-185,Design Right,no,0,13,2,2,0,,,1404;;D14/485,0,0,,,,ACTIVE
236,US,A1,US 2020/0226685 A1,049-507-636-836-737,2020-07-16,2020,US 201916248089 A,2019-01-15,US 201916248089 A,2019-01-15,SYSTEMS AND METHODS FOR CHANGE IN LANGUAGE-BASED TEXTUAL ANALYSIS,"Systems and methods for change in language-based textual analysis are disclosed. In one embodiment, in an information processing apparatus comprising at least one computer processor, a method for change in language-based textual analysis may include: (1) retrieving, from a data source, a first document of a first type; (2) retrieving, from the data source, a second document of the first type, the second document being subsequent in time to the first document; (3) identifying changes between the first document and the second document; (4) calculating a change score based on the changes; and (5) providing the change score to a downstream system for projecting a performance of an investment associated with the first document.",JPMORGAN CHASE BANK NA,HART PHIL;;TSE JONATHAN;;KHOT SANTOSH;;ZHENG DAN;;PATEL MANAN;;CHOI WONSEOK;;ZHAO HAORAN;;RUHL DENNIS S;;MOREAU ERIC,,https://lens.org/049-507-636-836-737,Patent Application,yes,8,0,1,1,0,G06Q40/06;;G06Q30/018;;G06F40/194;;G06F40/205;;G06Q40/06;;G06F16/93;;G06Q10/04;;G06F40/20;;G06F40/194,G06Q40/06;;G06F16/93;;G06Q10/04,,0,0,,,,DISCONTINUED
237,US,S,US D0794657 S,002-269-639-210-178,2017-08-15,2017,US 201529550278 F,2015-12-31,US 201529550278 F,2015-12-31,Display screen or portion thereof with transitional graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/002-269-639-210-178,Design Right,no,0,15,1,1,0,,,1404;;D14/485,0,0,,,,ACTIVE
238,US,S,US D0794043 S,063-226-801-426-536,2017-08-08,2017,US 201529550232 F,2015-12-31,US 201529550232 F,2015-12-31,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/063-226-801-426-536,Design Right,no,0,21,1,1,0,,,1404;;D14/485,0,0,,,,ACTIVE
239,US,S,US D0794044 S,125-787-006-461-874,2017-08-08,2017,US 201529550249 F,2015-12-31,US 201529550249 F,2015-12-31,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,SUNG SOPHIA H;;GAISER JONATHAN P;;TURKSTRA CHRIS;;KEENE MAXEL J;;KO HEEJIN;;SEO JANGWON;;JULIEN JAE;;CHOI YOOJIN,SAMSUNG ELECTRONICS CO. LTD (2016-01-15),https://lens.org/125-787-006-461-874,Design Right,no,0,24,2,2,0,,,1404;;D14/485,0,0,,,,ACTIVE
240,WO,A1,WO 2023/043786 A1,054-679-092-275-215,2023-03-23,2023,US 2022/0043451 W,2022-09-14,US 202163244589 P,2021-09-15,METHODS FOR VECTOR-BASED TARGETING OF THE HUMAN CENTRAL THALAMUS TO GUIDE DEEP BRAIN STIMULATION AND DEVICES THEREFOR,"Methods and devices for vector-based targeting of the human central thalamus (CT) to guide deep brain stimulation (DBS) are disclosed. In some examples, electrode(s) each with a plurality contacts are provided. A three-dimensional orientation of a dominant axis of a central lateral nucleus dorsal tegmental tract medial component (CL/DTTm) fiber bundle of a human subject is determined. The contacts of the electrode(s) are positioned in the subject's CT fibers in substantial alignment with the three-dimensional orientation. An electrical stimulus is applied to the contacts to selectively activate the CT fibers. The positioning and the applying are carried out to maximize activation of a central lateral nucleus and medial dorsal tegmental tract fiber pathway in the subject and to minimize activation of a centromedian-parafascicularis fiber pathway in the subject. Methods and devices for surgical planning involving for vector-based targeting of the human CT to guide DBS are also disclosed.",UNIV CORNELL;;THE UNIV OF UTAH;;UNIV LELAND STANFORD JUNIOR,SCHIFF NICHOLAS;;BAKER JONATHAN;;BUTSON CHRISTOPHER;;JANSON ANDREW;;O'SULLIVAN KYLE;;HENDERSON JAIMIE;;CHOI EUN YOUNG;;RUTT BRIAN;;RADOVAN MATTHEW,,https://lens.org/054-679-092-275-215,Patent Application,yes,5,0,1,1,0,A61N1/0534;;A61N1/3606;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36103;;A61N1/36146;;A61B34/10;;A61B2034/101;;A61B2034/102;;A61B2034/104;;A61B2034/105;;A61B2034/107,A61N1/36;;A61N1/05;;A61N1/20,,2,2,042-904-891-104-589;;021-401-879-330-704,10.1152/jn.01129.2015;;27582298;;pmc5116485;;26208259;;10.1109/tbme.2015.2457873;;pmc4732574,"BAKER JONATHAN L., JAE-WOOK RYOU, XUEFENG F. WEI, CHRISTOPHER R. BUTSON, NICHOLAS D. SCHIFF, KEITH P. PURPURA: ""Robust modulation of arousal regulation, performance, and frontostriatal activity through central thalamic deep brain stimulation in healthy nonhuman primates"", JOURNAL OF NEUROPHYSIOLOGY, vol. 116, 31 August 2016 (2016-08-31), pages 2383 - 2404, XP093050097, DOI: 10.1152/jn.01129.2015;;XIAO YIZI; PENA EDGAR; JOHNSON MATTHEW D.: ""Theoretical Optimization of Stimulation Strategies for a Directionally Segmented Deep Brain Stimulation Electrode Array"", IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, IEEE, USA, vol. 63, no. 2, 1 February 2016 (2016-02-01), USA, pages 359 - 371, XP011595461, ISSN: 0018-9294, DOI: 10.1109/TBME.2015.2457873",PENDING
241,EP,A2,EP 2007904 A2,003-511-075-707-240,2008-12-31,2008,EP 07753058 A,2007-03-13,US 2007/0006405 W;;US 78188206 P;;US 78190106 P,2006-03-13,PROPAGATION OF PRIMARY CELLS,,VERIDEX LLC,CHOWDARY DONDAPATI;;SKELTON JOANNE;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT;;BADEN JONATHAN F;;CHOI CHANG H;;CURTIN KATHLEEN M;;WANG HAIYING,,https://lens.org/003-511-075-707-240,Patent Application,yes,0,0,18,20,53,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12Q1/68;;C12N15/85,,0,0,,,,DISCONTINUED
242,WO,A1,WO 2023/249872 A1,123-578-753-818-386,2023-12-28,2023,US 2023/0025385 W,2023-06-15,US 202263353998 P,2022-06-21,SUBSTITUTED FUSED BICYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,"The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Also provided related pharmaceutical compositions and methods of treating narcolepsy or cataplexy in a subject in need thereof comprising administering to the subject a compound or a pharmaceutically acceptable salt thereof, or a composition.",ALKERMES INC,HANDE SUDHIR;;HU YUAN;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;RAYMER BRIAN;;WILHELMSEN CHRISTOPHER;;PENNINGTON LEWIS;;LEHMANN JONATHAN,,https://lens.org/123-578-753-818-386,Patent Application,yes,4,0,1,1,0,A61K31/445;;A61K31/4035;;A61K31/404;;C07D401/14;;C07D405/14;;C07D401/12;;C07D413/14;;C07D417/14,A61K31/445;;A61K31/4035;;A61K31/404;;C07D211/06;;C07D263/54,,0,0,,,,PENDING
243,US,A1,US 2009/0047656 A1,129-566-165-385-596,2009-02-19,2009,US 71783507 A,2007-03-13,US 71783507 A;;US 78188206 P;;US 78190106 P,2006-03-13,Molecular analysis of primary cells,"The present invention provides a method of propagating cells of interest obtained from a biological specimen by a) enriching the cells under conditions that maintain sufficient cell viability; and b) propagating the cells under conditions effective to allow cell viability, proliferation and integrity.",BADEN JONATHAN F;;CHOI CHANG H;;CHOWDARY DONDAPATI;;CURTIN KATHLEEN M;;VENER TATIANA;;WANG HAIYING;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT,BADEN JONATHAN F;;CHOI CHANG H;;CHOWDARY DONDAPATI;;CURTIN KATHLEEN M;;VENER TATIANA;;WANG HAIYING;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT,VERIDEX LLC (2007-06-07),https://lens.org/129-566-165-385-596,Patent Application,yes,30,7,18,20,53,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12Q1/02;;C12Q1/70;;C12Q1/68;;G01N33/53,435/5;;435/6;;435/29;;435/7.1;;435/7.21;;435/7.2,0,0,,,,DISCONTINUED
244,KR,B1,KR 101993391 B1,032-604-291-293-307,2019-06-26,2019,KR 20180003570 A,2018-01-10,KR 20180003570 A,2018-01-10,Method for manufacturing surface-modified dental implant materials,"The present invention relates to a production method of surface-modified implant material through room temperature atmospheric plasma treatment and an implant material produced thereby. Specifically, by treating room temperature atmospheric plasma controlling proper applied power, treatment time, and flow rate of inlet gas, carbon content is reduced in a surface of the implant material and titanium content is increased as increasing hydrophilicity and surface energy. The stable modified implant material having improved hydrophobic bacterial adhesion resistance, cell adhesion and differentiation in a shorter time can be obtained.",UNIV DANKOOK CHEONAN CAMPUS IND ACADEMIC COOPERATION FOUNDATION;;UNIV YONSEI IACF;;UNIV KWANGWOON IND ACAD COLLAB,LEE HAE HYOUNG;;LEE JUNGHWAN;;HAE WON KIM;;JONATHAN CAMPBELL KNOWLES;;KIM KWANG MAHN;;JAE SUNG KWON;;CHOI EUN HA,,https://lens.org/032-604-291-293-307,Granted Patent,no,4,4,1,1,0,A61C13/0003;;A61C8/0006;;A61C8/0012;;B01J19/088,A61C13/00;;A61C8/00;;A61C8/02;;B01J19/08,,0,0,,,,ACTIVE
245,AT,T1,AT E496898 T1,163-061-681-464-177,2011-02-15,2011,AT 07855368 T,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,BICYCLISCHE PYRIMIDINONE UND DEREN VERWENDUNG,,AVEXA LTD,JONES ERIC;;COATES JONATHAN;;RHODES DAVID;;DEADMAN JOHN;;VANDEGRAFF NICHOLAS;;WINFIELD LISA;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/163-061-681-464-177,Granted Patent,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,,,0,0,,,,INACTIVE
246,ES,T3,ES 2358550 T3,090-741-008-414-260,2011-05-11,2011,ES 07855368 T,2007-12-21,AU 2007/902479 A,2007-05-09,PIRIMIDINONAS BICICLICAS Y SUS USOS.,"Un compuesto de Fórmula I o un hidrato, sal o profármaco del mismo en el que: A es un resto aromático o heteroaromático monocíclico o bicíclico fusionado con el anillo que contiene nitrógeno; X se selecciona entre el grupo que consiste en O y S; Y se selecciona entre el grupo que consiste en O y S; R1 tiene 0-3 sustituyentes cada uno de los cuales se selecciona independientemente entre el grupo que consiste en CN, alquilo C1-10, alquenilo C2-10, alquilo C1-10PO3H2, -O-alquilo C1-10, alquilo C1-10NR3R4, -O-alquilo C1-10NR3R4, halo, NR3R4, alquilarilo, alquilheteroarilo, arilo, heteroarilo, -O-alquilarilo, SO2NR3R4; R3 y R4 se seleccionan cada uno independientemente entre el grupo que consiste en hidrógeno, CO2 alquilo C1-4, C(O) alquil C1-4 alquilo C1-10, C1-10NR5R6, -NH(CO)(CO)NH alquilo C1-4, o R3 y R4 tomados conjuntamente con el nitrógeno unido forman un anillo heterocíclico de 5-7 miembros que contiene de cero a dos heteroátomos adicionales seleccionados entre N, O o S, en el que S puede estar en el estado de oxidación S, S(O) o S(O)2 y en el que dicho anillo heterocíclico se sustituye opcionalmente en los átomos de carbono o nitrógeno con uno o más sustituyentes seleccionados entre halo, arilo, C(O) alquilo C1-4, SO2 alquilo C1-4, SO2H, alquilo C1-4, CO2H, CO2 alquilo C1-4, NR5R8; alquiloC1-4NR5R6; R5 y R6 se seleccionan cada uno independientemente entre el grupo que consiste en H, alquilo C1-4 o R5 y R6 y junto con el nitrógeno unido forman un anillo heterocíclico de 5-7 miembros que contiene de cero a dos heteroátomos adicionales seleccionados entre N, O o S, en el que S puede estar en el estado de oxidación S, S(O) o S(O)2 y en el que dicho anillo heterocíclico se sustituye opcionalmente en los átomos de carbono o nitrógeno con uno o más sustituyentes seleccionados entre halo y alquilo C1-4; cuando R1 es alquilarilo u -O-alquilarilo, el grupo arilo de dicho sustituyente alquilarilo se sustituye opcionalmente con un sustituyente seleccionado entre alquilo C1-10, -O-alquilo C1-10, alquilo C1-10NR3R4, -O-alquilo C1-10NR3R4, halo, NR3R4, alquilarilo, -O-alquilarilo, SO2NR3R4 B está ausente o es -C(O)-; C está ausente o se selecciona entre el grupo que consiste en -O-, -NH- y -NH-NH-C(O)-; R2 se selecciona entre el grupo que consiste en heteroarilo y heterociclilo; y en el que dicho profármaco comprende (i) un compuesto en el que un resto aminoácido, o una cadena de polipéptido o dos o más restos aminoácidos se unen covalentemente a un grupo amino, hidroxilo o de ácido carboxílico del compuesto de fórmula I, los restos de aminoácido incluyen los 20 aminoácidos naturales habitualmente designados por un símbolo de tres letras e incluye también, 4-hidroxiprolina, hidroxilisina, demosina, isodemosina, 3-metilhistidina, norvlina, betaalanina, ácido gamma-aminobutírico, citrulina, homocisteina, homoserina, ornitina y metionina sulfona (ii) un compuesto en el que un carbonato, carbamato, amida o éster de alquilo se une covalentemente a un grupo amino, hidroxilo, o de ácido carboxílico del compuesto de fórmula I mediante la cadena secundaria del profármaco que contiene el carbono carbonilo, o (iii) un compuesto que comprende un derivado de fosfato de un compuesto de fórmula I unido mediante un enlace fósforo-oxígeno a un hidroxilo libre de los compuestos de fórmula I; y en el que además cada grupo alquilo, cicloalquilo, alquilarilo, arilo, heterociclilo, o heteroarilo puede estar opcionalmente sustituido con uno o más de alquilo C1-C3, cicloalquilo C3-C6, arilo C6, heterociclilo, heteroarilo, alquilo C1-3OH, alquilarilo, OH, O alquilo C1-3O, halo, CN, NO2, CO2H, CO2 alquilo C1-3, CONH2, CONH (alquilo C1-C3), CON (alquilo C1-C3)2, trifluorometilo, NH2, NH (alquilo C1-C3) o N (alquilo C1-C3)2 y cada sustituyente alquilo, cicloalquilo, alquilarilo, arilo heterociclilo, o heteroarilo opcional puede estar también opcionalmente sustituido.",AVEXA LTD,JONES ERIC;;COATES JONATHAN;;RHODES DAVID;;DEADMAN JOHN;;VANDEGRAFF NICHOLAS;;WINFIELD LISA;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/090-741-008-414-260,Granted Patent,no,0,0,1,40,0,,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,ACTIVE
247,EP,A4,EP 2007904 A4,014-754-880-962-979,2009-06-10,2009,EP 07753058 A,2007-03-13,US 2007/0006405 W;;US 78188206 P;;US 78190106 P,2006-03-13,PROPAGATION OF PRIMARY CELLS,,VERIDEX LLC,CHOWDARY DONDAPATI;;SKELTON JOANNE;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT;;BADEN JONATHAN F;;CHOI CHANG H;;CURTIN KATHLEEN M;;WANG HAIYING,,https://lens.org/014-754-880-962-979,Search Report,no,2,0,18,20,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12Q1/68;;C12N15/85,,8,8,037-683-830-699-745;;120-204-964-834-719;;131-992-510-110-74X;;018-571-404-831-12X;;030-371-701-401-933;;050-949-808-604-988;;047-570-771-875-113;;029-737-820-431-690,10.1158/1078-0432.ccr-04-0378;;15501967;;16033103;;15595637;;15941083;;10.1080/10408360590913696;;10.1002/(sici)1098-2825(1997)11:6<346::aid-jcla7>3.0.co;2-3;;pmc6760733;;9406055;;15958538;;10.1158/0008-5472.can-04-4330;;11085508;;16048578;;10.1111/j.1440-1746.2005.03894.x,"ALLARD W JEFFREY ET AL: ""Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 20, 15 October 2004 (2004-10-15), pages 6897 - 6904, XP002466554, ISSN: 1078-0432;;ZIEGLSCHMID V ET AL: ""COMBINATION OF IMMUNOMAGNETIC ENRICHMENT WITH MULTIPLEX RT-PCR ANALYSIS FOR THE DETECTION OF DISSEMINATED TUMOR CELLS"", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS, GREECE, vol. 25, no. 3A, 1 May 2005 (2005-05-01), pages 1803 - 1810, XP008066219, ISSN: 0250-7005;;DEMEL U ET AL: ""Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay"", JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH, ROME, IT, vol. 23, no. 3, 1 September 2004 (2004-09-01), pages 465 - 468, XP002458613, ISSN: 0392-9078;;ZIEGLSCHMID V ET AL: ""DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD"", CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, CRC PRESS, BACA RATON, FL, US, vol. 42, no. 2, 1 January 2005 (2005-01-01), pages 155 - 196, XP008066221, ISSN: 1040-8363;;MAKAROVSKIY A N ET AL: ""APPLICATION OF IMMUNOMAGNETIC BEADS IN COMBINATION WITH RT-PCR FOR THE DETECTION OF CIRCULATING PROSTATE CANCER CELLS"", JOURNAL OF CLINICAL LABORATORY ANALYSIS, NEW YORK, NY, US, vol. 11, 1 January 1997 (1997-01-01), pages 346 - 350, XP000872241, ISSN: 0887-8013;;SMIRNOV D A ET AL: ""GLOBAL GENE EXPRESSION PROFILING OF CIRCULATING TUMOR CELLS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 65, no. 12, 15 June 2005 (2005-06-15), pages 4993 - 4997, XP003001873, ISSN: 0008-5472;;GOESSL C ET AL: ""Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 60, 1 November 2001 (2001-11-01), pages 5941 - 5945, XP002962896, ISSN: 0008-5472;;GUO JUNMING ET AL: ""Detection of cytokeratin 20 mRNA in the peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymeras chain reaction"", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, MELBOURNE, AU, vol. 20, no. 8, 1 August 2005 (2005-08-01), pages 1279 - 1284, XP002460701, ISSN: 0815-9319",DISCONTINUED
248,BR,A2,BR PI0709397 A2,108-984-533-863-652,2011-07-05,2011,BR PI0709397 A,2007-03-13,US 78188206 P;;US 78190106 P;;US 2007/0006405 W,2006-03-13,propagação de células primárias,"PROPAGAçãO DE CéLULAS PRIMáRIAS. A presente invenção refere-se a um método de propagar as células de interesse, obtidas de amostra biológica, por a) enriquecimento das células sob condições que mantenham uma viabilidade suficiente das células, e b) propagação das células sob condições efetivas para permitir a viabilidade, a proliferação e a integridade das células.",VERIDEX LLC,CHOWDARY DONDAPATI;;SKELTON JOANNE;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT;;BADEN JONATHAN F;;CHOI CHANG H;;CURTIN KATHLEEN M;;WANG HAIYING,,https://lens.org/108-984-533-863-652,Patent Application,no,0,0,18,20,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12Q1/68;;C12N15/85,,0,0,,,,DISCONTINUED
249,CA,A1,CA 2647280 A1,123-017-358-710-199,2007-09-20,2007,CA 2647280 A,2007-03-13,US 78188206 P;;US 78190106 P;;US 2007/0006405 W,2006-03-13,PROPAGATION OF PRIMARY CELLS,,VERIDEX LLC,SKELTON JOANNE;;BURNETT CHRISTINE A;;BADEN JONATHAN F;;CHOWDARY DONDAPATI;;MAZUMDER ABHIJIT;;CURTIN KATHLEEN M;;WANG HAIYING;;CHOI CHANG H,,https://lens.org/123-017-358-710-199,Patent Application,no,0,0,18,20,53,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12Q1/68;;C12N15/85,,0,0,,,,DISCONTINUED
250,MX,A,MX 2008011838 A,086-109-563-382-401,2009-04-07,2009,MX 2008011838 A,2007-03-13,US 78188206 P;;US 78190106 P;;US 2007/0006405 W,2006-03-13,PROPAGATION OF PRIMARY CELLS.,"The present invention provides a method of propagating cells of interest obtained from a biological specimen by a) enriching the cells under conditions that maintain sufficient cell viability; and b) propagating the cells under conditions effective to allow cell viability, proliferation and integrity.",VERIDEX LLC,MAZUMDER ABHIJIT;;WANG HAIYING;;CHOWDARY DONDAPATI;;BADEN JONATHAN F;;SKELTON JOANNE;;BURNETT CHRISTINE A;;CHOI CHANG H;;CURTIN KATHLEEN M,,https://lens.org/086-109-563-382-401,Patent Application,no,0,0,18,20,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12Q1/68,,0,0,,,,PENDING
251,WO,A1,WO 2024/006147 A1,000-934-850-054-443,2024-01-04,2024,US 2023/0025986 W,2023-06-22,US 202217852073 A;;US 202217852083 A,2022-06-28,SECURITY SUBSYSTEM FOR REMOTE ATTESTATION,Techniques for providing remote attestation at an integrated circuit device are described. The integrated circuit device may include a memory. The integrated circuit device may also include a write bitmap comprising a bitmap that tracks the write addresses of detected memory write operations to the memory. The integrated circuit device may further include a security subsystem configured to send one or more address ranges of interest to the write bitmap and obtain a bitmap status from the write bitmap indicating that a write address within the one or more address ranges of interest was detected.,AMAZON TECH INC,RAHBAR ALI;;QUACH NHON TOAI;;GUMMALLA SAMATHA;;CHANG DIANA;;CHOI DONGHYUN;;SOLANKI UTPAL VIJAYSINH;;ANANTHATEERTA GURURAJ;;WRIGHT JOHN CHARLES;;KANG JONATHAN,,https://lens.org/000-934-850-054-443,Patent Application,yes,1,0,2,4,0,G06F21/79;;G06F21/71;;G06F21/552;;G06F21/554;;G06F21/57,G06F21/55;;G06F21/57;;G06F21/71;;G06F21/79,,3,2,035-890-147-100-610;;041-692-741-090-005,10.1145/3427228.3427253;;10.1109/sp.2016.9,"DE OLIVEIRA NUNES IVAN IVANOLIV@MAIL RIT EDU ET AL: ""On the TOCTOU Problem in Remote Attestation"", PROCEEDINGS OF THE 32ND CONFERENCE ON L'INTERACTION HOMME-MACHINE, ACMPUB27, NEW YORK, NY, USA, 12 November 2021 (2021-11-12), pages 2921 - 2936, XP058942293, ISBN: 978-1-4503-8607-4, DOI: 10.1145/3460120.3484532;;AMMAR MAHMOUD MAHMOUD AMMAR@CS KULEUVEN BE ET AL: ""Verify&Revive: Secure Detection and Recovery of Compromised Low-end Embedded Devices"", 2021 THE 4TH INTERNATIONAL CONFERENCE ON COMPUTERS IN MANAGEMENT AND BUSINESS, ACMPUB27, NEW YORK, NY, USA, 7 December 2020 (2020-12-07), pages 717 - 732, XP058877344, ISBN: 978-1-4503-8871-9, DOI: 10.1145/3427228.3427253;;SONG CHENGYU ET AL: ""HDFI: Hardware-Assisted Data-Flow Isolation"", 2016 IEEE SYMPOSIUM ON SECURITY AND PRIVACY (SP), IEEE, 22 May 2016 (2016-05-22), pages 1 - 17, XP032945689, DOI: 10.1109/SP.2016.9",PENDING
252,WO,A1,WO 2023/249875 A1,099-636-621-789-661,2023-12-28,2023,US 2023/0025389 W,2023-06-15,US 202263353985 P,2022-06-21,SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HANDE SUDHIR;;HU YUAN;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;RAYMER BRIAN;;SUH BYUNG-CHUL;;PENNINGTON LEWIS;;LEHMANN JONATHAN,,https://lens.org/099-636-621-789-661,Patent Application,yes,5,0,1,1,0,C07D401/04;;C07D405/06;;C07D211/58;;C07D401/14;;C07D487/10;;C07D491/107;;C07D413/04;;C07D405/04;;A61P25/00,A61K31/395;;A61K31/18;;A61K31/33;;A61K31/435;;A61K31/445,,2,0,,,"DATABASE PubChem Compound 10 July 2017 (2017-07-10), PUBCHEM : ""4-[(Pyrrolidin-3-yloxy)methyl]piperidine "", XP093127417, retrieved from PubChem Database accession no. 130141993;;DATABASE Pubchem Compound 21 July 2009 (2009-07-21), ANONYMOUS : ""3-(Cyclohexylmethoxy)piperidine |"", XP093127424, retrieved from Pubchem Database accession no. 43196817",PENDING
253,WO,A1,WO 2024/006144 A1,163-913-015-651-146,2024-01-04,2024,US 2023/0025979 W,2023-06-22,US 202217852073 A;;US 202217852083 A,2022-06-28,SECURITY SUBSYSTEM FOR EXECUTION VERIFICATION,"Techniques for providing execution verification at an integrated circuit device are described. The integrated circuit device may include a processor core configured to execute instructions. The integrated circuit device may also include a trace block configured to extract an execution trace from the processor core, the execution trace indicating the instructions that have been executed by the processor core. The integrated circuit device may further include a verification core configured to receive the execution trace from the trace block, extract an address from a control transfer instruction in the execution trace, perform one or more checks on the address, and generate an alarm signal based on the one or more checks.",AMAZON TECH INC,RAHBAR ALI;;QUACH NHON TOAI;;GUMMALLA SAMATHA;;WRIGHT JOHN CHARLES;;KANG JONATHAN;;SOLANKI UTPAL VIJAYSINH;;ANANTHATEERTA GURURAJ;;CHANG DIANA;;CHOI DONGHYUN,,https://lens.org/163-913-015-651-146,Patent Application,yes,1,0,2,4,0,G06F21/79;;G06F21/71;;G06F21/552;;G06F21/554;;G06F21/57,G06F21/71;;G06F21/55;;G06F21/57;;G06F21/79,,3,3,042-378-569-716-299;;036-822-180-413-426;;111-402-803-486-558,10.1109/iccad45719.2019.8942142;;10.1007/978-3-030-87234-2_48;;10.1007/978-3-030-40186-3;;10.1007/s11265-021-01732-5,"DESSOUKY GHADA ET AL: ""CHASE: A Configurable Hardware-Assisted Security Extension for Real-Time Systems"", 2019 IEEE/ACM INTERNATIONAL CONFERENCE ON COMPUTER-AIDED DESIGN (ICCAD), IEEE, 4 November 2019 (2019-11-04), pages 1 - 8, XP033678210;;FENG LANG ET AL: ""FastCFI: Real-Time Control Flow Integrity Using FPGA Without Code Instrumentation"", 31 December 2019, TOPICS IN CRYPTOLOGY - CT-RSA 2020 : THE CRYPTOGRAPHERS' TRACK AT THE RSA CONFERENCE 2020, SAN FRANCISCO, CA, USA, FEBRUARY 24-28, 2020, PAGE(S) 221 - 238, XP047523185;;SPANG CHRISTOPH ET AL: ""DExIE - An IoT-Class Hardware Monitor for Real-Time Fine-Grained Control-Flow Integrity"", JOURNAL OF SIGNAL PROCESSING SYSTEMS, SPRINGER, US, vol. 94, no. 7, 6 January 2022 (2022-01-06), pages 739 - 752, XP037904300, ISSN: 1939-8018, [retrieved on 20220106], DOI: 10.1007/S11265-021-01732-5",PENDING
254,WO,A2,WO 2023/249873 A2,021-698-937-216-150,2023-12-28,2023,US 2023/0025386 W,2023-06-15,US 202263354025 P,2022-06-21,SUBSTITUTED FUSED BICYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HANDE SUDHIR MAHADEO;;HU YUAN;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;RAYMER BRIAN;;WILHELMSEN CHRISTOPHER;;PENNINGTON LEWIS;;LEHMANN JONATHAN,,https://lens.org/021-698-937-216-150,Patent Application,yes,0,0,1,1,0,A61K31/454;;C07D417/14;;C07D401/14;;C07D413/14;;C07D471/04;;C07D405/14,C07D401/12;;A61K31/454,,0,0,,,,PENDING
255,WO,A1,WO 2023/249871 A1,040-988-297-692-865,2023-12-28,2023,US 2023/0025384 W,2023-06-15,US 202263353982 P,2022-06-21,SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HANDE SUDHIR;;HU YUAN;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;RAYMER BRIAN;;SUH BYUNG-CHUL;;PENNINGTON LEWIS;;LEHMANN JONATHAN,,https://lens.org/040-988-297-692-865,Patent Application,yes,3,0,1,1,0,C07D211/58;;C07D401/04;;C07D401/06;;C07D401/14;;C07D413/06;;C07D417/06;;C07D487/10;;C07D413/14;;C07D405/06,A61K31/18;;A61K31/33;;C07D211/58;;C07D211/98;;C07D401/04;;C07D401/06,,0,0,,,,PENDING
256,NO,L,NO 975762 L,020-802-008-375-342,1998-02-06,1998,NO 975762 A,1997-12-08,US 48102495 A;;US 9609816 W,1995-06-07,"Substituerte (sulfinsyre, sulfonsyre, sulfonylamino eller sulfinylamino)-N-£(aminoiminometyl)fenyalkyl|-azaheterocyklylamidforbindelser",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YOUNG MI,,https://lens.org/020-802-008-375-342,Abstract,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;C07D223/10;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
257,KR,B1,KR 102496208 B1,061-712-885-035-639,2023-02-06,2023,KR 20220022030 A,2022-02-21,KR 20220022030 A,2022-02-21,A SYSTEM FOR DISCOVERING NEW DRUG CANDIDATES AND A COMPUTER PROGRAM THAT IMPLEMENTS A PLATFORM FOR DISCOVERING NEW DRUG CANDIDATES,"Provided is a computer program implementing a system for discovering a new drug candidate material and a platform for discovering a new drug candidate material. The system for discovering a new drug candidate material may comprise: an automatic data preprocessing module receiving target protein information from a user through a web interface and performing preprocessing on a protein structure file obtained based on the target protein information; a simulation setting module detecting an enzymatically active pocket for docking calculation (EAPDC) from the protein structure file using an artificial intelligence language model and determining a docking calculation site; and a docking simulation module performing docking simulation on the docking calculation site. Accordingly, an environment can be provided in which a user can focus on discovering a new drug candidate material.",CALICI CO LTD,CHOI JAE MUN;;PARK JIN HEE;;WILLIANTO JONATHAN;;LE VAN HUONG;;MAILIBAY DINMUKHAMED;;CHURIN ILIA;;SHADIEV NUZUP;;YUN YU KYUNG;;SUNG CHUL,,https://lens.org/061-712-885-035-639,Granted Patent,no,1,0,2,2,0,G16C20/70;;G16B40/00;;G16B5/00;;G16B50/00;;G16B15/30;;G16C20/50;;G06N3/08;;G16C20/64;;G16B30/00,G16C20/64;;G06N3/08;;G16B5/00;;G16B15/30;;G16B30/00;;G16B40/00;;G16B50/00;;G16C20/50;;G16C20/70,,3,3,040-036-400-216-851;;111-377-864-788-339;;094-108-075-327-388,10.1101/2021.01.31.429052;;pmc6375647;;30716081;;10.1371/journal.pcbi.1006718;;10.1039/c9cp02504a;;31389436,"K. -L. Tsai et al., DRDOCK: A drug repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme, bioRxiv 2021.01.31.429052(2021)*;;L. Pu et al., DeepDrug3D: Classification of ligand-binding pockets in proteins with a convolutional neural network, PLoS Comput. Biol. Vol.15, e1006718(2019)*;;O. Caldararu et al., Are crystallographic B-factors suitable for calculating protein conformational entropy?, Phys. Chem. Chem. Phys. Vol.21, 18149(2019)*",ACTIVE
258,US,B2,US 10608973 B2,087-797-031-090-609,2020-03-31,2020,US 201615362757 A,2016-11-28,US 201615362757 A,2016-11-28,Embedded codes in messaging protocol communications,"Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages for one or more processing codes or instructions that are embedded in the portion of the communication typically utilized solely to identify the subject matter of the communication, generally referred to as the topic portion of the communication. The receiving devices can then process the embedded codes to determine how the communication message will be routed or otherwise processed.",AMAZON TECH INC,KUO CALVIN YUE-REN;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON III JAMES CHRISTOPHER;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,AMAZON TECHNOLOGIES INC (2017-01-18),https://lens.org/087-797-031-090-609,Granted Patent,yes,58,19,2,18,0,H04L51/18;;H04L51/18,H04L12/58,,12,1,017-770-215-711-159,10.1155/2016/3292783,"Corbin, “MQTT is the de-facto standard and ISO standard for messaging protocols”, Jul. 1, 2016, developer.ibm.com (4 pages).;;Wikipedia, “Create, Read, Update, and Delete”, saved Oct. 1, 2018, en.wikipedia.com (3 pages).;;Lampkin, What is MQTT and how does it work with WebSphere MQ, www.ibm.com, Mar. 16, 2012 (6 pages).;;Wikipedia, IBM MQ, en.wikipedia.org, Jun. 3, 2019 (8 pages).;;Kim, M., et al., Developing an On-Demand Cloud-Based Sensing-as-a-Service System for Internet of Things, Journal of Computer Networks and Communications, vol. 2016, pp. 1-17, available at https://www.hindawi.com/journals/jcnc/2016/3292783, accessed Mar. 14, 2018.;;International Search Report and Written Opinion in PCT/US2017/063138 dated Mar. 6, 2018.;;International Search Report and Written Opinion in PCT/US2017/063302 dated Mar. 9, 2018.;;International Search Report and Written Opinion in PCT/US2017/063314 dated Feb. 9, 2018.;;Dang Van Mien, Five Security Strategies for IBM Websphere MQ Series, www.bus.umich.edu, published Sep. 12, 2003 (6 pages).;;International Preliminary Report on Patentability in PCT/US2017/063138 dated May 28, 2019.;;International Preliminary Report on Patentability in PCT/US2017/063302 dated May 28, 2019.;;International Preliminary Report on Patentability in PCT/US2017/063314 dated May 28, 2019.",ACTIVE
259,EP,A4,EP 0853618 A4,165-660-759-041-447,2000-03-15,2000,EP 96919298 A,1996-06-07,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,"AVENTIS PHARMACEUTICALS PRODUCTS INC. (2002-01-09);;AVENTIS PHARMACEUTICALS, INC. (2006-11-02)",https://lens.org/165-660-759-041-447,Search Report,no,5,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D223/10;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,16,14,037-924-312-490-356;;135-657-823-677-04X;;021-519-073-163-082;;122-203-622-477-094;;080-608-462-885-358;;106-967-208-944-451;;046-936-317-601-62X;;024-409-499-173-466;;022-595-010-992-650;;068-736-401-057-446;;167-180-732-239-963;;074-816-101-513-937;;064-771-446-279-85X;;009-827-306-945-035,10.1139/v85-136;;10.1021/jo00259a003;;3290485;;10.1021/jm00402a021;;10.1021/jo00274a037;;10.1016/s0040-4020(01)88493-3;;10.1021/ja00101a017;;10.1021/ja01638a047;;10.1039/c39800000687;;10.1016/0040-4020(82)80232-9;;3005569;;10.1021/jm00152a014;;10.1016/s0040-4020(01)89976-2;;10.1016/0040-4039(88)85099-8;;10.1021/jm00078a002;;8277495;;10.1016/s0960-894x(01)81273-7,"KAMBER M. & JUST G.: "".gamma.-Phosphono-.gamma.-lactones. The use of allyl esters as easily removable phosponate protecting groups"", CANADIAN JOURNAL OF CHEMISTRY, vol. 63, 1985, pages 823 - 827, XP002126444;;ZYDOWSKY T.M. ET AL.: ""Efficient and versatile synthesis of dipeptide isosteres containing .gamma.- or .delta.-lactams"", JOURNAL OF ORGANIC CHEMISTRY, vol. 53, no. 24, 25 November 1988 (1988-11-25), pages 5607 - 5616, XP002126445;;THAISRIVONGS S. ET AL.: ""Conformationally constrained renin inhibitory peptides: .gamma.-Lactam-bridged dipeptide isostere as conformational restriction"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 7, July 1988 (1988-07-01), pages 1369 - 1376, XP002126446;;WOLF J.-P. & RAPOPORT H.: ""Conformationally constrained peptides. Chirospecific synthesis of-4-alkyl-substituted .gamma.-lactam-bridged dipeptides from L-aspartic acid"", JOURNAL OF ORGANIC CHEMISTRY, vol. 54, no. 13, 23 June 1989 (1989-06-23), pages 3164 - 3173, XP002126447;;ROWLEY M. ET AL.: ""Routes to 4-substituted analogues of the glycine/NMDA antagonist HA-966. Enantioselective synthesis of (3R,4R) 3-amino-1-hydroxy-4-methyl-2-pyrrolidinone (L-687,414)"", TETRAHEDRON, vol. 48, no. 17, 1992, pages 3557 - 3570, XP002126450;;SMITH A.B. ET AL.: ""De novo design, synthesis, and X-ray crystal structures of pyrrolinone-based .beta.-strand peptidomimetics"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 116, no. 22, 1994, pages 9947 - 9962, XP002126451;;SONDHEIMER E. & HOLLEY R.W.: ""Imides from asparagine and glutamine"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 76, 5 May 1954 (1954-05-05), pages 2467 - 2470, XP002126452;;BEN-ISHAI D.: ""Intramolecular amidoalkylation of olefins"", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 15, 1980, pages 687 - 688, XP002126453;;GRAY C.J. ET AL.: ""Preparation and properties of some citrulline p-nitroanilide derivatives for possible use as protease substrates"", TETRAHEDRON, vol. 38, no. 10, 1982, pages 1465 - 1470, XP002126454;;THORSETT E.D. ET AL.: ""Conformationally restricted inhibitors of angiotensin converting enzyme: Synthesis and computations"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 2, February 1986 (1986-02-01), pages 251 - 260, XP002126455;;BEN-ISHAI D. ET AL.: ""Intra vs intermolecular amidoalkylation of aromatics"", TETRAHEDRON, vol. 43, no. 2, 1987, pages 439 - 450, XP002126456;;RANGANATHAN S. ET AL.: ""Spontaneous cyclization of a chain shortened lysine analog"", TETRAHEDRON LETTERS, vol. 29, no. 25, 1988, pages 3111 - 3114, XP002126448;;BUCSH R.A. ET AL.: ""Synthesis and antimicrobial evaluation of a series of 7-[3-amino-(or aminomethyl)-4-aryl (or cyclopropyl)-1-pyrrolidinyl]-4-quinolone- and -1,8-naphthyridone-3-carboxylic acids"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 26, 1993, pages 4139 - 4151, XP002126457;;SKILES J.W. ET AL.: ""Elastase inhibitors containing conformationally restricted lactams as P3-P2 dipeptide replacements"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 4, 1993, pages 773 - 778, XP000673137;;PATENT ABSTRACTS OF JAPAN vol. 17, no. 644 (C - 1134) 30 November 1993 (1993-11-30);;See also references of WO 9640679A1",EXPIRED
260,AU,A,AU 1996/061669 A,064-879-883-992-535,1996-12-30,1996,AU 1996/061669 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-{(aminoiminomethyl)phenylalkyl}-azaheterocy clylamide compounds",,AVENTIS PHARMA INC,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,AVENTIS PHARMACEUTICALS PRODUCTS INC. (2002-01-24);;AVENTIS PHARMACEUTICALS INC. (2002-06-13),https://lens.org/064-879-883-992-535,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
261,BG,A,BG 102162 A,120-475-254-462-855,1998-09-30,1998,BG 10216298 A,1998-01-06,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULPPHINIC ACID, SULPHONIC ACID, SULPHONYLAMINO OR SULPHINYLAMINO)N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAM IDE COMPOUNDS","The compounds have pharmacological activity, in particular asinhibitors of the factor Xa activity. They have the formula shownin the description. The invention also relates to compositionscontaining these compounds and to their application in the medicalpractice.55 claims",RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN S;;SPADA ALFRED P;;CHOI-SLEDESKI YONG M,,https://lens.org/120-475-254-462-855,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
262,CA,A1,CA 2223403 A1,175-581-761-450-79X,1996-12-19,1996,CA 2223403 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS","The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",RHONE POULENC RORER PHARMA,EWING WILLIAM R;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;BECKER MICHAEL R;;SPADA ALFRED P;;PAULS HENRY W;;CHOI-SLEDESKI YONG MI,,https://lens.org/175-581-761-450-79X,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
263,NO,D0,NO 975762 D0,190-622-732-993-041,1997-12-08,1997,NO 975762 A,1997-12-08,US 48102495 A;;US 9609816 W,1995-06-07,"Substituerte (sulfinsyre, sulfonsyre, sulfonylamino eller sulfinylamino)-N-£(aminoiminometyl)fenyalkyl|-azaheterocyklylamidforbindelser",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YOUNG MI,,https://lens.org/190-622-732-993-041,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;C07D223/10;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
264,MX,A,MX 2008011839 A,175-391-228-258-970,2008-11-04,2008,MX 2008011839 A,2007-03-13,US 78188206 P;;US 78190106 P;;US 2007/0006513 W,2006-03-13,PROPAGATION OF PRIMARY CELLS.,"The present invention provides a method of propagating cells of interest obtained from biological specimen by a) enriching the cells under conditions that maintain sufficient cell viability; and b) propagating the cells under conditions effective to allow cell viability, proliferation and integrity.",VERIDEX LLC,MAZUMDER ABHIJIT;;WANG HAIYING;;CHOWDARY DONDAPATI;;VENER TATIANA;;BADEN JONATHAN F;;BURNETT CHRISTINE A;;CHOI CHANG H;;CURTIN KATHLEEN M;;JOANNE SKELTON,,https://lens.org/175-391-228-258-970,Patent Application,no,0,0,18,20,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12N5/00;;C12N5/02,,0,0,,,,PENDING
265,US,A1,US 2018/0152405 A1,079-901-599-052-194,2018-05-31,2018,US 201615362757 A,2016-11-28,US 201615362757 A,2016-11-28,EMBEDDED CODES IN MESSAGING PROTOCOL COMMUNICATIONS,"Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages for one or more processing codes or instructions that are embedded in the portion of the communication typically utilized solely to identify the subject matter of the communication, generally referred to as the topic portion of the communication. The receiving devices can then process the embedded codes to determine how the communication message will be routed or otherwise processed.",AMAZON TECH INC,KUO CALVIN YUE-REN;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON III JAMES CHRISTOPHER;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,AMAZON TECHNOLOGIES INC (2017-01-18),https://lens.org/079-901-599-052-194,Patent Application,yes,0,23,2,18,0,H04L51/18;;H04L51/18,H04L12/58,,0,0,,,,ACTIVE
266,NO,B1,NO 310457 B1,183-855-235-741-971,2001-07-09,2001,NO 975762 A,1997-12-08,US 48102495 A;;US 9609816 W,1995-06-07,"Substituerte (sulfinsyre, sulfonsyre, sulfonylamino eller sulfinylamino)-N-[(aminoiminometyl)fenylalkyl]azaheterocyklylamidforbindelser",,AVENTIS PHARMA INC,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/183-855-235-741-971,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;C07D223/10;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
267,SK,A3,SK 160697 A3,013-998-052-015-41X,1998-11-04,1998,SK 160697 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"SUBSTITUTED DERIVATIVES OF (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO)-N- -[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN S;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/013-998-052-015-41X,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;C07D223/10;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
268,HU,A2,HU P9801882 A2,087-215-560-187-366,1998-12-28,1998,HU P9801882 A,1996-06-07,US 76141496 A;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","A találmány tárgyát az (I) általánős képletű vegyületek - melyképletben Ar1 jelentése fenil- vagy mőnőciklűsős heterőarilcsőpőrt, Rjelentése hidrőgénatőm, aril-alkil-, heterőaril-alkil-, vagy hidrőxi-alkilcsőpőrt, R1 jelentése hidrőgénatőm, R3S(O)p- vagy R3R4NS(O)p-csőpőrt, R2 jelentése hidrőgénatőm, alkil-, aril-alkil-, vagyheterőaril-alkil-csőpőrt, X1 és X1' jelentése hidrőgénatőm, alkil-,aril-, aril-alkil-, heerőaril, heterőaril-alkil- vagy hidrőxi-alkil-csőpőrt, vagy X1 és X1, együttesen őxőcsőpőrtőt alkőthat, X2 és X2'jelentése hidrőgénatőm, vagy X2 és X2' együttesen őxőcsőpőrtőtalkőhat, X3 jelentése hidrőgénatőm, hidrőxil-, alkil-, aril-,heterőaril-, aril-alkil, heterőaril-alkil-csőpőrt, vagy X3 az X1 ésX1' valamelyikével együtt 4-7 tagú gyűrűt képezhet, X4 jelentésehidrőgénatőm, alkil-, aril-alkil-, vagy hidrőxi-alkil-csőpőrt, X5 ésX5' jelentése H, vagy X4 és X5 együttesen =NR5 csőpőrtőt alkőthat, X6és X6' jelentése hidrőgénatőm, R7R8N-, R7R8NCO-, R7R8NSO2-, R9CO-csőpőrt, halőgénatőm, cianő-, vagy nitrőcsőpőrt, m értéke 0, 1, 2 vagy3, n értéke 1, 2 vagy 3 - az ilyen vegyületeket tartalmazókészítmények, valamint azők alkalmazási eljárásai képezik. A találmányszerinti vegyületek a Xa-faktőr inhibitőrai, melyek Xa-faktőr-inhibitőrők adagőlásával enyhíthető állapőtők kezelésérealkalmazhatók. ŕ",RHONE POULENC RORER PHARMA,BECKER MICHAEL R;;CHENEY DANIEL L;;CHOI-SLEDESKI YONG MI;;EWING WILLIAM R;;MASON JONATHAN STEPHEN;;PAULS HENRY W;;SPADA ALFRED P,,https://lens.org/087-215-560-187-366,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;C07D223/10;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
269,BR,A,BR 9608405 A,087-362-805-849-525,1999-08-24,1999,BR 9608405 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,Composto composi-Æo farmaceutica e processo para tratar um paciente que sofre de um distÚrbio fisiolÄgico,,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/087-362-805-849-525,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
270,BG,B1,BG 63628 B1,090-376-409-564-97X,2002-07-31,2002,BG 10216298 A,1998-01-06,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULPPHINIC ACID, SULPHONIC ACID, SULPHONYLAMINO OR SULPHINYLAMINO)N-[(AMINOIMINOMETHYL)PHENYLALKYL]- AZAHETEROCYCLYLAM IDE COMPOUNDS","The compounds have pharmacological activity, in particular as inhibitors of the factor Xa activity. They have the formula shown in the description. The invention also relates to compositions containing these compounds and to their application in the medical practice. 56 claims",AVENTIS PHARM PROD INC,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN S;;SPADA ALFRED P;;CHOI-SLEDESKI YONG M,,https://lens.org/090-376-409-564-97X,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
271,CZ,A3,CZ 385397 A3,011-585-996-636-004,1999-05-12,1999,CZ 385397 A,1996-06-07,US 48102495 A,1995-06-07,"SUBSTITUTED DERIVATIVES OF (SULFINIC AND SULFONIC ACIDS, SULFONYLAMINO OR SULFINYLAMINO)-N-(AMINOIMINOMETHYL)-PHENYLALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;ENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/011-585-996-636-004,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D223/10;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
272,OA,A,OA 10752 A,129-926-748-862-864,2001-07-04,2001,OA 70149 A,1997-12-03,US 48102495 A,1995-06-07,Substituted (sulfinic acid sulfonic acid sulfonylamino or sulfinylamino) n-Ä(aminoiminomethyl) phenylalkylÜ-azaheterocyclylamide compounds,,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/129-926-748-862-864,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;C07D223/10;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
273,CA,C,CA 2223403 C,147-592-990-900-959,2002-04-23,2002,CA 2223403 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS","The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in th e treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",RHONE POULENC RORER PHARMA,CHOI-SLEDESKI YONG MI;;PAULS HENRY W;;MASON JONATHAN STEPHEN;;BECKER MICHAEL R;;SPADA ALFRED P;;CHENEY DANIEL L;;EWING WILLIAM R,,https://lens.org/147-592-990-900-959,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
274,WO,A1,WO 2022/251304 A1,172-951-590-642-581,2022-12-01,2022,US 2022/0030841 W,2022-05-25,US 202163193256 P,2021-05-26,SUBSTITUTED CARBAMATE MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERME INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL,,https://lens.org/172-951-590-642-581,Patent Application,yes,17,0,4,4,0,A61P21/00;;A61P43/00;;C07D498/04,C07D498/04;;A61K31/4353;;A61P21/00;;A61P43/00,,22,11,064-654-501-659-108;;019-661-953-949-345;;134-787-395-407-586;;013-795-902-101-18X;;100-598-891-287-142;;118-152-222-665-107;;070-910-884-361-022;;010-870-611-029-091;;021-693-589-840-981;;129-917-326-539-78X;;077-295-491-167-117,10.3410/f.1014042.192612;;12797957;;10.1016/s0896-6273(03)00330-1;;10.1073/pnas.0400590101;;pmc384801;;15070772;;10.1007/s40263-012-0036-8;;23359095;;pmc8762453;;17491094;;10.1093/brain/awm097;;19117547;;pmc2630400;;10.1016/j.cmet.2008.10.010;;14580935;;10.1016/s0306-4522(03)00554-2;;15627867;;10.1159/000081757;;10.1016/s0196-9781(02)00110-9;;12217429;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1002/0470084960;;10.1002/0471220574,"CEL1, vol. 92, 1998, pages 573 - 585;;SAPER ET AL., TRENDS IN NEUROSCIENCE, 2001;;YARAANAKA ET AL., NEURON, vol. 38, 2003, pages 715 - 730;;SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014;;MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019;;PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654;;CELL, vol. 98, 1999, pages 437 - 451;;CNS DRUGS, vol. 27, 2013, pages 83 - 90;;BRAIN, vol. 130, 2007, pages 1586;;CELL METABOLISM, vol. 9, 2009, pages 64 - 76;;NEUROSCIENCE, vol. 121, 2003, pages 855 - 863;;RESPIRATION, vol. 71, 2004, pages 575 - 579;;PEPTIDES, vol. 23, 2002, pages 1683 - 1688;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;FIESER: ""Fieser's Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;""March, Advanced Organic Chemistry"", 1992, WILEY;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", vol. A, 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY",PENDING
275,AP,A,AP 799 A,023-064-492-700-502,2000-01-19,2000,AP 9701144 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) phenylalkyl]-azaheterocyclylamide compounds.","The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I) , compositions containing compounds of formula (I) , and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",AVENTIS PHARMACEUTICALS PRODUCTS INC,EWING WILLIAM R;;BECKER MICHAEL R;;CHOI-SLEDESKI YONG MI;;PAULS HEINRY W;;SPADA ALFRED P;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN,,https://lens.org/023-064-492-700-502,Granted Patent,no,1,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,1,0,,,"Chemical Abstract, vol. 119, No. 2, Col. 1, Abstract 28,018n, (MACK)",EXPIRED
276,US,B2,US 10637817 B2,144-572-631-385-206,2020-04-28,2020,US 201615362765 A,2016-11-28,US 201615362765 A,2016-11-28,Managing messaging protocol communications,Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages and process the message to determine how the communication message will be routed or otherwise processed according to business rules or logic.,AMAZON TECH INC,KUO CALVIN YUE-REN;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON III JAMES CHRISTOPHER;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,AMAZON TECHNOLOGIES INC (2017-01-18),https://lens.org/144-572-631-385-206,Granted Patent,yes,59,21,2,18,0,H04L12/1859;;H04L41/08;;H04L51/18;;H04L51/18;;H04L41/08;;H04L12/1859,H04L12/58;;H04L12/18;;H04L12/24,,12,1,017-770-215-711-159,10.1155/2016/3292783,"Corbin, “MQTT is the de-facto standard and ISO standard for messaging protocols”, Jul. 1, 2016, developer.ibm.com (4 pages).;;Lampkin, What is MQTT and how does it work with WebSphere MQ, www.ibm.com, Mar. 16, 2012 (6 pages).;;Wikipedia, IBM MQ, en.wikipedia.org, Jun. 3, 2019 (8 pages).;;Dang Van Mien, Five Security Strategies for IBM Websphere MQ Series, www.bus.umich.edu, published Sep. 12, 2003 (6 pages).;;Kim, M., et al., Developing an On-Demand Cloud-Based Sensing-as-a-Service System for Internet of Things, Journal of Computer Networks and Communications, vol. 2016, 10 pages, available online at https://www.hindawi.com/journals/jcnc/2016/3292783, accessed Mar. 14, 2018.;;International Search Report and Written Opinion in PCT/US2017/063138 dated Mar. 6, 2018.;;International Search Report and Written Opinion in PCT/US2017/063302 dated Mar. 9, 2018.;;International Search Report and Written Opinion in PCT/US2017/063314 dated Feb. 9, 2018.;;Wikipedia, Create, Read, Update, and Delete, available at https://en.wikipedia.com, accessed Oct. 1, 2018, 3 pages.;;International Preliminary Report on Patentability in PCT/US2017/063138 dated May 28, 2019.;;International Preliminary Report on Patentability in PCT/US2017/063302 dated May 28, 2019.;;International Preliminary Report on Patentability in PCT/US2017/063314 dated May 28, 2019.",ACTIVE
277,US,A,US 5958918 A,170-885-198-314-561,1999-09-28,1999,US 97603497 A,1997-11-21,US 97603497 A;;US 9609816 W;;US 48102495 A,1995-06-07,"Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminominomethyl)phenylalkyl]-azaheterocyclylamide compounds","The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,RHONE-POULENE RORER PHARMACEUTICALS IND (1997-12-05);;AVENTIS PHARMACEUTICALS PRODUCTS INC (1999-12-15),https://lens.org/170-885-198-314-561,Granted Patent,yes,2,5,1,64,0,A61P7/02;;A61P43/00;;C07D205/085;;C07D205/085;;C07D207/14;;C07D207/14;;C07D207/273;;C07D207/273;;C07D207/416;;C07D207/416;;C07D211/76;;C07D211/76;;C07D223/12;;C07D223/12;;C07D401/06;;C07D401/06;;C07D401/12;;C07D401/12;;C07D403/12;;C07D403/12;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D409/06;;C07D409/06;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,514/212;;514/307;;514/309;;514/329;;514/343;;514/422;;514/426;;540/606;;546/141;;546/223;;546/281;;546/139;;546/276.4;;548/527;;548/557,1,0,,,"Valerio et al, Synthesis, vol. 10, pp. 786 789, 1988.",EXPIRED
278,EP,A1,EP 0853618 A1,041-025-378-863-800,1998-07-22,1998,EP 96919298 A,1996-06-07,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,"AVENTIS PHARMACEUTICALS PRODUCTS INC. (2002-01-09);;AVENTIS PHARMACEUTICALS, INC. (2006-11-02)",https://lens.org/041-025-378-863-800,Patent Application,yes,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;C07D223/10;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
279,WO,A8,WO 2022/251304 A8,051-417-161-783-231,2023-01-05,2023,US 2022/0030841 W,2022-05-25,US 202163193256 P,2021-05-26,SUBSTITUTED CARBAMATE MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL,,https://lens.org/051-417-161-783-231,Amended Application,yes,0,0,4,4,0,A61P21/00;;A61P43/00;;C07D498/04,C07D498/04;;A61K31/4353;;A61P21/00;;A61P43/00,,0,0,,,,PENDING
280,EA,B1,EA 000700 B1,083-524-568-272-024,2000-02-28,2000,EA 199800043 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCYLLAMIDE COMPOUNDS","1. A compound of formula I is phenyl or monocyclic heteroaryl; R is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl or hydroxyalkyl; R1 is hydrogen, R3S(O)p or R3R4NS(O)p-; R2 is hydrogen, or when X5 and X5' taken together are -NR5, then R2 is hydrogen, optionally substituted lower alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl; R3 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted aralkenyl or optionally substituted heteroaralkenyl, or Rand R3 taken together form a 5 to 7 membered ring; and R4 is optionally suhstituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or R3 and R4 taken together with the nitrogen to which R3 and R4 are attached form an optionally substituted 4 to 7 membered heterocyclyl; X1 and X1' are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl or hydroxyalkyl, or X1 and X1' taken together form oxo; X2 and X2' are hydrogen, or taken together form oxo; X3 is hydrogen, hydroxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or X3 and one of X1 and X1' taken together form a 4 to 7 membered ring; X4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, orhydroxyalkyl; X5 and X5' are hydrogen or taken together are =NR5; R5 is hydrogen, R6O2C-, R6O-, cyano, R6CO-, optionally substituted lower alkyl, nitro or Y<1'>Y<2'>N-; Y<1'> and Y<2'> are independently hydrogen, alkyl, aralkyl or heteroaralkyl; X6 and X6' are independently hydrogen, R7R8N-, R9O-, R7R8NCO-, R7R8NSO2-, R9CO-, halo, cyano or nitro; R6 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl or optionally substituted heteroaralkyl; R7 and R8 are independently hydrogen or optionally substituted lower alkyl, or one of R7 and R8 is hydrogen and the other of R7 and R8 is R10(O)CCH2- or lower acyl; R9 is hydrogen, optionally substituted lower alkyl, lower acyl or R10(O)CCH2-; R10 is hydrogen, optionally substituted lower alkyl, alkoxy or hydroxy; m is 0, 1,2 or 3; n is 1, 2 or 3; or p is 1 or 2, a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof. 2. The compound of claim 1 wherein R3 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted thienyl or optionally substituted benzothienyl. 3. The compound of claim 1 wherein n is 1, and m is 1. 4.The compound of claim 1 wherein X2 and X2' taken together are oxo. 5. The compound of claim 1 wherein X1, X1', X3 and X4 are hydrogen. 6. The compound of claim 1 wherein X5 and X5' taken together are =NH. 7. The compound of claim 1 wherein X5 and X5' taken together are =NR5 wherein R is R6O2C-. 8. The compound of claim 1 wherein is phenyl and the carbon substituted with X5, X5' and HR2N- is attached to the 3-position of the phenyl. 9. The compound of claim 1 wherein is of the formula: 10. The compound of claim 1 wherein X1 is hydrogen and X1' is carboxyalkyl, alkoxycarbonylalkyl or aryl, or X1 and X1' taken together form oxo. 11. The compound of claim 1 wherein R1 is R3SO2-. 12. The compound of claim 1 wherein R1 is R3R4NSO2-. 13. The compound of claim 1 wherein one of X6 and X6' is amino in a para position relative to the moiety. 14. A compound according to claim 1 which is: Naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin- 3-(S)-yl}amide trifluoroacetate; Dibenzofuran-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-5-oxopyrrolidin- 3-yl}amide trifluoroacetate; Toluene-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 3,4-Dihydro-1H-isoquinoline-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 3'-Methoxy-biphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; Naphthalene-1-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Pyrid-2-ylthiophene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; Biphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Ethoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-6-methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-6,7-dimethoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Aminonaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; Naphthalene-2-sulfonic acid {1-[4-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid [1-(3-aminomethylbenzyl)-2-oxopyrrolidin-3-(S)-yl]amide trifluoroacetate; Naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide trifluoroacetate; Naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]pyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2,5-dioxopyrrolidin-3-(S)-yl}amide trifluoroacetate; Naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopiperidin-3-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-azepan-3-(S)-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide trifluoroacetate; 6-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 6-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-6-methoxynaphthalene-2-sulfonylamino]-N-phenethylacetamide trifluoroacetate; 9,10-Dioxo-8a, 9, 10, 10a-tetrahydroanthracene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 8-Chloro-7-methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[4-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 6,7-Dimethoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; Naphtho(2,3-d)-(1,3)dioxole-6-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]- 2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Benzyloxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Hydroxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 6-Hydroxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide trifluoroacetate; 7-Methylnaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Ethylnaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-6-aminonaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 7-Methylaminonaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 2-Methyl-1,2,3,4-tetrahydroisoquinolinyl-7-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 1,2,3,4-Tetrahydroisoquinolinyl-7-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide dihydrochloride; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-(4-nitrobenzyl)amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-(4-aminobenzyl)amide bistrifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}(3-nitrobenzyl)amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}(3-aminobenzyl)amide bistrifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-(2-nitrobenzyl)amide trifluoroacetate; 3-[2-Oxo-3(S)-(2-phenylethenesulfonylamino)pyrrolidin-1-ylmethyl]-benzamidine trifluoroacetate; 3-[2-Oxo-3(S)-(2-phenylethanesulfonylamino)pyrrolidin-1-ylmethyl]-benzamidine trifluoroacetate; [Imino-(3-{3-[7-Methoxynaphthalene-2-sulfonyl)methylamino]-2-oxo-3(S)-pyrrolidin-1-ylmethyl]phenyl)methyl]carbamic acid ethyl ester; 3-[2-Oxo-3(S-{2-(pyridin-4-ylamino)-ethanesulfonylamino}-pyrrolidin-1-ylmethyl]-benzamidine bistrifluoroacetate; 2'-Methoxybiphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl} amide trifluoroacetate; 5,6,7,8-Tetrahydrophenanthrene-3-sulfonic acid {1-[3-",RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI JONG MI,,https://lens.org/083-524-568-272-024,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;C07D223/10;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
281,AU,A1,AU 2022/280804 A1,130-755-135-024-931,2023-11-30,2023,AU 2022/280804 A,2022-05-25,US 202163193256 P;;US 2022/0030841 W,2021-05-26,SUBSTITUTED CARBAMATE MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL,,https://lens.org/130-755-135-024-931,Patent Application,no,0,0,4,4,0,A61P21/00;;A61P43/00;;C07D498/04,C07D498/04;;A61K31/4353;;A61P21/00;;A61P43/00,,0,0,,,,PENDING
282,AU,B2,AU 714319 B2,060-552-889-228-677,2000-01-06,2000,AU 1996/061669 A,1996-06-07,US 48102495 A;;US 9609816 W,1995-06-07,"Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-Ý(aminoiminomethyl)phenylalkyl¨- azaheterocyclylamide compounds",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,AVENTIS PHARMACEUTICALS PRODUCTS INC. (2002-01-24);;AVENTIS PHARMACEUTICALS INC. (2002-06-13),https://lens.org/060-552-889-228-677,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D223/10;;A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
283,EP,B1,EP 0853618 B1,129-210-565-730-822,2011-08-17,2011,EP 96919298 A,1996-06-07,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS",,AVENTIS PHARMA INC,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,"AVENTIS PHARMACEUTICALS PRODUCTS INC. (2002-01-09);;AVENTIS PHARMACEUTICALS, INC. (2006-11-02)",https://lens.org/129-210-565-730-822,Granted Patent,yes,5,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,C07D207/26;;A61K31/395;;C07D223/10;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D407/06;;C07D407/12;;C07D409/06;;C07D409/12;;C07D409/14,,16,0,,,"KAMBER M. & JUST G.: "".gamma.-Phosphono-.gamma.-lactones. The use of allyl esters as easily removable phosponate protecting groups"" CANADIAN JOURNAL OF CHEMISTRY, vol. 63, 1985, pages 823-827, XP002126444;;ZYDOWSKY T.M. ET AL.: ""Efficient and versatile synthesis of dipeptide isosteres containing .gamma.- or .delta.-lactams"" JOURNAL OF ORGANIC CHEMISTRY, vol. 53, no. 24, 25 November 1988 (1988-11-25), pages 5607-5616, XP002126445;;THAISRIVONGS S. ET AL.: ""Conformationally constrained renin inhibitory peptides: .gamma.-Lactam-bridged dipeptide isostere as conformational restriction"" JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 7, July 1988 (1988-07), pages 1369-1376, XP002126446;;WOLF J.-P. & RAPOPORT H.: ""Conformationally constrained peptides. Chirospecific synthesis of-4-alkyl-substituted .gamma.-lactam-bridged dipeptides from L-aspartic acid"" JOURNAL OF ORGANIC CHEMISTRY, vol. 54, no. 13, 23 June 1989 (1989-06-23), pages 3164-3173, XP002126447;;ROWLEY M. ET AL.: ""Routes to 4-substituted analogues of the glycine/NMDA antagonist HA-966. Enantioselective synthesis of (3R,4R) 3-amino-1-hydroxy-4-methyl-2-pyrrolidinone (L-687,414)"" TETRAHEDRON, vol. 48, no. 17, 1992, pages 3557-3570, XP002126450;;SMITH A.B. ET AL.: ""De novo design, synthesis, and X-ray crystal structures of pyrrolinone-based .beta.-strand peptidomimetics"" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 116, no. 22, 1994, pages 9947-9962, XP002126451;;SONDHEIMER E. & HOLLEY R.W.: ""Imides from asparagine and glutamine"" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 76, 5 May 1954 (1954-05-05), pages 2467-2470, XP002126452;;BEN-ISHAI D.: ""Intramolecular amidoalkylation of olefins"" JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 15, 1980, pages 687-688, XP002126453;;GRAY C.J. ET AL.: ""Preparation and properties of some citrulline p-nitroanilide derivatives for possible use as protease substrates"" TETRAHEDRON, vol. 38, no. 10, 1982, pages 1465-1470, XP002126454;;THORSETT E.D. ET AL.: ""Conformationally restricted inhibitors of angiotensin converting enzyme: Synthesis and computations"" JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 2, February 1986 (1986-02), pages 251-260, XP002126455;;BEN-ISHAI D. ET AL.: ""Intra vs intermolecular amidoalkylation of aromatics"" TETRAHEDRON, vol. 43, no. 2, 1987, pages 439-450, XP002126456;;RANGANATHAN S. ET AL.: ""Spontaneous cyclization of a chain shortened lysine analog"" TETRAHEDRON LETTERS, vol. 29, no. 25, 1988, pages 3111-3114, XP002126448;;BUCSH R.A. ET AL.: ""Synthesis and antimicrobial evaluation of a series of 7-[3-amino-(or aminomethyl)-4-aryl (or cyclopropyl)-1-pyrrolidinyl]-4-quinolone- and -1,8-naphthyridone-3-carboxylic acids"" JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 26, 1993, pages 4139-4151, XP002126457;;SKILES J.W. ET AL.: ""Elastase inhibitors containing conformationally restricted lactams as P3-P2 dipeptide replacements"" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 4, 1993, pages 773-778, XP000673137;;PATENT ABSTRACTS OF JAPAN vol. 17, no. 644 (C-1134), 30 November 1993 (1993-11-30) & JP 05 201971 A (HOKURIKU SEIYAKU CO. LTD.), 10 August 1993 (1993-08-10);;CHEMICAL ABSTRACTS, vol. 119, no. 2, 19 July 1993, Columbus, Ohio, US; abstract no. 28018N, MACK ET AL.: 'Preparation and thrombin inhibition activity of (2-arylsulfonamido)oxopiperidino-3-(4-amino dinophenyl)propionates and analogs' page 861; & DE 41 21 947 A1",EXPIRED
284,SI,A,SI 9620093 A,003-622-168-865-944,1999-02-28,1999,SI 9620093 A,1996-06-07,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-/(AMINOIMINOMETHYL)PHENYLALKYL/AZAHETEROCYCLYLAMIDE COMPOUNDS","The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/003-622-168-865-944,Granted Patent,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;C07D223/10;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
285,US,A1,US 2018/0152406 A1,160-013-323-143-423,2018-05-31,2018,US 201615362765 A,2016-11-28,US 201615362765 A,2016-11-28,MANAGING MESSAGING PROTOCOL COMMUNICATIONS,Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages and process the message to determine how the communication message will be routed or otherwise processed according to business rules or logic.,AMAZON TECH INC,KUO CALVIN YUE-REN;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON III JAMES CHRISTOPHER;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,AMAZON TECHNOLOGIES INC (2017-01-18),https://lens.org/160-013-323-143-423,Patent Application,yes,0,28,2,18,0,H04L12/1859;;H04L41/08;;H04L51/18;;H04L51/18;;H04L41/08;;H04L12/1859,H04L12/58;;H04L12/24,,0,0,,,,ACTIVE
286,PL,A1,PL 323780 A1,187-631-350-619-552,1998-04-27,1998,PL 32378096 A,1996-06-07,US 9609816 W;;US 48102495 A,1995-06-07,"SUBSTITUTED COMPOUNDS: (SULPHINIC, SULPHONIC, SYLPHONYLAAMINO SULPHINYLAMINO) N-[(AMINOIMINOMETHYL)-PHENYLALKYL]-AZAHETEROCYCLIC AMIDES",,RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/187-631-350-619-552,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;C07D223/10;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
287,WO,A1,WO 1996/040679 A1,145-871-638-380-308,1996-12-19,1996,US 9609816 W,1996-06-07,US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS","The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",RHONE POULENC RORER PHARMA;;EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI SLEDESKI YONG MI,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,,https://lens.org/145-871-638-380-308,Patent Application,yes,1,49,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;A61K31/40;;C07D223/10;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,2,0,,,"CHEMICAL ABSTRACTS, vol. 119, no. 2, 19 July 1993, Columbus, Ohio, US; abstract no. 28018N, MACK ET AL.: ""Preparation and thrombin inhibition activity of (2-arylsulfonamido)oxopiperidino-3-(4-aminodinophenyl)propionates and analogs"" page 861;;See also references of EP 0853618A4",PENDING
288,MX,A,MX 9709977 A,175-849-411-182-013,1998-07-31,1998,MX 9709977 A,1997-12-08,US 48102495 A,1995-06-07,"SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS.","The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.",RHONE POULENC RORER PHARMA,EWING WILLIAM R;;BECKER MICHAEL R;;PAULS HENRY W;;CHENEY DANIEL L;;MASON JONATHAN STEPHEN;;SPADA ALFRED P;;CHOI-SLEDESKI YONG MI,"GPI NIL HOLDINGS, INC. (2004-12-31)",https://lens.org/175-849-411-182-013,Patent Application,no,0,0,33,64,0,C07D205/085;;C07D207/14;;C07D207/273;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14;;A61P43/00;;A61P7/02;;C07D401/06;;A61K31/44;;C07D207/273;;C07D403/12;;C07D205/085;;C07D409/06;;C07D409/12;;C07D405/12;;C07D409/14;;C07D207/14;;C07D211/76;;C07D223/12;;C07D401/12;;C07D401/06;;C07D405/06;;C07D207/416,A61K31/395;;A61K31/397;;C07D223/10;;A61K31/40;;A61K31/4015;;A61K31/4025;;A61K31/415;;A61K31/44;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/445;;A61K31/47;;A61K31/505;;A61K31/55;;A61P7/02;;A61P43/00;;C07D205/085;;C07D207/14;;C07D207/26;;C07D207/273;;C07D207/40;;C07D207/416;;C07D211/76;;C07D223/12;;C07D401/06;;C07D401/12;;C07D403/12;;C07D405/06;;C07D405/12;;C07D409/06;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
289,BR,A2,BR PI0709396 A2,039-769-097-903-677,2011-07-05,2011,BR PI0709396 A,2007-03-13,US 78188206 P;;US 78190106 P;;US 2007/0006513 W,2006-03-13,propagação de células primárias,"PROPAGAçãO DE CéLULAS PRIMáRIAS. A presente invenção refere-se a um método de propagar as células de interesse, obtidas de amostra biológica, por a) enriquecimento das células sob condições que mantenham uma viabilidade suficiente das células, e b) propagação das células sob condições efetivas para permitir a viabilidade, a proliferação e a integridade das células.",VERIDEX LLC,CHOWDARY DONDAPATI;;SKELTON JOANNE;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT;;BADEN JONATHAN F;;CHOI CHANG H;;CURTIN KATHELEEN M;;WANG HAIYING;;VENER TATIANA I,,https://lens.org/039-769-097-903-677,Patent Application,no,0,0,18,20,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12N5/00;;C12N5/02,,0,0,,,,DISCONTINUED
290,WO,A1,WO 2023/158002 A1,091-409-082-328-522,2023-08-24,2023,KR 2022002602 W,2022-02-22,KR 20220022030 A,2022-02-21,CANDIDATE MATERIAL DISCOVERY SYSTEM FOR NEW DRUG AND COMPUTER PROGRAM IMPLEMENTING CANDIDATE MATERIAL DISCOVERY PLATFORM FOR NEW DRUG,Provided are a candidate material discovery system for a new drug and a computer program implementing a candidate material discovery platform for a new drug. The candidate material discovery system for a new drug may comprise: an automatic data preprocessing module for receiving target protein information from a user through a web interface and preprocessing a protein structure file acquired on the basis of the target protein information; a simulation set module for using an artificial intelligence language model to detect enzymatically active pocket for docking calculation (EAPDC) from the protein structure file and calculating a docking calculation site; and a docking simulation module for performing docking simulation for the docking calculation site.,CALICI CO LTD,CHOI JAE MUN;;PARK JIN HEE;;WILLIANTO JONATHAN;;LE VAN HUONG;;MAILIBAY DINMUKHAMED;;PARK YOUNG BIN;;SHADIEV NUZUP;;YUN YU KYUNG;;SUNG CHUL,,https://lens.org/091-409-082-328-522,Patent Application,yes,2,0,2,2,0,G16C20/70;;G16B40/00;;G16B5/00;;G16B50/00;;G16B15/30;;G16C20/50;;G06N3/08;;G16C20/64;;G16B30/00,G16C20/64;;G06N3/08;;G16B5/00;;G16B15/30;;G16B30/00;;G16B40/00;;G16B50/00;;G16C20/50;;G16C20/70,,3,3,040-036-400-216-851;;111-377-864-788-339;;094-108-075-327-388,10.1101/2021.01.31.429052;;pmc6375647;;30716081;;10.1371/journal.pcbi.1006718;;10.1039/c9cp02504a;;31389436,"TSAI KUN-LIN, YANG LEE-WEI: ""DRDOCK: A Drug Repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme"", BIORXIV, 2 June 2021 (2021-06-02), XP093001651, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.01.31.429052v3.full> [retrieved on 20221124], DOI: 10.1101/2021.01.31.429052;;PU LIMENG, GOVINDARAJ RAJIV GANDHI, LEMOINE JEFFREY MITCHELL, WU HSIAO-CHUN, BRYLINSKI MICHAL: ""DeepDrug3D: Classification of ligand-binding pockets in proteins with a convolutional neural network"", PLOS COMPUTATIONAL BIOLOGY, vol. 15, no. 2, 4 February 2019 (2019-02-04), pages e1006718, XP093086822, DOI: 10.1371/journal.pcbi.1006718;;OCTAV CALDARARU, KUMAR ROHIT, OKSANEN ESKO, LOGAN DEREK T., RYDE ULF: ""Are crystallographic B -factors suitable for calculating protein conformational entropy?"", PHYSICAL CHEMISTRY CHEMICAL PHYSICS, vol. 21, no. 33, 21 August 2019 (2019-08-21), pages 18149 - 18160, XP055746150, ISSN: 1463-9076, DOI: 10.1039/C9CP02504A",PENDING
291,AU,B2,AU 2017/363368 B2,151-407-396-493-083,2021-03-25,2021,AU 2017/363368 A,2017-11-27,US 201615362757 A;;US 201615362751 A;;US 201615362765 A;;US 2017/0063314 W,2016-11-28,Managing messaging protocol communications,Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages and process the message to determine how the communication message will be routed or otherwise processed according to business rules or logic.,AMAZON TECH INC,KUO CALVIN YUE-REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/151-407-396-493-083,Granted Patent,no,4,0,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L29/06;;H04L12/58;;H04L12/66;;H04L29/08;;H04W4/00,,2,0,,,"CORBIN, L., 'MQTT is the de-facto standard and ISO standard for messaging protocols', published 1 July 2016 [retreived from the Internet 2 March 2020] <URL: https://developer.ibm.com/dwblog/2016/mqtt-de-facto-standard-iso-messaging/>;;BOYD B. et. al., 'Building Real-time Mobile Solutions with MQTT and IBM MessageSight' [retrieved from the Internet 21 July 2020] <URL: http://www.redbooks.ibm.com/redbooks/pdfs/sg248228.pdf> published October 2014",ACTIVE
292,EP,B1,EP 3545662 B1,154-736-882-100-085,2023-10-18,2023,EP 17875038 A,2017-11-27,US 201615362757 A;;US 201615362765 A;;US 201615362751 A;;US 2017/0063314 W,2016-11-28,MANAGING MESSAGING PROTOCOL COMMUNICATIONS,,AMAZON TECH INC,KUO CALVIN YUE-REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/154-736-882-100-085,Granted Patent,yes,5,0,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L69/329;;G06F9/54;;H04L41/0894;;H04L41/0895;;H04L51/18;;H04L51/214;;H04L67/02;;H04L67/12;;H04L67/55;;H04L67/63;;H04W4/06,,2,0,,,"Bryan Boyd ET AL: ""Building Real-time Mobile Solutions with MQTT and IBM MessageSight"", , 10 November 2014 (2014-11-10), XP055517851, United States? ISBN: 978-0-7384-4005-7 Retrieved from the Internet: URL:http://www.redbooks.ibm.com/redbooks/p dfs/sg248228.pdf;;Sasu Tarkoma: ""Publish / Subscribe Systems: Design and Principles 1st Edition"" In: ""Publish / Subscribe Systems: Design and Principles 1st Edition"", 13 August 2012 (2012-08-13), Wiley, XP055575481, ISBN: 978-1-119-95154-4 * the whole document *",ACTIVE
293,US,B2,US 11461154 B2,159-348-006-706-391,2022-10-04,2022,US 202017027233 A,2020-09-21,US 202017027233 A;;US 201615362707 A,2016-11-28,Localized device coordinator with mutable routing information,"Systems and methods are described for implementing a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinator can be provisioned with a set of tasks, each task corresponding to a segment of code that can be executed by the coordinator, such as to manage the coordinated devices. The coordinator can further be provisioned with event flow information designating a routing of inputs to the coordinator computing device to destinations, such as task executions or coordinated devices. On receiving input, the coordinator can reference the event flow information to pass the input to an appropriate destination.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN,AMAZON TECHNOLOGIES INC (2022-06-14),https://lens.org/159-348-006-706-391,Granted Patent,yes,75,0,4,17,0,G06F9/5027;;G06F9/547;;G06F9/547;;G06F9/5027,G06F9/54;;G06F9/50,,9,0,,,"U.S. Appl. No. 16/198,676, Management of Protected Data in a Localized Device Coordinator, filed Nov. 21, 2018.;;U.S. Appl. No. 16/363,453, Remote Filesystem Permissions Management for On-Demand Code Execution, filed Mar. 25, 2019.;;Office Action in Japanese Application No. 2019-528553 dated Jun. 18, 2020.;;Office Action in JP Application No. 2019-528546 dated Sep. 28, 2020.;;Office Action in European Application No. 17817468.6 dated Aug. 21, 2020.;;Extended European Search Report for Application No. 17817468.6 dated Jun. 29, 2021.;;Office Action in Japanese Application No. 2019-528553 dated Jan. 25, 2021.;;Office Action in European Application No. 17875038.6 dated Mar. 30, 2021.;;Office Action in European Application No. 17817964.4 dated Aug. 18, 2021.",ACTIVE
294,KR,A,KR 20190082926 A,088-271-179-599-751,2019-07-10,2019,KR 20197017310 A,2017-11-27,US 201615362757 A;;US 201615362765 A;;US 201615362751 A;;US 2017/0063314 W,2016-11-28,메시징 프로토콜 통신 관리,통신 네트워크에서 컴퓨팅 디바이스간에 송신되는 데이터를 관리하기 위한 시스템 및 방법이 설명된다. 관리 컴포넌트는 통신 메시지에 임베디드 코드를 해석하기 위해 디바이스에 의해 교환될 메시지의 통신 경로에 있는 하나 이상의 디바이스를 구성할 수 있다. 수신 디바이스는 착신 메시지를 검토하여 통신 메시지가 어떻게 라우팅될 것인지 또는 그렇지 않으면 비지니스 규칙 또는 로직에 따라 프로세싱 될 것 인지를 결정하기 위해 메시지를 프로세싱할 수 있다.,AMAZON TECH INC,KUO CALVIN YUE REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/088-271-179-599-751,Patent Application,no,3,3,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L29/08;;H04L12/24;;H04W4/06,,2,1,066-405-654-202-067,10.1002/9781118354261,"Bryan Boyd ET AL, ""Building Real-time Mobile Solutions with MQTT and IBM MessageSight""(2014.11.10.)*;;Sasu Tarkoma, ""Publish/Subscribe Systems: Design and Principles 1st Edition""(Wiley, 2012.08.13.)",ACTIVE
295,US,A1,US 2021/0004281 A1,082-019-351-476-161,2021-01-07,2021,US 202017027233 A,2020-09-21,US 202017027233 A;;US 201615362707 A,2016-11-28,LOCALIZED DEVICE COORDINATOR WITH MUTABLE ROUTING INFORMATION,"Systems and methods are described for implementing a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinator can be provisioned with a set of tasks, each task corresponding to a segment of code that can be executed by the coordinator, such as to manage the coordinated devices. The coordinator can further be provisioned with event flow information designating a routing of inputs to the coordinator computing device to destinations, such as task executions or coordinated devices. On receiving input, the coordinator can reference the event flow information to pass the input to an appropriate destination.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TYRAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN,AMAZON TECHNOLOGIES INC (2022-06-14),https://lens.org/082-019-351-476-161,Patent Application,yes,0,3,4,17,0,G06F9/5027;;G06F9/547;;G06F9/547;;G06F9/5027,G06F9/54;;G06F9/50,,0,0,,,,ACTIVE
296,CA,A1,CA 2646254 A1,181-062-535-840-709,2007-09-20,2007,CA 2646254 A,2007-03-13,US 78188206 P;;US 78190106 P;;US 2007/0006513 W,2006-03-13,PROPAGATION OF PRIMARY CELLS,,VERIDEX LLC,MAZUMDER ABHIJIT;;VENER TATIANA I;;BURNETT CHRISTINE A;;CHOI CHANG H;;BADEN JONATHAN F;;CHOWDARY DONDAPATI;;SKELTON JOANNE;;WANG HAIYING;;CURTIN KATHLEEN M,,https://lens.org/181-062-535-840-709,Patent Application,no,0,0,18,20,53,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12N5/00;;C12N5/02,,0,0,,,,DISCONTINUED
297,EP,A4,EP 2007874 A4,041-631-744-646-145,2009-06-10,2009,EP 07753162 A,2007-03-13,US 2007/0006513 W;;US 78188206 P;;US 78190106 P,2006-03-13,PROPAGATION OF PRIMARY CELLS,,VERIDEX LLC,CHOWDARY DONDAPATI;;SKELTON JOANNE;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT;;CHOI CHANG H;;BADEN JONATHAN F;;VENER TATIANA I;;CURTIN KATHLEEN M;;WANG HAIYING,,https://lens.org/041-631-744-646-145,Search Report,no,3,0,18,20,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12N5/00;;C12N5/02;;G01N33/574,,0,0,,,,DISCONTINUED
298,EP,A1,EP 3545662 A1,026-868-304-816-608,2019-10-02,2019,EP 17875038 A,2017-11-27,US 201615362757 A;;US 201615362765 A;;US 201615362751 A;;US 2017/0063314 W,2016-11-28,MANAGING MESSAGING PROTOCOL COMMUNICATIONS,,AMAZON TECH INC,KUO CALVIN YUE-REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/026-868-304-816-608,Patent Application,yes,0,3,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L29/06;;H04L12/58;;H04L12/66;;H04L29/08;;H04W4/00,,0,0,,,,ACTIVE
299,EP,A2,EP 2007874 A2,114-984-165-167-043,2008-12-31,2008,EP 07753162 A,2007-03-13,US 2007/0006513 W;;US 78188206 P;;US 78190106 P,2006-03-13,PROPAGATION OF PRIMARY CELLS,,VERIDEX LLC,CHOWDARY DONDAPATI;;SKELTON JOANNE;;BURNETT CHRISTINE A;;MAZUMDER ABHIJIT;;CHOI CHANG H;;BADEN JONATHAN F;;VENER TATIANA I;;CURTIN KATHLEEN M;;WANG HAIYING,,https://lens.org/114-984-165-167-043,Patent Application,yes,0,0,18,20,53,C12Q1/6886;;C12Q2600/118;;C12Q2600/154;;C12Q2600/16;;C12Q2600/178;;A61P35/00;;C12Q1/6886;;C12Q2600/178;;C12Q2600/154;;C12Q2600/16;;C12Q2600/118,C12N5/00;;C12N5/02;;G01N33/574,,0,0,,,,DISCONTINUED
300,CN,A,CN 110326255 A,155-112-710-915-027,2019-10-11,2019,CN 201780075588 A,2017-11-27,US 201615362757 A;;US 201615362765 A;;US 201615362751 A;;US 2017/0063314 W,2016-11-28,MANAGING MESSAGING PROTOCOL COMMUNICATIONS,Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages and process the message to determine how the communication message will be routed or otherwise processed according to business rules or logic.,AMAZON TECH INC,KUO CALVIN YUE-REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/155-112-710-915-027,Patent Application,no,4,1,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L12/24;;H04L29/08,,1,0,,,"BRYAN BOYD: ""“Building Real-time Mobile Solutions with MQTT and IBM MessageSight”"", 《HTTP://WWW.REDBOOKS.IBM.COM/REDBOOKS/PDFS/SG248228》",ACTIVE
301,EP,A4,EP 3545662 A4,108-274-608-463-922,2020-07-08,2020,EP 17875038 A,2017-11-27,US 201615362757 A;;US 201615362765 A;;US 201615362751 A;;US 2017/0063314 W,2016-11-28,MANAGING MESSAGING PROTOCOL COMMUNICATIONS,,AMAZON TECH INC,KUO CALVIN YUE-REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/108-274-608-463-922,Search Report,no,0,0,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L29/06;;G06F9/54;;H04L12/24;;H04L12/58;;H04L12/66;;H04L29/08;;H04W4/00;;H04W4/70,,3,1,066-405-654-202-067,10.1002/9781118354261,"BRYAN BOYD ET AL: ""Building Real-time Mobile Solutions with MQTT and IBM MessageSight"", 10 November 2014 (2014-11-10), United States?, XP055517851, ISBN: 978-0-7384-4005-7, Retrieved from the Internet <URL:http://www.redbooks.ibm.com/redbooks/pdfs/sg248228.pdf>;;""Publish / Subscribe Systems: Design and Principles 1st Edition"", 13 August 2012, WILEY, ISBN: 978-1-119-95154-4, article SASU TARKOMA: ""Publish / Subscribe Systems: Design and Principles 1st Edition"", XP055575481;;See also references of WO 2018098445A1",ACTIVE
302,AU,A1,AU 2017/363368 A1,157-149-306-250-870,2019-07-04,2019,AU 2017/363368 A,2017-11-27,US 201615362757 A;;US 201615362751 A;;US 201615362765 A;;US 2017/0063314 W,2016-11-28,Managing messaging protocol communications,Systems and methods are described for management of data transmitted between computing devices in a communication network. An administrative component can configure one or more devices in the communication path of messages to be exchanged by devices to interpret codes embedded in the communication messages. A receiving device can review incoming messages and process the message to determine how the communication message will be routed or otherwise processed according to business rules or logic.,AMAZON TECH INC,KUO CALVIN YUE-REN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER;;RAFN MARK EDWARD;;TANDON AMBUJ;;TUROW JONATHAN I;;CHOI KYUNGHWAN;;MCCLENAHAN WEILI ZHONG,,https://lens.org/157-149-306-250-870,Patent Application,no,0,2,12,18,0,H04W4/06;;H04L67/12;;H04L69/329;;H04L51/18;;H04L67/02;;G06F2209/549;;G06F9/542;;H04L51/214;;H04L67/55;;H04L67/63;;H04L41/0895;;H04L41/0894;;H04W4/06;;H04L67/55;;H04L67/63;;H04L51/214;;H04L67/02;;G06F9/542;;H04L69/329,H04L29/06;;H04L12/58;;H04L12/66;;H04L29/08;;H04W4/00,,0,0,,,,ACTIVE
303,EP,A1,EP 3629929 A1,194-749-619-096-975,2020-04-08,2020,EP 18809064 A,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P;;US 2018/0035661 W,2017-06-02,MICROFLUIDIC SYSTEMS FOR EPIDERMAL SAMPLING AND SENSING,,UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;CHOI JUNGIL;;RAY TYLER R;;REEDER JONATHAN T;;SEKINE YURINA;;BANDODKAR AMAY J;;ZHANG YI;;GUO HEXIA;;KIM SUNGBONG;;OSTOJICH DIANA,,https://lens.org/194-749-619-096-975,Patent Application,yes,0,0,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/15;;B01L3/00;;F16K17/02;;F16K17/40;;G01N33/487,,0,0,,,,PENDING
304,WO,A1,WO 2022/251302 A1,024-085-000-156-352,2022-12-01,2022,US 2022/0030839 W,2022-05-25,US 202163193243 P,2021-05-26,SUBSTITUTED FUSED BICYCLIC MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful as orexin-2 receptor agonists for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HUYNH HOAN;;PENNINGTON LEWIS;;CHOI YOUNGGI;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL,,https://lens.org/024-085-000-156-352,Patent Application,yes,20,0,3,3,0,C07D498/18;;C07D498/08;;A61P43/00,A61P43/00;;A61K31/4162;;A61K31/4353;;A61K31/519;;C07D498/08;;C07D498/18,,22,13,044-928-520-255-205;;168-592-990-567-692;;064-654-501-659-108;;019-661-953-949-345;;134-787-395-407-586;;013-795-902-101-18X;;100-598-891-287-142;;118-152-222-665-107;;070-910-884-361-022;;010-870-611-029-091;;021-693-589-840-981;;129-917-326-539-78X;;077-295-491-167-117,10.1016/s0092-8674(00)80949-6;;9491897;;11718878;;10.1016/s0166-2236(00)02002-6;;10.3410/f.1014042.192612;;12797957;;10.1016/s0896-6273(03)00330-1;;10.1073/pnas.0400590101;;pmc384801;;15070772;;10.1007/s40263-012-0036-8;;23359095;;pmc8762453;;17491094;;10.1093/brain/awm097;;19117547;;pmc2630400;;10.1016/j.cmet.2008.10.010;;14580935;;10.1016/s0306-4522(03)00554-2;;15627867;;10.1159/000081757;;10.1016/s0196-9781(02)00110-9;;12217429;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1002/0470084960;;10.1002/0471220574,"CELL, vol. 92, 1998, pages 573 - 585;;SAPER, TRENDS IN NEUROSCIENCE, 2001;;YARAANAKA, NEURON, vol. 38, 2003, pages 715 - 730;;SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014;;MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019;;PROC. NAT! ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654;;CELL, vol. 98, 1999, pages 437 - 451;;CNS DRUGS, vol. 27, 2013, pages 83 - 90;;BRAIN, vol. 130, 2007, pages 1586 - 1595;;CELL METABOLISM, vol. 9, 2009, pages 64 - 76;;NEUROSCIENCE, vol. 121, 2003, pages 855 - 863;;RESPIRATION, vol. 71, 2004, pages 575 - 579;;PEPTIDES, vol. 23, 2002, pages 1683 - 1688;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;""Fieser and Fieser's Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, VCH PUBLISHERS INC.;;""March, Advanced Organic Chemistry"", 1992, WILEY;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY",PENDING
305,WO,A1,WO 2022/232025 A1,053-625-007-458-798,2022-11-03,2022,US 2022/0026144 W,2022-04-25,US 202163179616 P,2021-04-26,SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY,The present invention provides compounds of formula (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,CHOI YOUNGGI;;HU YUAN;;HUYNH HOAN;;AQUILA BRIAN;;RAYMER BRIAN;;MUGGE INGO;;WOODS JAMES;;PENNINGTON LEWIS;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL;;VALIULIN ROMAN,,https://lens.org/053-625-007-458-798,Patent Application,yes,14,0,5,5,0,C07D498/04;;C07D498/14;;A61P25/00,A61P25/00;;A61K31/4353;;C07D498/04;;C07D498/14,,21,9,044-928-520-255-205;;019-661-953-949-345;;134-787-395-407-586;;013-795-902-101-18X;;118-152-222-665-107;;070-910-884-361-022;;010-870-611-029-091;;021-693-589-840-981;;077-295-491-167-117,10.1016/s0092-8674(00)80949-6;;9491897;;10.1073/pnas.0400590101;;pmc384801;;15070772;;10.1007/s40263-012-0036-8;;23359095;;pmc8762453;;17491094;;10.1093/brain/awm097;;14580935;;10.1016/s0306-4522(03)00554-2;;15627867;;10.1159/000081757;;10.1016/s0196-9781(02)00110-9;;12217429;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1002/0471220574,"CELL, vol. 92, 1998, pages 573 - 585;;SAPER ET AL., TRENDS IN NEUROSCIENCE, 2001;;YAMANAKA ET AL., NEURON, vol. 38, 2003, pages 715 - 730;;SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014;;MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019;;PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654;;CELL, vol. 98, 1999, pages 437 - 451;;CNS DRUGS, vol. 27, 2013, pages 83 - 90;;BRAIN, vol. 130, 2007, pages 1586 - 1595;;CD] METABOLISM, vol. 9, 2009, pages 64 - 76;;NEUROSCIENCE, vol. 121, 2003, pages 855 - 863;;RESPIRATION, vol. 71, 2004, pages 575 - 579;;PEPTIDES, vol. 23, 2002, pages 1683 - 1688;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;""Fieser and Fieser's Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY",PENDING
306,EP,A4,EP 3629929 A4,069-420-986-263-231,2021-06-09,2021,EP 18809064 A,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P;;US 2018/0035661 W,2017-06-02,MICROFLUIDIC SYSTEMS FOR EPIDERMAL SAMPLING AND SENSING,,UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;CHOI JUNGIL;;RAY TYLER R;;REEDER JONATHAN T;;SEKINE YURINA;;BANDODKAR AMAY J;;ZHANG YI;;GUO HEXIA;;KIM SUNGBONG;;OSTOJICH DIANA,,https://lens.org/069-420-986-263-231,Search Report,no,2,0,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/145;;A61B5/00;;B01L3/00;;G01N33/487;;G01N33/543,,4,3,026-793-234-501-067;;026-793-234-501-067;;005-500-952-231-299,28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355;;28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355;;pmc5429097;;10.1126/scitranslmed.aaf2593;;27881826,"JUNGIL CHOI ET AL: ""Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat"", ADVANCED HEALTHCARE MATERIALS, vol. 6, no. 5, 20 January 2017 (2017-01-20), DE, pages 1601355, XP055561869, ISSN: 2192-2640, DOI: 10.1002/adhm.201601355;;JUNGIL CHOI ET AL: ""Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat"", ADVANCED HEALTHCARE MATERIALS, vol. 6, no. 5, 20 January 2017 (2017-01-20), DE, pages 1601355, XP055766423, ISSN: 2192-2640, DOI: 10.1002/adhm.201601355;;AHYEON KOH ET AL: ""A soft, wearable microfluidic device for the capture, storage, and colorimetric sensing of sweat"", SCIENCE TRANSLATIONAL MEDICINE, 23 November 2016 (2016-11-23), United States, pages 366ra165 - 366ra165, XP055521314, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/8/366/366ra165> [retrieved on 20210119], DOI: 10.1126/scitranslmed.aaf2593;;See also references of WO 2018223033A1",PENDING
307,KR,A,KR 20200015919 A,156-245-382-680-323,2020-02-13,2020,KR 20197038829 A,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P;;US 2018/0035661 W,2017-06-02,표피 샘플링 및 감지를 위한 마이크로유체 시스템,"생체 유체 특성을 모니터링하기 위한 마이크로유체 시스템 및 관련 방법이 제공된다. 유연한 기재와, 캡핑층 및 유체 도관과 제어기를 포함하는, 특별히 구성된 마이크로유체 네트워크 및 관련 구조적 지지와 기능적 요소는 신뢰할 수 있는 생체 유체 수집을 제공한다. 광학 구성요소와 표시기는, 마이크로유체 네트워크 내에서 직접 수집되는 생체 유체를 포함하여, 다수의 생체 유체 특성 중 어느 하나를 포함하는, 신뢰할 수 있고 쉽게 관찰할 수 있는 판독값을 제공한다.",UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;CHOI JUNGIL;;RAY TYLER R;;REEDER JONATHAN T;;SEKINE YURINA;;BANDODKAR AMAY J;;ZHANG YI;;GUO HEXIA;;KIM SUNGBONG;;OSTOJICH DIANA,,https://lens.org/156-245-382-680-323,Patent Application,no,1,3,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/145;;A61B5/00;;A61B5/053;;A61B5/1455;;A61B5/1491;;A61B5/1495;;A61B5/15;;A61B10/00;;B01L3/00;;G01N33/543,,0,0,,,,ACTIVE
308,CN,A,CN 111093501 A,198-188-961-624-17X,2020-05-01,2020,CN 201880049165 A,2018-06-01,US 201762514374 P;;US 201762514515 P;;US 201762514436 P;;US 201762514520 P;;US 201762514455 P;;US 201762514546 P;;US 201762514468 P;;US 201762514559 P;;US 201762514489 P;;US 2018/0035661 W,2017-06-02,MICROFLUIDIC SYSTEMS FOR EPIDERMAL SAMPLING AND SENSING,"Provided are microfluidic systems for monitoring a biofluid property and related methods. Specially configured microfluidic networks and associated structural support and functional elements, including flexible substrates, capping layers, and fluidic conduits and controllers, provide reliable biofluid collection. Optical components and indicators provide a reliable and readily observable readout,including of any of a number of biofluid properties, including directly from biofluid collected in the microfluidic network.",UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;CHOI JUNGIL;;RAY TYLER R;;REEDER JONATHAN T;;SEKINE YURINA;;BANDODKAR AMAY J;;ZHANG YI;;GUO HEXIA;;KIM SUNGBONG;;OSTOJICH DIANA,,https://lens.org/198-188-961-624-17X,Patent Application,no,9,2,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/15;;B01L3/00;;F16K17/02;;F16K17/40;;G01N33/487,,1,1,026-793-234-501-067,28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355,"JUNGIL CHOI ET AL: ""Thin soft skin-mounted microfluidic networks with capillary bursting valves for chrono-sampling of sweat"", 《ADVACED HEALTHCARE MATERIALS》",DISCONTINUED
309,AU,A1,AU 2022/281345 A1,170-745-109-579-329,2023-11-30,2023,AU 2022/281345 A,2022-05-25,US 202163193243 P;;US 2022/0030839 W,2021-05-26,SUBSTITUTED FUSED BICYCLIC MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful as orexin-2 receptor agonists for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HUYNH HOAN;;PENNINGTON LEWIS;;CHOI YOUNGGI;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL,,https://lens.org/170-745-109-579-329,Patent Application,no,0,0,3,3,0,C07D498/18;;C07D498/08;;A61P43/00,A61P43/00;;A61K31/4162;;A61K31/4353;;A61K31/519;;C07D498/08;;C07D498/18,,0,0,,,,PENDING
310,CN,A,CN 111803084 A,180-088-276-730-597,2020-10-23,2020,CN 202010460709 A,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P;;CN 201880049165 A,2017-06-02,MICROFLUIDIC SYSTEMS FOR EPIDERMAL SAMPLING AND SENSING,"Provided are microfluidic systems for monitoring a biofluid property and related methods. Specially configured microfluidic networks and associated structural support and functional elements, including flexible substrates, capping layers, and fluidic conduits and controllers, provide reliable biofluid collection. Optical components and indicators provide a reliable and readily observable readout,including of any of a number of biofluid properties, including directly from biofluid collected in the microfluidic network.",UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;CHOI JUNGIL;;RAY TYLER R;;REEDER JONATHAN T;;SEKINE YURINA;;BANDODKAR AMAY J;;ZHANG YI;;GUO HEXIA;;KIM SUNGBONG;;OSTOJICH DIANA,,https://lens.org/180-088-276-730-597,Patent Application,no,7,4,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/1455;;A61B5/00;;A61B5/01;;A61B5/053;;A61B5/103;;A61B5/145;;A61B5/1491;;A61B5/1495;;A61B5/15;;A61B10/00;;B01L3/00;;G01N33/543,,2,2,005-500-952-231-299;;026-793-234-501-067,pmc5429097;;10.1126/scitranslmed.aaf2593;;27881826;;28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355,"AHYEON KOH，ET AL: ""A Soft, Wearable Microfluidic Device For The Capture, Storage, And Colorimetric Sensing Of Sweat"", 《SCIENCE TRANSLATIONAL MEDICINE》;;JUNGIL CHOI ET AL: ""Thin soft skin-mounted microfluidic networks with capillary bursting valves for chrono-sampling of sweat"", 《ADVACED HEALTHCARE MATERIALS》",DISCONTINUED
311,WO,A1,WO 2018/223033 A1,190-270-816-421-845,2018-12-06,2018,US 2018/0035661 W,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P,2017-06-02,MICROFLUIDIC SYSTEMS FOR EPIDERMAL SAMPLING AND SENSING,"Provided are microfluidic systems for monitoring a biofluid property and related methods. Specially configured microfluidic networks and associated structural support and functional elements, including flexible substrates, capping layers, and fluidic conduits and controllers, provide reliable biofluid collection. Optical components and indicators provide a reliable and readily observable readout, including of any of a number of biofluid properties, including directly from biofluid collected in the microfluidic network.",UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;CHOI JUNGIL;;RAY TYLER R;;REEDER JONATHAN T;;SEKINE YURINA;;BANDODKAR AMAY J;;ZHANG YI;;GUO HEXIA;;KIM SUNGBONG;;OSTOJICH DIANA,,https://lens.org/190-270-816-421-845,Patent Application,yes,5,13,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/15;;B01L3/00;;F16K17/02;;F16K17/40;;G01N33/487,,1,0,,,See also references of EP 3629929A4,PENDING
312,AU,A1,AU 2022/267220 A1,199-934-410-577-504,2023-10-19,2023,AU 2022/267220 A,2022-04-25,US 202163179616 P;;US 2022/0026144 W,2021-04-26,SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY,The present invention provides compounds of formula (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,CHOI YOUNGGI;;HU YUAN;;HUYNH HOAN;;AQUILA BRIAN;;RAYMER BRIAN;;MUGGE INGO;;WOODS JAMES;;PENNINGTON LEWIS;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL;;VALIULIN ROMAN,,https://lens.org/199-934-410-577-504,Patent Application,no,0,0,5,5,0,C07D498/04;;C07D498/14;;A61P25/00,A61P25/00;;A61K31/4353;;C07D498/04;;C07D498/14,,0,0,,,,PENDING
313,US,A1,US 2017/0077522 A1,103-077-153-018-392,2017-03-16,2017,US 201615263125 A,2016-09-12,US 201615263125 A;;US 201562216427 P,2015-09-10,STRAIN ENHANCEMENT OF FUNCTIONAL OXYGEN DEFECTS IN ELECTROCHEMICAL METAL OXIDES,"Methods for tailoring an oxygen defect concentration, such as oxygen vacancies, in a transition metal oxide and the resulting materials are provided. An epitaxial strain, such as in the form of a biaxial tensile strain of up to 5%, is applied to the transition metal oxide to increase the oxygen defect concentration in the transition metal oxide to result in a product comprising the transition metal oxide having an increased oxygen defect concentration.",UT BATTELLE LLC,ERES GYULA;;LEE HO NYUNG;;REBOREDO FERNANDO A;;CHOI WOO SEOK;;FREELAND JOHN W;;JEEN HYOUNG JEEN;;MEYER TRICIA L;;MITRA CHANDRIMA;;PETRIE JONATHAN R,UCHICAGO ARGONNE LLC (2017-07-12);;OAK RIDGE ASSOCIATED UNIVERSITIES (2017-02-08);;UT-BATTELLE LLC (2016-11-17),https://lens.org/103-077-153-018-392,Patent Application,yes,1,1,1,1,0,C30B23/025;;C30B29/22;;H01M4/9033;;C30B33/02;;Y02E60/50;;H01M4/9033;;C30B33/02;;C30B29/22,H01M4/90;;C30B29/22;;C30B33/02,,0,0,,,,DISCONTINUED
314,DE,D1,DE 602007012308 D1,121-535-883-572-30X,2011-03-10,2011,DE 602007012308 T,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,BICYCLISCHE PYRIMIDINONE UND DEREN VERWENDUNG,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/121-535-883-572-30X,Granted Patent,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,ACTIVE
315,US,A1,US 2010/0168063 A1,122-029-759-497-554,2010-07-01,2010,US 51927307 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,AVEXA LIMITED (2009-07-21),https://lens.org/122-029-759-497-554,Patent Application,yes,0,0,34,40,3,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,A61K31/675;;A61K31/519;;A61K31/5377;;A61K31/541;;A61P31/12;;A61P31/18;;C07D279/06;;C07D401/14;;C07D413/14;;C07F9/38,514/80;;544/119;;544/244;;544/3;;544/282;;544/117;;514/233.2;;514/222.2;;514/259.5,0,0,,,,INACTIVE
316,CA,C,CA 2673183 C,062-296-616-138-142,2014-06-10,2014,CA 2673183 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/062-296-616-138-142,Granted Patent,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,INACTIVE
317,CN,A,CN 101627019 A,188-583-655-172-15X,2010-01-13,2010,CN 200780051562 A,2007-12-21,AU 2007/001980 W;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,DALE JONES ERIC;;VICTOR COATES JONATHAN ALAN;;IAN RHODES DAVID;;JOSEPH DEADMAN JOHN;;ANDREW VANDEGRAFF NICHOLAS;;JANE WINFIELD LISA;;NEERANAT THIENTHONG;;WILLIAM ISSA;;NEIL CHOI;;KATHERINE MACFARLANE,,https://lens.org/188-583-655-172-15X,Patent Application,no,0,2,3,40,0,,C07D239/70,,0,0,,,,INACTIVE
318,AU,A1,AU 2021/409664 A1,080-921-872-793-131,2023-05-25,2023,AU 2021/409664 A,2021-12-21,US 202063128511 P;;US 2021/0064484 W,2020-12-21,SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,,https://lens.org/080-921-872-793-131,Patent Application,no,0,0,8,8,0,C07D401/04;;C07D498/04;;C07D487/04;;C07D471/04;;C07D401/06;;C07D211/58;;C07D401/14;;A61P25/26;;A61P25/26;;C07D211/98;;C07D401/04;;C07D401/14;;C07D471/04;;C07D487/04,C07D211/58;;A61K31/4545;;A61P25/26;;C07D401/04;;C07D401/06;;C07D401/14;;C07D471/04;;C07D487/04;;C07D498/04,,0,0,,,,PENDING
319,EP,A1,EP 2114903 A1,113-241-320-380-431,2009-11-11,2009,EP 07855368 A,2007-12-21,AU 2007/001980 W;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/113-241-320-380-431,Patent Application,yes,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,ACTIVE
320,EP,A1,EP 2269992 A1,173-360-379-224-386,2011-01-05,2011,EP 10164218 A,2007-12-21,EP 07855368 A;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,Bicyclic pyrimidinones for the treatment of viral infections,"The present invention relates to novel bicyclic pyrimidinone compounds and analogues thereof for the treatment of viral infections, particularly HIV infections.
 ",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/173-360-379-224-386,Patent Application,yes,6,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,17,14,108-111-372-900-578;;038-942-956-771-853;;016-915-782-204-346;;008-292-006-774-284;;014-066-574-367-486;;004-418-596-716-038;;029-630-817-558-121;;010-381-136-579-90X;;011-622-038-422-213;;108-111-372-900-578;;075-795-869-325-446;;070-077-683-331-305;;002-029-791-571-493;;120-154-241-164-149,10.1080/00304949009356320;;10.1021/ar040278m;;16104688;;15380204;;10.1016/j.bmcl.2004.07.075;;10.1016/0016-3287(90)90119-3;;15801831;;10.1021/jm049354h;;10.1016/s0040-4020(01)80648-7;;10.1248/cpb.32.2536;;6499081;;10514279;;10.1021/jm990229t;;15561191;;10.1016/j.phytochem.2004.10.006;;10.1080/00304949009356320;;10.1016/s0040-4020(00)00084-3;;10.1016/s0040-4020(01)90411-9;;10.1016/0040-4020(95)00478-q;;10.1016/s0040-4039(00)00839-x,"TISLER M ET AL: ""An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines"", ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL,, vol. 22, no. 4, 1 January 1990 (1990-01-01), pages 532 - 534, XP008110052;;GENERAL PROCEDURE 1: ADAPTION OF ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 22, no. 4, 1990, pages 532 - 534;;B. R. ROBERTS; C. R. STRAUSS: ""Toward Rapid, 'Green' Predictable Microwave-assisted Synthesis"", ACC. CHEM. RES., vol. 38, 2005, pages 653 - 661;;I.STANSFIELD ET AL.: ""Active site inhibitors of HCV NS5B polymerase"", BIO-ORG. MED-CHEM. LETT, vol. 14, 2004, pages 5085 - 5088;;OPPI, vol. 22, no. 4, 1990, pages 532 - 534;;J. MED. CHEM., vol. 48, no. 7, 2005, pages 2388 - 2406;;TETRAHEDRON, vol. 50, no. 21, 1994, pages 6287 - 6298;;CHEM. PHARM. BULL., vol. 32, no. 7, 1984, pages 2536 - 2543;;J. MED. CHEM., vol. 42, no. 20, 1999, pages 4088 - 4098;;OVENDEN ET AL., PHYTOCHEMISTRY, vol. 65, no. 24, December 2004 (2004-12-01), pages 3255 - 9;;TISLER, M.; ZUPET, R., ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 22, no. 4, 1990, pages 532 - 534;;VOMPE A.F.; TURITSYNA N.F., J.GEN.CHEM.OF THE USSR, vol. 27, 1957, pages 3318 - 3325;;MARTINEZ-BARRASA V.; DELGADO F.; BURGOS C.; GARCIA-NAVIO J.L.; IZQUIERDO M.L.; ALVAREZ-BUILLA J., TETRAHEDRON, vol. 56, 2000, pages 2481 - 2490;;CARCELLER R.; GARCIA-NAVIO J.L.; IZQUIERDO M.L.; ALVAREZ-BUILLA J.; FAJARDO M.; GOMEZ-SAL P.; GAGO F., TETRAHEDRON, vol. 50, no. 17, 1994, pages 4995 - 5012;;BURGOS C.; DELGADO F.; GARCIA-NAVIO J.L.; IZAQUIERDO M.L.; ALVAREZ-BUILLA J., TETRAHEDRON, vol. 51, no. 31, 1995, pages 8649 - 8654;;DE LA ROSA R.; MARTINEZ-BARRASA V.; BURGOS C.; ALVAREZ-BUILLA J., TET.LET., vol. 41, 2000, pages 5837 - 5840;;BEHRMAN E.J.; KISER R.L.; GARAS W.F.; BEHRMAN E.C.; PITT B.M., J.CHEM.RES.(M), 1995, pages 1051 - 1063",DISCONTINUED
321,US,A1,US 2011/0009366 A1,002-196-033-171-712,2011-01-13,2011,US 76651010 A,2010-04-23,US 76651010 A;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;US 51927309 A;;AU 2007/001980 W,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINIE,,https://lens.org/002-196-033-171-712,Patent Application,yes,0,0,34,40,3,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,A61K31/519;;A61K31/5377;;A61K31/541;;A61K31/675;;A61P31/12;;A61P31/18;;C07D471/04;;C07D491/048,514/80;;544/282;;544/116;;544/281;;544/278;;544/117;;544/3;;544/244;;514/259.4;;514/233.2;;514/259.41;;514/259.31;;514/259.2;;514/252.16;;514/222.2,0,0,,,,INACTIVE
322,EP,A4,EP 2114903 A4,053-642-015-457-052,2009-12-30,2009,EP 07855368 A,2007-12-21,AU 2007/001980 W;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/053-642-015-457-052,Search Report,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,1,0,,,No further relevant documents disclosed,ACTIVE
323,CN,B,CN 101880280 B,051-374-210-099-819,2014-07-16,2014,CN 201010148170 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,,SHANGHAI INST ORGANIC CHEM;;AVEXA LTD,JONES ERIC DALE;;VANDEGRAFF NICHOLAS ANDREW;;DEADMAN JOHN JOSEPH;;RHODES DAVID IAN;;THIENTHONG NEERANAT;;MACFARLANE KATHERINE;;CHOI NEIL;;COATES JONATHAN ALAN VICTOR;;ISSA WILLIAM;;WINFIELD LISA JANE,,https://lens.org/051-374-210-099-819,Granted Patent,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D471/04;;A61K31/519;;A61P31/16;;A61P31/18;;C07D487/04;;C07D498/04;;C07D513/04,,0,0,,,,INACTIVE
324,JP,A,JP 2010222370 A,168-838-014-272-827,2010-10-07,2010,JP 2010129801 A,2010-06-07,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,"BICYCLIC PYRIMIDINONE, AND USE THEREOF","<P>PROBLEM TO BE SOLVED: To provide a method for treatment or prophylaxis of viral infection, particularly HIV infection. <P>SOLUTION: There is provided a compound represented by formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Furthermore, there are provided a pharmaceutical composition including the compound, and a pharmaceutically acceptable carrier, diluent or excipient thereof. <P>COPYRIGHT: (C)2011,JPO&INPIT",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/168-838-014-272-827,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D471/04;;A61K31/519;;A61K31/5377;;A61P31/12;;A61P31/18;;C07D487/04;;C07D498/04;;C07D513/04,,0,0,,,,DISCONTINUED
325,CN,A,CN 101880280 A,037-277-785-923-58X,2010-11-10,2010,CN 201010148170 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a bicyclic pyrimidinones and uses thereof. Particularly provided is a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",SHANGHAI INST ORGANIC CHEM;;AVEXA LTD,ANDREW VANDEGRAFF NICHOLAS;;DALE JONES ERIC;;JOSEPH DEADMAN JOHN;;IAN RHODES DAVID;;NEERANAT THIENTHONG;;KATHERINE MACFARLANE;;NEIL CHOI;;VICTOR COATES JONATHAN ALAN;;WILLIAM ISSA;;JANE WINFIELD LISA,,https://lens.org/037-277-785-923-58X,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D471/04;;A61K31/519;;A61P31/16;;A61P31/18;;C07D487/04;;C07D498/04;;C07D513/04,,0,0,,,,INACTIVE
326,US,B2,US 8207334 B2,038-925-217-308-537,2012-06-26,2012,US 76651010 A,2010-04-23,US 76651010 A;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;US 51927309 A;;AU 2007/001980 W,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.",JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINIE;;AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINIE,,https://lens.org/038-925-217-308-537,Granted Patent,yes,3,0,34,40,3,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;C07D487/00,544/281;;544/282,4,2,108-111-372-900-578;;108-111-372-900-578,10.1080/00304949009356320;;10.1080/00304949009356320,"Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.;;Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.;;Tisler, et al., An Improved Synthesis of Dimethyl Diacetoxyfumarate and Its Condensation with Heterocyclic Amines, Organic Preparations and Procedures International, 22(4), 532-4 (1990).;;Tisler, M. et al., ""An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines"", Organic Preparations and Procedures International (1990), vol. 22, No. 4, pp. 532-534.",INACTIVE
327,WO,A1,WO 2022/140317 A1,151-217-393-660-627,2022-06-30,2022,US 2021/0064484 W,2021-12-21,US 202063128511 P,2020-12-21,SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,,https://lens.org/151-217-393-660-627,Patent Application,yes,13,1,8,8,0,C07D401/04;;C07D498/04;;C07D487/04;;C07D471/04;;C07D401/06;;C07D211/58;;C07D401/14;;A61P25/26;;A61P25/26;;C07D211/98;;C07D401/04;;C07D401/14;;C07D471/04;;C07D487/04,C07D211/58;;A61K31/4545;;A61P25/26;;C07D401/04;;C07D401/06;;C07D401/14;;C07D471/04;;C07D487/04;;C07D498/04,,23,12,044-928-520-255-205;;019-661-953-949-345;;134-787-395-407-586;;013-795-902-101-18X;;100-598-891-287-142;;118-152-222-665-107;;070-910-884-361-022;;010-870-611-029-091;;021-693-589-840-981;;129-917-326-539-78X;;077-295-491-167-117;;020-282-843-362-629,10.1016/s0092-8674(00)80949-6;;9491897;;10.1073/pnas.0400590101;;pmc384801;;15070772;;10.1007/s40263-012-0036-8;;23359095;;pmc8762453;;17491094;;10.1093/brain/awm097;;19117547;;pmc2630400;;10.1016/j.cmet.2008.10.010;;14580935;;10.1016/s0306-4522(03)00554-2;;15627867;;10.1159/000081757;;10.1016/s0196-9781(02)00110-9;;12217429;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1002/0470084960;;10.1002/0471220574;;10.1023/a:1018943613122;;8378254,"CELL, vol. 92, 1998, pages 573 - 585;;SAPER ET AL., TRENDS IN NEUROSCIENCE, 2001;;YAMANAKA ET AL., NEURON, vol. 38, 2003, pages 715 - 730;;SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014;;MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019;;PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654;;CELL, vol. 98, 1999, pages 437 - 451;;CNS DRUGS, vol. 27, 2013, pages 83 - 90;;BRAIN, vol. 130, 2007, pages 1586 - 1595;;CELL METABOLISM, vol. 9, 2009, pages 64 - 76;;NEUROSCIENCE, vol. 121, 2003, pages 855 - 863;;RESPIRATION, vol. 71, 2004, pages 575 - 579;;PEPTIDES, vol. 23, 2002, pages 1683 - 1688;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;""Fieser's Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;""March, Advanced Organic Chemistry"", 1992, WILEY;;""Carey and Sundberg, Advanced Organic Chemistry"", vol. A, B, 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;;DAVIES B.MORRIS T.: ""Physiological Parameters in Laboratory Animals and Humans"", PHARMARES, vol. 10, no. 7, 1993, pages 1093 - 1095",PENDING
328,KR,A,KR 20100049698 A,047-100-330-681-472,2010-05-12,2010,KR 20107008711 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/047-100-330-681-472,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D277/60;;A61K31/519;;A61P31/12;;C07D275/04,,0,0,,,,DISCONTINUED
329,HK,A1,HK 1131615 A1,058-525-158-654-546,2010-01-29,2010,HK 09110584 A,2009-11-12,AU 2007/001980 W;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/058-525-158-654-546,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,A61K/;;A61P/;;C07D/,,0,0,,,,DISCONTINUED
330,ZA,B,ZA 200904321 B,101-072-073-793-094,2010-08-25,2010,ZA 200904321 A,2007-12-21,AU 2006/907283 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEDMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/101-072-073-793-094,Granted Patent,no,0,0,3,40,0,,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
331,MX,A,MX 2009006764 A,180-318-901-665-622,2009-11-26,2009,MX 2009006764 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF.,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,COATES JONATHAN ALAN VICTOR;;JONES ERIC DALE;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/180-318-901-665-622,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,ACTIVE
332,AU,A1,AU 2007/336703 A1,089-608-153-686-66X,2008-07-03,2008,AU 2007/336703 A,2007-12-21,AU 2006/907283 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/902479 A;;AU 2007/001980 W;;AU 2007/336703 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,,AVEXA LTD,VANDEGRAFF NICHOLAS ANDREW;;JONES ERIC DALE;;DEADMAN JOHN JOSEPH;;RHODES DAVID IAN;;THIENTHONG NEERANAT;;MACFARLANE KATHERINE;;CHOI NEIL;;COATES JONATHAN ALAN VICTOR;;ISSA WILLIAM;;WINFIELD LISA JANE,,https://lens.org/089-608-153-686-66X,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,INACTIVE
333,CA,A1,CA 2673183 A1,173-503-890-047-327,2008-07-03,2008,CA 2673183 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutica lly acceptable derivative, salt or prodrug thereof. Further provided is a me thod of treatment or prophylaxis of a viral infection in a subject comprisin g administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A p harmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,VANDEGRAFF NICHOLAS ANDREW;;MACFARLANE KATHERINE;;COATES JONATHAN ALAN VICTOR;;JONES ERIC DALE;;THIENTHONG NEERANAT;;CHOI NEIL;;ISSA WILLIAM;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;WINFIELD LISA JANE,,https://lens.org/173-503-890-047-327,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,INACTIVE
334,CN,B,CN 101627019 B,063-509-938-446-212,2013-07-10,2013,CN 200780051562 A,2007-12-21,AU 2007/001980 W;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/063-509-938-446-212,Granted Patent,no,0,0,3,40,0,,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,INACTIVE
335,KR,A,KR 20090097194 A,134-943-333-024-215,2009-09-15,2009,KR 20097014886 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/134-943-333-024-215,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D277/60;;A61K31/519;;A61P31/12;;C07D275/04,,0,0,,,,DISCONTINUED
336,WO,A1,WO 2008/077188 A1,047-178-388-541-237,2008-07-03,2008,AU 2007/001980 W,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD;;JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/047-178-388-541-237,Patent Application,yes,6,32,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,13,11,108-111-372-900-578;;038-942-956-771-853;;016-915-782-204-346;;008-292-006-774-284;;010-381-136-579-90X;;011-622-038-422-213;;108-111-372-900-578;;075-795-869-325-446;;070-077-683-331-305;;002-029-791-571-493;;120-154-241-164-149,10.1080/00304949009356320;;10.1021/ar040278m;;16104688;;15380204;;10.1016/j.bmcl.2004.07.075;;10.1016/0016-3287(90)90119-3;;10514279;;10.1021/jm990229t;;15561191;;10.1016/j.phytochem.2004.10.006;;10.1080/00304949009356320;;10.1016/s0040-4020(00)00084-3;;10.1016/s0040-4020(01)90411-9;;10.1016/0040-4020(95)00478-q;;10.1016/s0040-4039(00)00839-x,"TISLER M. ET AL.: ""An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines"", ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 22, no. 4, 1990, pages 532 - 534, XP008110052;;B. R. ROBERTS; C. R. STRAUSS, ACC. CHEM. RES., vol. 38, 2005, pages 653 - 661;;I.STANSFIELD ET AL.: ""Active site inhibitors of HCV NS5B polymerase"", BIO-ORG. MED-CHEM. LETT, vol. 14, 2004, pages 5085 - 5088, XP004565437, DOI: doi:10.1016/j.bmcl.2004.07.075;;OPPI, vol. 22, no. 4, 1990, pages 532 - 534;;J. MED. CHEM., vol. 42, no. 20, 1999, pages 4088 - 4098;;OVENDEN ET AL., PHYTOCHEMISTRY, vol. 65, no. 24, December 2004 (2004-12-01), pages 3255 - 9;;TISLER, M.; ZUPET, R., ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 22, no. 4, 1990, pages 532 - 534;;VOMPE A.F.; TURITSYNA N.F., J.GEN.CHEM.OF THE USSR, vol. 27, 1957, pages 3318 - 3325;;MARTINEZ-BARRASA V.; DELGADO F.; BURGOS C.; GARCIA-NAVIO J.L.; LZQUIERDO M.L.; ALVAREZ-BUILLA J., TETRAHEDRON, vol. 56, 2000, pages 2481 - 2490;;CARCELLER R.; GARCIA-NAVIO J.L.; LZQUIERDO M.L.; ALVAREZ-BUILLA J.; FAJARDO M.; GOMEZ-SAL P.; GAGO F., TETRAHEDRON, vol. 50, no. 17, 1994, pages 4995 - 5012;;BURGOS C.; DELGADO F.; GARCIA-NAVIO J.L.; IZAQUIERDO M.L.; ALVAREZ-BUILLA J., TETRAHEDRON, vol. 51, no. 31, 1995, pages 8649 - 8654;;DE LA ROSA R.; MARTINEZ-BARRASA V.; BURGOS C.; ALVAREZ-BUILLA J., TET.LET., vol. 41, 2000, pages 5837 - 5840;;BEHRMAN E.J.; KISER R.L.; GARAS W.F.; BEHRMAN E.C.; PITT B.M., J.CHEM.RES.(M), 1995, pages 1051 - 1063",PENDING
337,BR,A2,BR PI0720564 A2,010-477-848-662-943,2011-08-16,2011,BR PI0720564 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,pirimidinonas biciclìcas e seus usos,"<B>PIRIMIDINONAS BICìCLICAS E SEUS USOS<D>. A presente invenção fornece um composto de Fórmula I ou um derivado, sal ou pró-droga farmaceuticamente aceitável deste. é ainda fornecido um método de tratamento ou profilaxia de uma infecção viral em um indivíduo compreendendo a administração ao referido indivíduo de uma quantidade eficaz de um composto de Fórmula I ou um derivado, sal ou pró-droga farmaceuticamente aceitável deste. Uma composição farmacêutica ou medicamento compreendendo um composto de Fórmula I também é fornecido.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;CHOI NEIL;;MACFARLANE KATHERINE;;ISSA WILLIAM,AVEXA LIMITED (AU) (2015-12-08),https://lens.org/010-477-848-662-943,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,DISCONTINUED
338,DK,T3,DK 2114903 T3,044-143-915-461-265,2011-04-18,2011,DK 07855368 T,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,Bicykliske pyrimidinoner og anvendelser deraf,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/044-143-915-461-265,Granted Patent,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,ACTIVE
339,NZ,A,NZ 577491 A,154-523-327-006-963,2011-06-30,2011,NZ 57749107 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,"2-heteroaryl-3-hydroxy-4-oxo-pyrido[1,2-a]pyrimidines and uses thereof","Disclosed are compounds of general formula (I) and particularly those which are 3-hydroxy-4-oxo-pyrido[1,2-a]pyrimidine derivatives which are useful for the treatment of viral infections, wherein: A is a monocyclic or bicyclic aromatic or heteroaromatic moiety fused to the nitrogen containing ring; X and Y are independently selected from the group consisting of O and S; B and C are absent; R2 is an optionally substituted heteroaryl or heterocyclyl group; and wherein the other substituents are as defined herein.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/154-523-327-006-963,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/4375;;A61K31/517;;A61K31/519;;A61P31/12;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60;;C07D487/04,,0,0,,,,DISCONTINUED
340,US,A1,US 2012/0232035 A1,198-647-913-046-424,2012-09-13,2012,US 201213405511 A,2012-02-27,US 201213405511 A;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;US 51927309 A;;AU 2007/001980 W,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.",JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE;;AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/198-647-913-046-424,Patent Application,yes,0,1,34,40,3,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,A61K31/5377;;A61K31/519;;A61K31/675;;A61P31/12;;A61P31/14;;A61P31/18,514/80;;514/259.4;;514/233.2;;514/259.41,2,0,,,"Wolff et. al., ""Burger's Medicinal Chemistry and Drug Discovery,"" 5th Ed. Part 1, pp. 975-977 (1995);;Banker, et. al., (1996), Modern Pharmaceuticals, p.596.",INACTIVE
341,BR,A2,BR PI0722411 A2,065-729-715-075-204,2012-06-05,2012,BR PI0722411 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,pirimidinonas bicìclicas e seus usos,"PIRIMIDINONAS BICìCLICAS E SEUS USOS. (Dividido do pedido de patente PI 0720564-3 de 22/06/2009). A presente invenção fornece um composto de Fórmula 1) ou um derivado, sal ou pró-droga farmaceuticàrnente aceitável deste. é ainda fornecido um método de tratamento ou profilaxia de uma infecção viral em um indivíduo compreendendo a administração ao referido indivíduo de uma quantidade eficaz de um composto de Fórmula I ou um derivado, sal ou pró-droga farmaceuticamente aceitável deste. Uma composição farmacêutica ou medicamento compreendendo um composto de Fórmula I também é fornecido.",AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/065-729-715-075-204,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,DISCONTINUED
342,AU,B9,AU 2007/336703 B9,197-076-185-936-935,2014-03-27,2014,AU 2007/336703 A,2007-12-21,AU 2006/907283 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/902479 A;;AU 2007/001980 W;;AU 2007/336703 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,WINFIELD LISA JANE;;RHODES DAVID IAN;;ISSA WILLIAM;;THIENTHONG NEERANAT;;DEADMAN JOHN JOSEPH;;MACFARLANE KATHERINE;;COATES JONATHAN ALAN VICTOR;;JONES ERIC DALE;;CHOI NEIL;;VANDEGRAFF NICHOLAS ANDREW,,https://lens.org/197-076-185-936-935,Amended Patent,no,1,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,1,0,,,"TISLER, M. et al. Org. Prep. & Proc. Intl. (1990), Vol. 22, No. 4, pages 532-534",INACTIVE
343,EP,B1,EP 2114903 B1,049-839-948-018-945,2011-01-26,2011,EP 07855368 A,2007-12-21,AU 2007/001980 W;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A,2006-12-22,BICYCLIC PYRIMIDINONES AND USES THEREOF,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/049-839-948-018-945,Granted Patent,yes,2,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,1,0,,,"TISLER M. ET AL.: 'An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines' ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL vol. 22, no. 4, 1990, pages 532 - 534, XP008110052",ACTIVE
344,US,B2,US 8143268 B2,149-858-449-856-521,2012-03-27,2012,US 51927307 A,2007-12-21,AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/001980 W,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.",JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE;;AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VANDEGRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,AVEXA LIMITED (2009-07-21),https://lens.org/149-858-449-856-521,Granted Patent,yes,2,0,34,40,3,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,A01N43/42;;A61K31/44;;C07D475/00,514/282;;544/259.5,4,1,108-111-372-900-578,10.1080/00304949009356320,"Wolff et. al., ""Burger's Medicinal Chemistry and Drug Discovery,"" 5th Ed. Part 1, pp. 975-977 (1995).;;Banker, et. al., Modern Pharmaceuticals, (1996) p. 596.;;Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.;;Tisler, M. et al., ""An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines"", Organic Preparations and Procedures Internationa, (1990), vol. 22, No. 4, pp. 532-534.",INACTIVE
345,AU,B2,AU 2007/336703 B2,151-455-860-163-915,2012-04-12,2012,AU 2007/336703 A,2007-12-21,AU 2006/907283 A;;AU 2007/903401 A;;AU 2007/904114 A;;AU 2007/902479 A;;AU 2007/001980 W;;AU 2007/336703 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.",AVEXA LTD,VANDEGRAFF NICHOLAS ANDREW;;JONES ERIC DALE;;DEADMAN JOHN JOSEPH;;RHODES DAVID IAN;;THIENTHONG NEERANAT;;MACFARLANE KATHERINE;;CHOI NEIL;;COATES JONATHAN ALAN VICTOR;;ISSA WILLIAM;;WINFIELD LISA JANE,,https://lens.org/151-455-860-163-915,Granted Patent,no,1,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,1,0,,,"TISLER, M. et al. Org. Prep. & Proc. Intl. (1990), Vol. 22, No. 4, pages 532-534",INACTIVE
346,AU,A1,AU 2021/409403 A1,024-840-813-047-117,2023-05-25,2023,AU 2021/409403 A,2021-12-21,US 202063128404 P;;US 202163190937 P;;US 2021/0064483 W,2020-12-21,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL;;KARRA SRINIVASA;;VALIULIN ROMAN;;MATHARU DALJIT,,https://lens.org/024-840-813-047-117,Patent Application,no,0,0,8,9,0,C07D498/04;;C07D498/14;;C07D498/04;;C07D498/14;;C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14;;C07D498/04;;C07D498/14,C07D498/04;;A61K31/4353;;A61P41/00;;C07D498/14,,0,0,,,,PENDING
347,AU,A1,AU 2010/201160 A1,156-335-974-882-307,2010-04-15,2010,AU 2010/201160 A,2010-03-24,AU 2007/336703 A;;AU 2010/201160 A;;AU 2007/001980 W;;AU 2007/902479 A;;AU 2007/904114 A;;AU 2007/903401 A;;AU 2006/907283 A,2006-12-22,Bicyclic pyrimidinones and uses thereof,,AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;DEGRAFF NICHOLAS ANDREW VAN;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/156-335-974-882-307,Patent Application,no,0,0,34,40,0,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,C07D239/70;;A61K31/519;;A61P31/12;;A61P31/14;;C07D261/20;;C07D263/52;;C07D275/04;;C07D277/60,,0,0,,,,DISCONTINUED
348,US,A1,US 2021/0405378 A1,037-898-538-602-764,2021-12-30,2021,US 202117474349 A,2021-09-14,US 202117474349 A;;US 2020/0050189 W;;US 201962902721 P,2019-09-19,Optical Systems with Low Resolution Peripheral Displays,"An electronic device may include an optical combiner with a waveguide. The waveguide may have an output coupler that directs high resolution light towards an eye box within a field of view. Peripheral light sources may provide low resolution peripheral light to the eye box about a periphery of the field of view. The peripheral light sources may be mounted to a frame for the waveguide, to an additional substrate mounted to the frame and overlapping the waveguide, in a low resolution projector that projects the peripheral light towards reflective structures in the additional substrate, or in a display module that produces the high resolution light. The optical combiner may overlay real world light with the high resolution light and the low resolution peripheral light.",APPLE INC,CHOI HYUNGRYUL;;STEELE BRADLEY C;;LAU BRIAN S;;HARDER CAMERON A;;KALINOWSKI DAVID A;;HANSOTTE ERIC J;;PENG GUOLIN;;DELAPP SCOTT M;;BHAKTA VIKRANT;;MOISANT-THOMPSON JONATHAN C,,https://lens.org/037-898-538-602-764,Patent Application,yes,0,0,2,2,0,G02B27/0172;;G02B5/32;;G02B6/005;;G02B27/0172;;G02B2027/0174;;G02F1/137;;G03H1/0248,G02B27/01;;F21V8/00;;G02B5/32;;G02F1/137;;G03H1/02,,0,0,,,,PENDING
349,EP,A1,EP 3629901 A1,051-797-501-001-994,2020-04-08,2020,EP 18809483 A,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P;;US 2018/0035738 W,2017-06-02,"EPIDERMAL SENSING SYSTEMS FOR OPTICAL READOUT, VISUALIZATION AND ANALYSIS OF BIOFLUIDS",,UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;REEDER JONATHAN T;;BANDODKAR AMAY J;;KIM SUNGBONG;;SEKINE YURINA;;CHOI JUNGIL;;RAY TYLER R;;HOURLIER-FARGETTE AURELIE;;GUTRUF PHILIPP;;LEE KUN HYUK;;RAJ MILAN,,https://lens.org/051-797-501-001-994,Patent Application,yes,0,1,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/00,,0,0,,,,DISCONTINUED
350,WO,A1,WO 2022/140316 A1,090-301-784-705-74X,2022-06-30,2022,US 2021/0064483 W,2021-12-21,US 202163190937 P;;US 202063128404 P,2020-12-21,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN;;MUGGE INGO;;HU YUAN;;WOODS JAMES;;RAYMER BRIAN;;BENTZIEN JÖRG;;LEHMANN JONATHAN;;HALE MICHAEL;;KARRA SRINIVASA;;VALIULIN ROMAN;;MATHARU DALJIT,,https://lens.org/090-301-784-705-74X,Patent Application,yes,15,3,8,9,0,C07D498/04;;C07D498/14;;C07D498/04;;C07D498/14;;C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14;;C07D498/04;;C07D498/14,C07D498/04;;A61K31/4353;;A61P41/00;;C07D498/14,,24,12,017-939-264-188-49X;;044-928-520-255-205;;019-661-953-949-345;;134-787-395-407-586;;013-795-902-101-18X;;100-598-891-287-142;;118-152-222-665-107;;070-910-884-361-022;;010-870-611-029-091;;021-693-589-840-981;;077-295-491-167-117;;020-282-843-362-629,19406641;;10.1016/j.bmcl.2009.04.026;;10.1016/s0092-8674(00)80949-6;;9491897;;10.1073/pnas.0400590101;;pmc384801;;15070772;;10.1007/s40263-012-0036-8;;23359095;;pmc8762453;;17491094;;10.1093/brain/awm097;;19117547;;pmc2630400;;10.1016/j.cmet.2008.10.010;;14580935;;10.1016/s0306-4522(03)00554-2;;15627867;;10.1159/000081757;;10.1016/s0196-9781(02)00110-9;;12217429;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1002/0471220574;;10.1023/a:1018943613122;;8378254,"COX CHRISTOPHER D ET AL: ""Conformational analysis ofN,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 11, 2009, pages 2997 - 3001, XP029439852, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2009.04.026;;CELL, vol. 92, 1998, pages 573 - 585;;SAPER ET AL., TRENDS IN NEUROSCIENCE, 2001;;YAMANAKA ET AL., NEURON, vol. 38, 2003, pages 715 - 730;;SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014;;MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019;;PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654;;CELL, vol. 98, 1999, pages 437 - 451;;CNS DRUGS, vol. 27, 2013, pages 83 - 90;;BRAIN, vol. 130, 2007, pages 1586 - 1595;;CELL METABOLISM, vol. 9, 2009, pages 64 - 76;;NEUROSCIENCE, vol. 121, 2003, pages 855 - 863;;RESPIRATION, vol. 71, 2004, pages 575 - 579;;PEPTIDES, vol. 23, 2002, pages 1683 - 1688;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;FIESER: ""Fieser's Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;MARCH: ""Organic Chemistry"", 1992, WILEY;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", vol. A, B, 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;;DAVIES B.MORRIS T.: ""Physiological Parameters in Laboratory Animals and Humans"", PHARMARES, vol. 10, no. 7, 1993, pages 1093 - 1095",PENDING
351,EP,A4,EP 3629901 A4,145-955-711-147-480,2021-09-01,2021,EP 18809483 A,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P;;US 2018/0035738 W,2017-06-02,"EPIDERMAL SENSING SYSTEMS FOR OPTICAL READOUT, VISUALIZATION AND ANALYSIS OF BIOFLUIDS",,UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;REEDER JONATHAN T;;BANDODKAR AMAY J;;KIM SUNGBONG;;SEKINE YURINA;;CHOI JUNGIL;;RAY TYLER R;;HOURLIER-FARGETTE AURELIE;;GUTRUF PHILIPP;;RAJ MILAN;;LEE KUN HYUK,,https://lens.org/145-955-711-147-480,Search Report,no,2,0,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/145;;A61B5/00;;A61B10/00;;B01L3/00;;G01N33/543;;G16H40/67,,4,3,005-500-952-231-299;;026-793-234-501-067;;026-793-234-501-067,pmc5429097;;10.1126/scitranslmed.aaf2593;;27881826;;28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355;;28105745;;10.1002/adhm.201770023;;10.1002/adhm.201601355,"AHYEON KOH ET AL: ""A soft, wearable microfluidic device for the capture, storage, and colorimetric sensing of sweat"", SCIENCE TRANSLATIONAL MEDICINE, 23 November 2016 (2016-11-23), United States, pages 366ra165 - 366ra165, XP055521314, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/8/366/366ra165> [retrieved on 20210119], DOI: 10.1126/scitranslmed.aaf2593;;JUNGIL CHOI ET AL: ""Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat"", ADVANCED HEALTHCARE MATERIALS, vol. 6, no. 5, 20 January 2017 (2017-01-20), DE, pages 1601355, XP055561869, ISSN: 2192-2640, DOI: 10.1002/adhm.201601355;;JUNGIL CHOI ET AL: ""Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat"", ADVANCED HEALTHCARE MATERIALS, vol. 6, no. 5, 20 January 2017 (2017-01-20), DE, pages 1601355, XP055766423, ISSN: 2192-2640, DOI: 10.1002/adhm.201601355;;See also references of WO 2018223090A1",DISCONTINUED
352,WO,A1,WO 2018/223090 A1,159-735-479-775-928,2018-12-06,2018,US 2018/0035738 W,2018-06-01,US 201762514374 P;;US 201762514436 P;;US 201762514455 P;;US 201762514468 P;;US 201762514489 P;;US 201762514515 P;;US 201762514520 P;;US 201762514546 P;;US 201762514559 P,2017-06-02,"EPIDERMAL SENSING SYSTEMS FOR OPTICAL READOUT, VISUALIZATION AND ANALYSIS OF BIOFLUIDS","The invention provides a versatile sensing platform for sensing and analysis of biofluids, particularly well-suited for sensing and analysis of sweat. Systems of the invention allows for sensitive and selective detection of a range of analytes in sweat including metabolites, electrolytes and biomarkers. Systems of the invention provide a noninvasive and accurate means for quantitative characterization of important sweat characteristics including sweat volume, sweat loss and sweat rate. Systems of the invention are compatible with materials and device geometries for important class of conformal tissue mounted electronic devices, including epidermal electronic devices.",UNIV NORTHWESTERN;;UNIV ILLINOIS,ROGERS JOHN A;;REEDER JONATHAN T;;BANDODKAR AMAY J;;KIM SUNGBONG;;SEKINE YURINA;;CHOI JUNGIL;;RAY TYLER R;;HOURLIER-FARGETTE AURELIE;;GUTRUF PHILIPP;;LEE KUN HYUK;;RAJ MILAN,,https://lens.org/159-735-479-775-928,Patent Application,yes,6,16,20,33,0,A61B5/14517;;A61B5/6806;;A61B5/7225;;A61B5/0022;;A61B5/0531;;A61B5/14556;;A61B5/150022;;B01L3/502715;;A61B5/1032;;A61B5/14532;;A61B5/1491;;A61B5/1495;;G01N33/5438;;A61B5/01;;A61B5/053;;A61B5/14539;;A61B10/0064;;A61B5/14542;;A61B5/14546;;A61B5/4842;;A61B5/6898;;A61B5/0002;;A61B5/6833;;A61B5/0077;;A61B5/1455;;A61B5/150358;;A61B2562/0214;;A61B5/1486;;B01L2300/0654;;B01L2300/022;;B01L2300/0803;;B01L2200/10;;B01L2300/025;;B01L2400/0406;;B01L2300/0645;;B01L2400/0688;;A61B2560/0214;;A61B2562/0261;;B01L2200/16;;B01L2300/0663;;B01L2300/0864;;B01L2300/126;;B01L2300/16;;A61B2562/028;;B01L2300/123;;A61B2562/125;;A61B2562/164;;B01L2300/0883;;B01L3/502715;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;G01N33/5438;;A61B5/6898;;A61B5/0022;;A61B5/0077;;A61B5/01;;A61B5/0531;;A61B5/1032;;A61B5/14517;;A61B5/14532;;A61B5/14539;;A61B5/14542;;A61B5/14546;;A61B5/14556;;A61B5/1486;;A61B5/1495;;A61B5/7225;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;A61B5/150022;;A61B5/150358;;G16H40/67;;B01L3/502707;;B01L2400/0688;;B01L2300/0816;;B01L2300/069;;B01L2300/0663;;B01L2300/023;;B01L2200/0684;;A61B5/4266;;A61B5/6833;;A61B10/0064;;A61B5/1455;;A61B5/1477;;A61B2562/164;;A61B5/14517;;A61B5/150358;;A61B5/150022;;A61B5/14546;;A61B10/0064;;B01L3/502715;;G01N33/5438;;A61B5/1491;;A61B5/1495;;A61B5/1455;;A61B5/6833;;A61B5/0077;;A61B5/0022;;A61B5/0531;;A61B2010/0006;;A61B2560/0214;;A61B2562/0214;;A61B2562/0261;;A61B2562/125;;B01L2200/10;;B01L2200/16;;B01L2300/022;;B01L2300/0645;;B01L2300/0654;;B01L2300/0803;;B01L2300/0864;;B01L2300/0883;;B01L2300/123;;B01L2300/126;;B01L2300/16;;B01L2400/0406;;A61B5/0002;;A61B5/053;;A61B5/1032;;A61B5/14517;;A61B5/14539;;A61B5/14546;;A61B5/1455;;A61B5/4842;;A61B5/6806;;A61B5/6833;;A61B2562/028;;A61B2562/164;;B01L3/502715;;B01L2300/025;;B01L2300/0663;;B01L2300/0803;;B01L2300/0864;;B01L2300/123;;B01L2400/0406;;B01L2400/0688;;A61B5/0022;;A61B5/01;;A61B5/14532;;A61B5/1477;;A61B5/1486;;A61B5/4266;;A61B2562/0242;;A61B2562/0276,A61B5/00,,1,0,,,See also references of EP 3629901A4,PENDING
353,US,B2,US 8859563 B2,193-666-429-175-437,2014-10-14,2014,US 201213405511 A,2012-02-27,US 201213405511 A;;AU 2006/907283 A;;AU 2007/902479 A;;AU 2007/903401 A;;AU 2007/904114 A;;US 51927309 A;;AU 2007/001980 W,2006-12-22,Bicyclic pyrimidinones and uses thereof,"The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.",JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VAN DE GRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE;;AVEXA LTD,JONES ERIC DALE;;COATES JONATHAN ALAN VICTOR;;RHODES DAVID IAN;;DEADMAN JOHN JOSEPH;;VAN DE GRAFF NICHOLAS ANDREW;;WINFIELD LISA JANE;;THIENTHONG NEERANAT;;ISSA WILLIAM;;CHOI NEIL;;MACFARLANE KATHERINE,,https://lens.org/193-666-429-175-437,Granted Patent,yes,4,0,34,40,3,C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P43/00;;C07D277/60;;C07D275/04;;A61K31/519;;C07D487/04;;C07D498/04;;C07D513/04;;C07D471/04,A01N43/90;;A61K31/519;;C07D239/70;;C07D471/04;;C07D487/04;;C07D498/04;;C07D513/04,514/259.41;;544/282,7,1,108-111-372-900-578,10.1080/00304949009356320,"Wolff et. al., ""Burger's Medicinal Chemistry and Drug Discovery,"" 5th Ed. Part 1, pp. 975-977 (1995).;;Banker, et. al., (1996), Modern Pharmaceuticals, p. 596.;;Tisler, M. et al., ""An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines"", Organic Preparations and Procedures International, (1990), vol. 22, No. 4, pp. 532-534.;;Wolff et al., ""Burger's Medicinal Chemistry and Drug Discovery"", 5th Ed. Part 1, pp. 975-977 (1995).;;Banker, et al., Modern Pharmaceuticals, (1996) p. 596.;;Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. 1X of Preface.;;Office Action which issued on Sep. 11, 2012 in the corresponding Japanese application No. 2009-541695.",INACTIVE
354,CA,A1,CA 3219490 A1,072-976-849-191-325,2022-12-01,2022,CA 3219490 A,2022-05-25,US 202163193256 P;;US 2022/0030841 W,2021-05-26,SUBSTITUTED CARBAMATE MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R,,https://lens.org/072-976-849-191-325,Patent Application,no,0,0,4,4,0,A61P21/00;;A61P43/00;;C07D498/04,C07D498/04,,0,0,,,,PENDING
355,CA,A1,CA 3219506 A1,099-328-176-554-770,2022-12-01,2022,CA 3219506 A,2022-05-25,US 202163193243 P;;US 2022/0030839 W,2021-05-26,SUBSTITUTED FUSED BICYCLIC MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful as orexin-2 receptor agonists for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HUYNH HOAN;;PENNINGTON LEWIS D;;CHOI YOUNGGI;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R,,https://lens.org/099-328-176-554-770,Patent Application,no,0,0,3,3,0,C07D498/18;;C07D498/08;;A61P43/00,C07D498/08;;C07D498/18,,0,0,,,,PENDING
356,WO,A1,WO 2021/055651 A1,004-728-092-076-245,2021-03-25,2021,US 2020/0051341 W,2020-09-18,US 201962902218 P,2019-09-18,EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS,"Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/004-728-092-076-245,Patent Application,yes,20,3,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,12,12,046-466-265-915-788;;007-941-550-134-396;;056-927-238-058-233;;077-944-718-939-984;;079-710-480-414-539;;068-891-744-027-96X;;009-089-404-005-299;;010-033-916-647-466;;096-027-466-267-27X;;033-755-023-720-012;;035-033-630-366-420;;032-966-633-823-653,31318208;;10.1021/acs.jmedchem.9b00444.s001;;10.1021/acs.jmedchem.9b00444.s002;;10.1021/acs.jmedchem.9b00444;;19040386;;10.1021/mp8000793;;31341059;;10.1126/scitranslmed.aaw1736;;21606247;;10.4049/jimmunol.1003244;;pmc3377589;;10.1371/journal.pone.0039141;;22723949;;17088085;;10.1016/j.immuni.2006.09.009;;10.3410/f.1053726.505648;;10.4049/jimmunol.0902740;;19917699;;10.1093/brain/awr010;;21354972;;22482804;;pmc3322238;;10.1016/j.ajhg.2012.02.020;;10.1093/rheumatology/kel449;;17384181;;23143596;;10.1038/ng.2462;;pmc3605761;;10.1023/a:1011910801212;;9619777,"STEPHEN T. WROBLESKI ET AL: ""Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165"", JOURNAL OF MEDICINAL CHEMISTRY, 18 July 2019 (2019-07-18), XP055629848, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00444;;DWAYNE T. FRIESEN ET AL: ""Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview"", MOLECULAR PHARMACEUTICS, vol. 5, no. 6, 1 December 2008 (2008-12-01), pages 1003 - 1019, XP055056966, ISSN: 1543-8384, DOI: 10.1021/mp8000793;;JAMES R. BURKE ET AL: ""Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain"", SCIENCE TRANSLATIONAL MEDICINE, vol. 11, no. 502, 24 July 2019 (2019-07-24), US, pages eaaw1736, XP055682305, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaw1736;;ISHIZAKI, M. ET AL.: ""Involvement of tyrosine kinase-2 in both the IL-12/Thl and IL-23/Thl7 axes in vivo"", J. IMMUNOL., vol. 187, 2011, pages 181 - 189;;PRCHAL-MURPHY, M. ET AL.: ""TYK2 kinase activity is required for functional type I interferon responses in vivo"", PLOS ONE, vol. 7, 2012, pages e39141;;MINEGISHI, Y. ET AL.: ""Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity"", IMMUNITY, vol. 25, 2006, pages 745 - 755, XP055573304, DOI: 10.1016/j.immuni.2006.09.009;;OYAMADA, A. ET AL.: ""Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis"", J. IMMUNOL., vol. 183, 2009, pages 7539 - 7546;;COUTURIER, N. ET AL.: ""Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility"", BRAIN, vol. 134, 2011, pages 693 - 703;;ELLINGHAUS, D. ET AL.: ""Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci"", AM. J. HUM. GENET., vol. 90, 2012, pages 636 - 647;;GRAHAM, D. ET AL.: ""Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families"", RHEUMATOLOGY (OXFORD, vol. 46, 2007, pages 927 - 930;;EYRE, S. ET AL.: ""High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis"", NAT. GENET., vol. 44, 2012, pages 1336 - 1340;;GALIA ET AL.: ""Evaluation of Various Dissolution Media for Predicting in vivo Performance of Class I and II Drugs"", PHARM RES., vol. 15, 1998, pages 698 - 705",PENDING
357,AU,A1,AU 2020/348783 A1,102-700-063-614-524,2022-03-31,2022,AU 2020/348783 A,2020-09-18,US 201962902218 P;;US 2020/0051341 W,2019-09-18,Extended release dosage forms for Tyk2 inhibitors,"Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/102-700-063-614-524,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
358,WO,A1,WO 2021/055652 A1,029-466-911-467-11X,2021-03-25,2021,US 2020/0051342 W,2020-09-18,US 201962902218 P,2019-09-18,DOSAGE FORMS FOR TYK2 INHIBITORS,"Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy- 3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3- carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/029-466-911-467-11X,Patent Application,yes,19,6,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,12,12,046-466-265-915-788;;007-941-550-134-396;;056-927-238-058-233;;077-944-718-939-984;;079-710-480-414-539;;068-891-744-027-96X;;009-089-404-005-299;;010-033-916-647-466;;096-027-466-267-27X;;033-755-023-720-012;;035-033-630-366-420;;032-966-633-823-653,31318208;;10.1021/acs.jmedchem.9b00444.s001;;10.1021/acs.jmedchem.9b00444.s002;;10.1021/acs.jmedchem.9b00444;;19040386;;10.1021/mp8000793;;31341059;;10.1126/scitranslmed.aaw1736;;21606247;;10.4049/jimmunol.1003244;;pmc3377589;;10.1371/journal.pone.0039141;;22723949;;17088085;;10.1016/j.immuni.2006.09.009;;10.3410/f.1053726.505648;;10.4049/jimmunol.0902740;;19917699;;10.1093/brain/awr010;;21354972;;22482804;;pmc3322238;;10.1016/j.ajhg.2012.02.020;;10.1093/rheumatology/kel449;;17384181;;23143596;;10.1038/ng.2462;;pmc3605761;;10.1023/a:1011910801212;;9619777,"STEPHEN T. WROBLESKI ET AL: ""Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165"", JOURNAL OF MEDICINAL CHEMISTRY, 18 July 2019 (2019-07-18), XP055629848, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00444;;DWAYNE T. FRIESEN ET AL: ""Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview"", MOLECULAR PHARMACEUTICS, vol. 5, no. 6, 1 December 2008 (2008-12-01), pages 1003 - 1019, XP055056966, ISSN: 1543-8384, DOI: 10.1021/mp8000793;;JAMES R. BURKE ET AL: ""Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain"", SCIENCE TRANSLATIONAL MEDICINE, vol. 11, no. 502, 24 July 2019 (2019-07-24), US, pages eaaw1736, XP055682305, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaw1736;;ISHIZAKI, M. ET AL.: ""Involvement of tyrosine kinase-2 in both the IL-12/Thl and IL-23/Thl7 axes in vivo"", J. IMMUNOL., vol. 187, 2011, pages 181 - 189;;PRCHAL-MURPHY, M. ET AL.: ""TYK2 kinase activity is required for functional type I interferon responses in vivo"", PLOS ONE, vol. 7, 2012, pages e39141;;MINEGISHI, Y. ET AL.: ""Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity"", IMMUNITY, vol. 25, 2006, pages 745 - 755, XP055573304, DOI: 10.1016/j.immuni.2006.09.009;;OYAMADA, A. ET AL.: ""Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis"", J. IMMUNOL., vol. 183, 2009, pages 7539 - 7546;;COUTURIER, N. ET AL.: ""Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility"", BRAIN, vol. 134, 2011, pages 693 - 703;;ELLINGHAUS, D. ET AL.: ""Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci"", AM. J. HUM. GENET., vol. 90, 2012, pages 636 - 647;;GRAHAM, D. ET AL.: ""Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families"", RHEUMATOLOGY (OXFORD, vol. 46, 2007, pages 927 - 930;;EYRE, S. ET AL.: ""High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis"", NAT. GENET., vol. 44, 2012, pages 1336 - 1340;;GALIA ET AL.: ""Evaluation of Various Dissolution Media for Predicting in vivo Performance of Class I and II Drugs"", PHARM RES., vol. 15, 1998, pages 698 - 705",PENDING
359,AU,A1,AU 2020/349524 A1,121-197-258-327-115,2022-03-31,2022,AU 2020/349524 A,2020-09-18,US 201962902218 P;;US 2020/0051342 W,2019-09-18,Dosage forms for Tyk2 inhibitors,"Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy- 3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3- carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/121-197-258-327-115,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
360,EP,A1,EP 4031109 A1,127-549-655-355-843,2022-07-27,2022,EP 20781718 A,2020-09-18,US 201962902218 P;;US 2020/0051341 W,2019-09-18,EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS,,BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/127-549-655-355-843,Patent Application,yes,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
361,EP,A1,EP 4031110 A1,162-747-775-353-97X,2022-07-27,2022,EP 20781719 A,2020-09-18,US 201962902218 P;;US 2020/0051342 W,2019-09-18,DOSAGE FORMS FOR TYK2 INHIBITORS,,BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/162-747-775-353-97X,Patent Application,yes,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
362,MX,A,MX 2022003146 A,013-102-963-746-112,2022-04-06,2022,MX 2022003146 A,2020-09-18,US 201962902218 P;;US 2020/0051341 W,2019-09-18,EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS.,"Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazo l-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,YATES IAN;;BLOOM COREY;;BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A,,https://lens.org/013-102-963-746-112,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
363,MX,A,MX 2022003150 A,082-046-957-526-390,2022-04-06,2022,MX 2022003150 A,2020-09-18,US 201962902218 P;;US 2020/0051342 W,2019-09-18,DOSAGE FORMS FOR TYK2 INHIBITORS.,"Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy- 3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)py ridazine-3- carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,YATES IAN;;BLOOM COREY;;BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A,,https://lens.org/082-046-957-526-390,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
364,CA,A1,CA 3151137 A1,125-740-737-161-842,2021-03-25,2021,CA 3151137 A,2020-09-18,US 201962902218 P;;US 2020/0051342 W,2019-09-18,DOSAGE FORMS FOR TYK2 INHIBITORS,"Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy- 3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3- carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/125-740-737-161-842,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
365,US,A1,US 2022/0331315 A1,089-355-708-883-972,2022-10-20,2022,US 202017639481 A,2020-09-18,US 202017639481 A;;US 201962902218 P;;US 2020/0051342 W,2019-09-18,DOSAGE FORMS FOR TYK2 INHIBITORS,"Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES LAN,BRISTOL-MYERS SQUIBB COMPANY (2021-01-11);;BEND RESEARCH INC (2022-06-28),https://lens.org/089-355-708-883-972,Patent Application,yes,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K31/501;;A61K9/00;;A61K9/20;;A61K9/28;;A61K45/06,,0,0,,,,PENDING
366,IL,A,IL 291453 A,015-438-709-814-265,2022-05-01,2022,IL 29145322 A,2022-03-16,US 201962902218 P;;US 2020/0051341 W,2019-09-18,Dosage forms for tyk2 inhibitors,,BRISTOL MYERS SQUIBB CO;;BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/015-438-709-814-265,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,,,0,0,,,,PENDING
367,KR,A,KR 20220066105 A,039-784-105-833-222,2022-05-23,2022,KR 20227012287 A,2020-09-18,US 201962902218 P;;US 2020/0051341 W,2019-09-18,TYK2 억제제를 위한 연장 방출 투여 형태,"고체 중합체 매트릭스 중 고체 무정형 6-(시클로프로판아미도)-4-((2-메톡시-3-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)아미노)-N-(메틸-d3)피리다진-3-카르복스아미드 (화학식 (I); BMS-986165)의 분산물 (예를 들어, 분무-건조 분산물)을 포함하는 안정하고 생체이용가능한 연장 방출 제제 및 투여 형태가 자가면역 질환 및 자가염증성 질환, 예컨대 염증성 장 질환 (IBD) 및 건선의 치료를 위해 제공된다. JPEGpct00020.jpg4736",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/039-784-105-833-222,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/16;;A61K9/00;;A61K9/20;;A61K31/501;;A61P1/00;;A61P29/00;;A61P37/06,,0,0,,,,PENDING
368,KR,A,KR 20220066310 A,149-012-891-704-687,2022-05-24,2022,KR 20227012286 A,2020-09-18,US 201962902218 P;;US 2020/0051342 W,2019-09-18,TYK2 억제제를 위한 투여 형태,"고체 중합체 매트릭스 중 고체 무정형 6-(시클로프로판아미도)-4-((2-메톡시-3-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)아미노)-N-(메틸-d3)피리다진-3-카르복스아미드 (화학식 (I); BMS-986165)의 분산물 (예를 들어, 분무-건조 분산물)을 포함하는 안정하고 생체이용가능한 제제 및 투여 형태가 자가면역 질환 및 자가염증성 질환, 예컨대 염증성 장 질환 (IBD) 및 건선의 치료를 위해 제공된다. TIFFpct00020.tif2532",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/149-012-891-704-687,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/14;;A61K9/00;;A61K9/20;;A61K31/501;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38;;A61P1/00;;A61P29/00;;A61P37/06,,0,0,,,,PENDING
369,CA,A1,CA 3151369 A1,001-647-519-071-23X,2021-03-25,2021,CA 3151369 A,2020-09-18,US 201962902218 P;;US 2020/0051341 W,2019-09-18,EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS,"Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/001-647-519-071-23X,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
370,BR,A2,BR 112022004216 A2,132-039-708-793-11X,2022-05-31,2022,BR 112022004216 A,2020-09-18,US 2020/0051341 W;;US 201962902218 P,2019-09-18,Formas de dosagem de liberação prolongada para inibidores de tyk2,"formas de dosagem de liberação prolongada para inibidores de tyk2. a presente invenção refere-se a formulações de liberação prolongada e formas de dosagem estáveis e biodisponíveis que compreendem uma dispersão (por exemplo, dispersão seca por pulverização) de 6-(ciclopropanamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3-carboxamida amorfa sólida (fórmula (i); bms-986165) em uma matriz polimérica sólida para o tratamento de doenças autoimunes e doenças autoinflamatórias, tais como doença inflamatória intestinal (ibd) e psoríase.",BRISTOL MYERS SQUIBB CO,BALVINDER S VIG;;CANDICE Y CHOI;;GESENBERG CHRISTOPH;;CHRISTOPHER A ZORDAN;;BLOOM COREY;;YATES IAN;;JOHN WYNNE JONES;;JONATHAN R BROWN;;SHERIF IBRAHIM FARAG BADAWY;;KESTUR UMESH;;GRAY VIVIENNE;;XIAOTIAN S YIN,,https://lens.org/132-039-708-793-11X,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
371,US,B1,US 11762490 B1,058-691-743-040-549,2023-09-19,2023,US 202117407702 A,2021-08-20,US 202117407702 A;;US 202063076762 P,2020-09-10,Electronic device displays with visibly matched borders,"An electronic device may have a display with an active area configured to display images and an inactive area that is free of pixels and that does not display images. Touch sensor sense lines may have portions located in the active area and portions located in the inactive area. The active and inactive areas may be characterized by respective reflectivity values. To match the reflectivities of the active and inactive areas and thereby avoid undesired visually distinguishable differences in the appearances of these areas, the touch sensor circuitry in the inactive areas may be configured to match the reflectivity values of the active and inactive areas. Sense line portions in the inactive area may have metal traces of enhanced reflectivity and/or uneven surface topology to enhance ambient light reflections through a circular polarizer that overlaps the active and inactive areas.",APPLE INC,KIM KYOUNGHWAN;;JAMSHIDI ROUDBARI ABBAS;;CHEN CHIA-HSIANG;;LEE CHIEN-YA;;CHUANG CHING-SANG;;CHOI JAE WON;;BECK JONATHAN H;;TAI MING E;;RIEUTORT-LOUIS WARREN S;;HSIEH WEN-I;;CHE YUCHI,APPLE INC (2021-08-12),https://lens.org/058-691-743-040-549,Granted Patent,yes,14,0,1,1,0,G06F3/0412;;G06F3/044;;H10K59/40;;H10K59/8791;;G06F3/0412;;G06F3/044;;H10K59/40;;H10K59/50,G06F3/044;;G06F3/041;;H10K59/40;;H10K59/50,,0,0,,,,ACTIVE
372,IL,A,IL 291452 A,190-829-578-270-037,2022-05-01,2022,IL 29145222 A,2022-03-16,US 201962902218 P;;US 2020/0051342 W,2019-09-18,Dosage forms for tyk2 inhibitors,,BRISTOL MYERS SQUIBB CO;;BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GRAY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,,https://lens.org/190-829-578-270-037,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,,,0,0,,,,PENDING
373,BR,A2,BR 112022004550 A2,125-552-261-638-79X,2022-05-31,2022,BR 112022004550 A,2020-09-18,US 2020/0051342 W;;US 201962902218 P,2019-09-18,Formas de dosagem para inibidores de tyk2,"formas de dosagem para inibidores de tyk2. a presente invenção refere-se a formulações e formas de dosagem estáveis e biodisponíveis que compreendem uma dispersão (por exemplo, dispersão seca por pulverização) de 6-(ciclopropanamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3-carboxamida amorfa sólida (fórmula (i); bms-986165) em uma matriz polimérica sólida para o tratamento de doenças autoimunes e doenças autoinflamatórias, tais como doença inflamatória intestinal (ibd) e psoríase: fórmula (i)",BRISTOL MYERS SQUIBB CO,BALVINDER S VIG;;CANDICE Y CHOI;;GESENBERG CHRISTOPH;;CHRISTOPHER A ZORDAN;;BLOOM COREY;;YATES IAN;;JOHN WYNNE JONES;;JONATHAN R BROWN;;SHERIF IBRAHIM FARAG BADAWY;;KESTUR UMESH;;GRAY VIVIENNE;;XIAOTIAN S YIN,,https://lens.org/125-552-261-638-79X,Patent Application,no,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K47/02;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,PENDING
374,US,A1,US 2023/0255964 A1,098-511-569-344-319,2023-08-17,2023,US 202017639489 A,2020-09-18,US 202017639489 A;;US 201962902218 P;;US 2020/0051341 W,2019-09-18,EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS,"Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyrid azine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.",BRISTOL MYERS SQUIBB CO,BADAWY SHERIF IBRAHIM FARAG;;BROWN JONATHAN R;;CHOI CANDICE Y;;GESENBERG CHRISTOPH;;GARY VIVIENNE;;JONES JOHN WYNNE;;KESTUR UMESH;;VIG BALVINDER S;;YIN XIAOTIAN S;;ZORDAN CHRISTOPHER A;;BLOOM COREY;;YATES IAN,BRISTOL-MYERS SQUIBB COMPANY (2022-04-29);;BEND RESEARCH INC (2022-04-26),https://lens.org/098-511-569-344-319,Patent Application,yes,0,0,22,22,0,A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K9/146;;A61K47/38;;A61K47/02;;A61K47/12;;A61K47/26;;A61K31/501;;A61P29/00;;A61P37/06;;Y02A50/30;;A61K9/1652;;A61K9/1694;;A61K9/0053;;A61K47/02;;A61K9/146;;A61P37/06;;A61K47/26;;A61K31/501;;A61K47/38;;A61P29/00;;A61K47/12;;A61K9/1652;;A61K9/2054;;A61K9/0053;;A61K31/501;;A61P37/06;;A61P29/00;;A61P1/00;;A61K9/146;;A61K47/38;;A61K47/26;;A61K47/12;;A61K47/02;;A61K9/0053;;A61K9/2009;;A61K9/2054;;A61K9/284;;A61K31/501;;A61K45/06;;A61K9/2013;;A61K9/2018,A61K31/501;;A61K9/20,,0,0,,,,PENDING
375,EP,A1,EP 4329877 A1,195-730-297-168-783,2024-03-06,2024,EP 22724964 A,2022-04-25,US 202163179616 P;;US 2022/0026144 W,2021-04-26,SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY,,ALKERMES INC,CHOI YOUNGGI;;HU YUAN;;HUYNH HOAN;;AQUILA BRIAN M;;RAYMER BRIAN KENNETH;;MUGGE INGO ANDREAS;;WOODS JAMES R;;PENNINGTON LEWIS D;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R;;VALIULIN ROMAN A,,https://lens.org/195-730-297-168-783,Patent Application,yes,0,0,5,5,0,C07D498/04;;C07D498/14;;A61P25/00,A61P25/00;;A61K31/4353;;C07D498/04;;C07D498/14,,0,0,,,,PENDING
376,CA,A1,CA 3215210 A1,157-705-802-785-342,2022-11-03,2022,CA 3215210 A,2022-04-25,US 202163179616 P;;US 2022/0026144 W,2021-04-26,SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY,The present invention provides compounds of formula (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,CHOI YOUNGGI;;HU YUAN;;HUYNH HOAN;;AQUILA BRIAN M;;RAYMER BRIAN KENNETH;;MUGGE INGO ANDREAS;;WOODS JAMES R;;PENNINGTON LEWIS D;;BENTZIEN JORG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R;;VALIULIN ROMAN A,,https://lens.org/157-705-802-785-342,Patent Application,no,0,0,5,5,0,C07D498/04;;C07D498/14;;A61P25/00,C07D498/04;;C07D498/14,,0,0,,,,PENDING
377,US,B2,US 11760747 B2,159-214-533-313-115,2023-09-19,2023,US 202117556295 A,2021-12-20,US 202117556295 A;;US 202063128511 P,2020-12-21,Substituted piperidino compounds and related methods of treatment,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,ALKERMES INC (2022-09-06),https://lens.org/159-214-533-313-115,Granted Patent,yes,60,0,8,8,0,C07D401/04;;C07D498/04;;C07D487/04;;C07D471/04;;C07D401/06;;C07D211/58;;C07D401/14;;A61P25/26;;A61P25/26;;C07D211/98;;C07D401/04;;C07D401/14;;C07D471/04;;C07D487/04,C07D401/14;;A61P25/26;;C07D211/98;;C07D401/04;;C07D471/04;;C07D487/04,,7,7,017-939-264-188-49X;;010-340-944-245-27X;;011-727-607-829-023;;021-693-589-840-981;;116-403-826-254-123;;155-646-431-415-552;;016-275-586-497-951,19406641;;10.1016/j.bmcl.2009.04.026;;10.1073/pnas.1700499114;;pmc5465922;;28507129;;pmc3927067;;24488306;;10.1007/s10822-014-9710-x;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1021/acsmedchemlett.0c00501;;pmc7667653;;33214817;;pmc5456073;;28575023;;10.1371/journal.pone.0178526;;31654653;;10.1016/j.pbb.2019.172794,"Cox, C. D. et al., “Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding”, Bioorganic & Medicinal Chemistry Letters, 19, DOI:10. 1016/J.BMCL.2009. 04.026, 2009, 2997-3001.;;Irukayama-Tomobe, Y. et al., “Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models”, PNAS, vol. 114, No. 22, May 30, 2017, 5731-5736.;;McGaughey, G. et al., “Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs”, J. Comput. Aided Mol. Des., 28, 2014, 5-12.;;Nagahara, T. et al., “Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists”, J. Med. Chem., 58, 2015, 7931-7937.;;Sabnis, R. W., “Novel 5-Alkyl Pyrrolidine Orexin Receptor Agonists for Treating Sleep Disorders”, ACS Med. Chem. Lett., vol. 11, 11 (online at https://dx.doi.org/10.1021/acsmedchemlett.0c00501), Sep. 29, 2020, 2085-2086.;;Turku, A. et al., “Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity”, PLOS One, 12(6): e0178526 (online at doi:10.1371/journal.pone.0178526), Jun. 2, 2017, 1-15.;;Yukitake, H. et al., “TAK-925, an orexin 2 receptor-selective agonist, shows robust wakepromoting effects in mice”, Pharmacology, Biochemistry and Behavior, 187, 2019, 172794.",ACTIVE
378,CA,A1,CA 3172862 A1,013-361-772-857-633,2022-06-30,2022,CA 3172862 A,2021-12-21,US 202063128511 P;;US 2021/0064484 W,2020-12-21,SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;LEHMANN JONATHAN WARD;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,,https://lens.org/013-361-772-857-633,Patent Application,no,0,0,8,8,0,C07D401/04;;C07D498/04;;C07D487/04;;C07D471/04;;C07D401/06;;C07D211/58;;C07D401/14;;A61P25/26;;A61P25/26;;C07D211/98;;C07D401/04;;C07D401/14;;C07D471/04;;C07D487/04,C07D211/58;;A61K31/4545;;A61P25/26;;C07D401/04;;C07D401/06;;C07D401/14;;C07D471/04;;C07D487/04;;C07D498/04,,0,0,,,,PENDING
379,EP,A1,EP 4263506 A1,119-053-724-111-836,2023-10-25,2023,EP 21854780 A,2021-12-21,US 202063128511 P;;US 2021/0064484 W,2020-12-21,SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT,,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,,https://lens.org/119-053-724-111-836,Patent Application,yes,0,0,8,8,0,C07D401/04;;C07D498/04;;C07D487/04;;C07D471/04;;C07D401/06;;C07D211/58;;C07D401/14;;A61P25/26;;A61P25/26;;C07D211/98;;C07D401/04;;C07D401/14;;C07D471/04;;C07D487/04,C07D211/58;;A61K31/4545;;A61P25/26;;C07D401/04;;C07D401/06;;C07D401/14;;C07D471/04;;C07D487/04;;C07D498/04,,0,0,,,,PENDING
380,US,A1,US 2022/0064316 A1,146-136-923-627-15X,2022-03-03,2022,US 202117359211 A,2021-06-25,US 202117359211 A;;CN 2014082586 W;;CN 2014090501 W;;US 201816197565 A;;US 201514805193 A,2014-07-21,TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR,"The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.",UNIV PENNSYLVANIA;;NOVARTIS AG,BROGDON JENNIFER;;CHOI EUGENE;;EBERSBACH HILMAR ERHARD;;GLASS DAVID JONATHAN;;HUET HEATHER;;JUNE CARL H;;MANNICK JOAN;;MILONE MICHAEL C;;MURPHY LEON;;PLESA GABRIELA;;RICHARDSON CELESTE;;RUELLA MARCO;;SINGH RESHMA;;WANG YONGQIANG;;WU QILONG,CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (2015-07-16);;THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (2015-07-20);;NOVARTIS AG (2015-07-15);;NOVARTIS PHARMA AG (2015-07-14);;NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC (2015-07-14),https://lens.org/146-136-923-627-15X,Patent Application,yes,0,11,33,34,1117,A61K35/17;;C07K16/2878;;C12N5/0636;;C12N5/0646;;A61K38/00;;A61K48/00;;C07K2319/00;;C07K2317/92;;C07K2317/565;;C07K2317/622;;C07K2317/24;;C07K2319/30;;C07K16/2878;;C07K2317/24;;C07K2317/622;;C07K2317/92;;C07K2319/00;;A61K38/177;;C07K2317/565;;C07K2319/30;;A61P35/00;;C07H21/04;;A61P35/02;;A61K35/12;;A61K35/17;;A61K38/00;;A61K38/177;;A61K39/395;;A61K48/00;;A61P35/00;;A61P35/02;;C07H21/04;;C07K14/705;;C07K14/7151;;C07K16/28;;C07K16/2878;;C07K19/00;;C07K2317/24;;C07K2317/565;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/30;;C12N5/00;;C12N5/0636;;C12N5/0646;;C12N15/63;;C07K14/705;;C07K16/2878;;A61K35/17;;A61K38/177;;C07K2317/24;;C07K2317/565;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K35/17;;A61K38/177;;A61P35/00;;A61P35/02;;C07K16/2878;;C12N15/63;;A61K35/12;;A61K38/177;;C07K14/705;;C07K2317/565;;C07K2319/30;;C07K16/28;;C07K14/7151;;A61K39/395;;A61P35/00;;C07K19/00;;C07H21/04;;C12N15/63;;C12N5/00;;C07K16/2878;;C07K2317/24;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/03;;C07K2319/33;;C07K2319/70;;C07K14/7051;;A61K39/3955;;A61K39/39558;;C07K14/70578;;C07K2319/74;;A61K39/4611,C07K16/28;;A61K35/12;;A61K38/17;;A61K39/395;;A61P35/00;;C07H21/04;;C07K14/705;;C07K14/715;;C07K14/725;;C07K19/00;;C12N5/00;;C12N15/63,,2,2,055-760-610-523-763;;004-792-488-008-093,21536144;;10.1016/j.bbmt.2011.03.011;;23692500;;10.1517/14712598.2013.799132,"Hallett et al (2011. Biol Blood Marrow Transplant. 17: 1133-1145).;;Gentile et al, 2013. Expert Opinion on Biological Therapy. 13:sup1, S1-22.",PENDING
381,US,A1,US 2019/0153061 A1,015-986-637-385-98X,2019-05-23,2019,US 201816197565 A,2018-11-21,US 201816197565 A;;CN 2014082586 W;;CN 2014090501 W;;US 201514805193 A,2014-07-21,TREATMENT OF CANCER USING 5 HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR,"The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.",NOVARTIS AG;;UNIV PENNSYLVANIA,BROGDON JENNIFER;;CHOI EUGENE;;EBERSBACH HILMAR ERHARD;;GLASS DAVID JONATHAN;;HUET HEATHER;;JUNE CARL H;;MANNICK JOAN;;MILONE MICHAEL C;;MURPHY LEON;;PLESA GABRIELA;;RICHARDSON CELESTE;;RUELLA MARCO;;SINGH RESHMA;;WANG YONGQIANG;;WU QILONG,CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (2015-07-16);;THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (2015-07-20);;NOVARTIS AG (2015-07-15);;NOVARTIS PHARMA AG (2015-07-14);;NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC (2015-07-14),https://lens.org/015-986-637-385-98X,Patent Application,yes,0,30,33,34,1117,A61K35/17;;C07K16/2878;;C12N5/0636;;C12N5/0646;;A61K38/00;;A61K48/00;;C07K2319/00;;C07K2317/92;;C07K2317/565;;C07K2317/622;;C07K2317/24;;C07K2319/30;;C07K16/2878;;C07K2317/24;;C07K2317/622;;C07K2317/92;;C07K2319/00;;A61K38/177;;C07K2317/565;;C07K2319/30;;A61P35/00;;C07H21/04;;A61P35/02;;A61K35/12;;A61K35/17;;A61K38/00;;A61K38/177;;A61K39/395;;A61K48/00;;A61P35/00;;A61P35/02;;C07H21/04;;C07K14/705;;C07K14/7151;;C07K16/28;;C07K16/2878;;C07K19/00;;C07K2317/24;;C07K2317/565;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/30;;C12N5/00;;C12N5/0636;;C12N5/0646;;C12N15/63;;C07K14/705;;C07K16/2878;;A61K35/17;;A61K38/177;;C07K2317/24;;C07K2317/565;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K35/17;;A61K38/177;;A61P35/00;;A61P35/02;;C07K16/2878;;C12N15/63;;A61K35/12;;A61K38/177;;C07K14/705;;C07K2317/565;;C07K2319/30;;C07K16/28;;C07K14/7151;;A61K39/395;;A61P35/00;;C07K19/00;;C07H21/04;;C12N15/63;;C12N5/00;;C07K16/2878;;C07K2317/24;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/03;;C07K2319/33;;C07K2319/70;;C07K14/7051;;A61K39/3955;;A61K39/39558;;C07K14/70578;;C07K2319/74;;A61K39/4611,C07K14/705;;A61K35/12;;A61K38/17;;C07H21/04;;C07K16/28;;C12N5/00;;C12N15/63,,0,0,,,,ACTIVE
382,US,B2,US 11084880 B2,182-376-822-085-169,2021-08-10,2021,US 201816197565 A,2018-11-21,US 201816197565 A;;CN 2014082586 W;;CN 2014090501 W;;US 201514805193 A,2014-07-21,Anti-BCMA chimeric antigen receptor,"The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.",NOVARTIS AG;;UNIV PENNSYLVANIA,BROGDON JENNIFER;;CHOI EUGENE;;EBERSBACH HILMAR ERHARD;;GLASS DAVID JONATHAN;;HUET HEATHER;;JUNE CARL H;;MANNICK JOAN;;MILONE MICHAEL C;;MURPHY LEON;;PLESA GABRIELA;;RICHARDSON CELESTE;;RUELLA MARCO;;SINGH RESHMA;;WANG YONGQIANG;;WU QILONG,CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (2015-07-16);;THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (2015-07-20);;NOVARTIS AG (2015-07-15);;NOVARTIS PHARMA AG (2015-07-14);;NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC (2015-07-14),https://lens.org/182-376-822-085-169,Granted Patent,yes,290,3,33,34,1117,A61K35/17;;C07K16/2878;;C12N5/0636;;C12N5/0646;;A61K38/00;;A61K48/00;;C07K2319/00;;C07K2317/92;;C07K2317/565;;C07K2317/622;;C07K2317/24;;C07K2319/30;;C07K16/2878;;C07K2317/24;;C07K2317/622;;C07K2317/92;;C07K2319/00;;A61K38/177;;C07K2317/565;;C07K2319/30;;A61P35/00;;C07H21/04;;A61P35/02;;A61K35/12;;A61K35/17;;A61K38/00;;A61K38/177;;A61K39/395;;A61K48/00;;A61P35/00;;A61P35/02;;C07H21/04;;C07K14/705;;C07K14/7151;;C07K16/28;;C07K16/2878;;C07K19/00;;C07K2317/24;;C07K2317/565;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/30;;C12N5/00;;C12N5/0636;;C12N5/0646;;C12N15/63;;C07K14/705;;C07K16/2878;;A61K35/17;;A61K38/177;;C07K2317/24;;C07K2317/565;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K35/17;;A61K38/177;;A61P35/00;;A61P35/02;;C07K16/2878;;C12N15/63;;A61K35/12;;A61K38/177;;C07K14/705;;C07K2317/565;;C07K2319/30;;C07K16/28;;C07K14/7151;;A61K39/395;;A61P35/00;;C07K19/00;;C07H21/04;;C12N15/63;;C12N5/00;;C07K16/2878;;C07K2317/24;;C07K2317/622;;C07K2317/92;;C07K2319/00;;C07K2319/03;;C07K2319/33;;C07K2319/70;;C07K14/7051;;A61K39/3955;;A61K39/39558;;C07K14/70578;;C07K2319/74;;A61K39/4611,C07K16/28;;A61K35/12;;A61K38/17;;A61K39/395;;A61P35/00;;C07H21/04;;C07K14/705;;C07K14/715;;C07K14/725;;C07K19/00;;C12N5/00;;C12N15/63,,236,186,048-283-566-683-846;;002-245-824-815-236;;039-029-464-216-059;;066-435-526-223-848;;077-787-635-414-633;;025-654-757-581-979;;035-689-052-241-408;;010-533-182-167-404;;073-212-088-312-095;;012-542-224-772-678;;030-711-289-533-595;;096-586-457-956-090;;184-406-953-355-699;;003-965-481-653-512;;062-915-083-335-003;;050-318-511-556-953;;051-174-930-383-301;;048-175-875-309-69X;;090-821-708-772-253;;053-160-570-826-935;;022-282-817-336-139;;022-282-817-336-139;;045-942-104-775-903;;045-942-104-775-903;;085-846-216-284-034;;001-779-867-387-972;;017-256-533-407-038;;102-224-103-044-817;;036-380-686-892-617;;121-701-943-413-038;;026-589-266-128-73X;;036-720-513-195-600;;016-203-996-044-020;;023-271-586-851-637;;123-609-509-566-243;;025-740-247-660-539;;093-835-278-608-168;;099-197-016-916-712;;006-770-570-942-243;;016-166-700-584-053;;016-166-700-584-053;;012-803-875-488-163;;012-803-875-488-163;;024-098-633-679-295;;100-041-294-232-313;;105-909-731-422-410;;023-443-551-777-383;;042-944-720-996-072;;062-068-291-977-903;;007-179-877-992-008;;029-088-425-868-932;;045-755-719-196-525;;053-783-298-552-453;;023-629-183-831-408;;014-111-125-220-702;;010-901-227-513-259;;030-011-261-747-674;;034-333-036-615-808;;088-156-513-960-044;;009-167-292-889-448;;069-135-449-999-806;;073-813-895-256-644;;028-715-009-310-415;;032-942-121-304-562;;031-713-527-112-83X;;079-410-686-051-556;;007-141-940-555-764;;064-734-376-566-227;;019-054-728-196-071;;094-932-237-235-562;;034-266-141-027-453;;082-367-772-899-374;;006-029-995-110-547;;075-399-350-570-328;;004-810-720-575-225;;033-696-372-073-725;;002-092-148-812-173;;001-238-733-309-766;;092-940-811-628-908;;016-043-458-024-989;;017-903-200-905-934;;029-940-302-663-794;;095-334-545-560-259;;095-334-545-560-259;;068-210-720-709-636;;040-268-015-115-598;;032-491-363-297-334;;139-176-933-976-006;;084-509-210-795-657;;117-955-817-996-143;;088-125-134-949-599;;006-264-790-231-302;;049-021-985-873-114;;028-251-364-222-812;;046-387-887-018-218;;075-987-120-610-743;;046-976-028-552-303;;186-745-328-415-739;;102-155-174-961-181;;018-807-770-252-927;;065-063-689-244-933;;103-932-348-507-545;;047-798-771-039-642;;029-924-753-266-827;;047-016-551-330-594;;007-710-471-361-701;;004-826-556-496-512;;021-397-724-251-949;;046-099-948-978-735;;014-113-432-888-031;;049-364-227-500-305;;003-289-680-098-944;;016-415-965-080-824;;020-273-453-652-888;;046-695-104-089-875;;047-804-772-318-06X;;028-915-309-904-924;;066-249-452-655-525;;013-196-935-848-429;;056-396-761-881-515;;050-237-051-859-202;;046-851-689-909-083;;005-537-684-547-551;;026-949-693-446-886;;087-530-752-587-073;;007-635-587-431-030;;027-477-313-726-928;;103-763-773-729-419;;010-721-317-666-410;;038-910-802-311-647;;033-958-075-663-494;;030-973-809-430-443;;056-606-747-567-215;;021-555-582-011-595;;018-716-403-601-247;;014-532-166-673-578;;063-640-832-834-034;;005-559-002-484-90X;;050-125-427-191-516;;039-350-342-139-973;;048-583-808-216-648;;039-518-641-312-613;;002-484-320-236-685;;007-538-000-443-231;;051-707-000-800-833;;183-143-678-156-514;;055-916-457-134-654;;055-277-004-615-449;;051-456-611-567-889;;032-710-499-765-843;;016-265-697-674-181;;013-511-140-356-129;;013-142-717-038-23X;;066-909-208-515-740;;003-587-964-526-387;;047-651-157-853-47X;;043-696-848-759-507;;011-956-180-765-276;;092-206-015-079-366;;086-448-571-453-106;;012-935-740-641-225;;001-364-223-015-538;;070-951-785-775-802;;001-110-663-834-764;;005-397-066-142-010;;010-461-210-569-209;;089-195-259-654-292;;130-008-135-656-913;;075-319-960-720-757;;023-078-614-743-461;;036-691-203-666-761;;060-589-636-791-858;;017-712-091-114-524;;097-612-949-291-956;;013-682-080-232-349;;083-366-317-945-166;;001-955-296-807-709;;031-100-076-670-370;;049-103-245-316-047;;010-042-083-500-420;;005-104-551-691-441;;007-761-275-786-358;;150-676-123-093-622;;077-034-558-952-043;;035-028-964-856-917;;021-085-074-395-461,10.1158/1078-0432.ccr-08-2810;;19638467;;pmc2771629;;10.1007/s00280-002-0556-x;;12655435;;10.1158/0008-5472.can-04-1659;;15548716;;10.1158/1538-7445.am10-2933;;pmc3237694;;21838572;;10.1089/hum.2011.070;;10914732;;19158846;;10.1038/gt.2008.189;;10.1182/blood-2005-09-3716;;16293601;;10.1101/gr.10.4.398;;10779480;;10203816;;10.1016/s0168-9525(99)01706-0;;17855649;;10.1158/1078-0432.ccr-07-0674;;10.1038/mt.2010.31;;pmc2862525;;20357779;;10.1016/s1525-0016(16)39441-2;;23515080;;pmc3742551;;10.1126/scitranslmed.3005930;;10.1038/nm827;;12579196;;10.1182/blood-2011-04-348540;;pmc3208293;;21849486;;7722445;;10.1084/jem.181.5.1653;;pmc2192006;;pmc2730985;;10.1007/s11060-009-9889-1;;19387557;;10.1146/annurev.immunol.23.021704.115625;;15771567;;pmc2651342;;19211796;;10.1073/pnas.0813101106;;23344265;;pmc3630268;;10.1158/1078-0432.ccr-12-2422;;23344265;;pmc3630268;;10.1158/1078-0432.ccr-12-2422;;12850000;;10.1016/s0006-291x(03)01131-8;;12850000;;10.1016/s0006-291x(03)01131-8;;24016461;;10.1182/blood-2013-04-493361;;10.1006/jmbi.1999.3192;;10543973;;10.1158/1078-0432.ccr-11-3050;;22291136;;pmc6390958;;16960154;;pmc1785096;;10.1182/blood-2006-04-015958;;21742772;;10.1158/0008-5472.can-11-0103;;24329791;;10.1111/imr.12125;;10.1182/blood-2002-01-0008;;12200383;;10.1038/sj.onc.1207350;;14691452;;10.1016/s0168-9525(98)01486-3;;9635409;;7888675;;10.1182/blood.v85.6.1580.bloodjournal8561580;;10.1111/imr.12131;;24329793;;pmc3874724;;10.1089/hum.2006.17.577;;16776567;;10.1097/cji.0b013e318053ed8e;;17667524;;10.1128/jvi.72.11.8463-8471.1998;;pmc110254;;9765382;;10.3816/clm.2009.n.010;;19362970;;pmc3632213;;8421711;;pmc45737;;10.1073/pnas.90.2.720;;8421711;;pmc45737;;10.1073/pnas.90.2.720;;10.4049/jimmunol.172.1.104;;14688315;;10.4049/jimmunol.172.1.104;;14688315;;10.4049/jimmunol.161.6.2791;;9743337;;10.1155/2010/956304;;pmc2864912;;20467460;;23321953;;10.1038/leu.2013.17;;18025285;;10.1158/1535-7163.mct-07-0464;;10.1182/blood-2011-07-366419;;22031866;;pmc3251238;;pmc2190991;;8459204;;10.1084/jem.177.4.1093;;10.1016/0092-8674(91)90314-o;;1705867;;10.1371/journal.pone.0057838;;pmc3585808;;23469246;;20439624;;10.1182/blood-2010-01-043737;;pmc2938125;;10.1111/imr.12139;;24329794;;pmc3991306;;10.1016/j.bbmt.2010.03.014;;20304086;;pmc3383803;;23873688;;10.1158/1078-0432.ccr-13-0458;;pmc2929689;;19451549;;10.1182/blood-2009-03-211714;;pmc3412112;;19859065;;10.1038/nri2635;;pmc3809038;;23890063;;10.1016/j.immuni.2013.07.002;;21832238;;pmc3393096;;10.1126/scitranslmed.3002842;;pmc3784795;;10.3389/fimmu.2013.00304;;24098300;;23880905;;10.1038/nrc3565;;pmc2154351;;17062687;;10.1158/1078-0432.ccr-06-1183;;9541583;;10.1002/(sici)1521-4141(199803)28:03<881::aid-immu881>3.0.co;2-0;;pmc2747302;;19561539;;10.1097/cji.0b013e3181ac6138;;20668228;;10.1182/blood-2010-04-281931;;pmc2993617;;10.1084/jem.188.4.619;;9705944;;pmc2213361;;10.3389/fonc.2013.00322;;pmc3876295;;24427741;;10.4161/rna.8.1.13767;;21289486;;3122749;;10.1016/0006-291x(87)90502-x;;10.1073/pnas.86.6.1963;;2784565;;pmc286825;;8165126;;pmc523635;;10.1093/nar/22.7.1147;;10.1200/jco.2005.04.3836;;16520464;;16648493;;10.1200/jco.2006.05.9964;;22127019;;10.1038/mt.2011.256;;pmc3293635;;12763934;;10.1182/blood-2003-01-0095;;10.1158/0008-5472.can-10-0552;;21487038;;pmc3094720;;pmc4119811;;10.1158/1078-0432.ccr-11-1920;;22589486;;1833767;;10.1073/pnas.88.20.8905;;pmc52619;;pmc1635018;;10.1073/pnas.0608138103;;17090675;;22593441;;10.1073/pnas.93.25.14815;;8962138;;pmc26219;;10.1002/eji.200323763;;12884307;;10.1006/jmbi.1996.0548;;8876650;;10.1006/jmbi.1996.0548;;8876650;;11753365;;10.1038/nbt0102-70;;10.1182/blood-2013-11-492231;;24578504;;pmc3999751;;10.1158/2326-6066.cir-13-0006;;pmc3888798;;24432303;;24777247;;23444214;;10.1158/1078-0432.ccr-13-0168;;pmc3630266;;10.7164/antibiotics.44.688;;1712766;;pmc3624013;;23263452;;10.1007/s00262-012-1384-4;;10.1089/10430349950018968;;10022542;;10.1002/(sici)1521-4141(199803)28:03<1116::aid-immu1116>3.0.co;2-a;;9541607;;19384291;;pmc2805264;;10.1038/mt.2009.83;;10.1146/annurev.med.59.060906.220345;;18186705;;10.1016/s1525-0016(16)35533-2;;20179677;;pmc2862534;;10.1038/mt.2010.24;;22780919;;10.1089/hum.2012.041;;pmc3472555;;8593604;;pmc43776;;7910405;;10.1073/pnas.91.10.4318;;10.1111/j.1349-7006.2000.tb00882.x;;pmc5926257;;11050475;;10.1126/science.272.5259.263;;8602510;;10.1007/978-1-4684-6831-1_14;;10.1016/s0161-5890(97)00144-2;;9566763;;14512299;;10.1182/blood-2003-06-2043;;pmc4019893;;10.1186/2051-1426-1-21;;24829757;;20880333;;10.1111/j.1349-7006.2010.01734.x;;pmc2074493;;8645581;;10.1038/bjc.1996.260;;pmc4697441;;20423671;;17299405;;10.1038/sj.mt.6300104;;12218124;;10.4049/jimmunol.169.6.3076;;10.1038/sj.gt.3300831;;10435091;;10.1371/journal.pone.0083250;;24376672;;pmc3869762;;24504024;;10.1038/leu.2014.62;;10.1056/nejmoa1103849;;pmc3387277;;21830940;;16269610;;10.1182/blood-2005-08-3373;;10.7150/jca.2.331;;21716851;;pmc3119397;;10.4049/jimmunol.1103028;;22573804;;10.3410/f.721265929.793531781;;10.1016/j.molimm.2012.03.023;;22503210;;10.1038/nm.1882;;18978797;;pmc2749734;;10.1038/leu.2014.189;;24919807;;10.1038/nm1310;;16227990;;10.1158/0008-5472.can-12-3874;;23576561;;pmc3686869;;10.1007/978-1-62703-260-5_12;;23296935;;10.1038/nm0795-621;;7585134;;1900456;;10.1016/0092-8674(91)90327-u;;10.1038/sj.cgt.7700500;;12189521;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1016/j.it.2007.06.001;;17597006;;10.1016/j.coi.2009.02.009;;pmc5548385;;19327974;;12509765;;10.1038/nrc971;;10.1182/blood-2014-08-593137;;25662332;;pmc4375105;;pmc4352777;;25730880;;10.1073/pnas.1500712112;;24352643;;10.3410/f.718213671.793491682;;pmc3943170;;10.1158/1078-0432.ccr-13-0709;;10.1172/jci46110;;pmc3083795;;21540550;;18490778;;10.4049/jimmunol.180.11.7736;;22641678;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1016/j.molimm.2007.07.028;;17825416;;22117050;;10.1182/blood-2011-03-344275;;pmc2200822;;17916744;;10.1182/blood-2007-07-098483;;22798667;;10.4049/jimmunol.1200552;;pmc3522079;;10.1182/blood-2007-12-128843;;18509084;;pmc2532803;;10.1182/blood.v71.1.13.13;;3257143;;10.1182/blood.v71.1.13.bloodjournal71113;;pmc3319867;;22315351;;10.1158/0008-5472.can-11-3890;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1021/ja00019a057;;9826581;;10.1006/smim.1998.0157;;10.1016/s1525-0016(16)35165-6;;10.1158/2326-6066.cir-15-0054;;pmc4490943;;25941351;;pmc3897565;;10.4161/onci.26492;;24490126;;10.1021/bi00489a001;;2271534;;12507815;;10.1016/s0198-8859(02)00730-9;;10556035;;10.1006/jmbi.1999.3141;;pmc4055922;;10.1182/blood-2014-01-552174;;24782509;;10.3324/haematol.2009.009811;;19648166;;pmc2805740;;19843940;;pmc6292203;;10.4049/jimmunol.0900447;;12883552;;10.1038/ni958;;9306402;;10.1038/nbt0997-871;;15626734;;10.1182/blood-2004-09-3737;;24411699;;10.1016/s0006-291x(87)80273-5;;2825682;;11149976;;10.1053/tmrv.2001.19949;;10.1182/blood.v98.8.2364;;11588032;;10.1097/00002371-200203000-00002;;12074044;;10.1182/blood-2013-09-529537;;24596416;;pmc3983612;;10.1038/sj.neo.7900018;;pmc1508130;;10933046;;15170741;;10.1002/jgm.489;;pmc3392079;;10.1016/j.bbmt.2010.10.011;;21195313;;11223070;;10.1016/s0022-1759(00)00344-6;;10.1096/fasebj.6.15.1464371;;1464371;;2513569;;10.1073/pnas.86.24.10024;;pmc298636;;10.1056/nejmoa1215134;;23527958;;pmc4058440;;pmc2959087;;20925961;;10.1186/1472-6750-10-72;;10.1182/blood-2007-06-093906;;18216293;;pmc2972576;;10.1002/(sici)1097-0215(19961009)68:2<232::aid-ijc16>3.0.co;2-c;;8900434;;10.1016/s1535-6108(03)00113-2;;12781360;;pmc2683970;;19238016;;10.1097/cji.0b013e318194a6e8;;16989900;;10.1016/j.molimm.2006.08.001;;16940422;;10.1182/blood-2006-04-015024;;12109217;;10.2174/1566523024605573;;20428207;;10.1038/leu.2010.75;;pmc2888148;;18565862;;pmc3277288;;10.1056/nejmoa0800251;;10.1038/mt.2011.179;;21878902;;pmc3242659;;10.1038/sj.leu.2403302;;14961035;;15755898;;10.1182/blood-2004-12-4797;;pmc1895123;;24661086;;10.1517/14712598.2014.900540,"Altvater et al. “2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells” Clinical Cancer Research (2009) vol. 15, No. 15, pp. 4857-4866.;;Baeksgaard & Sorensen, “Acute tumor lysis syndrome in solid tumors—a case report and review of the literature” Cancer Chemotherapy Pharmacology (2003) vol. 51 pp. 187-192.;;Bakker et al. “C-typelectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia”, Cancer Research (2004) vol. 64, No. 22,pp. 8443-8450.;;Barrett, et al., “Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells” Cancer Research:AACR 101st Annual Meeting, Abstract 2933 (Apr. 17-21, 2010).;;Barrett, et al., “Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells” Human Gene Therapy, 22(12):1575-1586 (2011).;;Beers, et al., “Immunotoxins with Increased Activity against Epidermal Growth Factor Receptor vIII-expressing Cells Produced by Antibody Phage Display” Clinical Cancer Research, 6:2835-2843 (2000).;;Bendig, M.M. Humanization of rodent monoclonal antibodies by CDR grafting. Methods: A Companion to Methods in Enzymology, 1995; vol. 8, p. 83-93.;;Birkholz et al. “Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer,” Gene Therapy 16:596-604 (2009).;;Bondanza et al. “Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes” Blood (2006) vol. 107 No. 5 pp. 1828-1836.;;Bork “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle” Genome Research (2000) vol. 10, pp. 398-400.;;Brenner “Errors in genome annotation” TIG (1999) vol. 15, No. 4, pp. 132-133.;;Brentjens et al. “Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts”, Clinical Cancer Research(2007) vol. 13, No. 18, pp. 5426-5435.;;Brentjens et al. “Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial” The American Society of Gene Therapy (2010) vol. 18 No. 4 pp. 666-668.;;Brentjens et al., “A Phase I Trial for the Treatment of chemo-Refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells” Molecular Therapy (2008) vol. 16 Suppl 1 p. S15.;;Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia,” Sci. Transl. Med. 5:177ra138 (2013).;;Brentjens et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15” Nature Medicine (2003) vol. 9 No. 3 pp. 279-286.;;Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias” Blood (2011) vol. 118 No. 18 pp. 4817-4828.;;Brocker and Karjalainen, “Signals through T Cell Receptor-Chain alone Are Insufficient to Prime Resting T Lymphocytes” J. Exp. Med. (1995) vol. 181 pp. 1653-1659.;;Bullain, et al., “Genetically engineered T cells to target EGFRvIII expressing glioblastoma” J Neurooncol, 94:373-382 (2009).;;Call & Wucherpfennig, “The T Cell Receptor: Critical Role of the Membrane Environment in Receptor Assembly and Function” Annu. Rev. Immunol. (2005) vol. 23 pp. 101-125.;;Carpenito et al. “Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains”, Proc Natl Acad Sci USA (2009) vol. 106 pp. 3360-3365.;;Carpenter et al. “B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma” Clinical Cancer Research (2013) vol. 19, No. 8, pp. 2048-2060.;;Carpenter, Robert O. et al. “B-cell Maturation Antigen is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma”, Clinical Cancer Research, Apr. 15, 2013, vol. 19 No. 8, pp. 2048-2060.;;Casset et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design” Biochemical and Biophysical Research Communications (2003) vol. 307, pp. 198-205.;;Casset F, et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003, vol. 307, p. 198-205.;;Casucci et al. “CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma”, Blood (2013) vol. 122 No. 20 pp. 3461-3472.;;Chen et al. “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen” J Mol Biol. (1999) vol. 293, 865-881.;;Chinnasamy et al. “Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice”, Clinical Cancer Research, vol. 18, No. 6, Jan. 30, 2012, pp. 1672-1683.;;Chiu et al. “Hodgkin lymphoma cells express TACI and BCMAreceptors and generate survival and proliferation signals in response to BAFF and APRIL”, Blood (2007) vol. 109 No. 2, pp. 729-739.;;Chmielewski et al. “IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression”, Cancer Research, vol. 71, No. 17, Jul. 8, 2011, pp. 5697-7506.;;Chmielewski et al. “Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma”, Immunological Reviews, vol. 257, No. 1, Jan. 13, 2014, pp. 83-90.;;Chaudio et al. “A molecular compendium of genes expressed in multiple myeloma”, Blood (2002) vol. 100 No. 6, pp. 2175-2186.;;Cohen et al. “Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)” Blood (2017) vol. 130, Supplement 1, No. 505 (Abstract), pp. 1-3.;;Davila et al. “B Cell Aplasia in a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen” 53rd ASH Annual Meeting and Exposition (2010) Oral and Poster Abstract.;;Deshayes et al. “Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor”, Oncogene (2004) vol. 23 No. 17, pp. 3005-3012.;;Doerks et al. “Protein annotation: detective work for function prediction” TIG (1998) vol. 14, No. 6, pp. 248-250.;;Dohner et al., “p53 Gene Deletion Predicts for Poor Survival and Non-Response to Therapy With Purine Analogs in Chronic B-Cell Leukemias” Blood (1995) vol. 85 No. 6 pp. 1580-1589.;;Dotti et al. “Design and development of therapies using chimeric antigen receptor-expressing T cells”, Immunological Reviews, vol. 257, No. 1, Dec. 13, 2013, pp. 107-126.;;Dropulic and June, “Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome” Human Gene Therapy (2006) vol. 17 pp. 577-588.;;Du et al., “New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia Cells” J. Immunother. vol. 30, No. 6 pp. 607-613 (2007).;;Dull et al, “A Third-Generation Lentivirus Vector with a Conditional Packaging System” Journal of Virology (1998) vol. 12 No. 11 pp. 8463-8471.;;Elsawa et al. “Cytokines in the Microenvironment of Waldenström's Macroglobulinemia”, Clin Lymphoma Myeloma (2009) vol. 9 No. 1 pp. 43-45.;;Eshhar et al. “Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody binding domains and the y or C subunits of the immunoglobulin and T-cell receptors” PNAS (1993) vol. 90, pp. 120-724.;;Eshhar et al., “Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors,” PNAS USA 90: 720-724 (1993).;;European Search Report for EP Application No. 12820516.8, dated Mar. 30, 2015.;;Extended European Search Report for EP Application No. 12832609.7, dated Mar. 25, 2015.;;Finney et al. “Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRz Chain” The Journal of Immunology (2004) vol. 172, pp. 104-113.;;Finney et al., “Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 (4-1BB) in series with signals from the TCR zeta chain,” J. Immunol. 172: 104-113 (2004).;;Finney et al., “Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product,” J. Immunol. 161: 2791-2797 (1998).;;Frey, N. “Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy” (2015) Clinical Trial NCT01029366.;;Cartellieri et al. “Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer” Journal of Biomedicine and Biotechnology (2010) doi: 10.1155/2010/956304, Article ID 956304, pp. 1-13.;;International Search Report and Written Opinion for International Application No. PCT/US2018/063255 dated May 13, 2019.;;Park et al. “A phase lb GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse” Leukemia (2013) vol. 27, No. 7, pp. 1479-1486.;;Ryan et al. “Antibody targeting of B-cell maturation antigen on malignant plasma cells” Mol Cancer Ther (2007) vol. 6, No. 11, pp. 3009-3018.;;Terakura et al. “Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific memory T cells” Blood (2012) vol. 119, No. 1, pp. 72-82.;;International Search Report from PCT/US2011/064191 dated Jan. 5, 2012.;;International Search Report including Written Opinon for PCT/US2014/017328 dated Jun. 26, 2014.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for International Application No. PCT/US2014/065408, dated Feb. 4, 2015.;;Irving et al. “Functional Characterization of a Signal Transducing Motif Present in the T Cell Antigen Receptor” J Exp Med (1993) vol. 177, pp. 1093-1103.;;Irving et al., “The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways,” Cell 64: 891-901 (1991).;;Jena et al. “Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials,” PLOS 8(3): e57838 (2013).;;Jena, Bipulendu et al. “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, May 3, 2010”, vol. 116, No. 7, pp. 1035-1044.;;Jensen et al. “Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells” Immunological Reviews (2014) vol. 257, pp. 127-144.;;Jensen et al., “Anti-Transgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Re-directed T Cells in Humans” Biol Blood Marrow Transplant (2010) vol. 16 No. 9 pp. 1245-1256.;;John et al, “Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells”, Clinical Cancer Research, The American Association for Cancer Research, US (2013) vol. 19, No. 20, pp. 5636-5646.;;Johnson et al., “Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen” Blood (2009) vol. 114 No. 3 pp. 535-545.;;June et al., “Engineering lymphocyte subsets: tools, trials and tribulations” Nat Rev Immunol (2009) vol. 9 No. 10 pp. 704-716.;;Kalos et al “Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology”, Immunity, Cell Press, US, vol. 39, No. 1, Jul. 25, 2013. pp. 49-60.;;Kalos et al. “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia”, Science Translation Medicine (2011) vol. 3 No. 95 95ra73.;;Kerkar. “‘Model T’ Cells: A Time-Tested Vehicle for Gene Therapy.” Frontiers in Immunology 4 (2013): 304. PMC. Web. Aug. 18, 2015.;;Kershaw et al. “Gene-engineered T cells for cancer therapy”, Nature Reviews Cancer, vol. 13, No. 8, Jul. 24, 2013, pp. 525-541.;;Kershaw et al., “A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer,” Clin. Cancer Res. 12(20 Pt 1): 6106-6115 (2006).;;Kim et al., “Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses” Eur. J. Immunol. (1998) vol. 28 pp. 881-890.;;Kochenderfer et al, “A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-Cd19-CAR-Transduced T Cells” Blood (2010) vol. 116 No. 21 pp. 1179-1180 & 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL, USA; Dec. 4-7, 2010 abstract.;;Kochenderfer et al. “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor”, J Immunother (2009) vol. 32, No. 7, pp. 689-702.;;Kochenderfer et al., “Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19,” Blood 116: 4099-4102 (2010).;;Kraus et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes” J. Exp. Med. (1998) vol. 188 Np 4 pp. 619-626.;;Krebs et al. “Genetically Modified T Cells to Target Glioblastoma”, Frontiers in Oncology, vol. 3, Jan. 1, 2013.;;Kuhn, et al., “Determinants of intracellular RNA pharmacokinetics: Implication for RNA-based immunotherapeutics” RNA Biology, 8(1):35-43 (2011).;;Kuwana et al., “Expression of Chimeric Receptor Composed of Immunoglobulin-derived V Resions and T-cell Receptor-derived C Regions” Biochem. Biophys. Res. Commun. 149: 964-968 (1987).;;Kwon et al., “cDNA sequences of two inducible T-cell genes”. Proc. Natl. Acad. Sci. U.S.A. 86(6): 1963-1967 (1989).;;Laabi et al. “The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed”, Nucleic Acids Research (1994) vol. 22, No. 7, pp. 1147-1154.;;Lamanna et al., “Pentostatin, Cyclophosphamide, and Rutuximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia” Journal of Clinical Oncology (2008) vol. 24 No. 10 pp. 1575-1581.;;Lamers et al., “Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience,” J. Clin. Oncol. 24(13): e20-e22 (2006).;;Lanitis et al., “Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor” Molecular Therapy, 20(3):633-643 (2012).;;Laport et al., “Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34 +-selected hematopoietic cell transplantation” Blood (2003) vol. 102 No. 6 pp. 2004-2013.;;Lee et al., “In vivo Inhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy” Cancer Research (2011) vol. 71 No. 8 pp. 2871-2881.;;Lee et al., “The Future is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer,” Clin. Cancer Res. 18: 2780-2790 (2012).;;Letourneur et al., “T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins,” Proc. Natl. Acad. Sci. U.S.A 88: 8905-8909 (1991).;;Levine et al., “Gene transfer in humans using a conditionally replicating lentiviral vector” PNAS (2006) vol. 103 No. 46 pp. 17372-17377.;;Liu et al, “Metformin and the mTOR Inhibitor Everolimus (RAD001) Sensitize Breast Cancer Cells to the Cytotoxic Effect of Chemotherapeutic Drugs In Vitro”, Anticancer Research, 32: 1627-1638 (2012).;;Lorimer, et al., “Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display” Proc. Natl. Acad. Sci. USA, 93:14815-14820 (1996).;;MaCallan et al., “Measurement and modeling of human T cell kinetics” European Journal of Immunology (2003) vol. 33 pp. 2316-2326.;;MacCallum et al. “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography” J. Mol. Biol. (1996) vol. 262, pp. 732-745.;;MacCallum R.M. et al, Antibody-antigen interactions: Contact analysis and binding site topography. J. Mol. Bioi., 1998, vol. 262, p. 732-745.;;Maher et al., “Human T lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor,” Nat. Biotechnol. 20: 70-75 (2002).;;Mardiros et al., “CD123-Specific Chimeric Antigen Receptor Redirected T Cells Exhibit Potent Cytolytic Activity and Multiple Effector Functions Against Acute Myeloid Leukemia without Altering Normal Hematopoietic Colony Formation in Vitro” Blood 120(21): abstract 950 (2011).;;Maus et al. “Antibody-modified T cells: CARs take the front seat for hematologic malignancies” Blood (2014) vol. 123, No. 17, pp. 2625-2635.;;Maus et al., “T cells expressing chimeric antigen receptors can cause anaphylaxis in humans” Cancel Immunol Res, 1:26-31 (2013).;;Maus, Marcela V. et al. “Zoom zoom: racing CARs for multiple myeloma”, Clinical Cancer Research, Apr. 15, 2013, vol. 19 No. 8, pp. 1917-1919.;;McAlpine et al. “Revised NMR Assignments for Rapamycin”, The Journal of Antibiotics (1991) vol. 44 No. 6, pp. 688-690.;;McCormack et al., “Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors,” Cancer Immunol. Immunother. 62:773-785 (2012).;;McGuinness et al., “Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor,” Hum. Gene Ther. 10: 165-173 (1999).;;Melero et al., “Amplification of Tumor Immunity by Gene Transfer of the Co-Stimulatory 4-1BB Ligand: Synergy with the CD28 Co-Stimulatory Pathway,” Eur. J. Immunel. 28(3): 1116-1121 abstract (1998).;;Milone et al, “Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo” Molecular Therapy (2009) vol. 17 No. 8 pp. 1453-1464.;;Molina, “A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma” Annu. Rev. Med. (2008) vol. 59 pp. 237-250.;;Moon, et al., “A PDI-CD28 ‘Switch Receptor’ Is Able to Augment Mesothelin-Directed Chimeric Antigen Receptor T Cell Therapy in a Resistant In Vivo Model of Human Tumor” 17th Annual Meeting of the American Society of Gene and Cell Therapy, Abstract 520 (May 21-24, 2014).;;Morgan et al., “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Anitgen Receptor Recognizing ErbB2,” Mol. Ther. 18(4): 843-851 (2010).;;Morgan, et al., “Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma” Human Gene Therapy, 23:1043-1053 (2012).;;Moritz and Groner, “A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity,” Gene Therapy 2(8): 539-546 (1995).;;Moritz et al., “Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells” Proc. Natl. Acad. Sci (1994) vol. 91 pp. 4318-4322.;;Nakayashiki, et al., “Production of a Single-chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor” Jpn. J. Cancer Res., 91:1035-1043 (2000).;;Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector” Science (1996) vol. 272 pp. 263-267.;;NCBI accession HM_852952 accessed Sep. 29, 2015 from http://www.ncbi.nlm.nih.gov/nuccore/hm852952.;;NCBI accession NM_001192.2 accessed Sep. 28, 2015 from <http://www.ncbi.nlm.nih.gov/nuccore/23238191>.;;NCBI accession NP_0011832 accessed Sep. 28, 2015 from <http://www.ncbi.nlm.nih.gov/protein/23238192>.;;Ngo et al. “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14:Computational Complexity, Protein Structure Prediction and Levinthal Paradox” (1994) pp. 433-440.;;Nicholson et al., “Construction and Characterisation of a Function CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukaemia and Lymphoma,” Molecular Immunology 34(I6-I7): 1157-1165 (1997).;;Notification of Transmittal of the International Search Report and Written Opinion of the International Search Authority for International Application No. PCT/US2014/065408 dated May 6, 2015.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Search Authority for International Application No. PCT/US2015/012284 dated May 8, 2015.;;Novak et al. “Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival”, Blood (2004) vol. 103 No. 2, pp. 689-694.;;Ohno, et al., “Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts” Journal of ImmunoTherapy of Cancer, 1:21 (2013).;;Ohno, et al., “Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen” Cancer Science, 101(12):2518-2524 (2010).;;Okamoto, et al., “Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor” British Journal of Cancer, 73:1366-1372 (1996).;;Park and Brentjens “Adoptive Immunotherapy for B-cell Malignancies with Autologous Chimeric Antigen Receptor Modified Tumor Targeted T Cells” Discovery Medicine (2010) vol. 9 No. 47 pp. 277-288.;;Park et al. “Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma”, Molecular Therapy (2007) vol. 15 No. 4 pp. 825-833.;;Pascalis et al. “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody” The Journal of Immunology (2002) vol. 169, pp. 3076-3084.;;Patel et al., “Impact of chimeric immune receptor extracellular protein domains on T cell function” Gene Therapy (1999) vol. 6 pp. 412-419.;;Paul, W.E. Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.;;Pelekanou et al. “BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 Proteins Are Related to Human Glioma Tumor Grade: Immunohistochemistry and Public Microarray Data Meta-Analysis” Plos One (2013) vol. 8 No. 12 pp. 1-11.;;Pizzitola et al, “Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo”, Leukemia (2014) vol. 28 No. 8 pp. 1596-1605.;;Porter et al. “Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia”, The New England Journal of Medicine (2011) vol. 365 No. 8 pp. 725-733.;;Porter et al., “A phase 1 trial of donor lumphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation” Blood (2006) vol. 107 No. 4 pp. 1325-1331.;;Porter et al., “Chimeric Antigen Receptor Therapy for B-cell Malignancies” Journal of Cancer (2011) vol. 2 pp. 331-332.;;Prinz et al., “High DGK-a and Disabled MAPK Pathways cause Dysfunction of Human Tumor-Infiltrating CD8+ T Cells That Is Reversable by Pharmacologic Intervention,” The Journal of Immunology 188: 5990-6000, 2012.;;Prosser, et al., “Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1: CD28 chimeric receptor” Molecular Immunology, 51:263-272 (2012).;;Pule et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma” Nat. Med. (2008) vol. 14 No. 11 pp. 1264-1270.;;Radhika et al., “Targeting Leukemias by CD123 Specific Chimerica Antigen Receptor” Blood(ASH Annual Meeting Abstracts) 118(21): abstract 1908 (2011).;;Rambaldi et al, “Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches”,Leukemia (2014).,vol. 29, No. 1, pp. 1-10.;;Rapoport et al., “Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer” Nature Medicine (2005) vol. 11 No. 11 pp. 1230-1237.;;Riese et al “Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases”, Cancer Research (2013) vol. 73 No. 12 pp. 3566-3577.;;Riet et al. “Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy”, Methods in Molecular Biology, Humana Press, Inc, US, vol. 969, Jan. 1, 2013, pp. 187-201.;;Roederer, “T-cell dynamics of immunodeficiency” Nature Medicine (1995) vol. 1 No. 7 pp. 621-622.;;Romeo et al., “Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides,” Cell 64:1037-1046 (1991).;;Rouas et al. “Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: Optimized design and procedures for highly efficient transduction compatible with clinical constraints”. Cancer Gene Therapy (2002) vol. 9 pp. 715-724.;;Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity” Proc Natl Acad Sci (1982) vol. 79, pp. 1979-1983.;;Sabbagh et al., “TNF family ligands define niches for T cell memory” Trends in Immunology (2007) vol. 28 No. 8 pp. 333-339.;;Sadelain et al. “The promise and potential pitfalls of chimeric antigen receptors.” Current Opinion Immunology (2009) vol. 21 No. 2 pp. 215-223.;;Sadelain et al., “Targeting Tumours with Genetically Enhanced T Lymphocytes,” Nature Reviews: Cancer 3: 35-45 (2003).;;Sagiv-Barfi, et al., “Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma” Blood, 125(13):2079-2086 (2015).;;Sagiv-Barfi, et al., “Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK” PNAS, 112(9):E966-E972 (2015).;;Sampson, et al., “EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss” Clinical Cancer Research, 20(4):972-984 (2013).;;Savoldo et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients” The Journal of Clinical Investigation (2011) vol. 121 No. 5 pp. 1822-1826.;;Sebestyen et al., “Human TCR That Incorporate CD3 Induce Highly Preferred Pairing between TCR and Chains following Gene Transfer” Journal of Immunology (2008) vol. 180 pp. 7736-7746.;;Shirasu et al., “Functional Design of Chimeric T-Cell Antigen Receptors for Adoptive Immunotherapy of Cancer: Architecture and Outcomes,” AntiCancer Res. 32: 2377-2384 (2012).;;Singapore Search Report and Written Opinion for Singapore Application No. 11201700476V dated Nov. 6, 2017.;;Singh, et al., “Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function” Blood: Ash Annual Meeting Abstracts; 114:22 (2009).;;Skolnick et al. “From genes to protein structure and function: novel applications of computational approachesin the genomic era” TIBTECH (2000) vol. 18, pp. 34-39.;;Smirnova et al. “Identification of new splice variants of the genes BAFF and BCMA”, Molecular Immunology (2008) vol. 45, pp. 1179-1183.;;Song et al. “CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo” Blood (2012) Bol 119, No. 3, pp. 696-706.;;Sorror et al., “Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia” Blood (2008) vol. 111 No. 1 pp. 446-452.;;Stromnes et al. “Abrogation of Src Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo”,The Journal of Immunology, (2012) vol. 189, No. 4, pp. 1812-1825.;;Tettamanti et al., “Targeting of the acute myeloid leukemia stem cells through immunotherapy: development of novel chimeric receptors specific for the CD123 antigen,” OMICS group conference 2nd world congress on biotechology (2011) retrieved from internet www.omicsonline.org/biotechnology2011.;;Till et al., “Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells” Blood (2008) vol. 112 No. 6 pp. 2261-2271.;;Uckun et al., “Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins” Blood (1988) vol. 71 pp. 13-29.;;Uniprot identifier Q02223-2 accessed Sep. 28, 2015 from <http://www.uniprot.org/uniprot/Q02223>.;;Urbanska et al., “A Universal Strategy for Adoptive Immunotherapy of Cancer Through Use of a Novel T-Cell Antigen Receptor,” Cancer Res. 72(7): 1844-1852 (2012).;;Vajdos et al. “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-Erb82 Antibody Obtained with Shotgun Scanning Mutagenesis” J Mol Biol (2002) vol. 320, pp. 415-428.;;Van Duyne et al. “Atomic Structure of the Rapamycin Human Immunophilin FKBP-12 Complex” American Chemical Society (1991) vol. 113, pp. 7433-7434.;;Vinay & Kwon, “Role of 4-1BB in immune responses” Immunology (1998) vol. 10 pp. 481-489.;;Wang et al. “A Chimeric Antigen Receptor (CARs) Based Upon a Killer Immunoglobulin-Like Receptor (KIR) Triggers Robust Cytotoxic Activity in Solid Tumors” Molecular Therapy (2014) vol. 22, Supplement 1, pp. S57.;;Wang et al. “Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors” Cancer Immunology Research (2015) vol. 3, No. 7, pp. 815-826.;;Wang et al. “Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road”, Oncoimmunology (2013) vol. 2, No. 11, p. e264921-3.;;Weijyens, “Immuno-gene therapy for renal cancer chimeric receptor-mediated lysis of tumorcells,” Thesis: 1-128 (2001).;;Wells “Additivity of Mutational Effects in Proteins” Biochemistry (1990) vol. 29, No. 37, pp. 8509-8517.;;Willemsen et al., “Genetic Engineering of T Cell Specificity for Immunotherapy of Cancer” Human Immunology (2003) vol. 64 pp. 56-68.;;Written Opinion for PCT Application No. PCT/US2014/034570 dated Oct. 17, 2015.;;Written Opinion for PCT/US13/63083. dated Jan. 17, 2014.;;Written Opinion of the International Searching Authority for International Application No. PCT/US13/032029, dated Oct. 11, 2014.;;Wu et al. “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues” J Mol Biol (1999) vol. 294, pp. 151-162.;;Y. XU, M. ZHANG, C. A. RAMOS, A. DURETT, E. LIU, O. DAKHOVA, H. LIU, C. J. CREIGHTON, A. P. GEE, H. E. HESLOP, C. M. ROONEY, B. SA: ""Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15"", BLOOD, vol. 123, no. 24, 12 June 2014 (2014-06-12), pages 3750 - 3759, XP055201372, ISSN: 00064971, DOI: 10.1182/blood-2014-01-552174;;Zhao et al. “Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia”, Haematologica (2010) vol. 95 No. 1 pp. 71-78. et al.",ACTIVE
383,US,A1,US 2022/0194926 A1,003-568-343-560-853,2022-06-23,2022,US 202117556295 A,2021-12-20,US 202117556295 A;;US 202063128511 P,2020-12-21,SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,ALKERMES INC (2022-09-06),https://lens.org/003-568-343-560-853,Patent Application,yes,1,0,8,8,0,C07D401/04;;C07D498/04;;C07D487/04;;C07D471/04;;C07D401/06;;C07D211/58;;C07D401/14;;A61P25/26;;A61P25/26;;C07D211/98;;C07D401/04;;C07D401/14;;C07D471/04;;C07D487/04,C07D401/14;;A61P25/26;;C07D211/98;;C07D401/04;;C07D471/04;;C07D487/04,,0,0,,,,ACTIVE
384,US,A1,US 2024/0076283 A1,150-050-009-926-550,2024-03-07,2024,US 18230329,2023-08-04,,,Substituted Piperidino Compounds and Related Methods of Treatment,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,"Alkermes, Inc.",Lewis D. Pennington;;Younggi Choi;;Hoan Huynh;;Brian M. Aquila;;Ingo Andreas Mugge;;Yuan Hu;;James R. Woods;;Brian Kenneth Raymer;;Jörg Martin Bentzien;;Jonathan Ward Lehmann;;Srinivasa Karra;;Roman A. Valiulin;;Daljit Matharu,,https://lens.org/150-050-009-926-550,Patent Application,yes,0,0,1,1,0,C07D401/14;;A61P25/26;;C07D211/98;;C07D401/04;;C07D471/04;;C07D487/04,C07D401/14;;A61P25/26;;C07D211/98;;C07D401/04;;C07D471/04;;C07D487/04,,0,0,,,,UNKNOWN
385,US,A1,US 2013/0316437 A1,127-732-432-839-846,2013-11-28,2013,US 201313802533 A,2013-03-13,US 201313802533 A;;US 84384410 A;;US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;BP CORP NORTH AMERICA INC;;UNIV ILLINOIS,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-04);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/127-732-432-839-846,Patent Application,yes,0,0,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/81;;C12N15/80,435/252.31;;435/254.21;;435/252.3;;435/254.22;;435/254.4;;435/254.23;;435/254.2;;435/254.11,0,0,,,,INACTIVE
386,KR,A,KR 20220106793 A,030-644-651-674-941,2022-07-29,2022,KR 20227021501 A,2020-11-25,US 201962939825 P;;US 202063030979 P;;US 2020/0062320 W,2019-11-25,치환된 마크로사이클릭 화합물 및 관련 치료 방법,본 발명은 이를 필요로 하는 대상에서 기면증(narcolepsy) 또는 탈력발작(cataplexy)의 치료에 유용한 화합물을 제공한다. 관련된 약제학적 조성물 및 방법이 또한 본원에 제공된다.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,,https://lens.org/030-644-651-674-941,Patent Application,no,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/04;;A61K31/407;;A61K31/4353;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14,,0,0,,,,PENDING
387,EP,A1,EP 3545408 A1,156-612-151-144-509,2019-10-02,2019,EP 17817468 A,2017-11-22,US 201615362709 A;;US 201615362691 A;;US 2017/0063138 W,2016-11-28,LOCALIZED DEVICE COORDINATOR WITH ON-DEMAND CODE EXECUTION CAPABILITIES,,AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER III;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,,https://lens.org/156-612-151-144-509,Patent Application,yes,0,3,8,12,0,G06F8/63,G06F8/61,,0,0,,,,ACTIVE
388,AU,A8,AU 2010/275388 A8,104-663-276-827-198,2012-06-14,2012,AU 2010/275388 A,2010-07-26,US 28552609 P;;US 27183309 P;;US 2010/0043279 W,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",BP CORP NORTH AMERICA INC;;UNIV ILLINOIS;;UNIV CALIFORNIA,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOO RIN;;JIN YONG-SU;;LI SIJIN;;YANG XIAOMIN,,https://lens.org/104-663-276-827-198,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/52;;C12N15/62;;C12N15/87;;C12P19/00;;C12R1/865,,0,0,,,,DISCONTINUED
389,US,B2,US 10372486 B2,196-229-865-557-777,2019-08-06,2019,US 201615362691 A,2016-11-28,US 201615362691 A,2016-11-28,Localized device coordinator,"Systems and methods are described for configuring a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinated devices may include devices configured to be managed remotely, such as thin devices, devices with alternative primary functions (e.g., appliances, household objects, etc.), or devices with limited localized user interfaces. To manage the set of coordinated devices, the coordinator can execute tasks, each task corresponding to a set of portable code executable by the coordinator to implement a desired functionality. A user may generate one or more tasks, and submit them to a service provider environment for deployment to the coordinator. The service provider environment can utilize a device shadow to notify the coordinator of the obtained tasks, and thereafter deliver the tasks to the coordinator, thus modifying a configuration of the coordinator.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON III JAMES CHRISTOPHER;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,AMAZON TECHNOLOGIES INC (2017-03-06),https://lens.org/196-229-865-557-777,Granted Patent,yes,52,8,2,12,0,G06F9/5027;;G06F9/5027,G06F9/48,,13,0,,,"Kim, “Developing an on-Demand Cloud-Based Sensing-as-a-Service System for Internet of Things,” vol. 2016, Article 3292783, pp. 1-17.;;International Search Report and Written Opinion in PCT/US2017/063138 dated Mar. 6, 2018.;;International Search Report and Written Opinion in PCT/US2017/063302 dated Mar. 9, 2018.;;International Search Report and Written Opinion in PCT/US2017/063314 dated Feb. 9, 2018.;;Corbin, “MQTT is the de-facto standard and ISO standard for messaging protocols”, Jul. 1, 2016, developer.ibm.com, 4 pages.;;Wikipedia, “Create, Read, Update, and Delete”, saved Oct. 1, 2018, en.wikipedia.com, 3 pages.;;U.S. Appl. No. 15/362,709, Localized Device Coordinator With On-Demand Code Execution Capabilities, filed Nov. 28, 2016.;;U.S. Appl. No. 15/362,751, Managing Security in Messaging Protocol Communications, filed Nov. 28, 2016.;;U.S. Appl. No. 15/362,757, Embedded Codes in Messaging Protocol Communications, filed Nov. 28, 2016.;;U.S. Appl. No. 15/362,765, Managing Messaging Protocol Communications, filed Nov. 28, 2016.;;U.S. Appl. No. 15/362,696, On-Demand Code Execution in a Localized Device Coordinator, filed Nov. 28, 2016.;;U.S. Appl. No. 15/362,708, Intra-Code Communication in a Localized Device Coordinator, filed Nov. 28, 2016.;;U.S. Appl. No. 15/362,707, Remote Invocation of Code Execution in a Localized Device Coordinator, filed Nov. 28, 2016.",INACTIVE
390,EP,A1,EP 4065585 A1,022-500-028-049-121,2022-10-05,2022,EP 20828463 A,2020-11-25,US 201962939825 P;;US 202063030979 P;;US 2020/0062320 W,2019-11-25,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,,https://lens.org/022-500-028-049-121,Patent Application,yes,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/04;;A61K31/407;;A61K31/4353;;A61P43/00;;C07D498/14,,0,0,,,,PENDING
391,US,B2,US 8431360 B2,025-523-301-458-497,2013-04-30,2013,US 84384410 A,2010-07-26,US 84384410 A;;US 27183309 P;;US 28552609 P,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN;;UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-08);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/025-523-301-458-497,Granted Patent,yes,6,8,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N1/00;;C12P21/04;;C12P21/06,435/69.1;;435/71.1;;435/243,99,92,036-488-749-216-726;;018-131-004-326-715;;085-321-081-635-287;;077-037-312-000-740;;002-773-429-424-488;;052-392-453-181-409;;020-807-488-825-412;;031-884-777-774-381;;102-059-025-734-508;;120-631-641-472-887;;131-148-740-048-845;;138-054-623-673-534;;004-878-049-430-388;;015-339-468-695-846;;099-940-450-305-541;;025-622-213-088-485;;068-183-326-130-940;;086-354-734-216-897;;061-774-608-000-01X;;011-250-531-318-343;;057-722-409-149-269;;083-475-617-712-21X;;060-906-287-443-607;;003-546-581-906-613;;032-443-849-864-806;;085-737-768-545-623;;057-694-351-421-112;;054-822-635-975-947;;033-828-770-147-584;;036-168-690-647-51X;;082-205-686-084-150;;004-711-972-902-946;;022-335-231-721-618;;033-860-685-078-510;;030-350-370-854-336;;028-055-567-547-811;;037-545-767-307-239;;035-301-483-062-782;;131-017-124-330-126;;007-667-415-133-658;;021-098-855-044-026;;008-183-028-841-916;;095-106-736-472-740;;049-405-579-110-966;;075-047-009-973-44X;;037-512-177-952-712;;060-800-340-605-623;;009-503-052-316-157;;007-925-955-154-483;;103-275-711-667-846;;023-587-280-394-438;;066-131-422-349-11X;;099-469-838-794-693;;102-281-190-744-117;;019-536-721-226-591;;001-204-399-695-503;;020-062-829-864-759;;067-737-153-284-487;;022-330-591-260-234;;135-137-082-731-766;;046-023-237-903-496;;093-045-312-080-541;;121-518-383-520-090;;033-498-549-394-94X;;079-520-583-100-711;;003-242-603-416-269;;067-150-855-259-97X;;010-178-649-896-819;;108-881-221-014-430;;004-311-145-219-702;;042-512-329-777-273;;046-036-735-898-442;;027-383-914-262-471;;040-264-748-392-762;;058-481-550-920-376;;073-835-353-251-029;;072-988-828-027-794;;069-708-899-792-963;;087-563-759-995-134;;012-175-186-083-895;;000-251-872-888-737;;012-958-316-105-812;;046-336-987-580-902;;122-000-826-139-951;;043-675-992-731-59X;;131-185-766-019-199;;003-638-443-959-029;;186-029-266-464-799;;096-045-894-674-161;;001-512-749-137-742;;006-577-722-573-48X;;128-071-138-067-970,21637011;;pmc3225656;;10.4161/bbug.2.4.15624;;21705527;;10.1128/aem.05228-11;;pmc3165266;;21187422;;pmc3021080;;10.1073/pnas.1010456108;;10.1007/s00253-011-3345-9;;21655987;;10.1099/00221287-148-9-2783;;12213924;;pmc95372;;10.1128/jb.183.17.4979-4984.2001;;11489849;;18524919;;10.1099/mic.0.2007/015511-0;;20871937;;10.1039/c0mb00063a;;9529885;;pmc98904;;10.1128/mmbr.62.1.1-34.1998;;14681414;;pmc308751;;10.1128/aem.00724-10;;pmc2937500;;20656867;;10.1002/bit.23014;;21246505;;10.1007/s00253-011-3164-z;;21336923;;10.1080/15572536.2005.11832998;;21148830;;10.1038/nbt1290;;17334359;;18676954;;pmc2547062;;10.1128/ec.00195-08;;10.1093/nar/gki953;;pmc1283539;;16287898;;10.1016/j.enzmictec.2008.03.001;;16575564;;10.1007/s00253-006-0402-x;;9836873;;10.1006/jmbi.1998.1750;;18640601;;10.1263/jbb.105.622;;10.1007/bf00167144;;8366083;;10.1016/s0021-9258(19)36523-8;;10.1007/s10295-008-0327-8;;18338189;;14554198;;10.1016/s1567-1356(03)00141-7;;pmc212329;;3298207;;10.1128/jb.169.7.2932-2937.1987;;16402921;;10.1042/bj20051465;;pmc1462686;;pmc37976;;10.1073/pnas.93.22.12251;;8901566;;10.1038/nbt0208-169;;18259168;;pmc120791;;10.1128/mmbr.66.3.506-577.2002;;12209002;;10.1007/s00253-008-1794-6;;19050860;;20348908;;10.1038/nature08867;;10.3410/f.1120793.577044;;10.1038/nbt1403;;18454138;;10.1073/pnas.0809575106;;19193860;;pmc2644145;;15122302;;10.1038/nbt967;;18751695;;10.1007/s00253-008-1649-1;;10.1016/s0040-4039(00)71455-9;;12964247;;10.1016/s0065-2164(03)01010-4;;10.1002/(sici)1097-0290(19980905)59:5<621::aid-bit13>3.0.co;2-c;;10.1002/(sici)1097-0290(19980905)59:5<621::aid-bit13>3.3.co;2-n;;10099380;;10392441;;10.1002/(sici)1097-0061(19990615)15:8<633::aid-yea407>3.0.co;2-o;;pmc1828828;;10.1128/aem.02515-06;;17261518;;10.1016/j.enzmictec.2008.04.003;;19777228;;10.1007/s00253-009-2236-9;;10.1006/jmbi.2000.4042;;10964570;;10.1007/bf02716813;;12962626;;10.1016/s0969-2126(03)00167-9;;16369541;;10.2210/pdb2b3p/pdb;;10.1038/nbt1172;;28563048;;10.2307/2407702;;10.1111/j.1558-5646.1976.tb00910.x;;pmc211617;;3053662;;10.1128/jb.170.11.5375-5377.1988;;10.1006/bbrc.1997.7558;;9367847;;10.1111/j.1432-1033.1997.00324.x;;9151960;;10.1016/s0141-0229(99)00035-6;;pmc2849174;;10.1038/nprot.2010.5;;20360767;;10.1038/nature07190;;18704079;;15486203;;pmc524302;;10.1093/nar/gkh894;;19002682;;10.1007/s00253-008-1773-y;;10.1186/1754-6834-3-5;;20236521;;pmc2851583;;12698321;;10.1007/s10295-003-0049-x;;17180689;;10.1007/s00253-006-0747-1;;2340178;;10.1007/3-540-45300-8_7;;11816810;;10.1016/s0074-7696(08)61935-x;;4267163;;10.1128/jb.179.17.5318-5320.1997;;9286982;;pmc179398;;pmc2483294;;10.1186/1471-2164-9-327;;18620557;;19074487;;10.1093/nar/gkn991;;pmc2632897;;10.1093/genetics/122.1.19;;2659436;;pmc1203683;;8929394;;10.1007/s002940050151;;10880472;;10.1093/genetics/155.3.1095;;pmc1461168;;10.1007/bf01021255;;10.1007/978-1-4612-0057-4_20;;12721449;;10.1385/abab:106:1-3:255;;10.1126/science.1139612;;17289987;;10.1007/s00253-007-1322-0;;18197406;;17938906;;10.1007/s00253-007-1225-0;;10.1016/s0960-8524(01)00212-7;;12058826;;10.1007/bf00279894;;8264527;;pmc2794032;;10.1073/pnas.0906810106;;20018766;;17449655;;pmc1951524;;10.1128/ec.00078-07;;10.1186/1471-2105-5-54;;15128431;;pmc420235;;10.1186/gb-2002-3-12-research0071;;12537560;;pmc151173;;10.1016/j.jbiotec.2005.06.013;;16084620;;10.1016/j.tibtech.2006.06.008;;16820235;;17768247;;10.1099/mic.0.2007/007856-0;;10.1093/nass/49.1.309;;10.1074/jbc.m409443200;;15623532;;pmc2292587;;18263741;;10.1128/aem.02395-07;;pmc1951023;;10.1128/aem.00177-07;;17545317;;10.1128/aem.02268-08;;pmc2643596;;19074603;;10.1128/aem.71.3.1642-1647.2005;;pmc1065158;;15746370;;10.1128/aem.00314-09;;19376920;;pmc2698378;;10.1016/0141-0229(93)90117-k;;10.1016/j.ab.2007.03.030;;pmc1949046;;17481563;;10.1016/j.biotechadv.2007.09.002;;17964107,"Galazka et al., ""A New Diet for Yeast to Improve Biofuel Production"", Bioengineered Bugs, vol. 2, Issue 4, Jul./Aug. 2011, pp. 1-4.;;Glazka et al., ""Improving the Bioconversion of Plant Biomass to Biofuels: A Multidisciplinary Approach"", Energy & Environmental Science, vol. 4, 2011, pp. 3329-3333.;;Ha et al., ""Cofermentation of Cellobiose and Galactose by an Engineered Saccharomyces cerevisiae Strain"", Applied and Environment Microbiology, vol. 77, No. 16, Aug. 2011, pp. 5822-5825.;;Ha et al., ""Engineered Saccharomyces cerevisiae Capable of Simultaneous Cellobiose and Xylose Fermentation"", Porceeding of the National Academy of Sciences, vol. 108, No. 2 Jan. 11, 2011, pp. 504-509.;;Ha, et al., ""Xylitol Does Inhibit Xylose Fermentation by Engineered Saccharomyces cerevisiae Expressing XyIA as Serverely as its Inhibits Xylose Isomerase Reaction in Vitro"", Applied Microbiology and Biotechnology, 2011, 8 pages.;;Hamacher et al., ""Characterization of the Xylose-transporting Properties of Yeast Hexose Transporters and their Influence on Xylose Utilization"", Microbiology, vol. 148, 2002, pp. 2783-2788.;;Koning et al., ""Cellobiose Uptake in the Hyperthermophilic Archaeon Pyrococcus furiosus Is Mediated by an Inducible, High-Affinity ABC Transporter"", Journal of Bacteriology, vol. 183, No. 17, Sep. 2001, pp. 4979-4984.;;Leandro et al., ""The Expression Saccharomyces cerevisiae of Glucose/xylose Symporter from Candida intermedia is Affected by Presence of a Glucose/xylose Facilitator"", Microbiology, vol. 154, 2008, pp. 1646-1655.;;Li et al., ""Overcoming Glucose Repressionin Mixed Sugar Fermentation by Co-expressing a Cellobiose Transporter and a beta-glucosidase in Saccharomyces cerevisiae"", Molecular BioSystems, vol. 6, 2010, pp. 2129-2132.;;Pao et al., ""Major Facilitator Superfamily"", Microbiology and Molecular Biology Reviews, vol. 62, No. 1, Mar. 1998, pp. 1-34.;;Ren et al., ""TransportDB: A Relational Database of Cellular Membrane Transport Systems"", Nucleic Acids Research, vol. 32, Database Issue, 2004, pp. D284-D288.;;Suzuki et al., ""Cellotriose and Cellotetraose as Inducers of the Genes Encoding Cellobiohydrolases in the Basidiomycete Phanerochaete chrysosporium"", Applied and Environmental Microbiology, vol. 76, No. 18, Sep. 2010, pp. 6164-6170.;;Shill et al., ""Ionic Liquid Pretreatment of Cellulosic Biomass: Enzymatic Hydrolysis and Ionic Liquid Recycle"" Biotechnology and Bioengineering, vol. 108, No. 3, Mar. 2011, pp. 511-520.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2010/43279, mailed on Apr. 26, 2011, 7 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2010/043279, mailed on Jul. 7, 2011, 16 pages.;;Sadie et al., ""Co-expression of a cellobiose phosphorylase and lactose permease enables intracellular cellobiose utilisation by Saccharomyces cerevisiae"", Applied Microbiology and Biotechnology, Feb. 20, 2011, 8 pages.;;Jacobson et al. (2004). ""Neurospora in temperate forests of western North America."" Mycologia 96(1):66-74.;;Jeffries et al. (2007). ""Genome sequence of the lignocellulose-bioconverting and xylose-fermenting yeast Pichia stipitis."" Nat Biotechnol 25(3):319-326.;;Kasuga et al. (2008). ""Dissecting colony development of Neurospora crassa using mRNA profiling and comparative genomics approaches."" Eukaryot Cell 7(9): 1549-64.;;Kasuga et al. (2005). ""Long-oligomer microarray profiling in Neurospora crassa reveals the transcriptional program underlying biochemical and physiological events of conidial germination."" Nucleic Acids Res 33(20): 6469-85.;;Katahira et al. (2008) ""Improvement of ethanol productivity during xylose and glucose co-fermentation by xylose-assimilating S. cerevisiae via expression of glucose transpoter Sut1."" Enzyme Microb Tech 43(2):115-119.;;Kathahira et al. (2006). ""Ethanol fermentation from lignocellulosic hydrolysates by a recombinant xylose- and cellooligosaccharide-assimilating yeast strain."" Appl Microbiol Biotechnol 72(6):1136-1143.;;Korkhin et al. (1998) ""NADP-dependent bacterial alcohol dehydrogenases: crystal structure, cofactor-binding and cofactor specificity of the ADHs of Clostridium beijerinckii and Thermoanaerobacter brockii."" J Mol Biol 278(5):967-981.;;Kotaka et al. (2008). ""Direct ethanol production from barley beta-glucan by sake yeast displaying Aspergillus oryzae beta-glucosidase and endoglucanases."" J Biosci Bioeng 105(6):622-627.;;Kötter, P. and M. Ciriacy (1993). ""Xylose fermentation by Saccharomyces cerevisiae."" Appl Microbiol Biotechnol 38(6):776-783.;;Kubicek et al. (1993). ""Triggering of cellulase biosynthesis by cellulose in Trichoderma reesei. Involvement of a constitutive, sophorose-inducible, glucose inhibited beta-diglucoside permease."" J Biol Chem 268(26):19364-19368.;;Kumar et al. (2008). ""Bioconversion of lignocellulosic biomass: biochemical and molecular perspectives."" J Ind Microbiol Biotechnol 35(5):377-391.;;Kuyer et al. (2003). ""High-level functional expession of a fungal xylose isomerase: the key to efficient ethanolic fermentation of xylose by Saccharomyces cerevisiae?"" FEMS Yeast Res 4(1):69-78.;;Lang, J. M. and V. P. Cirillo (1987). ""Glucose transport in a kinaseless Saccharomyces cerevisiae mutant."" J Bacteriol 169(7):2932-2937.;;Leandro et al. (2006). ""Two glucose/xylose transporter genes from the yeast Candida intermedia: first molecular characterization of a yeast xylose-H+ symporter."" Biochem J 395(3):543-549.;;Linder, M. and T. T. Teeri (1996). ""The cellulose-binding domain of the major cellobiohydrolase of Trichoderma reesei exhibits true reversibility and high exchang rate on crystalline cellulose."" Proc Natl Acad Sci USA 93(22):12251-12255.;;Lynd et al. (2008). ""How biotech can transform biofuels."" Nat. Biotechnol. 26(2):169-172.;;Lynd et al. (2002). ""Microbial cellulose utilization: fundamental and biotechnology."" Microbiol Mol Biol Rev 66(3):506-77, table of contents.;;Madhavan et al. (2009). ""Xylose isomerase from polycentric fungus orpinomyces: gene sequencing, cloning, and expression in Saccharomyces cerevisiae for bioconversion of xylose to ethanol.""Appl Microbiol Biotechnol 82(6):1067-1078.;;Martin et al. (2010). ""Périgord black truffle genome uncovers evolutionary origins and mechanisms and symbiosis."" Nature 464(7291):1033-1038.;;Martinez et al. (2008). ""Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina)."" Nat Biotechnol 36(5):553-60.;;Martinez et al. (2009). ""Genome, transcriptome, and secretome analysis of wood decay fungus Postia placenta supports unique mechanisms of lignocellulose conversion."" Proc Natl Acad Sci USA 106(6):1954-1959.;;Martinez et al. (2004). ""Genome sequence of the lignocellulose degrading fungus Phanerochaete chrysosporium strain RP78."" Nat Biotechnol 22(6):695-700.;;Matsushika et al. (2008) ""Expression of protein engineered NADP+-dependent xylitol dehydrogenase increases ethanol production from xylose in recombinant Saccharomyces cerevisiae."" Appl Microbiol Biotechnol 81(2):243-255.;;Matteucci, M. D. and M. H. Caruthers (1980). ""The synthesis of oligodeoxypyrimidines on a polymer support,"" Tetrahedron Lett 21:719-722.;;McCluskey, K. (2003). ""The Fungal Genetics Stock Center: from molds to molecules."" Adv Appl Mircrobiol 52:245-262.;;Medve et al. (1998). ""Hydrolysis of microcrystalline cellulose by cellobiohydrolas I and endoglucanase II from Trichoderma reesei: adsorption, sugar production pattern, and synergism of the enzymes."" Biotechnol Bioeng 59(5):621-34.;;Miyasaka, H. (1999). ""The positive relationship between codon usage bias and translation initiation AUG context in Saccharomyces cerevisiae."" Yeast 15(8):633-637.;;Nair, N. and H. Zhao (2007). ""Biochemical characterization of an L-Xylulose reductase from Neurospora crassa."" Appl Environ Microbiol 73(6):2001-2004.;;Nakamura et al. (2008). ""Effective xylose/cellobiose co-fermentation and ethanol production by xylose-assimilation S. cerevisiae via expression of beta-glucosidase on its cell surface."" Enzyme Microb Tech 43(3):233-236.;;Noguchi et al. (2009) ""Genes regulated by AoXlnR, the xylanolytic and cellulolytic transcriptional regulator, in Aspergillus oryzae."" Appl Microbiol Biotechnol 85(1):141-154.;;Notredame et al. (2000). ""T-Coffee: A novel method for fast and accurate multiple sequence alignment."" J Mol Biol 302(1):205-217.;;Pandit, A. and R. Maheshwari (1996). ""Life-history of Neurospora intermedia in a sugar cane field.""J biosci (Bangalore) 21(1):57-79.;;Pauly et al. (2003). ""X-ray crystallographic and kinetic studies of human sorbitol dehydrogenase."" Structure 11(9):1071-1085.;;Pedelacq et al. (2006). ""Engineering anc characterization of a superfolder green fluorescent protein."" Nat Biotechnol 24(1):79-88.;;Perkins et al. (1976). ""Strains of Neurospora collected from nature."" Evolution 30: 281-313.;;Ramos et al. (1988). ""Relationship between low- and high-affinity glucose transport systems of Saccharomyces cerevisiae."" J Bacteriol 170(11):5375-5377.;;Rawat, U. and M. Rao (1997). ""Site and significance of cysteine residues in xylose reductase from Neurospora crassa as deduced by fluorescence studies."" Biochemical and Biophysical Research Communications 239(3): 789-93.;;Reifenberger et al. (1997). ""Kinetic characterization of individual hexose transporters of Saccharomyces cerevisiae and their relation to the triggering mechanisms of glucose repression."" Eur J Biochem 245(2):324-333.;;Romero et al. (1999). ""Cellulase production by Neurospora crassa on wheat straw."" Enzyme Microb Tech 25: 244-250.;;Roy et al. (2010). ""I-TASSER: a unified platform for automated protein structure and function prediction."" Nat Protoc 5(4):725-738.;;Rubin E. M. (2008). ""Genomics of cellulosic biofuels."" Nature 454(7206):841-845.;;Ruepp et al. (2004). ""The FunCat, a functional annotation scheme for systematic classification of proteins from whole genomes."" Nucleic Acids Res 32(18):5539-5545.;;Runquist et al. (2009). ""Expression of the Gxf1 transporter from Candida intermedia improves fermentation performance in recombinant xylose-utilizing Saccharomyces cerevisiae."" Appl Microbiol Biotechnol 82(1):123-130.;;Runquist et al. (2010). ""Comparison of heterologous xylose transporter in recombinant Saccharomyces cerevisiae."" Biotechnol Biofuels 3:5.;;Saha, B. C. (2003). ""Hemicellulose bioconversion."" J Ind Microbiol Biotechnol 30:279-291.;;Saloheimo et al. (2007). ""Xylose transport studies with xylose-utilizing Saccharomyces cerevisiae strains expressing heterologous and homologous permeases."" Appl Microbiol Biotechnol 74(5):1041-1052.;;Sarkar, G. and S. S. Sommer (1990). ""The ""megaprimer"" method of site-directed mutagenesis."" Biotechniques 8(4):404-407.;;Sauer, U. (2001). ""Evolutionary engineering of industrially important microbial phenotypes."" Adv Biochem Eng Biotechnol 73:129-169.;;Scarborough, G. A. (1973). ""Transport in Neurospora."" Int Rev Cytol 34:103-122.;;Seiboth et al. (1997). ""Role of four major cellulases in triggering of cellulase gene expression by cellulose in Trichoderma reesei."" J Bacteriol 179(17):5318-5320.;;Seidl et al. (2008). ""The Hypocrea jecorina (Trichoderma reesei) hypercellulolytic mutant RUT C30 lacks a 85 kb (29 gene-encoding) region of the wild-type genome."" BMC Genomics 9:327.;;Shao et al. (2009). ""DNA assembler, an in vivo genetic method for rapid construction of biochemical pathways."" Nucleic Acids Res. 37(2):e16.;;Sikorski, R. S. and P. Hieter (1989). ""A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae."" Genetics 122(1):19-27.;;Skory et al. (1996). ""Expression and secretion of the Candida wickerhamii extracellular beta-glucosidase gene, bgIB, in Saccharomyces cerevisiae."" Curr Genet 30(5):417-422.;;Smith et al. (2000). ""Vegetative imcompatibility in the het-6 region of Neurospora crassa is mediated by two linked genes."" Genetics 155(3):1095-1104.;;Spindler et al. (May 1992). ""Evaluation of the cellobiose-fermenting yeast Brettanomyces custersii in the simultaneous saccharification and fermentation of cellulose,"" Biotech Lett 15(5):403-407.;;Spinder et al. (1989). ""Simultaneous saccharification and fermentation of pretreated wheat straw to ethanol with selected yeast strains of betaglucosidase supplementation,"" App. Biochem Biotech 20:529.;;Stambuk et al. (2003). ""D-Xylose transport by Candida succiphila and Kluyveromyces marxianus."" Appl Biochem Biotechnol 105-108:255-263.;;Stephanopoulos, G. (2007). ""Challenges in Engineering Microbes for Biofuels Production."" Science 315(5813):801-804.;;Stricker et al. (2008). ""Regulation of transcription of cellulases- and hemicellulases-encoding genes in Aspergillus niger and Hypocrea jecorina (Trichoderma reesei)."" Appl Microbiol Biotechnol 78(2):211-220.;;Sullivan, R. and H. Zhao (2007). ""Cloning, characterization, and mutational analysis of a highly active and stable L-arabinitol 4-dehydrogenase from Neuropora crassa."" Appl Microbiol Biotechnol 77(4):845-52.;;Sun Y. and J. Cheng (2002). ""Hydrolysis of lignocellulosic materials for ethanol production: a review."" Bioresource Technol 83(1):1-11.;;Suominen et al. (1993). ""High frequency one-step gene replacement in Trichoderma reesei. II. Effects of deletions of individual cellulase genes."" Mol Gen Genet 241(5-6):523-530.;;Tian et al. (2009). ""Systems analysis of plant cell wall degradation by the model filamentous fungus Neurospora crassa."" Proc Natl Acad Sci USA 106(52):22157-22162.;;Tian et al. (2007). ""Transcriptional profiling of cross pathway control in Neurospora crassa and comparative analysis of the Gcn4 and CPC1 regulons."" Eukaryot Cell 6(6): 1018-1029.;;Townsend J. P. (2004). ""Resolution of large and small differences in gene expression using models for the Bayesian analysis of gene expression levels and spotted DNA microarrays."" BMC Bioinformatics 5:54.;;Townsend J. P. and D. L. Hartl (2002). ""Bayesian analysis of gene expression levels: statistical quantification of relative mRNA level across multiple strains or treatments."" Genome Biol 3(12):research0071.1-0071.16.;;USDA, ""The Economic Feasibility of Ethanol Production from Sugar in the United States,"" United States Department of Agriculture (2006), 78 pages.;;Van Rooyen et al. (2005). ""Construction of cellobiose-growing and fermenting Saccharomyces cerevisiae strains."" J Biotechnol 120(3):284-295.;;Vogel, H. J. (1956). ""A convenient growth medium fro Neurospora."" Microbiol. Genet. Bull. 13:42-46.;;Wagner et al. (2006). ""Rationalizing membrane protein overexpression."" Trends Biotechnol 24(8):364-371.;;Watanabe et al. (2007). ""Ethanol production from xylose by recombinant Saccharomyces cerevisiae expressing protein-engineered NADH-preferring xylose reductase from Pichia stipitis."" Microbiology 153(Pt 9):3044-3054.;;Watanabe et al. (2005). ""L-Arabinose 1-dehydrogenase: a novel enzyme involving in bacterial L-arabinose metabolism."" Nucleic Acids Symp Ser (Oxf) 48:309-310.;;Watanabe et al. (2005). ""Complete reversal of coenzyme specificity of xylitol dehydrogenase and increase of thermostability by the introduction of structural zinc."" J Biol Chem 280(11):10340-10349.;;Wiedemann, B. and E. Boles (2008). ""Codon-optimized bacterial genes improve L-arabinose fermentation in recombinant Saccharomyces cerevisiae."" Appl Environ Microbiol 74(7):2043-2050.;;Wisselink et al. (2007). ""Engineering of Saccharomyces cerevisiae for efficient anaerobic alcoholic fermentation of L-arabinose."" Appl Environ Microbiol 73(15):4881-4891.;;Wisselink et al. (2009). ""Novel Evolutionary Engineering Approach for Accelerated Utilization of Glucose, Xylose, and Arabinose Mixtures by Engineered Saccharomyces cerevisiae Strains."" Appl Environ Microbiol 75(4):907-914.;;Woodyer et al. (2005). ""Heterologous expression, purification, and characterization of a highly active xylose reductase from Neurospora crassa."" Appl. Environ Microbiol 71(3): 1642-7;;Wymelenberg et al. (2009). ""Transcriptome and Secretome Analyses of Phanerochaete Chrysosporium Reveal Complex Patterns of Gene Expression."" Appl Environ Microbiol 75(12):4058-4068.;;Xin et al. (1993). ""Acceleration of ethanol production from paper mill waste fiber by supplementation with beta-glucosidase."" Enzyme Microb Tech 15(1):62.;;International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2010/043279, mailed on Feb. 2, 2012, 10 pages.;;Arendt et al. (2007). ""Genetic selection for a highly functional cysteine-less membrane protein using site saturation mutagenesis."" Anal Biochem 365(2):185-193.;;Bai et al. (2008). ""Ethanol fermentation technologies from sugar and starch feedstocks."" Biotechnol Adv 26(1): 89-105.",INACTIVE
392,WO,A1,WO 2018/098366 A1,174-495-459-286-688,2018-05-31,2018,US 2017/0063138 W,2017-11-22,US 201615362709 A;;US 201615362691 A,2016-11-28,LOCALIZED DEVICE COORDINATOR WITH ON-DEMAND CODE EXECUTION CAPABILITIES,"Systems and methods are described for configuring a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinated devices may include devices configured to be managed remotely, such as thin devices, devices with alternative primary functions (e.g., appliances, household objects, etc.), or devices with limited localized user interfaces. To manage the set of coordinated devices, the coordinator can execute tasks, each task corresponding to a set of portable code executable by the coordinator to implement a desired functionality. A user may generate one or more tasks, and submit them to a service provider environment for deployment to the coordinator. The service provider environment can utilize a device shadow to notify the coordinator of the obtained tasks, and thereafter deliver the tasks to the coordinator, thus modifying a configuration of the coordinator.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKKER MARC JOHN;;SORENSON JAMES CHRISTOPHER III;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,,https://lens.org/174-495-459-286-688,Patent Application,yes,4,9,8,12,0,G06F8/63,G06F8/61,,0,0,,,,PENDING
393,BR,A2,BR 112022009938 A2,167-953-634-301-147,2022-09-13,2022,BR 112022009938 A,2020-11-25,US 2020/0062320 W;;US 201962939825 P;;US 202063030979 P,2019-11-25,COMPOSTOS MACROCÍCLICOS SUBSTITUÍDOS E MÉTODOS DE TRATAMENTO RELACIONADOS,COMPOSTOS MACROCÍCLICOS SUBSTITUÍDOS E MÉTODOS DE TRATAMENTO RELACIONADOS. A presente invenção fornece os compostos (I) e (II) úteis para o tratamento de narcolepsia ou cataplexia em um indivíduo em necessidade do mesmo. Composições farmacêuticas e métodos relacionados também são fornecidos na presente invenção.,ALKERMES INC,LEWIS D PENNINGTON;;YOUNGGI CHOI;;HOAN HUYNH;;BRIAN M AQUILA;;INGO MUGGE;;YUAN HU;;JAMES R WOODS;;ROMAN A VALIULIN;;BRIAN KENNETH RAYMER;;JORG MARTIN BENTZIEN;;MICHAEL R HALE;;JONATHAN WARD LEHMANN;;DALJIT MATHARU;;SRINIVASA KARRA,,https://lens.org/167-953-634-301-147,Patent Application,no,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/04;;A61K31/407;;A61K31/4353;;A61P43/00;;C07D498/14,,0,0,,,,PENDING
394,US,A1,US 2015/0010985 A1,088-096-962-158-848,2015-01-08,2015,US 201414289570 A,2014-05-28,US 201414289570 A;;US 201313802533 A;;US 84384410 A;;US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-04);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/088-096-962-158-848,Patent Application,yes,0,2,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/81;;C12N15/80,435/252.31;;435/254.2;;435/254.21;;435/254.23;;435/254.11;;435/254.22;;435/252.3;;435/252.33;;435/254.4,0,0,,,,INACTIVE
395,KR,A,KR 20230127254 A,132-476-779-379-499,2023-08-31,2023,KR 20237024587 A,2021-12-21,US 202063128404 P;;US 202163190937 P;;US 2021/0064483 W,2020-12-21,치환된 거대고리 화합물 및 관련 치료방법,본 발명은 이를 필요로 하는 대상체에서 기면증 또는 탈력발작의 치료에 유용한 화합물을 제공한다. 관련 약제학적 조성물 및 방법이 또한 본원에 제공된다.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JOERG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,,https://lens.org/132-476-779-379-499,Patent Application,no,0,0,8,9,0,C07D498/04;;C07D498/14;;C07D498/04;;C07D498/14;;C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14;;C07D498/04;;C07D498/14,C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14,,0,0,,,,PENDING
396,WO,A8,WO 2018/098366 A8,004-240-177-733-68X,2019-06-06,2019,US 2017/0063138 W,2017-11-22,US 201615362709 A;;US 201615362691 A,2016-11-28,LOCALIZED DEVICE COORDINATOR WITH ON-DEMAND CODE EXECUTION CAPABILITIES,"Systems and methods are described for configuring a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinated devices may include devices configured to be managed remotely, such as thin devices, devices with alternative primary functions (e.g., appliances, household objects, etc.), or devices with limited localized user interfaces. To manage the set of coordinated devices, the coordinator can execute tasks, each task corresponding to a set of portable code executable by the coordinator to implement a desired functionality. A user may generate one or more tasks, and submit them to a service provider environment for deployment to the coordinator. The service provider environment can utilize a device shadow to notify the coordinator of the obtained tasks, and thereafter deliver the tasks to the coordinator, thus modifying a configuration of the coordinator.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER III;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,,https://lens.org/004-240-177-733-68X,Amended Application,yes,0,0,8,12,0,G06F8/63,G06F8/61,,0,0,,,,PENDING
397,CN,A,CN 110352401 A,140-089-186-503-706,2019-10-18,2019,CN 201780076093 A,2017-11-22,US 201615362709 A;;US 201615362691 A;;US 2017/0063138 W,2016-11-28,LOCALIZED DEVICE COORDINATOR WITH ON-DEMAND CODE EXECUTION CAPABILITIES,"Systems and methods are described for configuring a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinated devices may include devices configured to be managed remotely, such as thin devices, devices with alternative primary functions (e.g., appliances, household objects, etc.), or devices with limited localized user interfaces. To manage the set of coordinated devices, the coordinator can execute tasks, each task corresponding to a set of portable code executable by the coordinator to implement a desiredfunctionality. A user may generate one or more tasks, and submit them to a service provider environment for deployment to the coordinator. The service provider environment can utilize a device shadowto notify the coordinator of the obtained tasks, and thereafter deliver the tasks to the coordinator, thus modifying a configuration of the coordinator.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKKER MARC JOHN;;SORENSON JAMES CHRISTOPHER III;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,,https://lens.org/140-089-186-503-706,Patent Application,no,2,0,8,12,0,G06F8/63,G06F8/61,,1,0,,,"郑小奔等: ""基于ZigBee的远程温度监测系统"", 《电子世界》",ACTIVE
398,US,A1,US 2021/0155636 A1,003-100-859-813-248,2021-05-27,2021,US 202017104993 A,2020-11-25,US 202017104993 A;;US 201962939825 P;;US 202063030979 P,2019-11-25,Substituted Macrocyclic Compounds and Related Methods of Treatment,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,ALKERMES INC (2022-09-06),https://lens.org/003-100-859-813-248,Patent Application,yes,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/08;;A61P25/26;;C07D498/18;;C07D498/22,,0,0,,,,ACTIVE
399,AU,A1,AU 2020/394444 A1,083-890-024-170-61X,2022-05-19,2022,AU 2020/394444 A,2020-11-25,US 201962939825 P;;US 202063030979 P;;US 2020/0062320 W,2019-11-25,Substituted macrocyclic compounds and related methods of treatment,The present invention provides compounds (I) and (II) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,,https://lens.org/083-890-024-170-61X,Patent Application,no,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/04;;A61K31/407;;A61K31/4353;;A61P43/00;;C07D498/14,,0,0,,,,PENDING
400,US,B2,US 8765410 B2,135-122-476-114-566,2014-07-01,2014,US 201313802533 A,2013-03-13,US 201313802533 A;;US 84384410 A;;US 27183309 P;;US 28552609 P,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-04);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/135-122-476-114-566,Granted Patent,yes,6,2,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N1/00;;C12P21/04;;C12P21/06,435/69.1;;435/71.1;;435/243,99,90,103-762-254-011-523;;065-546-909-769-86X;;060-671-554-793-705;;128-879-801-420-972;;053-720-311-324-984;;015-339-468-695-846;;099-940-450-305-541;;025-622-213-088-485;;068-183-326-130-940;;061-774-608-000-01X;;086-354-734-216-897;;052-392-453-181-409;;011-250-531-318-343;;057-722-409-149-269;;083-475-617-712-21X;;060-906-287-443-607;;003-546-581-906-613;;032-443-849-864-806;;085-737-768-545-623;;007-156-472-140-294;;020-807-488-825-412;;057-694-351-421-112;;031-884-777-774-381;;054-822-635-975-947;;033-828-770-147-584;;036-168-690-647-51X;;082-205-686-084-150;;004-711-972-902-946;;030-350-370-854-336;;022-335-231-721-618;;033-860-685-078-510;;037-545-767-307-239;;028-055-567-547-811;;035-301-483-062-782;;131-017-124-330-126;;007-667-415-133-658;;021-098-855-044-026;;008-183-028-841-916;;095-106-736-472-740;;049-405-579-110-966;;127-130-779-608-635;;075-047-009-973-44X;;102-059-025-734-508;;037-512-177-952-712;;060-800-340-605-623;;009-503-052-316-157;;007-925-955-154-483;;103-275-711-667-846;;023-587-280-394-438;;120-631-641-472-887;;066-131-422-349-11X;;012-175-186-083-895;;099-469-838-794-693;;102-281-190-744-117;;006-577-722-573-48X;;128-071-138-067-970;;081-290-558-102-206;;035-843-917-830-483;;063-678-090-852-543;;012-664-972-064-410;;162-539-202-235-435;;019-074-494-534-434;;037-097-619-482-303;;068-890-487-449-365;;075-835-132-348-380;;008-696-490-221-024;;011-280-629-876-084;;103-562-826-985-766;;033-588-082-976-645;;046-341-173-970-705;;149-091-707-097-038;;011-229-298-780-032;;019-223-124-229-682;;111-467-548-133-866;;021-609-197-843-61X;;010-298-278-480-203;;164-351-930-733-836;;041-866-054-953-283;;080-024-606-821-929;;097-365-853-642-277;;069-678-872-167-450;;052-186-686-935-921;;074-085-602-018-663;;072-144-107-528-054;;044-593-766-784-615;;068-301-509-352-604;;036-488-749-216-726;;066-616-314-405-933;;014-838-854-923-114;;050-107-176-956-094,10.1111/j.1364-3703.2007.00458.x;;18705852;;pmc6640386;;20829451;;10.1126/science.1192838;;15612919;;10.1111/j.1365-2958.2004.04374.x;;11713254;;10.1074/jbc.m109157200;;10.1093/oxfordjournals.jbchem.a123761;;1587797;;10.1080/15572536.2005.11832998;;21148830;;10.1038/nbt1290;;17334359;;18676954;;pmc2547062;;10.1128/ec.00195-08;;10.1093/nar/gki953;;pmc1283539;;16287898;;16575564;;10.1007/s00253-006-0402-x;;10.1016/j.enzmictec.2008.03.001;;pmc95372;;10.1128/jb.183.17.4979-4984.2001;;11489849;;9836873;;10.1006/jmbi.1998.1750;;18640601;;10.1263/jbb.105.622;;10.1007/bf00167144;;8366083;;10.1016/s0021-9258(19)36523-8;;10.1007/s10295-008-0327-8;;18338189;;14554198;;10.1016/s1567-1356(03)00141-7;;pmc212329;;3298207;;10.1128/jb.169.7.2932-2937.1987;;10.1146/annurev.micro.61.080706.093329;;18537473;;pmc2612782;;18524919;;10.1099/mic.0.2007/015511-0;;16402921;;10.1042/bj20051465;;pmc1462686;;20871937;;10.1039/c0mb00063a;;pmc37976;;10.1073/pnas.93.22.12251;;8901566;;10.1038/nbt0208-169;;18259168;;pmc120791;;10.1128/mmbr.66.3.506-577.2002;;12209002;;10.1007/s00253-008-1794-6;;19050860;;20348908;;10.1038/nature08867;;15122302;;10.1038/nbt967;;10.3410/f.1120793.577044;;10.1038/nbt1403;;18454138;;10.1073/pnas.0809575106;;19193860;;pmc2644145;;10.1016/s0040-4039(00)71455-9;;18751695;;10.1007/s00253-008-1649-1;;12964247;;10.1016/s0065-2164(03)01010-4;;10.1002/(sici)1097-0290(19980905)59:5<621::aid-bit13>3.0.co;2-c;;10.1002/(sici)1097-0290(19980905)59:5<621::aid-bit13>3.3.co;2-n;;10099380;;10392441;;10.1002/(sici)1097-0061(19990615)15:8<633::aid-yea407>3.0.co;2-o;;pmc1828828;;10.1128/aem.02515-06;;17261518;;10.1016/j.enzmictec.2008.04.003;;19777228;;10.1007/s00253-009-2236-9;;10.1006/jmbi.2000.4042;;10964570;;10.1016/s0006-3495(98)77529-0;;9649402;;pmc1299714;;10.1007/bf02716813;;9529885;;pmc98904;;10.1128/mmbr.62.1.1-34.1998;;12962626;;10.1016/s0969-2126(03)00167-9;;16369541;;10.2210/pdb2b3p/pdb;;10.1038/nbt1172;;28563048;;10.2307/2407702;;10.1111/j.1558-5646.1976.tb00910.x;;pmc211617;;3053662;;10.1128/jb.170.11.5375-5377.1988;;10.1006/bbrc.1997.7558;;9367847;;10.1111/j.1432-1033.1997.00324.x;;9151960;;14681414;;pmc308751;;10.1016/s0141-0229(99)00035-6;;10.1016/j.jbiotec.2005.06.013;;16084620;;pmc2849174;;10.1038/nprot.2010.5;;20360767;;10.1038/nature07190;;18704079;;10.1016/j.ab.2007.03.030;;pmc1949046;;17481563;;10.1016/j.biotechadv.2007.09.002;;17964107;;10.1016/0168-1656(92)90074-j;;18752628;;10.1111/j.1567-1364.2008.00428.x;;19416504;;pmc2688486;;10.1186/1754-6834-2-9;;pmc204077;;16347439;;10.1128/aem.53.9.2175-2182.1987;;7966338;;10.1006/jmbi.1994.1728;;18636256;;10.1007/s00253-008-1572-5;;10.1128/aem.02522-08;;pmc2675233;;19218403;;10.1016/0076-6879(88)60152-2;;18838391;;pmc2686590;;10.1093/nar/gkn663;;pmc2847552;;20181208;;10.1186/1754-6834-3-3;;7727348;;10.1016/0141-8130(94)90065-5;;1544568;;10.1016/0378-1119(92)90454-w;;17524590;;10.1016/j.biotechadv.2007.04.001;;16801547;;pmc1482798;;10.1073/pnas.0601456103;;pmc306460;;10.1093/nar/15.22.9163;;2825130;;pmc1221054;;10.1042/0264-6021:3480201;;10.2210/pdb1dys/pdb;;10.1042/bj3480201;;10794732;;10.1038/nrg797;;11988765;;10.1021/bp050189o;;16321042;;17012538;;10.1128/ec.00253-06;;pmc1694810;;10.1007/978-1-60761-214-8_17;;19768628;;10.1080/10242420802564358;;pmc3673015;;10.1016/s0065-2660(06)57002-6;;17352902;;10.1007/bf00261920;;pmc235191;;15975;;10.1128/jb.130.1.181-186.1977;;10.1016/s0076-6879(82)87025-0;;7176924;;pmc2441463;;10.1186/gb-2008-9-5-r77;;18460219;;17627668;;10.1111/j.1742-4658.2007.05892.x;;2115884;;10.1016/s0021-9258(19)38239-0;;10.1128/aem.57.3.655-659.1991;;2039228;;pmc182775;;10.1038/nature01554;;12712197;;21637011;;pmc3225656;;10.4161/bbug.2.4.15624;;10.1039/c1ee01569a;;10.1016/0378-1119(91)90104-j;;2013411;;10.1080/10635150390235520;;14530136,"Office Action recieved for Chinese Patent Application No. 201080039858.9, mailed on Feb. 5, 2013, 12 pages (5 pages of English Translation and 7 pages of Office Action).;;Extended European Search Report and Search Opinion received for European Patent Application No. 10803022.2, mailed on Dec. 3, 2012, 7 pages.;;Bluhm et al., ""Involvement of ZFR1 of Fusarium verticillioides in Kernel Colonization and the Regulation of FST1, a Putative Sugar Transporter Gene Required for Fumonisin Biosynthesis on Maize Kernels"", Molecular Plant Pathology, vol. 9, No. 2, 2008, pp. 203-211.;;Galazka et al., ""Cellodextrin Transport in Yeast for Improved Biofuel Production"", Science, vol. 330, Oct. 1, 2010, pp. 84-86.;;Karlyshev et al., ""Analysis of Campylobacter jejuni Capsular Loci Reveals Multiple Mechanisms for the Generation of Structural Diversity and the Ability to Form Complex Heptoses"", Molecular Microbiology, vol. 55, No. 1, 2005, pp. 90-103.;;Mueckler et al., ""Analysis of Transmembrane Segment 10 of the Glut1 Glucose Transporter by Cysteine-Scanning Mutagenesis and Substituted Cysteine Accessibility"", The Journal of Biological Chemistry, vol. 277, No. 5, Feb. 1, 2002, pp. 3498-3503.;;Hosaka et al., ""A Dominant Mutation that Alters the Regulation of INO1 Expression in Saccharomyces cerevisiae"" , J. Biochem., vol. 111, No. 3, 1992, pp. 352-358.;;Jacobson et al., ""Neurospora in Temperate Forests of Western North America"", Mycologia, vol. 96, No. 1, 2004, pp. 66-74.;;Jeffries et al., ""Genome Sequence of the Lignoceliulose-Bioconverting and Xylose-Fermenting Yeast Pichia stipitis"", Nature Biotechnology vol. 25, No. 3, Mar. 2007, pp. 319-326.;;Kasuga et al., ""Dissecting Colony Development of Neurospora crassa Using mRNA Profiling and Comparative Genomics Approaches"", Eukaryotic Cell, vol. 7, No. 9, Sep. 2008, pp. 1549-1564.;;Kasuga et al., ""Long-Oligomer Microarray Profiling in Neurospora crassa Reveals the Transcriptional Program Underlying Biochemical and Physiological Events of Conidial Germination"", Nucleic Acids Research, vol. 33, No. 20, Nov. 14, 2005, pp. 6469-6485.;;Katahira et al., ""Ethanol Fermentation from Lignocellulosic Hydrolysate by a Recombinant Xylose- and Cellooligosaccharide-Assimilating Yeast Strain"", Appl Microbiol. Biotechnol, vol. 72, Mar. 31, 2006, pp. 1136-1143.;;Katahira et al., ""Improvement of Ethanol Productivity During Xylose and Glucose Co-Fermentation by Xylose-Assimilating S. cerevisiae via Expression of Glucose Transporter Sut1"", Enzyme and Microbial Technology, vol. 43, 2008, pp. 115-119.;;Koning et al., ""Cellobiose Uptake in the Hyperthermophilic Archaeon Pyrococcus furiosus is Mediatied by an Inducibile, High-Affinity ABC Transporter"", Journal of Bacteriology, vol. 183, No. 17, Sep. 2001, pp. 4979-4984.;;Korkhin et al., ""NADP-Dependent Bacterial Alcohol Dehydrogenases: Crystal Structure, Cofactor-Binding and Cofactor Specificity of the ADHs of Clostridium beijerinckii and Thermoanaerobacter brockii"", J. Mol. Biol., vol. 278, 1998, pp. 967-981.;;Kotaka et al., ""Direct Ethanol Production from Barley Beta-Glucan by Sake Yeast Displaying Aspergillus oryzae Beta-Glucosidase and Endoglucanase"", Journal of Bioscience and Bioengineering, vol. 105, No. 6, 2008, pp. 622-627.;;Kotter et al., ""Xylose Fermentation by Saccharomyces cerevisiae"", Appl Microbiol. Biotechnol, vol. 38, 1993, pp. 776-783.;;Kubicek et al., ""Triggering of Cellulase Biosynthesis by Cellulose in Trichoderma reesei-Involvement of a Constitutive, Sophorose-Inducible, Glucose-Inhibited Beta-Diglucoside Permease"", Journal of Biological Chemistry, vol. 268, No. 26, Sep. 15, 1993, pp. 19364-19368.;;Kumar et al., ""Bioconversion of Lignocellulosic Biomass : Biochemical and Molecular Perspectives"", J lnd Microbiol Biotechnol, vol. 35, Mar. 13, 2008, pp. 377-391.;;Kuyper et al., ""High-level Functional Expression of a Fungal Xylose Isomerase: The Key to Efficient Ethanolic Fermentation of Xylose by Saccharomyces cerevisiae?"", FEMS Yeast Research, vol. 4, May 13, 2003, pp. 69-78.;;Lang et al., ""Glucose Transport in a Kinaseless Saccharomyces cerevisiae Mutant"", Journal of Bacteriology, vol. 169, No. 7, Jul. 1987, pp. 2932-2937.;;Law et al., ""Ins and Outs of Major Facilitator Superfamily Antiporters"", NIH Public Access, Author Manuscript, Annu Rev Microbiol., vol. 62, 2008, pp. 289-305.;;Leandro et al., ""The Expression in Saccharomyces cerevisiae of a Glucose/Xylose Symporter from Candida intermedia is Affected by the Presence of a Glucose/Xylose Facilitator"", Microbiology, vol. 154, 2008, pp. 1646-1655.;;Leandro et al., ""Two Glucose/Xylose Transporter Genes from the Yeast Candida intermedia: First Molecular Characterization of a Yeast Xylose/H+ Symporter"", Biochemical Journal, Jan. 11, 2006, pp. 1-28.;;Li et al., ""Overcoming Glucose Repression in Mixed Sugar Fermentation by Co-expressing a Cellobiose Transporter and a beta-glucosidase in Saccharomyces cerevisiae"", Molecular BioSystems, vol. 6, 2010, pp. 2129-2132.;;Linder et al., ""The Cellulose-Binding Domain of the Major Cellobiohydrolase of Trichoderma reesei Exhibits True Reversibility and a High Exchange Rate on Crystalline Cellulose"", Biochemistry, Proc. Natl. Acad. Sci. USA, vol. 93, Oct. 1996, pp. 12251-12255.;;Lynd et al., ""How Biotech Can Transform Biofuels"", Nature Biotechnology, vol. 26, No. 2, Feb. 2008, pp. 169-172.;;Lynd et al., ""Microbial Cellulose Utilization: Fundamentals and Biotechnology"", Microbiology and Molecular Biology Reviews, vol. 66, No. 3, Sep. 2002, pp. 506-577.;;Madhavan et al., ""Xylose Isomerase from Polycentric Fungus Orpinomyces: Gene Sequencing, Cloning, and Expression in Saccharomyces cerevisiae for Bioconversion of Xylose to Ethanol"", Appl Microbiol Biotechnol, vol. 82, 2009, pp. 1067-1078.;;Martin et al., ""Perigord Black Truffle Genome Uncovers Evolutionary Origins and Mechanisms of Symbiosis"", Nature Latters, vol. 464, Apr. 15, 2010, pp. 1033-1038.;;Martinez et al., ""Genome Sequence of the Lignocellulose Degrading Fungus Phanerochaete chrysosporium Strain RP78"", Nature Biotechnology, vol. 22, No. 6, Jun. 2004, pp. 695-700.;;Martinez et al., ""Genome Sequencing and Analysis of the Biomass-Degrading Trichoderma reesei (Syn. Hypocrea jecorina)"", Nature Biotechnology, vol. 26, No. 5, May 2008, pp. 553-560.;;Martinez et al., ""Genome, Transcriptome, and Secretome Analysis of Wood Decay Fungus Postia placenta Supports Unique Mechanisms of Lignocellulose Conversion"", PNAS, vol. 106, No. 6, Feb. 10, 2009, pp. 1954-1959.;;Matteucci et al., ""The Synthesis of Oligodeoxypyrimidines on a Polymer Support"", Tetrahedron Letters, vol. 21, 1980, pp. 719-722.;;Matsushika et al., ""Expression of Protein Engineered NADP+-Dependent Xylitol Dehydrogenase Increases Ethanol Production from Xylose in Recombinant Saccharomyces cerevisiae"", Appl Microbiol Biotechnol, vol. 81, Aug. 27, 2008, pp. 243-255.;;McCluskey, Kevin, ""The Fungal Genetics Stock Center: from Molds to Molecules"", Advances in Applied Microbiology, vol. 52, 2003, pp. 245-262.;;Medve et al., ""Hydrolysis of Microcrystalline Cellulose by Cellobiohydrolase I and Endoglucanase II from Trichoderma reesei: Adsorption, Sugar Production Pattern, and Synergism of the Enzymes"", Biotechnology and Bioengineering, vol. 59, No. 5, Sep. 5, 1998, pp. 621-634.;;Miyasaka, Hitoshi, ""The Positive Relationship Between Codon Usage Bias and Translation Initiation AUG Context in Saccharomyces cerevisiae"", Yeast, vol. 15, 1999, pp. 633-637.;;Nair et al., ""Biochemical Characterization of an L-Xylulose Reductase from Neurospora crassa"", Applied and Environmental Microbiology, vol. 73, No. 6, Mar. 2007, pp. 2001-2004.;;Nakamura et al., ""Effective Xylose/Cellobiose Co-Fermentation and Ethanol Production by Xylose-Assimilating S. cerevisiae via Expression of Beta-Glucosidase on its Cell Surface"", Enzyme and Microbial Technology, vol. 43, 2008, pp. 233-236.;;Noguchi et al., ""Genes Regulated by AoXInR, the Xylanolytic and Cellulolytic Transcriptional Regulator, in Aspergillus oryzae"", Appl Microbiol Biotechnol, vol. 85, Sep. 24, 2009, pp. 141-154.;;Notredame et al., ""T-Coffee: A Novel Method for Fast and Accurate Multiple Sequence Alignment"", J. Mol. Biol., vol. 302, 2000, pp. 205-217.;;Pace et al., ""A Helix Propensity Scale Based on Experimental Studies of Peptides and Proteins"" Biophysical Journal, vol. 75, Jul. 1998, pp. 422-427.;;Pandit et al., ""Life-History of Neurospora intermedia in a Sugar Cane Field"" J. Biosci., vol. 21, No. 1, Mar. 1996, pp. 57-79.;;Pao et al., ""Major Facilitator Superfamily"", Microbiology and Molecular Biology Reviews, vol. 62, No. 1, Mar. 1998, pp. 1-34.;;Pauly et al., ""X-Ray Crystallographic and Kinetic Studies of Human Sorbitol Dehydrogenase"", Structure, vol. 11, Sep. 2003, pp. 1071-1085.;;Pedelacq et al., ""Engineering and Characterization of a Superfolder Green Fluorescent Protein"", Nature Biotechnology, vol. 24, No. 1, Jan. 2006, pp. 79-88.;;Perkins et al., ""Strains of Neurospora Collected from Nature"", Evolution, vol. 30, Jun. 1976, pp. 281-313.;;Ramos et al., ""Relationship Between Low- and High-Affinity Glucose Transport Systems of Saccharomyces cerevisiae"" Journal of Bacteriology, vol. 170, No. 11, Nov. 1988, pp. 5375-5377.;;Rawat et al., ""Site and Significance of Cysteine Residues in Xylose Reductase from Neurospora crassa as Deduced by Fluorescence Studies"", Biochemical and Biophysical Research Communications, Article No. RC977558, vol. 239, No. 3, 1997, pp. 789-793.;;Reifenberger et al., ""Kinetic Characterization of Individual Hexose Transporters of Saccharomyces cerevisiae and their Relation to the Triggering Mechanisms of Glucose Repression"", Eur. J. Biochem., vol. 245, 1997, pp. 324-333.;;Ren et al. ""TransportDB: A Relational Database of Cellular Membrane Transport Systems"", Nucleic Acids Research, vol. 32, Database Issue, 2004, pp. D284-D288.;;Romero et al., ""Cellulase Production by Neurospora crassa on Wheat Straw"", Enzyme and Mlcrobial Technology, vol. 25, 1999, pp. 244-250.;;Rooyen et al., ""Construction of Cellobiose-Growing and Fermenting Saccharomyces cerevisiae Strains"", Journal of Biotechnology, vol. 120, 2005, pp. 284-295.;;Roy et al., ""I-Tasser: A Unified Platform for Automated Protein Structure and Function Prediction"", Nature Protocols, vol. 5, No. 4, 2010, pp. 725-738.;;Rubin, Edward M., ""Genomics of Cellulosic Biofuels"", Nature, vol. 454, Aug. 14, 2008, pp. 841-845.;;Invitation to Pay Additional Fees recieved for PCT Patent Application No. PCT/US2010/043279, mailed on Apr. 26, 2011, 7 pages.;;International Search Report and Written Opinion recieved for PCT Patent Application No. PCT/US2010/043279, mailed on Jul. 7, 2011, 16 pages.;;International Preliminary Report on Patentability recieved for PCT Patent Application No. PCT/US2010/043279, mailed on Feb. 2, 2012, 10 pages.;;Non Final Office Action recieved for U.S. Appl. No. 12/843,844, mailed on Jul. 2, 2012, 11 pages.;;Notice of Allowance recieved for U.S. Appl. No. 12/843,844, mailed on Dec. 26, 2012, 7 pages.;;Arendt et al., ""Genetic Selection for a Highly Functional Cysteine-Less Membrane Protein Using Site Saturation Mutagenesis"", Analytical Biochemistry, vol. 365, 2007, pp. 185-193.;;Bai et al., ""Ethanol Fermentation Techniques from Sugar and Starch Feedstocks"", Biotechnology Advances, vol. 26, 2008, pp. 89-105.;;Bailey et al., ""Interlaboratory Testing of Methods for Assay of Xylanase Activity"", Journal of Biotechnology, vol. 23, 1992, pp. 257-270.;;Basso et al., ""Yeast Selection for Fuel Ethanol Production in Brazil"", FEMS Yeast Res, vol. 8, Aug. 22, 2008, pp. 1155-1163.;;Becker et al., ""Manipulation of Yeast Genes-Introduction of DNA into Yeast Cells"", Current Protocols in Molecular Biology, Section III, Unit 13.7, 1993, pp. 13.7.1-13.7.10.;;Bendtsen et al., ""Improved Prediction of Signal Peptides: SignaIP 3.0"", J. Mol. Biol., 2004, pp. 1-22.;;Bengsston et al., ""Xylose Reductase from Pichia stipitis with Altered Coenzyme Preference Improves Ethanolic Xylose Fermentation by Recombinant Saccharomyces cerevisiae"", Biotechnology for Biofuels, vol. 2, May 5, 2009, 10 pages.;;Bhat et al., ""Sporotrichum thermophile Growth, Cellulose Degradation, and Cellulase Activity"", Applied and Environmental Microbiology, vol. 53, No. 9, Sep. 1987, pp. 2175-2182.;;Bouffard et al., ""Dependence of Lactose Metabolism upon Mutarotase Encoded in the Gal Operon in Escherichia coli"", J. Mol. Biol., vol. 244, 1994, pp. 269-278.;;Bouws et al., ""Fungal Secretomes-Nature's Toolbox for White Biotechnology"", Appl Microbiol Biotechnol, vol. 80, 2008, pp. 381-388.;;Brat et al., ""Functional Expression of a Bacterial Xylose Isomerase in Saccharomyces cerevisiae"", Applied Environmental Microbiology, vol. 75, No. 8, Apr. 2009, pp. 2304-2311.;;Canevascini, Giorgio, ""Cellobiose Dehydrogenase from Sporotrichum thermophile"", Methods in Enzymology, vol. 160, 1988, pp. 443-448.;;Cantarel et al., ""The Carbohydrate-Active EnZymes Database (CAZy): an Expert Resource for Glycogenomics"", Nucleic Acids Research, vol. 37, Database issue, 2009, pp. D233-238.;;Chauve et al., ""Comparative Kinetic Analysis of Two Fungal Beta-Glucosidases"", Biotechnology for Biofuels, vol. 3, No. 3, 2010, pp. 1-8.;;Christakopoulos et al., ""Enzymatic Synthesis of Trisaccharides and Alkyl Beta-D-Glucosides by the Transglycosylation Reaction of Beta-Glucosidase from Fusarium oxysporum"", Int. J. Biol. Macromol., vol. 16, No. 6, 1994; pp. 331-334.;;Christianson et al., ""Multifunctional Yeast High-Copy-Number Shuttle Vectors"", Gene, vol. 110, 1992, pp. 119-122.;;Chu et al., ""Genetic Improvement of Saccharomyces cerevisiae for Xylose Fermentation"", Biotechnology Advances, vol. 25, Apr. 24, 2007, pp. 425-441.;;Colot et al., ""A High-Throughput Gene Knockout Procedure for Neurospora Reveals Functions for Multiple Transcription Factors"", PNAS, vol. 103, No. 27, Jul. 5, 2006, pp. 10352-10357.;;Cullen et al., ""Sequence and Centromere Proximal Location of a Transformation Enhancing Fragment ans1from Aspergillus nidulans"", Nucleic Acids Research, vol. 15, No. 22, 1987, pp. 9163-9175.;;Davies et al., ""Structure and Function of Humicola Insolens Family 6 Cellulases: Structure of the Endoglucanase, Cel6B, at 1.6 A Resolution"", Biochem. J., vol. 348, 2000, pp. 201-207.;;Davis et al., ""Neurospora: a Model of Model Microbes"", Timeline, Nature Reviews, Genetics, vol. 3, May 2002, pp. 7-13.;;De Groot et al., ""Metabolic Control Analysis of Aspergillus niger L-Arabinose Catabolism"", Biotechnol. Prog., vol. 21, No. 6, Oct. 20, 2005, pp. 1610-1616.;;Dementhon et al., ""VIB-1 is Required for Expression of Genes Necessary for Programmed Cell Death in Neurospora crassa"", Eukaryotic Cell, vol. 5, No. 12, Dec. 2006, pp. 2161-2173.;;Doran-Peterson et al., ""Simultaneous Saccharification and Fermentation and Partial Saccharification and Co-Fermentation of Lignocellulosic Biomass for Ethanol Production"", Chapter 17, Methods in Molecular Biology, vol. 581, 2009, pp. 263-280.;;Drissen et al., ""Modelling Ethanol Production from Cellulose: Separate Hydrolysis and Fermentation Versus Simultaneous Saccharification and Fermentation"", Biocatalysis and Biotransformation, vol. 27, No. 1, Jan.-Feb. 2009, pp. 27-35.;;Dunlap et al., ""Enabling a Community to Dissect an Organism: Overview of the Neurospora Functional Genomics Project"", Advances in Genetics, vol. 57, 2007, pp. 49-96.;;Du Preez et al., ""The Fermentation of Hexose and Pentose Sugars by Candida shehataeand Pichia stipitis"", Appl Microbial Biotechnol, vol. 23, 1986, pp. 228-233.;;Eberhart et al., ""Cellulase of Neurospora crassa"", Journal of Bacteriology, vol. 139, vol. 1, Apr. 1977, p. 181-186.;;Ellis et al., ""Buffers of Constant Ionic Strength for Studying pH-Dependent Processes"", Methods in Enzymology, vol. 87, 1982, pp. 405-426.;;Espagne et al., ""The Genome Sequence of the Model Ascomycete Fungus Podospora anserina"", Genome Biology, vol. 9, No. 5, Article R77, May 6, 2008, pp. R77.1-R77.22.;;Fonseca et al., ""L-Arabinose Transport and Catabolism in Yeast"", FEBS Journal, vol. 274, 2007, pp. 3589-3600.;;Freer et al., ""Transport of Glucose and Cellobiose by Candida wickerhamii and Clavispora lusitaniae"", Journal of Biological Chemistry, vol. 265, No. 22, Aug. 5, 1990, pp. 12864-12868.;;Freer, S. N., ""Fermentation and Aerobic Metabolism of Cellodextrins by Yeasts"" Applied and Environmental Microbiology, vol. 57, No. 3, Mar. 1991, pp. 655-659.;;Galagan et al., ""The Genome Sequence of the Filamentous Fungus Neurospora crassa"", Nature, vol. 422, Apr. 24, 2003, pp. 859-868.;;Galazka et al., ""A New Diet for Yeast to Improve Biofuel Production"", Bioengineered Bugs, vol. 2, No. 4, Jul./Aug. 2011, pp. 1-4.;;Galazka et al., ""Improving the Bioconversion of Plant Biomass to Biofuels: A Multidisciplinary Approach"", Energy & Environmental Science, vol. 4, 2011, pp. 3329-3333.;;Gems et al., ""An Autonomously Replicating Plasmid Transforms Aspergillus nidulans at High Frequency"", Gene, vol. 98, 1991, pp. 61-67.;;Guindon et al., ""A Simple, Fast, and Accurate Algorithm to Estimate Large Phylogenies by Maximum Likelihood"", Systematic Biology, vol. 52, No. 5, 2003, pp. 696-704.",INACTIVE
401,MX,A,MX 2012001071 A,141-708-474-524-17X,2012-10-09,2012,MX 2012001071 A,2010-07-26,US 27183309 P;;US 28552609 P;;US 2010/0043279 W,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS.","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JIN;;CHOI JIN HO;;CATE JANES H DOUDNA;;HA SUK JIN;;KIM SOON RIN;;JIN YOUNGSU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN;;GALAZKA JONATHAN M,,https://lens.org/141-708-474-524-17X,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,0,0,,,,ACTIVE
402,US,A1,US 2015/0299755 A1,193-370-629-162-312,2015-10-22,2015,US 201514608018 A,2015-01-28,US 201514608018 A;;US 201414289570 A;;US 201313802533 A;;US 84384410 A;;US 28552609 P;;US 27183309 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-04);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/193-370-629-162-312,Patent Application,yes,3,0,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12P21/02;;C07K14/705;;C12N15/80,,0,0,,,,DISCONTINUED
403,MX,A,MX 2022006206 A,069-632-407-912-60X,2022-09-09,2022,MX 2022006206 A,2020-11-25,US 201962939825 P;;US 202063030979 P;;US 2020/0062320 W,2019-11-25,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT.,The present invention provides compounds (I) and (II) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,HUYNH HOAN;;KARRA SRINIVASA;;PENNINGTON LEWIS D;;CHOI YOUNGGI;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT,,https://lens.org/069-632-407-912-60X,Patent Application,no,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,A61K31/407;;A61K31/4353;;A61P43/00;;C07D498/04;;C07D498/14,,0,0,,,,PENDING
404,EP,B1,EP 3545408 B1,194-262-480-814-930,2023-07-05,2023,EP 17817468 A,2017-11-22,US 201615362709 A;;US 201615362691 A;;US 2017/0063138 W,2016-11-28,LOCALIZED DEVICE COORDINATOR WITH ON-DEMAND CODE EXECUTION CAPABILITIES,,AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON JAMES CHRISTOPHER III;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,,https://lens.org/194-262-480-814-930,Granted Patent,yes,1,0,8,12,0,G06F8/63,G06F8/61,,0,0,,,,ACTIVE
405,US,B2,US 9012177 B2,059-751-783-682-405,2015-04-21,2015,US 201414289570 A,2014-05-28,US 201414289570 A;;US 201313802533 A;;US 84384410 A;;US 27183309 P;;US 28552609 P,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK-JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-04);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/059-751-783-682-405,Granted Patent,yes,6,3,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N1/00;;C12N15/80;;C12N15/81;;C12P21/04;;C12P21/06,435/69.1;;435/71.1;;435/243,99,92,019-536-721-226-591;;020-062-829-864-759;;001-204-399-695-503;;004-878-049-430-388;;067-737-153-284-487;;022-330-591-260-234;;135-137-082-731-766;;046-023-237-903-496;;093-045-312-080-541;;121-518-383-520-090;;033-498-549-394-94X;;079-520-583-100-711;;138-054-623-673-534;;003-242-603-416-269;;067-150-855-259-97X;;010-178-649-896-819;;108-881-221-014-430;;070-894-725-275-285;;004-311-145-219-702;;042-512-329-777-273;;046-036-735-898-442;;027-383-914-262-471;;040-264-748-392-762;;058-481-550-920-376;;131-148-740-048-845;;073-835-353-251-029;;072-988-828-027-794;;087-563-759-995-134;;069-708-899-792-963;;050-196-612-528-30X;;000-251-872-888-737;;122-000-826-139-951;;012-958-316-105-812;;046-336-987-580-902;;043-675-992-731-59X;;131-185-766-019-199;;003-638-443-959-029;;186-029-266-464-799;;096-045-894-674-161;;001-512-749-137-742;;103-762-254-011-523;;065-546-909-769-86X;;060-671-554-793-705;;128-879-801-420-972;;053-720-311-324-984;;015-339-468-695-846;;099-940-450-305-541;;025-622-213-088-485;;068-183-326-130-940;;061-774-608-000-01X;;086-354-734-216-897;;052-392-453-181-409;;011-250-531-318-343;;057-722-409-149-269;;083-475-617-712-21X;;060-906-287-443-607;;003-546-581-906-613;;032-443-849-864-806;;085-737-768-545-623;;007-156-472-140-294;;020-807-488-825-412;;057-694-351-421-112;;031-884-777-774-381;;054-822-635-975-947;;033-828-770-147-584;;036-168-690-647-51X;;082-205-686-084-150;;004-711-972-902-946;;030-350-370-854-336;;022-335-231-721-618;;033-860-685-078-510;;037-545-767-307-239;;028-055-567-547-811;;035-301-483-062-782;;131-017-124-330-126;;007-667-415-133-658;;021-098-855-044-026;;008-183-028-841-916;;095-106-736-472-740;;049-405-579-110-966;;127-130-779-608-635;;075-047-009-973-44X;;102-059-025-734-508;;037-512-177-952-712;;060-800-340-605-623;;009-503-052-316-157;;007-925-955-154-483;;103-275-711-667-846;;023-587-280-394-438;;120-631-641-472-887;;066-131-422-349-11X;;012-175-186-083-895,15486203;;pmc524302;;10.1093/nar/gkh894;;10.1186/1754-6834-3-5;;20236521;;pmc2851583;;19002682;;10.1007/s00253-008-1773-y;;10.1007/s00253-011-3164-z;;21336923;;12698321;;10.1007/s10295-003-0049-x;;17180689;;10.1007/s00253-006-0747-1;;2340178;;10.1007/3-540-45300-8_7;;11816810;;10.1016/s0074-7696(08)61935-x;;4267163;;10.1128/jb.179.17.5318-5320.1997;;9286982;;pmc179398;;pmc2483294;;10.1186/1471-2164-9-327;;18620557;;19074487;;10.1093/nar/gkn991;;pmc2632897;;10.1002/bit.23014;;21246505;;10.1093/genetics/122.1.19;;2659436;;pmc1203683;;8929394;;10.1007/s002940050151;;10880472;;10.1093/genetics/155.3.1095;;pmc1461168;;10.1007/bf01021255;;10.1007/bf02936507;;10.1007/978-1-4612-0057-4_20;;12721449;;10.1385/abab:106:1-3:255;;10.1126/science.1139612;;17289987;;10.1007/s00253-007-1322-0;;18197406;;17938906;;10.1007/s00253-007-1225-0;;10.1016/s0960-8524(01)00212-7;;12058826;;10.1007/bf00279894;;8264527;;10.1128/aem.00724-10;;pmc2937500;;20656867;;pmc2794032;;10.1073/pnas.0906810106;;20018766;;17449655;;pmc1951524;;10.1128/ec.00078-07;;10.1186/gb-2002-3-12-research0071;;12537560;;pmc151173;;10.1186/1471-2105-5-54;;15128431;;pmc420235;;10.1110/ps.04625404;;pmc2279939;;15215532;;10.1016/j.tibtech.2006.06.008;;16820235;;10.1074/jbc.m409443200;;15623532;;17768247;;10.1099/mic.0.2007/007856-0;;10.1093/nass/49.1.309;;pmc2292587;;18263741;;10.1128/aem.02395-07;;pmc1951023;;10.1128/aem.00177-07;;17545317;;10.1128/aem.02268-08;;pmc2643596;;19074603;;10.1128/aem.71.3.1642-1647.2005;;pmc1065158;;15746370;;10.1128/aem.00314-09;;19376920;;pmc2698378;;10.1016/0141-0229(93)90117-k;;10.1111/j.1364-3703.2007.00458.x;;18705852;;pmc6640386;;20829451;;10.1126/science.1192838;;15612919;;10.1111/j.1365-2958.2004.04374.x;;11713254;;10.1074/jbc.m109157200;;10.1093/oxfordjournals.jbchem.a123761;;1587797;;10.1080/15572536.2005.11832998;;21148830;;10.1038/nbt1290;;17334359;;18676954;;pmc2547062;;10.1128/ec.00195-08;;10.1093/nar/gki953;;pmc1283539;;16287898;;16575564;;10.1007/s00253-006-0402-x;;10.1016/j.enzmictec.2008.03.001;;pmc95372;;10.1128/jb.183.17.4979-4984.2001;;11489849;;9836873;;10.1006/jmbi.1998.1750;;18640601;;10.1263/jbb.105.622;;10.1007/bf00167144;;8366083;;10.1016/s0021-9258(19)36523-8;;10.1007/s10295-008-0327-8;;18338189;;14554198;;10.1016/s1567-1356(03)00141-7;;pmc212329;;3298207;;10.1128/jb.169.7.2932-2937.1987;;10.1146/annurev.micro.61.080706.093329;;18537473;;pmc2612782;;18524919;;10.1099/mic.0.2007/015511-0;;16402921;;10.1042/bj20051465;;pmc1462686;;20871937;;10.1039/c0mb00063a;;pmc37976;;10.1073/pnas.93.22.12251;;8901566;;10.1038/nbt0208-169;;18259168;;pmc120791;;10.1128/mmbr.66.3.506-577.2002;;12209002;;10.1007/s00253-008-1794-6;;19050860;;20348908;;10.1038/nature08867;;15122302;;10.1038/nbt967;;10.3410/f.1120793.577044;;10.1038/nbt1403;;18454138;;10.1073/pnas.0809575106;;19193860;;pmc2644145;;10.1016/s0040-4039(00)71455-9;;18751695;;10.1007/s00253-008-1649-1;;12964247;;10.1016/s0065-2164(03)01010-4;;10.1002/(sici)1097-0290(19980905)59:5<621::aid-bit13>3.0.co;2-c;;10.1002/(sici)1097-0290(19980905)59:5<621::aid-bit13>3.3.co;2-n;;10099380;;10392441;;10.1002/(sici)1097-0061(19990615)15:8<633::aid-yea407>3.0.co;2-o;;pmc1828828;;10.1128/aem.02515-06;;17261518;;10.1016/j.enzmictec.2008.04.003;;19777228;;10.1007/s00253-009-2236-9;;10.1006/jmbi.2000.4042;;10964570;;10.1016/s0006-3495(98)77529-0;;9649402;;pmc1299714;;10.1007/bf02716813;;9529885;;pmc98904;;10.1128/mmbr.62.1.1-34.1998;;12962626;;10.1016/s0969-2126(03)00167-9;;16369541;;10.2210/pdb2b3p/pdb;;10.1038/nbt1172;;28563048;;10.2307/2407702;;10.1111/j.1558-5646.1976.tb00910.x;;pmc211617;;3053662;;10.1128/jb.170.11.5375-5377.1988;;10.1006/bbrc.1997.7558;;9367847;;10.1111/j.1432-1033.1997.00324.x;;9151960;;14681414;;pmc308751;;10.1016/s0141-0229(99)00035-6;;10.1016/j.jbiotec.2005.06.013;;16084620,"Notice of Allowance recieved for U.S. Appl. No. 13/802,533, mailed on Feb. 20, 2014, 8 pages.;;Ruepp et al., ""The FunCat, a Functional Annotation Scheme for Systematic Classification of Proteins from Whole Genomes"", Nucleic Acids Research, vol. 32, No. 18, Oct. 14, 2004, pp. 5539-5545.;;Runquist et al., ""Comparison of Heterologous Xylose Transporters in Recombinant Saccharomyces cerevisiae"", Biotechnology for Biofuels, vol. 3, No. 5, 2010, pp. 1-7.;;Runquist et al., ""Expression of the Gxf1 Transporter from Candida Intermedia Improves Fermentation Performance in Recombinant Xylose-Utilizing Saccharomyces cerevisiae"", Appl Microbial Biotechnol, vol. 82, 2009, pp. 123-130.;;Sadie et al., ""Co-expression of a Cellobiose Phosphorylase and Lactose Permease Enables Intracellular Cellobiose Utilisation by Saccharomyces cerevisiae"", Applied Microbiology and Biotechnology, Feb. 20, 2011, 8 pages.;;Saha, Badal C., ""Hemicellulose Bioconversion"", J Ind Microbiol Biotechnol, vol. 30, 2003, pp. 279-291.;;Saloheimo et al., ""Xylose Transport Studies with Xylose-Utilizing Saccharomyces cerevisiae Strains Expressing Heterologous and Homologous Permeases"", Appl Microbiol Blotechnol, vol. 74. 2007, pp. 1041-1052.;;Sarkar et al., ""The ""Megaprimer"" Method of Site-Directed Mutagenesis"", Biotechniques, vol. 8, No. 4, 1990, pp. 404-407.;;Sauer, Uwe, ""Evolutionary Engineering of Industrially important Microbial Phenotypes"", Advances in Biochemical Engineering/Biotechnology, vol. 73, 2001, pp. 129-169.;;Scarborough, Gene A., ""Transport in Neurospora"", Int Rev Cytol, 1973, pp. 103-122.;;Seiboth et al., ""Role of Four Major Cellulases in Triggering of Cellulase Gene Expression by Cellulose in Trichoderma reesei"", Journal of Bacteriology, vol. 179, No. 17, Sep. 1997, pp. 5318-5320.;;Seidl et al., ""The Hypocrea Jecorina (Trichoderma reesei) Hypercellulolytic Mutant RUT C30 Lacks a 85 kb (29 gene-encoding) Region of the Wild-type Genome"" BMC Genomics, vol. 9, Jul. 11, 2008, 15 pages.;;Shao et al., ""DNA Assembler, an In vivo Genetic Method for Rapid Construction of Biochemical Pathways"", Nucleic Acids Research, vol. 37, No. 2, 2009, e16, pp. 1-10.;;Shill et al., ""Ionic Liquid Pretreatment of Cellulosic Biomass: Enzymatic Hydrolysis and Ionic Liquid Recycle"" Biotechnology and Bioengineering, vol. 108, No. 3, Mar. 2011, pp. 511-520.;;Sikorski et al., ""A System of Shuttle Vectors and Yeast Host Strains Designed for Efficient Manipulation of DNA in Saccharornyces cerevisiae"", Genetics, vol. 122, May 1989, pp. 19-27.;;Skory et al., ""Expression and Secretion of the Candida Wickerhamii Extracellular Beta-glucosidase Gene, bglB, in Saccharomyces cerevisiae."", Curr Genet, vol. 30, 1996, pp. 417-422.;;Smith et al., ""Vegetative Incompatibility in the Het-6 Region of Neurospora crassa is Mediated by Two Linked Genes"", Genetics, vol. 155, Jul. 2000, pp. 1095-1104.;;Spindler et al., ""Evaluation of the Cellobiose-Fermenting Yeast Brettanomyces Custersii in the Simultaneous Sacchanfication arid Fermentation of Cellulose"", Biotechnology Letters, vol. 15, No. 5, May 1992, pp. 403-407.;;Spindler et al., ""Simultaneous Saccharification and Fermentation of Pretreated Wheat Straw to Ethanol with Selected Yeast Strains and Beta-glucosidase Supplementation"", Applied Biochemistry and Biotechnology, vol. 20/21, 1989, pp. 529-540.;;Stambuk et al., ""D-Xylose Transport by Candida Succiphila and Kluyveromyces marxianus"", Applied Biochemistry and Biotechnology, vol. 105-108, 2003, pp. 255-263.;;Stephanopoulos, Gregory, ""Challenges in Engineering Microbes for Biofuels Production"", Science, vol. 315, Feb. 9, 2007, pp. 801-804.;;Stricker et al., ""Regulation of Transcription of Cellulases- and Hemicellulases Encoding Genes in Aspergillus Niger and Hypocrea Jecorina (Trichoderma reesei)"", Appl Microbiol Biotechnol, vol. 78, 2008, pp. 211-220.;;Stryer, Lubert, ""Moleculer Design of Life-Part 1"", Biochemistry Fourth Edition, 1995, pp. 28-30.;;Sullivan et al., ""Cloning, Characterization, and Mutational Analysis of a Highly Active and Stable L-arabinitol 4-dehydrogenase from Neurospora crassa"", Appl Microbiol Biotechnol, vol. 77, 2007, pp. 845-852.;;Sun et al., ""Hydrolysis of Lignocellulosic Materials for Ethanol Production: a Review"", Bioresource Technology, vol. 83, 2002, pp. 1-11.;;Suominen et al., ""High Frequency One-Step Gene Replacement in Trichoderma reesei-II. Effects of Deletions of Individual Cellulase Genes"", Mol Gen Genet, vol. 241, 1993, pp. 523-530.;;Suzuki et al., ""Cellotriose and Cellotetraose as Inducers of the Genes Encoding Cellobiohydrolases in the Basidiomycete Phanerochaete Chrysosporium"", Applied and Environmental Microbiology, vol. 76, No. 18, Sep. 2010, pp. 6164-6170.;;Tian et al., ""Systems Analysis of Plant Cell Wall Degradation by the Model Filamentous Fungus Neurospora crassa"", PNAS Early Edition, 2009, pp. 1-6.;;Tian et al., ""Transcriptional Profiling of Cross Pathway Control in Neurospora crassa and Comparative Analysis of the Gcn4 and CPC1 Regulons"", Eukaryotic Cell, vol. 6, No. 6, Jun. 2007, pp. 1018-1029.;;Townsend et al., ""Bayesian Analysis of Gene Expression Levels: Statistical Quantification of Relative mRNA Level Across Multiple Strains or Treatments"", Genome Biology, vol. 3, No. 12, Nov. 20, 2002, pp. 0071.1-0071.16.;;Townsend, Jeffrey P., ""Resolution of Large and Small Differences in Gene Expression Using Models for the Bayesian Analysis of Gene Expression Levels and Spotted DNA Microarrays"", BMC Bioinformatics, vol. 5, May 5, 2004. 13 pages.;;USDA, ""The Economic Feasibility of Ethanol Production from Sugar in the United States"", Jul. 2006, 78 pages.;;Viklund et al., ""Best alpha-Helical Transmembrane Protein Topology Predictions are Achieved using Hidden Markov Models and Evolutionary Information"", Protein Science, vol. 13, 2004, pp. 1908-1917.;;Vogel, H. J., ""A Convenient Growth Medium for Neurospora (Mediun N)"", Microbiol. Genet. Bull. vol. 3, Jan. 1956, pp. 42-45.;;Wagner et al., ""Rationalizing Membrane Protein Overexpression"", Trends in Biotechnology, vol. 24, No. 8, Jul. 3, 2006, pp. 384-371.;;Watanabe et al., ""Complete Reversal of Coenzyme Specificity of Xylitol Dehydrogenase and Increase of Thermostability by the Introduction of Structural Zinc"", The Journal of Biological Chemistry, vol. 280, No. 11, Mar. 18, 2005; pp. 10340-10349.;;Watanabe at al., ""Ethanol Production from Xylose by Recombinant Saccharomyces cerevisiae Expressing Protein-Engineered NADH-Preferring Xylose Reductase from Pichia stipitis"", Microbiology, vol. 153, 2007, pp. 3044-3054.;;Watanabe et al., ""L-Arabinose 1-Dehydrogenase: A Novel Enzyme Involving in Bacterial L-Arabinose Metabolism"", Nucleic Acids Symposium Series, vol. 49, 2005; pp. 309-310.;;Wiedemann et al., ""Codon-Optimized Bacterial Genes Improve L-Arabinose Fermentation in Recombinant Saccharomyces cerevisiae"", Appl Environ Microbiol, Feb. 8, 2008, 34 pages.;;Wisselink et al., ""Engineering of Saccharomyces cerevisiae for Efficient Anaerobic Alcoholic Fermentation of L-Arabinose"", Applied and Environmental Microbiology, vol. 73. No. 15, Aug. 2007, pp. 4881-4891.;;Wisselink et al., ""Novel Evolutionary Engineering Approach for Accelerated Utilization of Glucose, Xylose, and Arabinose Mixtures by Engineered Saccharomyces cerevisiae Strains"", Applied and Environmental Microbiology, vol. 75, No. 4, Feb. 2009, pp. 907-914.;;Woodyer et al., ""Heterologous Expression, Purification, and Characterization of a Highly Active Xylose Reductase from Neurospora crassa"", Applied and Environmental Microbiology, vol. 71, No. 3, Mar. 2005, pp. 1642-1647.;;Wymelenberg et al., ""Transcriptome and Secretome Analyses of Phanerochaete chrysosporium Reveal Complex Patterns of Gene Expression"", Applied and Environmental Microbiology, vol. 75, No. 12, Jun. 2009, pp. 4058-4068.;;Xin et al., ""Acceleration of Ethanol Production from Paper Mill Waste Fiber by Supplementation with Beta-Glucosidase"", Enzyme Microb. Technol., vol. 15, Jan. 1993, pp. 62-65.;;Office Action received for Chinese Patent Application No. 201089033858.9, mailed on Feb. 5, 2013, 12 pages (5 pages of English Translation and 7 pages of Office Action).;;Extended European Search Report and Search Opinion received for European Patent Application No. 10803022.2, mailed on Dec. 3, 2012, 7 pages.;;Bluhm et al., ""Involvement of ZFR1 of Fusarium verticillioides in Kernel Colonization and the Regulation of FST1, a Putative Sugar Transporter Gene Required for Fumonisin Biosynthesis on Maize Kernels"", Molecular Plant Pathology, vol. 9, No. 2, 2008, pp. 203-211.;;Galazka et al., ""Cellodextrin Transport in Yeast for Improved Biofuel Production"", Science, vol. 330, Oct. 1, 2010, pp. 84-86.;;Karlyshev et al., ""Analysis of Campylobacter Jejuni Capsular Loci Reveals Multiple Mechanisms for the Generation of Structural Diversity and the Ability to Form Complex Heptoses"", Molecular Microbiology, vol. 55, No. 1, 2005, pp. 90-103.;;Mueckler et al., ""Analysis of Transmembrane Segment 10 of the Glut1 Glucose Transporter by Cysteine-Scanning Mutagenesis and Substituted Cysteine Accessibility"", The Journal of Biological Chemistry, vol. 277, No. 5, Feb. 1, 2002, pp. 3498-3503.;;Office Action received for New Zealand Patent Application No. 597001, issued on Jun. 28, 2013, 3 pages.;;Hosaka et al., ""A Dominant Mutation that Alters the Regulation of INO1 Expression in Saccharomyces cerevisiae"", J. Biochem., vol. 11, No. 3, 1992, pp. 352-358.;;Jacobson et al., ""Neurospora in Temperate Forests of Western North America"", Mycologia, vol. 96, No. 1, 2004, pp. 66-74.;;Jeffries et al., ""Genome Sequence of the Lignocellulose-Bioconverting and Xylose-Fermenting Yeast Pichia stipitis"", Nature Biotechnology, vol. 25, No. 3, Mar. 2007, pp. 319-326.;;Kasuga et al., ""Dissecting Colony Development of Neurospora crassa Using mRNA Profilng and Comparative Genomics Approaches"", Eukaryotic Cell, vol. 7, No. 9, Sep. 2008, pp. 1549-1564.;;Kasuga et al., ""Long-Oligomer Microarray Profiling in Neurospora crassa Reveals the Transcriptional Program Underlyng Biochemical and Physiological Events of Conidial Germination"", Nucleic Acids Research, vol. 33, No. 20, Nov. 14, 2005, pp. 6469-6485.;;Katahira et al., ""Ethanol Fermentation from Lignocellulosic Hydrolysate by a Recombinant Xylose- and Cellooligosaccharide-Assimilating Yeast Strain"", Appl Microbiol. Biolechnol, vol. 72, Mar. 31, 2006, pp. 1136-1143.;;Katahira et al., ""Improvement of Ethanol Productivity During Xylose and Glucose Co-Fermentation by Xylose-Assimilating S. cerevisiae via Expression of Glucose Transporter Sutl"", Enzyme and Microbial Technology, vol. 43, 2008, pp. 115-119.;;Koning et al., ""Cellobiose Uptake in The Hyperthermophilic Archaeon Pyrococcus Furiosus is Mediated by an Inducible, High-Affinity ABC Transporter"", Journal of Bacteriology, vol. 183, No. 17, Sep. 2001, pp. 4979-4984.;;Korkhin et al., ""NADP-Dependent Bacterial Alcohol Dehydrogenases. Crystal Structure, Cofactor-Binding and Cofactor Specificity of the ADHs of Clostridium beijerinckii and Thermoanaerobacter brockii"", J. Mol. Biol., vol. 278, 1998. pp. 967-981.;;Kotaka et al., ""Direct Ethanol Production from Barley Beta-Glucan by Sake Yeast Displaying Aspergillus Oryzae Beta-Glucosidase and Endoglucanase"", Journal of Biosceince and Bioengineering, vol. 105, No. 6, 2008, pp. 622-627.;;Kotter et al., ""Xylose Fermentation by Saccharomyces cerevisiae"", Appl Microbiol. Biotechnol, vol. 38, 1993, pp. 776-783.;;Kubicek et al., ""Triggering of Cellulose Biosynthesis by Cellulose in Trichoderma Reesei-Involvement of a Constitutive, Sophorose-Inducible, Glucose Inhibited Beta-Diglucoside Permease"", Journal of Biological Chemistry, vol. 268, No. 26, Sep. 15, 1993, pp. 19364-19368.;;Kumar et al., ""Bioconversion of Lignocellulosic Biomass : Biochemical and Molecular Perspectives"", J Ind Microbiol Biotechnol, vol. 35, Mar. 13, 2008, pp. 377-391.;;Kuyper et al., ""High-level Functional Expression of a Fungal Xylose Isomerase: The Key to Efficient Ethanolic Fermentation of Xylose by Saccharomyces cerevisiae?"", FEMS Yeast Research, vol. 4, May 13, 2003, pp. 69-78.;;Lang et al.. ""Glucose Transport in a Kinaseless Saccharomyses cerevisiae Mutant"", Journal of Bacteriology, vol. 169, No. 7, Jul. 1987, pp. 2932-2937.;;Law et al., ""Ins and Outs of Major Facilitator Superfamily Antiporters"", NIH Public Access, Author Manuscrpt, Annu Rev Microbiol., vol. 62, 2008, pp. 289-305.;;Leandro et al., ""The Expression in Saccharomyces cerevisiae of a Glucose/Xylose Symporter from Candida Intermedia is Affected by the Presence of a Glucose/Xylose Facilitator"", Microbiology, vol. 154, 2008, pp. 1646-1655.;;Leandro et al., ""Two Glucose/Xylose Transporter Genes from the Yeast Candida Intermedia: First Molecular Characterization of a Yeast Xylose/H+ Symporter"", Biochemical Journal, Jan. 11, 2006, pp. 1-28.;;Li et al., ""Overcoming Glucose Repression in Mixed Sugar Fermentation by Co-expressing a Cellobiose Transporter and a beta-glucosidase in Saccharomyces cerevisiae""., Molecular BioSystems, vol. 6, 2010; pp. 2129-2132.;;Linder et al., ""The Cellulose-Binding Domain of the Major Cellobiohydrolase of Trichoderma reesei Exhibits True Reversibility and a High Exchange Rate on Crystalline Cellulose"", Biochemistry, Proc Natl. Acad. Sci. USA, vol. 93, Oct. 1996, pp. 12251-12255.;;Lynd et al., ""How Biotech Can Transform Biofuels"", Nature Biotechnology, vol. 26, No. 2, Feb. 2008, pp. 169-172.;;Lynd et al., ""Microbial Cellulose Utilization: Fundamentals and Biotechnology"", Microbiology and Molecular Biology Reviews, vol. 66, No. 3. 2002, pp. 506-577.;;Madhavan et al., ""Xylose Isomerase from Polycentric Fungus Orpinomyces: Gene Sequencing, Cloning, and Expression in Saccharomyces cerevisiae for Bioconversion of Xylose to Ethanol"", Appl Microbiol Biotechnol, vol. 82, 2009, pp. 1067-1078.;;Martin et al., ""Perigord Black Truffle Genome Uncovers Evolutionary Origins and Mechanisms of Symbiosis"", Nature Latters, vol. 464, Apr. 15, 2010, pp. 1033-1038.;;Martinez et al., ""Genome Sequence of the Lignocellulose Degrading Fungus Phanerochaete Chrysosporium Strain RP78"", Nature Biotechnology, vol. 22, No. 6, Jun. 2004, pp. 695-700.;;Martinez et al., ""Genorne Sequencing and Analysis of the Biomass-Degrading Tungus Trichoderma reesei (Syn. Hypocrea Jecorina)"", Nature Biotechnology, vol. 26, No. 5, May 2008, pp. 553-560.;;Martinez et al., ""Genome, Transcriptome, and Secretome Analysis of Wood Decay Fungus Postia placenta Supports Unique Mechanisms of Lignocellulose Conversion"", PNAS, vol. 106, No. 6, Feb. 10, 2009, pp. 1954-1959.;;Matteucci et al., ""The Synthesis of Oligodeoxypyrimidines on a Polymer Support"", Tetrahedron Letters, vol. 21, 1980, pp. 119-722.;;Matsushika et al., ""Expression of Protein Engineered NADP+-Dependent Xylitol Dehydrogenase Increases Ethanol Production from Xylose in Recombinant Saccharomyces cerevisiae"", Appl Microbiol Biotechnol, vol. 81, Aug. 27, 2008, pp. 243-255.;;McCluskey, Kevin. ""The Fungal Genetics Stock Center: from Molds to Molecules"", Advances in Applied Microbiology, vol. 52, 2003, pp. 245-262.;;Medve et al., ""Hydrolysis of Microcrystalline Cellulose by Cellobiohydrolase I and Endoglucanase II from Trichoderma reesei: Adsorption, Sugar Production Pattern, and Synergism of the Enzymes"", Biotechnology and Bioengineering, vol. 59, No. 5, Sep. 5, 1998, pp. 621-634.;;Miyasaka, Hitoshi, ""The Positive Relationship Between Codon Usage Bias and Translation Initiation AUG Context in Saccharomyces cerevisiae"", Yeast, vol. 15, 1999, pp. 633-637.;;Nair et al., ""Biochemical Characterization of an L-Xylulose Reductase from Neurospora crassa"", Applied and Environmental Microbiology, vol. 73, No. 6, Mar. 2007, pp. 2001-2004.;;Nakamura et al., ""Effective Xylose/Cellobiose Co-Fermentation and Ethanol Production by Xylose-Assimilating S. cerevisiae via Expression of Beta-Glucosidase on its Cell Surface"", Enzyme and Microbial Technology, vol. 43, 2008, pp. 233-236.;;Noguchi et al., ""Genes Regulated by AoXinR, the Xylanolytic and Cellulolytic Transcriptional Regulator, in Aspergillus oryzae"", Appl Microbial Biotechnol, vol. 85, Sep. 24, 2009, pp. 141-154.;;Notredame et al., ""T-Coffe: A Novel Method for Fast and Accurate Multiple Sequence Alignment"", J. Mol. Biol., vol. 302, 2000, pp. 205-217.;;Pace et al., ""A Helix Propensity Seal Based on Experimental Studies of Peptides and Proteins"" Biophysical Journal, vol. 75, Jul. 1998, pp. 422-427.;;Pandit et al., ""Life-History of Neurospora intermedia in a Sugar Cane Field"" J. Biosci., vol. 21, No. 1, Mar. 1996, pp. 57-79.;;Pao et al., ""Major Facilitator Superfamily"", Microbiology and Molecular Biology Reviews, vol. 62, No. 1, Mar. 1998, pp. 1-34.;;Pauly et al., ""X-Ray Crystallographic and Kinetic Studies of Human Sorbitol Dehydrogenase"", Structure, vol. 11, Sep. 2003, pp. 1071-1085.;;Pedelacq et al., ""Engineering and Characterization of a Superfolder Green Fluorescent Protein"", Nature Biotechnology, vol. 24, No. 1, Jan. 2006, pp. 79-88.;;Perkins et al., ""Strains of Neurospora Collected from Nature"", Evolution, vol. 30, Jun. 1976, pp. 281-313.;;Ramos et al., ""Relationship Between Low- and High-Affinity Glucose Transport Systems of Saccharomyces cerevisiae"", Journal of Bacteriology, vol. 170, No. 11, Nov. 1988, pp. 5375-5377.;;Rawat et al., ""Site and Significance of Cysteine Residues in Xylose Reductase from Neurospora crassa as Deduced by Fluorescence Studies"", Biochemical and Biophysical Research Communications, Article No. RC977558, vol. 239, No. 3, 1997, pp. 789-793.;;Reifenberger et al., ""Kinetic Characterization of Individual Hexose Transporters of Saccharomyces cerevisiae and their Relation to the Triggering Mechanisms of Glucose Repression"", Eur. J. Biochem., vol. 245, 1997, pp. 324-333.;;Ren et al., ""TransportDB: A Relational Database of Cellular Membrane Transport Systems"", Nucleic Acids Research, vol. 32, Database Issue, 2004, pp. D284-D288.;;Romero et al., ""Cellulase Production by Neurospora crassa on Wheat Straw"", Enzyme and Microbial Technology, vol. 25, 1999, pp. 244-250.;;Rooyen et al., ""Construction of Cellobiose-Growing and Fermenting Saccharomyce cerevisiae Strains"", Journal of Biotechnology, vol. 120, 2005, pp. 284-295.",INACTIVE
406,US,A1,US 2018/0150318 A1,089-664-702-201-597,2018-05-31,2018,US 201615362691 A,2016-11-28,US 201615362691 A,2016-11-28,LOCALIZED DEVICE COORDINATOR,"Systems and methods are described for configuring a coordinator within a coordinated environment, which environment includes set of coordinated devices managed by the coordinator. The coordinated devices may include devices configured to be managed remotely, such as thin devices, devices with alternative primary functions (e.g., appliances, household objects, etc.), or devices with limited localized user interfaces. To manage the set of coordinated devices, the coordinator can execute tasks, each task corresponding to a set of portable code executable by the coordinator to implement a desired functionality. A user may generate one or more tasks, and submit them to a service provider environment for deployment to the coordinator. The service provider environment can utilize a device shadow to notify the coordinator of the obtained tasks, and thereafter deliver the tasks to the coordinator, thus modifying a configuration of the coordinator.",AMAZON TECH INC,KUO CALVIN YUE-REN;;AMIN RUDRESH;;CHEN YEN-LIN;;TUROW JONATHAN I;;PAN CHENG;;TARAN DMYTRO;;AITHA NAVEEN KUMAR;;TANDON AMBUJ;;CHOI KYUNGHWAN;;BROOKER MARC JOHN;;SORENSON III JAMES CHRISTOPHER;;MCCLENAHAN WEILI ZHONG;;RAFN MARK EDWARD,AMAZON TECHNOLOGIES INC (2017-03-06),https://lens.org/089-664-702-201-597,Patent Application,yes,4,10,2,12,0,G06F9/5027;;G06F9/5027,G06F9/48,,0,0,,,,INACTIVE
407,CA,A1,CA 3155885 A1,089-423-293-255-203,2021-06-03,2021,CA 3155885 A,2020-11-25,US 201962939825 P;;US 202063030979 P;;US 2020/0062320 W,2019-11-25,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds (I) and (II) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,,https://lens.org/089-423-293-255-203,Patent Application,no,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/04;;C07D498/14,,0,0,,,,PENDING
408,WO,A1,WO 2021/108628 A1,058-306-866-294-158,2021-06-03,2021,US 2020/0062320 W,2020-11-25,US 201962939825 P;;US 202063030979 P,2019-11-25,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds (I) and (II) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,,https://lens.org/058-306-866-294-158,Patent Application,yes,12,6,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,A61K31/407;;C07D498/04;;A61K31/4353;;A61P43/00;;C07D498/14,,22,10,044-928-520-255-205;;134-787-395-407-586;;013-795-902-101-18X;;100-598-891-287-142;;118-152-222-665-107;;070-910-884-361-022;;010-870-611-029-091;;021-693-589-840-981;;077-295-491-167-117;;020-282-843-362-629,10.1016/s0092-8674(00)80949-6;;9491897;;10.1007/s40263-012-0036-8;;23359095;;pmc8762453;;17491094;;10.1093/brain/awm097;;19117547;;pmc2630400;;10.1016/j.cmet.2008.10.010;;14580935;;10.1016/s0306-4522(03)00554-2;;15627867;;10.1159/000081757;;10.1016/s0196-9781(02)00110-9;;12217429;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1002/0471220574;;10.1023/a:1018943613122;;8378254,"CELL, vol. 92, 1998, pages 573 - 585;;SAPER ET AL., TRENDS IN NEUROSCIENCE, 2001;;YAMANAKA ET AL., NEURON, vol. 38, 2003, pages 715 - 730;;SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014;;MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019;;PROC. NATI, ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654;;CELL, vol. 98, 1999, pages 437 - 451;;CNS DRUGS, vol. 27, 2013, pages 83 - 90;;BRAIN, vol. 130, 2007, pages 1586 - 1595;;CELL METABOLISM, vol. 9, 2009, pages 64 - 76;;NEUROSCIENCE, vol. 121, 2003, pages 855 - 863;;RESPIRATION, vol. 71, 2004, pages 575 - 579;;PEPTIDES, vol. 23, 2002, pages 1683 - 1688;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;FIESERFIESER: ""Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;;DAVIES B.MORRIS T.: ""Physiological Parameters in Laboratory Animals and Humans"", PHARMARES, vol. 10, no. 7, 1993, pages 1093 - 1095",PENDING
409,BR,A2,BR 112012001664 A2,082-195-979-571-896,2018-12-26,2018,BR 112012001664 A,2010-07-26,US 2010/0043279 W;;US 27183309 P;;US 28552609 P,2009-07-24,"métodos e composições para melhorar o transporte de açúcar, fermentação com açúcar misturado e produção de biocombustíveis","métodos e composições para melhorar o transporte de açúcar, fermentação com açúcar misturado e produção de biocombustíveis a presente divulgação refere-se às células hospedeiras contendo um polinucleotídeo recombinante que codifica um polipeptídeo, onde o polipeptídeo transporta celodextrina para dentro da célula. a presente divulgação refere-se ainda aos métodos de aumentar o transporte de celodextrina para dentro de uma célula, métodos de aumentar o crescimento de uma célula em um meio contendo celodextrina, métodos de cofermentação de aç0cares derivados ri~ celulose e hemicelulose e métodos para fazer hidrocarbonetos ou derivados de hidrocarbonetos fornecendo uma célula hospedeira contendo um polinucleotídeo recombinante que codifica um polipeptídeo onde o polipeptídeo transporta celodextrina para dentro de uma célula. a presente descrição refere-se às células hospedeiras contendo um polinucleotídeo recombinante que codifica um polipeptídeo onde este transporta uma pentose para dentro da célula, métodos de aumento da multiplicação de uma célula em um meio contendo aç0cares pentose, e métodos para fazer hidrocarbonetos ou derivados de hidrocarbonetos fornecendo uma célula hospedeira que contém um polinucleotídeo recombinante que codifica um polipeptídeo, onde o polipeptídeo transporta uma pentose para dentro da célula.",BP CORP NORTH AMERICA INC;;UNIV ILLINOIS;;UNIV CALIFORNIA,CHAOGUANG TIAN;;HUIMIN ZHAO;;JAMES H DOUDNA CATE;;JIN HO CHOI;;JING DU;;JONATHAN M GALAZKA;;N LOUISE GLASS;;SIJIN LI;;SOO RIN KIM;;SUK JIN HA;;WILLIAM T IV BEESON;;XIAOMIN YANG;;YONG-SU JIN,,https://lens.org/082-195-979-571-896,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/52;;C12N15/62;;C12N15/87;;C12P19/00;;C12R1/865,,0,0,,,,DISCONTINUED
410,WO,A9,WO 2011/011796 A9,128-675-899-932-794,2011-06-23,2011,US 2010/0043279 W,2010-07-26,US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;TRUSTEES OF THE UNIVERSITY OF ILLINOS BOARD OF;;BP CORP NORTH AMERICA INC;;GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;JIN YOUG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;JIN YOUG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/128-675-899-932-794,Search Report,yes,0,1,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,0,0,,,,PENDING
411,IN,A,IN 345DEN2012 A,113-426-465-435-81X,2015-05-08,2015,IN 345DEN2012 A,2012-01-12,US 27183309 P;;US 28552609 P;;US 2010/0043279 W,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell. Fig. 25",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC;;GALAZKA JONATHAN M,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;LI SIJIN;;SU JIANPING;;YANG XIAOMIN;;JIN YOUG-SU,,https://lens.org/113-426-465-435-81X,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87,,0,0,,,,PENDING
412,US,A1,US 2011/0020910 A1,191-901-383-951-895,2011-01-27,2011,US 84384410 A,2010-07-26,US 84384410 A;;US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BRITISH PETROLEUM TECHNOLOGY VENTURES INC,GLASS N LOUISE C;;TIAN CHAOGUANG;;BEESON IV WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK JIN;;JIN YONG-SU;;KIM SOO RIN;;LI SIJIN;;YANG XIAOMIN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2010-09-08);;THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-09-17);;BP CORPORATION NORTH AMERICA INC (2010-10-06),https://lens.org/191-901-383-951-895,Patent Application,yes,6,30,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N1/21;;C12N1/15;;C12N1/19,435/252.31;;435/252.3;;435/252.33;;435/254.11;;435/254.2;;435/254.21;;435/254.22;;435/254.23,0,0,,,,INACTIVE
413,WO,A3,WO 2011/011796 A3,042-325-291-400-732,2011-09-09,2011,US 2010/0043279 W,2010-07-26,US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;TRUSTEES OF THE UNIVERSITY OF ILLINOS BOARD OF;;BP CORP NORTH AMERICA INC;;GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;JIN YOUG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;JIN YOUG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/042-325-291-400-732,Search Report,yes,4,0,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,1,0,,,See also references of EP 2456878A4,PENDING
414,EP,A1,EP 4263555 A1,029-193-256-577-871,2023-10-25,2023,EP 21848371 A,2021-12-21,US 202063128404 P;;US 202163190937 P;;US 2021/0064483 W,2020-12-21,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,"ALKERMES, INC. (2024-02-28)",https://lens.org/029-193-256-577-871,Patent Application,yes,0,0,8,9,0,C07D498/04;;C07D498/14;;C07D498/04;;C07D498/14;;C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14;;C07D498/04;;C07D498/14,C07D498/04;;A61K31/4353;;A61P41/00;;C07D498/14,,0,0,,,,PENDING
415,CN,A,CN 102625844 A,117-523-886-045-633,2012-08-01,2012,CN 201080039858 A,2010-07-26,US 2010/0043279 W;;US 27183309 P;;US 28552609 P,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;TRUSTEES OF THE UNIVERSITY OF ILLINOS BOARD OF;;BP CORP NORTH AMERICA INC,LOUISE GLASS N;;CHAOGUANG TIAN;;BEESON WILLIAM T;;HUIMIN ZHAO;;JING DU;;HO CHOI JIN;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;JIN HA SUK;;RIN KIM SOON;;YOUG-SU JIN;;SIJIN LI;;JIANPING SUN;;XIAOMIN YANG,,https://lens.org/117-523-886-045-633,Patent Application,no,2,5,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,7,0,,,"GALAGAN,J.E. 等: ""hypothetical protein NCU00801[Neurospora crassa OR74A]"", 《GENBANK 数据库》;;JAMES E. GALAGAN 等: ""The genome sequence of the filamentous fungus Neurospora crassa"", 《NATURE》;;GALAGAN,J.E. 等: ""hypothetical protein NCU08114[Neurospora crassa OR74A]"", 《GENBANK 数据库》;;JONATHAN M. GALAZKA等: ""Cellodextrin Transport in Yeast for Improved Biofuel Production"", 《SCIENCE》;;CHAOGUANG TIAN等: ""Systems analysis of plant cell wall degradation by the model filamentous fungus Neurospora crassa"", 《PNAS》;;ANDREY V KARLYSHEV等: ""Analysis of Campylobacter jejuni Capsular Loci Reveals Multiple Mechanisms for the Generation of Structural Diversity and the Ability to Form Complex Heptoses"", 《MOLECULAR MICROBIOLOGY》;;B. H. BLUHM等: ""Involvement of ZFR1 of Fusarium verticillioides in kernel colonization and the regulation of FST1, a putative sugar transporter gene required for fumonisin biosynthesis on maize kernels"", 《MOLECULAR PLANT PATHOLOGY》",DISCONTINUED
416,WO,A2,WO 2011/011796 A2,015-087-747-290-894,2011-01-27,2011,US 2010/0043279 W,2010-07-26,US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;TRUSTEES OF THE UNIVERSITY OF ILLINOS BOARD OF;;BP CORP NORTH AMERICA INC;;GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;JIN YOUG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JANES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOON RIN;;JIN YOUG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/015-087-747-290-894,Patent Application,yes,0,7,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,1,0,,,See references of EP 2456878A4,PENDING
417,US,B2,US 11542276 B2,147-757-121-850-067,2023-01-03,2023,US 202017104993 A,2020-11-25,US 202017104993 A;;US 201962939825 P;;US 202063030979 P,2019-11-25,Substituted macrocyclic compounds and related methods of treatment,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,ALKERMES INC (2022-09-06),https://lens.org/147-757-121-850-067,Granted Patent,yes,56,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/04;;A61K31/395;;A61P25/26;;A61P43/00;;C07D498/08;;C07D498/14;;C07D498/18;;C07D498/22,,7,7,017-939-264-188-49X;;010-340-944-245-27X;;011-727-607-829-023;;021-693-589-840-981;;116-403-826-254-123;;155-646-431-415-552;;016-275-586-497-951,19406641;;10.1016/j.bmcl.2009.04.026;;10.1073/pnas.1700499114;;pmc5465922;;28507129;;pmc3927067;;24488306;;10.1007/s10822-014-9710-x;;26267383;;10.1021/acs.jmedchem.5b00988;;10.1021/acsmedchemlett.0c00501;;pmc7667653;;33214817;;pmc5456073;;28575023;;10.1371/journal.pone.0178526;;31654653;;10.1016/j.pbb.2019.172794,"Cox, C. D. et al., “Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding”, Bioorganic & Medicinal Chemistry Letters, 19, 2009, 2997-3001.;;Irukayama-Tomobe, Y. et al., “Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models”, PNAS, vol. 114, No. 22, May 30, 2017, 5731-5736.;;McGaughey, G. et al., “Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs”, J. Comput. Aided Mol. Des., 28, 2014, 5-12.;;Nagahara, T. et al., “Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists”, J. Med. Chem., 58, 2015, 7931-7937.;;Sabnis, R. W., “Novel 5-Alkyl Pyrrolidine Orexin Receptor Agonists for Treating Sleep Disorders”, ACS Med. Chem. Lett., vol. 11, 11 (online at https://dx.doi.org/10.1021/acsmedchemlett.0c00501), Sep. 29, 2020, 2085-2086.;;Turku, A. et al., “Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity”, PLOS One, 12(6): e0178526 (online at doi:10.1371/journal.pone.0178526), Jun. 2, 2017, 1-15.;;Yukitake, H. et al., “TAK-925, an orexin 2 receptor-selective agonist, shows robust wakepromoting effects in mice”, Pharmacology, Biochemistry and Behavior, 187, 2019, 172794.",ACTIVE
418,CA,A1,CA 3172841 A1,006-886-025-815-964,2022-06-30,2022,CA 3172841 A,2021-12-21,US 202063128404 P;;US 202163190937 P;;US 2021/0064483 W,2020-12-21,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JORG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,,https://lens.org/006-886-025-815-964,Patent Application,no,0,0,8,9,0,C07D498/04;;C07D498/14;;C07D498/04;;C07D498/14;;C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14;;C07D498/04;;C07D498/14,C07D498/04;;C07D498/14,,0,0,,,,PENDING
419,US,A1,US 2023/0339969 A1,080-770-873-008-478,2023-10-26,2023,US 202217991899 A,2022-11-22,US 202217991899 A;;US 202017104993 A;;US 201962939825 P;;US 202063030979 P,2019-11-25,SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;VALIULIN ROMAN A;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;HALE MICHAEL R;;LEHMANN JONATHAN WARD;;MATHARU DALJIT;;KARRA SRINIVASA,,https://lens.org/080-770-873-008-478,Patent Application,yes,0,0,13,13,0,C07D498/04;;C07D498/14;;A61P43/00;;C07D498/08;;A61P43/00;;C07D498/18;;C07D498/04;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/22;;C07D498/04;;A61K31/4353;;A61K31/407;;A61K31/55;;A61P25/00;;A61P25/08;;A61P43/00;;C07D498/14;;A61P25/26;;C07B2200/05;;C07D498/08;;C07D498/18;;C07D498/22,C07D498/08;;A61P25/26;;C07D498/18;;C07D498/22,,0,0,,,,PENDING
420,US,A1,US 2022/0194958 A1,112-234-303-042-439,2022-06-23,2022,US 202117556250 A,2021-12-20,US 202117556250 A;;US 202063128404 P;;US 202163190937 P,2020-12-21,Substituted Macrocyclic Compounds and Related Methods of Treatment,The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.,ALKERMES INC,PENNINGTON LEWIS D;;CHOI YOUNGGI;;HUYNH HOAN;;AQUILA BRIAN M;;MUGGE INGO ANDREAS;;HU YUAN;;WOODS JAMES R;;RAYMER BRIAN KENNETH;;BENTZIEN JÖRG MARTIN;;LEHMANN JONATHAN WARD;;HALE MICHAEL R;;KARRA SRINIVASA;;VALIULIN ROMAN A;;MATHARU DALJIT,ALKERMES INC (2022-09-06),https://lens.org/112-234-303-042-439,Patent Application,yes,0,0,8,9,0,C07D498/04;;C07D498/14;;C07D498/04;;C07D498/14;;C07D498/04;;A61K31/4353;;A61P25/00;;A61P25/10;;C07D498/14;;C07D498/04;;C07D498/14,C07D498/04;;C07D498/14,,0,0,,,,PENDING
421,EP,A4,EP 2456878 A4,144-462-589-939-107,2013-01-02,2013,EP 10803022 A,2010-07-26,US 27183309 P;;US 28552609 P;;US 2010/0043279 W,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS",,UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GALAZKA JONATHAN M;;GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T IV;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;HA SUK JIN;;KIM SOO RIN;;JIN YONG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/144-462-589-939-107,Search Report,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C07K14/37;;C12N5/00;;C12N15/00;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,3,3,060-671-554-793-705;;103-762-254-011-523;;128-879-801-420-972,15612919;;10.1111/j.1365-2958.2004.04374.x;;10.1111/j.1364-3703.2007.00458.x;;18705852;;pmc6640386;;11713254;;10.1074/jbc.m109157200,"ANDREY V KARLYSHEV ET AL: ""Analysis of Campylobacter jejuni Capsular Loci Reveals Multiple Mechanisms for the Generation of Structural Diversity and the Ability to Form Complex Heptoses"", MOLECULAR MICROBIOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 55, no. 1, 1 January 2005 (2005-01-01), pages 90 - 103, XP008126621, ISSN: 0950-382X, DOI: 10.1111/J.1365-2958.2004.04374.X;;B. H. BLUHM ET AL: ""Involvement of ZFR1 of Fusarium verticillioides in kernel colonization and the regulation of FST1, a putative sugar transporter gene required for fumonisin biosynthesis on maize kernels"", MOLECULAR PLANT PATHOLOGY, vol. 9, no. 2, 1 March 2008 (2008-03-01), pages 203 - 211, XP055044909, ISSN: 1464-6722, DOI: 10.1111/j.1364-3703.2007.00458.x;;M. MUECKLER: ""Analysis of Transmembrane Segment 10 of the Glut1 Glucose Transporter by Cysteine-scanning Mutagenesis and Substituted Cysteine Accessibility"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 5, 16 November 2001 (2001-11-16), pages 3498 - 3503, XP055044939, ISSN: 0021-9258, DOI: 10.1074/jbc.M109157200",DISCONTINUED
422,CA,A1,CA 2765313 A1,161-644-231-894-382,2011-01-27,2011,CA 2765313 A,2010-07-26,US 27183309 P;;US 28552609 P;;US 2010/0043279 W,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;GALAZKA JONATHAN M;;HA SUK JIN;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN;;BEESON WILLIAM T IV;;DOUDNA CATE JAMES H;;KIM SOO RIN;;JIN YONG-SU,,https://lens.org/161-644-231-894-382,Patent Application,no,0,0,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/52;;C12N15/62;;C12P19/00,,0,0,,,,DISCONTINUED
423,KR,A,KR 20120089631 A,029-359-320-167-840,2012-08-13,2012,KR 20127002889 A,2010-07-26,US 2010/0043279 W;;US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS",,UNIV CALIFORNIA;;BP CORP NORTH AMERICA INC;;UNIV ILLINOIS,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T IV;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOO RIN;;JIN YOUG SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/029-359-320-167-840,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N1/15;;C12N15/52;;C12N15/87,,0,0,,,,DISCONTINUED
424,EP,A2,EP 2456878 A2,048-045-998-527-800,2012-05-30,2012,EP 10803022 A,2010-07-26,US 27183309 P;;US 28552609 P;;US 2010/0043279 W,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS",,UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GALAZKA JONATHAN M;;GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T IV;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;HA SUK JIN;;KIM SOO RIN;;JIN YONG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/048-045-998-527-800,Patent Application,yes,0,0,24,24,96,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C07K14/37;;C12N5/00;;C12N15/00;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,0,0,,,,DISCONTINUED
425,AU,A1,AU 2010/275388 A1,121-501-228-847-949,2012-01-12,2012,AU 2010/275388 A,2010-07-26,US 28552609 P;;US 27183309 P;;US 2010/0043279 W,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",TRUSTEES OF THE UNIVERSITY OF ILLINOS BOARD OF;;BP CORP NORTH AMERICA INC;;UNIV CALIFORNIA,LOUISE GLASS N;;CHAOGUANG TIAN;;BEESON IV WILLIAM T;;HUIMIN ZHAO;;JING DU;;HO CHOI JIN;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;JIN HA SUK;;RIN KIM SOO;;YONG-SU JIN;;SIJIN LI;;JIANPING SUN;;XIAOMIN YANG,,https://lens.org/121-501-228-847-949,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,0,0,,,,DISCONTINUED
426,NZ,A,NZ 597001 A,078-398-694-378-465,2014-05-30,2014,NZ 59700110 A,2010-07-26,US 2010/0043279 W;;US 28552609 P;;US 27183309 P,2009-07-24,"Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels","Disclosed is a method of increasing transport of cellodextrin into a cell, comprising: -providing a non-human host cell, wherein the host cell comprises a recombinant polynucleotide encoding a polypeptide having the structure of a Major Facilitator Superfamily sugar transporter and comprising transmembrane αlpha-helix 1, αlpha-helix 2, αlpha-helix 3, αlpha-helix 4, αlpha-helix 5, αlpha-helix 6, αlpha-helix 7, αlpha-helix 8, αlpha-helix 9, αlpha–helix 10, αlpha-helix 11, αlpha-helix 12, and transmembrane αlpha-helix 1 comprises: -a leucine, isoleucine, valine or methionine at the position corresponding to amino acid 1 of SEQ ID NO: 1 -a tyrosine at the position corresponding to amino acid 2 of SEQ ID NO: 1; - a phenylalanine or leucine at the position corresponding to amino acid 3 of SEQ ID NO: 1; - a tyrosine or phenylalanine at the position corresponding to amino acid 17 of SEQ ID NO: 1; - an aspartate at the position corresponding to amino acid 18 of SEQ ID NO: 1; and -culturing the cell in a medium such that the recombinant polynucleotide is expressed, wherein expression of the recombinant polynucleotide results in increased transport of cellodextrin into the cell compared with a cell that does not comprise the recombinant polynucleotide. Note: The sequence identities are as disclosed in the specification.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T IV;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOO RIN;;JIN YONG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/078-398-694-378-465,Patent Application,no,0,0,24,24,0,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,0,0,,,,DISCONTINUED
427,WO,A8,WO 2011/011796 A8,058-049-448-905-353,2011-12-22,2011,US 2010/0043279 W,2010-07-26,US 27183309 P;;US 28552609 P,2009-07-24,"METHODS AND COMPOSITIONS FOR IMPROVING SUGAR TRANSPORT, MIXED SUGAR FERMENTATION, AND PRODUCTION OF BIOFUELS","The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose- derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell, methods of increasing transport of a pentose into a cell, methods of increasing growth of a cell on a medium containing pentose sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports a pentose into the cell.",UNIV CALIFORNIA;;UNIV ILLINOIS;;BP CORP NORTH AMERICA INC;;GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T IV;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOO RIN;;JIN YONG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,GLASS N LOUISE;;TIAN CHAOGUANG;;BEESON WILLIAM T IV;;ZHAO HUIMIN;;DU JING;;CHOI JIN HO;;DOUDNA CATE JAMES H;;GALAZKA JONATHAN M;;HA SUK JIN;;KIM SOO RIN;;JIN YONG-SU;;LI SIJIN;;SUN JIANPING;;YANG XIAOMIN,,https://lens.org/058-049-448-905-353,Amended Application,yes,0,0,24,24,97,C07K14/37;;C12P7/06;;C12P21/02;;C07K14/37;;C07K14/705;;C12N1/14;;C12N15/52;;C12N15/80;;C12N15/81;;C12N15/87;;Y02E50/10;;Y02E50/10,C12N15/87;;C12N15/52;;C12N15/62;;C12P19/00;;C12R1/865,,0,0,,,,PENDING
428,AU,A1,AU 2022/259801 A1,188-217-501-141-596,2024-02-01,2024,AU 2022/259801 A,2022-10-27,US 202217892597 A;;US 202263352779 P;;US 202263352811 P,2022-06-16,Native multi-tenancy for database system,"Systems and methods include creation of a first instance of a tenant object in a database instance, association of the first instance of the tenant object with a first plurality of database artifacts including first data associated with the first instance of the tenant object, creation of a second instance of the tenant object in the database instance, association of the second instance of the tenant object with a second plurality of database artifacts including second data associated with the second instance of the tenant object, and reception and response to queries on the first data associated with the first instance of the tenant object and to queries on the second data associated with the second instance of the tenant object. CUSTOMER CUSTOMER v v 120 MULTI-TENANT APPLICATION -- \115 ARTIFACTS A r -- - - - - 116 ARTIFACTS B ' :PEfRSISTENCE!",SAP SE,ANDREI MIHNEA;;BOEHM ALEXANDER;;MAY NORMAN;;KLINGSPORN URS;;BLOCK MEINOLF;;VOELKER PATRICK;;KIM HYUNJUN;;GLEBE THORSTEN;;BREGLER JONATHAN;;CHOI JAEYOUNG;;KITTEL MARTIN;;KWON YONG SIK;;HAHN UWE;;ZAHN HENNING;;HANDRECK MELANIE;;MACK HOLGER;;KIM EUNSANG;;RENKES FRANK;;LEE JUCHANG;;SCHINDEWOLF MARTIN;;BOWMAN IVAN;;DANNECKER LARS,,https://lens.org/188-217-501-141-596,Patent Application,no,0,0,5,7,0,G06F21/6218;;G06F16/27;;G06F21/602;;G06F21/602;;G06F21/6227;;H04L9/14,G06F16/21;;G06F16/28;;G06F21/60;;H04L41/5041,,0,0,,,,PENDING
429,CA,A1,CA 3179756 A1,160-656-348-048-034,2023-12-16,2023,CA 3179756 A,2022-10-25,US 202217892597 A;;US 202263352779 P;;US 202263352811 P,2022-06-16,NATIVE MULTI-TENANCY FOR DATABASE SYSTEM,"Systems and methods include creation of a first instance of a tenant object in a database instance, association of the first instance of the tenant object with a first plurality of database artifacts including first data associated with the first instance of the tenant object, creation of a second instance of the tenant object in the database instance, association of the second instance of the tenant object with a second plurality of database artifacts including second data associated with the second instance of the tenant object, and reception and response to queries on the first data associated with the first instance of the tenant object and to queries on the second data associated with the second instance of the tenant object.",SAP SE,ANDREI MIHNEA;;BOEHM ALEXANDER;;MAY NORMAN;;KLINGSPORN URS;;BLOCK MEINOLF;;VOELKER PATRICK;;KIM HYUNJUN;;GLEBE THORSTEN;;BREGLER JONATHAN;;CHOI JAEYOUNG;;KITTEL MARTIN;;KWON YONG SIK;;HAHN UWE;;ZAHN HENNING;;HANDRECK MELANIE;;MACK HOLGER;;KIM EUNSANG;;RENKES FRANK;;LEE JUCHANG;;SCHINDEWOLF MARTIN;;BOWMAN IVAN;;DANNECKER LARS,,https://lens.org/160-656-348-048-034,Patent Application,no,0,0,5,7,0,G06F21/6218;;G06F16/27;;G06F21/602;;G06F21/602;;G06F21/6227;;H04L9/14,G06F16/90;;G06F16/10;;G06F16/903;;G06F16/907;;G06F21/62,,0,0,,,,PENDING
430,EP,A1,EP 4293533 A1,197-496-033-914-738,2023-12-20,2023,EP 22204505 A,2022-10-28,US 202263352779 P;;US 202263352811 P;;US 202217892597 A,2022-06-16,NATIVE MULTI-TENANCY FOR DATABASE SYSTEM,"Systems and methods include creation of a first instance of a tenant object in a database instance, association of the first instance of the tenant object with a first plurality of database artifacts including first data associated with the first instance of the tenant object, creation of a second instance of the tenant object in the database instance, association of the second instance of the tenant object with a second plurality of database artifacts including second data associated with the second instance of the tenant object, and reception and response to queries on the first data associated with the first instance of the tenant object and to queries on the second data associated with the second instance of the tenant object.
",SAP SE,ANDREI MIHNEA;;BOEHM ALEXANDER;;MAY NORMAN;;KLINGSPORN URS;;BLOCK MEINOLF;;VOELKER PATRICK;;KIM HYUNJUN;;GLEBE THORSTEN;;BREGLER JONATHAN;;CHOI JAEYOUNG;;KITTEL MARTIN;;KWON YONG SIK;;HAHN UWE;;ZAHN HENNING;;HANDRECK MELANIE;;MACK HOLGER;;KIM EUNSANG;;RENKES FRANK;;LEE JUCHANG;;SCHINDEWOLF MARTIN;;BOWMAN IVAN;;DANNECKER LARS,,https://lens.org/197-496-033-914-738,Patent Application,yes,6,0,5,7,0,G06F21/6218;;G06F16/27;;G06F21/602;;G06F21/602;;G06F21/6227;;H04L9/14,G06F16/27;;G06F21/62,,1,1,030-653-169-274-936,10.1145/1951365.1951382,"OLIVER SCHILLER ET AL: ""Native support of multi-tenancy in RDBMS for software as a service"", EXTENDING DATABASE TECHNOLOGY, ACM, 2 PENN PLAZA, SUITE 701 NEW YORK NY 10121-0701 USA, 21 March 2011 (2011-03-21), pages 117 - 128, XP058002015, ISBN: 978-1-4503-0528-0, DOI: 10.1145/1951365.1951382",PENDING
431,US,A1,US 2023/0409730 A1,167-034-440-003-128,2023-12-21,2023,US 202217892597 A,2022-08-22,US 202217892597 A;;US 202263352779 P;;US 202263352811 P,2022-06-16,NATIVE MULTI-TENANCY FOR DATABASE SYSTEM,"Systems and methods include creation of a first instance of a tenant object in a database instance, association of the first instance of the tenant object with a first plurality of database artifacts including first data associated with the first instance of the tenant object, creation of a second instance of the tenant object in the database instance, association of the second instance of the tenant object with a second plurality of database artifacts including second data associated with the second instance of the tenant object, and reception and response to queries on the first data associated with the first instance of the tenant object and to queries on the second data associated with the second instance of the tenant object.",SAP SE,ANDREI MIHNEA;;BOEHM ALEXANDER;;MAY NORMAN;;KLINGSPORN URS;;BLOCK MEINOLF;;VOELKER PATRICK;;KIM HYUNJUN;;GLEBE THORSTEN;;BREGLER JONATHAN;;CHOI JAEYOUNG;;KITTEL MARTIN;;KWON YONG SIK;;HAHN UWE;;ZAHN HENNING;;HANDRECK MELANIE;;MACK HOLGER;;KIM EUNSANG;;RENKES FRANK;;LEE JUCHANG;;SCHINDEWOLF MARTIN;;BOWMAN IVAN;;DANNECKER LARS,SAP SE (2022-07-01),https://lens.org/167-034-440-003-128,Patent Application,yes,0,0,5,7,0,G06F21/6218;;G06F16/27;;G06F21/602;;G06F21/602;;G06F21/6227;;H04L9/14,G06F21/62;;G06F21/60;;H04L9/14,,0,0,,,,PENDING
432,US,S,US D0933688 S,002-451-855-608-00X,2021-10-19,2021,US 201829674811 F,2018-12-26,US 201829674811 F;;US 201629589359 F,2016-12-30,Display screen or portion thereof with graphical user interface,,SAMSUNG ELECTRONICS CO LTD,AKIYOSHI KUMI;;YANG MELINDA;;KIM JIMIN;;LEE EMILY;;SHUMSKAS TONY;;FIORI PATRICK J;;MCGILL KYLE T;;BEHNKE BRIAN;;GAISER JONATHAN P;;HU YUCHANG;;YSEBERT SCOTT;;AYRAPETOV NIKOLAY;;MOTA CHOI EUN SUN;;MILLER GARRET;;FURUYA MARICHE JORGE T;;ARRIOLA GEORGIANA;;KWON YONG HWAN;;DAMICO MARK M;;KATOR KRISTEN,,https://lens.org/002-451-855-608-00X,Design Right,no,52,5,1,1,0,,,1404;;D14/486;;D14/488,7,0,,,"Spencer, Rae, “Designing BBC iPlaye rfor Xbox 360” Aug. 29, 2012, BBC Internet Blog, site visited Jul. 13, 2018: http://www.bbc.co.uk/blogs/bbcinternet/2012/08/iplayer_xbox_360_design.html (Year: 2012).;;Dobra, Andrei, “New Xbox 360 Dashboard Update Highlights Indie Games Section” Feb. 22, 2012, Softpedia News, site visited Jul. 13, 2018: https://news.softpedia.com/news/New-Xbox-360-Dashboard-Update-Highlights-Indie-Games-Section-254327.shtml (Year: 2012).;;Pernice, Kara, “Carousel Usability: Designing an Effective UI for Websites with Content Overload” Sep. 14, 2013, Nielsen Norman Group, site visited Jun. 7, 2021: https://www.nngroup.com/articles/designing-effective-carousels/ (Year: 2013).;;Nudelman, Greg, “A Definitive Guide To The Android Carousel Design Pattern” Feb. 1, 2013, Smashing Magazine, site visited Jun. 7, 2021: https://www.smashingmagazine.com/2013/02/android-carousel-design-pattern/ (Year: 2013).;;“6 best Smart TV platforms in the world today” Apr. 4, 2013, YouTube, site visited Jun. 7, 2021: https://youtu.be/tZ_30gn-dTs (Year: 2013).;;“Samsung Smart TV Interface and Features” May 9, 2013, YouTube, site visited Jun. 7, 2021: https://www.youtube.com/watch?v=U4nlelcaH6l (Year: 2013).;;Salazar, Kim, “Smart-TV Usability: Accessing Content is Key” Sep. 20, 2015, Nielsen Norman Group, site visited Jun. 7, 2021: https://www.nngroup.com/articles/smart-tv-usability/ (Year: 2015).",ACTIVE
433,WO,A1,WO 2022/035882 A1,059-198-780-242-550,2022-02-17,2022,US 2021/0045421 W,2021-08-10,US 202063065951 P;;US 202117392138 A,2020-08-14,ELECTRONIC DEVICES WITH BORDERLESS DISPLAYS,"An electronic device display may have pixels formed from crystalline semiconductor light-emitting diode dies, organic light-emitting diodes, or other pixel structures. The pixels may be formed on a display panel substrate. A display panel may extend continuously across the display or multiple display panels may be tiled in two dimensions to cover a larger display area. Interconnect substrates may have outwardly facing contacts that are electrically shorted to corresponding inwardly facing contacts such as inwardly facing metal pillars associated with the display panels. The interconnect substrates may be supported by glass layers. Integrated circuits may be embedded in the display panels and/or in the interconnect substrates. A display may have an active area with pixels that includes non-spline pixels in a non-spline display portion located above a straight edge of the display and spline pixel in a spline display portion located above a curved edge of the display.",APPLE INC,GEHLEN ELMAR;;ZHANG ZHEN;;JACOB FRANCOIS;;DRZAIC PAUL;;CHANG HAN-CHIEH;;JAMSHIDI ROUDBARI ABBAS;;LIANG ANSHI;;BAE HOPIL;;FARROKH BAROUGHI MAHDI;;DEVINCENTIS MARC;;SACCHETTO PAOLO;;MOY TIFFANY;;RIEUTORT-LOUIS WARREN;;SUN YONG;;MAR JONATHAN;;WANG ZUOQIAN;;TRACY IAN;;KANG SUNGGU;;CHOI JAEIN;;MOLESA STEVEN;;CHALASANI SANDEEP;;LIAO JUI-CHIH;;ZHAO XIN;;AHMED IZHAR,,https://lens.org/059-198-780-242-550,Patent Application,yes,6,0,4,4,0,H05K2201/10128;;H05K2201/10106;;H05K2201/10151;;H05K3/4682;;H05K2203/016;;H05K2201/10378;;H01L25/0753;;H01L25/167;;G09F9/3026;;G06F1/163;;G06F1/1656;;G09G3/3225;;H01L25/167;;H01L25/0753,H01L25/075;;G09F9/302;;H05K3/46,,0,0,,,,PENDING
434,US,A1,US 2022/0050506 A1,024-996-383-425-800,2022-02-17,2022,US 202117392138 A,2021-08-02,US 202117392138 A;;US 202063065951 P,2020-08-14,Electronic Devices With Borderless Displays,"An electronic device display may have pixels formed from crystalline semiconductor light-emitting diode dies, organic light-emitting diodes, or other pixel structures. The pixels may be formed on a display panel substrate. A display panel may extend continuously across the display or multiple display panels may be tiled in two dimensions to cover a larger display area. Interconnect substrates may have outwardly facing contacts that are electrically shorted to corresponding inwardly facing contacts such as inwardly facing metal pillars associated with the display panels. The interconnect substrates may be supported by glass layers. Integrated circuits may be embedded in the display panels and/or in the interconnect substrates. A display may have an active area with pixels that includes non-spline pixels in a non-spline display portion located above a straight edge of the display and spline pixel in a spline display portion located above a curved edge of the display.",APPLE INC,GEHLEN ELMAR;;ZHANG ZHEN;;JACOB FRANCOIS R;;DRZAIC PAUL S;;CHANG HAN-CHIEH;;JAMSHIDI ROUDBARI ABBAS;;LIANG ANSHI;;BAE HOPIL;;FARROKH BAROUGHI MAHDI;;DEVINCENTIS MARC J;;SACCHETTO PAOLO;;MOY TIFFANY T;;RIEUTORT-LOUIS WARREN S;;SUN YONG;;MAR JONATHAN P;;WANG ZUOQIAN;;TRACY IAN D;;KANG SUNGGU;;CHOI JAEIN;;MOLESA STEVEN E;;CHALASANI SANDEEP;;LIAO JUI-CHIH;;ZHAO XIN;;AHMED IZHAR Z,APPLE INC (2021-05-14),https://lens.org/024-996-383-425-800,Patent Application,yes,0,1,4,4,0,H05K2201/10128;;H05K2201/10106;;H05K2201/10151;;H05K3/4682;;H05K2203/016;;H05K2201/10378;;H01L25/0753;;H01L25/167;;G09F9/3026;;G06F1/163;;G06F1/1656;;G09G3/3225;;H01L25/167;;H01L25/0753,G06F1/16;;G09G3/3225,,0,0,,,,PENDING
435,EP,A1,EP 4173040 A1,065-895-263-168-488,2023-05-03,2023,EP 21766036 A,2021-08-10,US 202063065951 P;;US 202117392138 A;;US 2021/0045421 W,2020-08-14,ELECTRONIC DEVICES WITH BORDERLESS DISPLAYS,,APPLE INC,GEHLEN ELMAR;;ZHANG ZHEN;;JACOB FRANCOIS R;;DRZAIC PAUL S;;CHANG HAN-CHIEH;;JAMSHIDI ROUDBARI ABBAS;;LIANG ANSHI;;BAE HOPIL;;FARROKH BAROUGHI MAHDI;;DEVINCENTIS MARC J;;SACCHETTO PAOLO;;MOY TIFFANY T;;RIEUTORT-LOUIS WARREN S;;SUN YONG;;MAR JONATHAN P;;WANG ZUOQIAN;;TRACY IAN D;;KANG SUNGGU;;CHOI JAEIN;;MOLESA STEVEN E;;CHALASANI SANDEEP;;LIAO JUI-CHIH;;ZHAO XIN;;AHMED IZHAR Z,,https://lens.org/065-895-263-168-488,Patent Application,yes,0,0,4,4,0,H05K2201/10128;;H05K2201/10106;;H05K2201/10151;;H05K3/4682;;H05K2203/016;;H05K2201/10378;;H01L25/0753;;H01L25/167;;G09F9/3026;;G06F1/163;;G06F1/1656;;G09G3/3225;;H01L25/167;;H01L25/0753,H01L25/075;;G09F9/302;;H05K3/46,,0,0,,,,PENDING
